は投与 3 日目の時点でプラセボ群と比較して有意に高かった。
青少年被験者では，共主要評価項目，様々な皮膚症状の改善及び反応の基準値に関する副次評価項目，並びにかゆみ及び他の症状の評価で，一貫した有効性が示された。

薬物動態の結果：
24 時間の投与間隔内での血漿中ウパダシチニブ濃度の平均値の範囲は，ウパダシチニブ 15 mg 群で 8.75～42.6 ng/mL，ウパダシチニブ 30 mg 群で 10.9～69.3 ng/mL であった。
ウパダシチニブの血漿中濃度の母集団薬物動態解析及び曝露-反応解析の結果は，他の報告書に示す予定である。これらの結果は，ウパダシチニブの他の試験のデータとの併合解析結果として示す可能性がある。

安全性の結果：
本試験では，ウパダシチニブはアトピー性皮膚炎患者に対し，おおむね安全で，忍容性も良好であった。ウパダシチニブの投与を受けた被験者でざ瘡の発現割合が高かったことを除き，ウパダシチニブの他の適応症（関節リウマチ及び乾癬性関節炎）の試験と比較して，新たな重大な安全性の懸念は認められなかった。重篤な有害事象及び治験薬の投与中止に至った有害事象の発現割合は，プラセボ対照期間を通してウパダシチニブ群及びプラセボ群で類似していた。データカットオフ日までにウパダシチニブの投与を受けたすべての被験者での，曝露期間で調整した重篤な有害事象の発現率は，ウパダシチニブ 30 mg 群及びウパダシチニブ 15 mg 群で類似していたが，曝露期間で調整した治験薬の投与中止に至った有害事象の発現率は，ウパダシチニブ 15 mg 群と比較してウパダシチニブ 30 mg 群で高かった。全体として，ウパダシチニブの投与を受けた被験者で発現割合が最も高かった有害事象は，ざ瘡及び上気道感染であった。本試験中に死亡は認められなかった。
ざ瘡の発現割合にはウパダシチニブの用量反応関係が認められ，ざ瘡の発現割合はプラセボ群と比較してウパダシチニブ群で高かった。ざ瘡の重症度は 1 件を除いて軽度又は中等度であり，ざ瘡による治験薬の投与中止はほとんど認められなかった。ほとんどのざ瘡は顔に発現し，主に炎症性丘疹，膿疱及び面皰であった。本試験のプラセボ及びウパダシチニブの投与群全体でざ瘡の既往歴を有する被験者の割合は高かった。この原因として，ざ瘡の有病率は若年層で高いため，本試験に登録されたアトピー性皮膚炎患者集団でもざ瘡の既往歴が高かった可能性がある。
アトピー性皮膚炎は本試験の対象疾患であるため，有害事象のアトピー性皮膚炎は既存疾患の悪化とした。これらの事象は予期された事象であり，アトピー性皮膚炎の発現割合がプラセボ群と比較して，ウパダシチニブ 30 mg 群及びウパダシチニブ 15 mg 群で低かったことは，アトピー性皮膚炎に対するウパダシチニブの治療効果を示している可能性がある。
データカットオフ日までにウパダシチニブの投与を受けたすべての被験者では，重篤な感染症の発現率は，ウパダシチニブ 15 mg 群と比較してウパダシチニブ 30 mg 群で高かった。日和見感染は，すべてヘルペス性状湿疹（カポジ水痘様発疹と同義）であった。ヘルペス性状湿疹は，アトピー性皮膚炎患者集団で最も多く認められるウイルス性の合併症であり，ヘルペス性状湿疹に易感染性のアトピー性皮膚炎患者集団の部分集団もあることが報告されている。帯状疱疹はヤヌスキナーゼ（以下「JAK」）阻害薬では予期される有害事象であり，その発現率はプラセボ群と比較してウパダシチニブ群で高く，ウパダシチニブ 15 mg 群と比較してウパダシチニブ 30 mg 群で高かった。84.2%の帯状疱疹が単一の皮節のみに認められた。
ウパダシチニブ 15 mg 群のコントロール不能の高血圧を有する被験者で，判定された主要心血管事象（非致死性脳卒中）が 1 件報告された。
全体として，肝障害（大部分が肝酵素増加），貧血，好中球減少症及びクレアチンホスホキナーゼ増加の発現率はおおむね低く，ウパダシチニブ 15 mg 群と比較してウパダシチニブ 30 mg 群で高かった。JAK 阻害薬では，これらの臨床検査異常に対するウパダシチニブの用量依存性は予期されている。
成人及び青少年の両方で中等度の体重増加が認められた。体重増加は成長期の青少年では予期されているものであるが，成人では様々な病因が考えられた。青少年の被験者で，身長と体重に関してウパダシチニブ投与による臨床的に意味のある差は認められなかった。
全体を通して，有害事象及び特に注目すべき有害事象の発現率は，青少年被験者集団及び全体集団で類似していた。青少年に対する新たなリスクは認められなかった。青少年被験者で，重篤な有害事象，重篤な感染症及び治

験薬の投与中止に至った有害事象の発現率がウパダシチニブ 15 mg 群と比較してウパダシチニブ 30 mg 群で高かったことの原因の 1 つに，1 名に同時に 4 件の重篤な感染症（血液培養陽性，尿培養陽性，ブドウ球菌性敗血症及び骨髄炎）が認められたことがある。 本試験では，データカットオフ日までに，活動性結核，リンパ腫，判定された消化管穿孔及び判定された静脈血栓塞栓症は報告されなかった。
結論： 中等症から重症のアトピー性皮膚炎患者を対象とした第 III 相試験である本試験（M16-045 試験）では，共主要評価項目及び副次評価項目により，皮膚での疾患活動性，かゆみ及び健康関連の生活の質（以下「QOL」）の改善が認められ，ウパダシチニブの有効性が一貫して示された。ウパダシチニブは，皮膚での迅速な作用発現及び効果の深さ，並びにかゆみの改善を示した。ウパダシチニブ 15 mg 及び 30 mg QD 投与は，おおむね安全で忍容性は良好であり，報告された有害事象は臨床的に管理可能であった。全体として，ウパダシチニブ 15 mg 及び 30 mg のベネフィット・リスクのプロファイルは良好と考えられた。共主要評価項目と，様々な皮膚症状の改善並びにかゆみ及び健康関連の QOL の反応の基準値に関する副次評価項目により，青少年被験者集団及び全体集団で一貫した有効性が示された。本試験の結果は，中等症から重症の青少年及び成人アトピー性皮膚炎患者に対し，ウパダシチニブは有効で忍容性が良好な治療の選択肢であることを支持している。

表 1. 二重盲検投与期で有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（二重盲検投与期の安全性解析対象集団）

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Total (N=566) n (%)
Any adverse event	166 (59.1)	176 (62.6)	209 (73.3)	385 (68.0)
血液およびリンパ系障害	6 (2.1)	5 (1.8)	18 (6.3)	23 (4.1)
貧血	1 (0.4)	0	4 (1.4)	4 (0.7)
白血球増加症	1 (0.4)	0	1 (0.4)	1 (0.2)
白血球減少症	0	0	1 (0.4)	1 (0.2)
リンパ節症	2 (0.7)	1 (0.4)	1 (0.4)	2 (0.4)
リンパ球減少症	0	1 (0.4)	1 (0.4)	2 (0.4)
好中球減少症	1 (0.4)	3 (1.1)	13 (4.6)	16 (2.8)
好中球増加症	1 (0.4)	0	0	0
汎血球減少症	0	0	1 (0.4)	1 (0.2)
血小板減少症	0	0	1 (0.4)	1 (0.2)
心臓障害	0	1 (0.4)	0	1 (0.2)
心血管障害	0	1 (0.4)	0	1 (0.2)
先天性、家族性および遺伝性障害	0	0	1 (0.4)	1 (0.2)
包茎	0	0	1 (0.4)	1 (0.2)
耳および迷路障害	3 (1.1)	1 (0.4)	1 (0.4)	2 (0.4)
耳垢栓塞	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
耳および迷路障害 (Cont.)				
外耳の炎症	1 (0.4)	0	0	0
耳鳴	1 (0.4)	0	0	0
回転性めまい	0	1 (0.4)	0	1 (0.2)
頭位性回転性めまい	1 (0.4)	0	0	0
内分泌障害	2 (0.7)	0	1 (0.4)	1 (0.2)
バセドウ病	0	0	1 (0.4)	1 (0.2)
甲状腺機能亢進症	1 (0.4)	0	0	0
甲状腺機能低下症	1 (0.4)	0	0	0
眼障害	9 (3.2)	5 (1.8)	7 (2.5)	12 (2.1)
眼瞼炎	0	0	1 (0.4)	1 (0.2)
白内障	1 (0.4)	1 (0.4)	0	1 (0.2)
アレルギー性結膜炎	4 (1.4)	1 (0.4)	2 (0.7)	3 (0.5)
ドライアイ	1 (0.4)	0	1 (0.4)	1 (0.2)
眼瞼湿疹	0	0	1 (0.4)	1 (0.2)
上強膜炎	1 (0.4)	0	0	0
眼そう痒症	0	0	1 (0.4)	1 (0.2)
緑内障	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
眼障害 (Cont.)				
流涙増加	1 (0.4)	0	0	0
黄斑変性	0	1 (0.4)	0	1 (0.2)
眼窩周囲腫脹	0	1 (0.4)	0	1 (0.2)
潰瘍性角膜炎	0	1 (0.4)	0	1 (0.2)
霧視	1 (0.4)	1 (0.4)	2 (0.7)	3 (0.5)
視力障害	0	1 (0.4)	0	1 (0.2)
胃腸障害	22 (7.8)	34 (12.1)	42 (14.7)	76 (13.4)
腹部不快感	1 (0.4)	0	0	0
腹部膨満	0	1 (0.4)	1 (0.4)	2 (0.4)
腹痛	2 (0.7)	0	2 (0.7)	2 (0.4)
上腹部痛	2 (0.7)	2 (0.7)	4 (1.4)	6 (1.1)
口角口唇炎	0	0	1 (0.4)	1 (0.2)
肛門直腸障害	1 (0.4)	0	0	0
アフタ性潰瘍	1 (0.4)	0	0	0
呼気臭	0	0	1 (0.4)	1 (0.2)
便秘	2 (0.7)	2 (0.7)	2 (0.7)	4 (0.7)
齲歯	3 (1.1)	2 (0.7)	1 (0.4)	3 (0.5)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
胃腸障害 (Cont.)				
下痢	7 (2.5)	8 (2.8)	10 (3.5)	18 (3.2)
口内乾燥	0	0	3 (1.1)	3 (0.5)
消化不良	0	2 (0.7)	2 (0.7)	4 (0.7)
嚥下障害	1 (0.4)	0	0	0
軟便	0	0	2 (0.7)	2 (0.4)
鼓腸	0	3 (1.1)	2 (0.7)	5 (0.9)
食中毒	0	1 (0.4)	2 (0.7)	3 (0.5)
胃潰瘍	0	1 (0.4)	1 (0.4)	2 (0.4)
胃炎	0	2 (0.7)	0	2 (0.4)
びらん性胃炎	0	0	1 (0.4)	1 (0.2)
胃食道逆流性疾患	0	1 (0.4)	4 (1.4)	5 (0.9)
歯肉痛	0	0	1 (0.4)	1 (0.2)
血便排泄	1 (0.4)	0	0	0
痔核	0	0	1 (0.4)	1 (0.2)
歯の知覚過敏	0	0	1 (0.4)	1 (0.2)
悪心	2 (0.7)	10 (3.6)	10 (3.5)	20 (3.5)
歯の障害	1 (0.4)	0	0	0

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
胃腸障害 (Cont.)				
埋伏歯	0	1 (0.4)	0	1 (0.2)
歯痛	1 (0.4)	0	1 (0.4)	1 (0.2)
嘔吐	1 (0.4)	2 (0.7)	6 (2.1)	8 (1.4)
一般・全身障害および投与部位の状態	12 (4.3)	17 (6.0)	21 (7.4)	38 (6.7)
無力症	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
胸部不快感	0	1 (0.4)	1 (0.4)	2 (0.4)
胸痛	1 (0.4)	1 (0.4)	0	1 (0.2)
悪寒	0	0	1 (0.4)	1 (0.2)
不快感	1 (0.4)	0	1 (0.4)	1 (0.2)
薬物不耐性	0	0	1 (0.4)	1 (0.2)
顔面浮腫	0	0	1 (0.4)	1 (0.2)
疲労	3 (1.1)	3 (1.1)	3 (1.1)	6 (1.1)
びくびく感	0	0	1 (0.4)	1 (0.2)
インフルエンザ様疾患	3 (1.1)	5 (1.8)	6 (2.1)	11 (1.9)
倦怠感	1 (0.4)	0	0	0
腫瘤	0	1 (0.4)	0	1 (0.2)
粘膜乾燥	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Total (N=566) n (%)
一般・全身障害および投与部位の状態 (Cont.)				
非心臓性胸痛	0	0	1 (0.4)	1 (0.2)
浮腫	0	0	1 (0.4)	1 (0.2)
末梢性浮腫	1 (0.4)	0	1 (0.4)	1 (0.2)
疼痛	0	1 (0.4)	1 (0.4)	2 (0.4)
発熱	3 (1.1)	5 (1.8)	4 (1.4)	9 (1.6)
腫脹	0	1 (0.4)	0	1 (0.2)
血管穿刺部位内出血	0	0	1 (0.4)	1 (0.2)
肝胆道系障害	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
胆石症	1 (0.4)	1 (0.4)	0	1 (0.2)
脂肪肝	0	0	1 (0.4)	1 (0.2)
免疫系障害	4 (1.4)	3 (1.1)	2 (0.7)	5 (0.9)
アナフィラキシー反応	0	0	1 (0.4)	1 (0.2)
アナフィラキシーショック	1 (0.4)	0	0	0
薬物過敏症	2 (0.7)	0	0	0
食物アレルギー	0	1 (0.4)	0	1 (0.2)
過敏症	0	2 (0.7)	0	2 (0.4)
季節性アレルギー	1 (0.4)	0	0	0

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
免疫系障害 (Cont.)				
1 型過敏症	0	0	1 (0.4)	1 (0.2)
感染症および寄生虫症	77 (27.4)	108 (38.4)	142 (49.8)	250 (44.2)
四肢膿瘍	1 (0.4)	0	1 (0.4)	1 (0.2)
膿疱性ざ瘡	0	1 (0.4)	0	1 (0.2)
虫垂炎	0	1 (0.4)	0	1 (0.2)
細菌感染	2 (0.7)	0	0	0
細菌性膣症	0	0	1 (0.4)	1 (0.2)
細菌尿	0	0	1 (0.4)	1 (0.2)
体部白癬	0	2 (0.7)	0	2 (0.4)
気管支炎	0	2 (0.7)	2 (0.7)	4 (0.7)
蜂巣炎	2 (0.7)	2 (0.7)	1 (0.4)	3 (0.5)
結膜炎	5 (1.8)	0	4 (1.4)	4 (0.7)
膀胱炎	1 (0.4)	0	0	0
感染性皮膚炎	0	1 (0.4)	0	1 (0.2)
皮膚糸状菌症	0	0	1 (0.4)	1 (0.2)
爪の皮膚糸状菌症	0	1 (0.4)	0	1 (0.2)
耳感染	2 (0.7)	0	6 (2.1)	6 (1.1)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
感染症および寄生虫症 (Cont.)				
膿瘡	0	1 (0.4)	0	1 (0.2)
ヘルペス性状湿疹	2 (0.7)	0	2 (0.7)	2 (0.4)
膿痂疹性湿疹	1 (0.4)	0	0	0
感染性湿疹	1 (0.4)	0	0	0
丹毒	1 (0.4)	0	0	0
眼感染	0	1 (0.4)	0	1 (0.2)
毛包炎	5 (1.8)	4 (1.4)	8 (2.8)	12 (2.1)
せつ	0	2 (0.7)	0	2 (0.4)
胃腸炎	4 (1.4)	0	6 (2.1)	6 (1.1)
ウイルス性胃腸炎	0	1 (0.4)	1 (0.4)	2 (0.4)
ウイルス性消化管感染	0	0	1 (0.4)	1 (0.2)
陰部ヘルペス	1 (0.4)	1 (0.4)	0	1 (0.2)
陰部単純ヘルペス	0	0	2 (0.7)	2 (0.4)
蠕虫感染	0	0	1 (0.4)	1 (0.2)
ヘルパンギーナ	0	0	1 (0.4)	1 (0.2)
ヘルペス性皮膚炎	0	0	1 (0.4)	1 (0.2)
単純ヘルペス	3 (1.1)	6 (2.1)	7 (2.5)	13 (2.3)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
感染症および寄生虫症 (Cont.)				
ヘルペスウイルス感染	0	1 (0.4)	1 (0.4)	2 (0.4)
帯状疱疹	0	5 (1.8)	6 (2.1)	11 (1.9)
麦粒腫	1 (0.4)	0	5 (1.8)	5 (0.9)
膿痂疹	6 (2.1)	5 (1.8)	3 (1.1)	8 (1.4)
感染性嚢腫	1 (0.4)	0	0	0
感染性皮膚嚢腫	1 (0.4)	0	0	0
感染	1 (0.4)	0	0	0
インフルエンザ	0	3 (1.1)	5 (1.8)	8 (1.4)
カポジ水痘様発疹	2 (0.7)	0	1 (0.4)	1 (0.2)
喉頭炎	0	0	1 (0.4)	1 (0.2)
ウイルス性喉頭炎	0	1 (0.4)	0	1 (0.2)
限局性感染	1 (0.4)	0	0	0
下気道感染	0	1 (0.4)	0	1 (0.2)
伝染性軟属腫	0	1 (0.4)	1 (0.4)	2 (0.4)
上咽頭炎	16 (5.7)	22 (7.8)	33 (11.6)	55 (9.7)
乳頭感染	0	1 (0.4)	0	1 (0.2)
眼部単純ヘルペス	0	1 (0.4)	1 (0.4)	2 (0.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
感染症および寄生虫症 (Cont.)				
口腔カンジダ症	0	0	3 (1.1)	3 (0.5)
口腔ヘルペス	3 (1.1)	5 (1.8)	14 (4.9)	19 (3.4)
中耳炎	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
急性中耳炎	0	0	1 (0.4)	1 (0.2)
爪囲炎	2 (0.7)	0	0	0
歯周炎	0	1 (0.4)	0	1 (0.2)
咽頭膿瘍	0	0	1 (0.4)	1 (0.2)
咽頭炎	0	1 (0.4)	2 (0.7)	3 (0.5)
咽頭扁桃炎	0	1 (0.4)	0	1 (0.2)
肺炎	0	1 (0.4)	0	1 (0.2)
ブドウ球菌性肺炎	0	0	1 (0.4)	1 (0.2)
膿疱	1 (0.4)	0	1 (0.4)	1 (0.2)
膿皮症	0	1 (0.4)	0	1 (0.2)
膿疱性皮疹	0	1 (0.4)	0	1 (0.2)
気道感染	0	2 (0.7)	2 (0.7)	4 (0.7)
ウイルス性気道感染	0	1 (0.4)	0	1 (0.2)
鼻炎	0	1 (0.4)	2 (0.7)	3 (0.5)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
感染症および寄生虫症 (Cont.)				
ライノウイルス感染	0	0	1 (0.4)	1 (0.2)
副鼻腔炎	3 (1.1)	4 (1.4)	1 (0.4)	5 (0.9)
皮膚細菌感染	4 (1.4)	2 (0.7)	1 (0.4)	3 (0.5)
皮膚カンジダ	0	1 (0.4)	1 (0.4)	2 (0.4)
皮膚感染	2 (0.7)	2 (0.7)	3 (1.1)	5 (0.9)
ブドウ球菌感染	0	0	2 (0.7)	2 (0.4)
ブドウ球菌皮膚感染	0	1 (0.4)	0	1 (0.2)
皮下組織膿瘍	0	1 (0.4)	1 (0.4)	2 (0.4)
細菌重複感染	0	1 (0.4)	0	1 (0.2)
股部白癬	0	0	2 (0.7)	2 (0.4)
足部白癬	0	1 (0.4)	0	1 (0.2)
癜風	0	2 (0.7)	0	2 (0.4)
扁桃炎	1 (0.4)	2 (0.7)	1 (0.4)	3 (0.5)
細菌性扁桃炎	0	0	1 (0.4)	1 (0.2)
歯膿瘍	0	1 (0.4)	2 (0.7)	3 (0.5)
歯感染	1 (0.4)	0	1 (0.4)	1 (0.2)
上気道感染	20 (7.1)	25 (8.9)	38 (13.3)	63 (11.1)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
感染症および寄生虫症 (Cont.)				
クラミジア性尿道炎	0	1 (0.4)	0	1 (0.2)
尿路感染	3 (1.1)	4 (1.4)	6 (2.1)	10 (1.8)
水痘	0	0	1 (0.4)	1 (0.2)
ウイルス感染	2 (0.7)	1 (0.4)	0	1 (0.2)
ウイルス性咽頭炎	0	1 (0.4)	0	1 (0.2)
ウイルス性発疹	0	1 (0.4)	0	1 (0.2)
ウイルス性上気道感染	2 (0.7)	5 (1.8)	5 (1.8)	10 (1.8)
外陰部腟カンジダ症	1 (0.4)	2 (0.7)	2 (0.7)	4 (0.7)
外陰腟真菌感染	1 (0.4)	1 (0.4)	0	1 (0.2)
創傷感染	0	0	1 (0.4)	1 (0.2)
ブドウ球菌性創感染	0	0	1 (0.4)	1 (0.2)
傷害、中毒および処置合併症	6 (2.1)	14 (5.0)	9 (3.2)	23 (4.1)
節足動物咬傷	0	1 (0.4)	1 (0.4)	2 (0.4)
節足動物刺傷	0	0	1 (0.4)	1 (0.2)
背部損傷	0	1 (0.4)	0	1 (0.2)
第 2 度熱傷	0	1 (0.4)	0	1 (0.2)
軟骨損傷	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Total (N=566) n (%)
傷害、中毒および処置合併症 (Cont.)				
挫傷	0	1 (0.4)	0	1 (0.2)
転倒	1 (0.4)	2 (0.7)	1 (0.4)	3 (0.5)
足骨折	0	1 (0.4)	1 (0.4)	2 (0.4)
損傷	1 (0.4)	1 (0.4)	0	1 (0.2)
関節脱臼	0	1 (0.4)	0	1 (0.2)
関節損傷	0	0	1 (0.4)	1 (0.2)
靱帯捻挫	1 (0.4)	2 (0.7)	0	2 (0.4)
四肢損傷	0	2 (0.7)	0	2 (0.4)
肉離れ	0	0	2 (0.7)	2 (0.4)
交通事故	0	1 (0.4)	1 (0.4)	2 (0.4)
皮膚擦過傷	0	1 (0.4)	1 (0.4)	2 (0.4)
皮膚裂傷	1 (0.4)	0	0	0
軟部組織損傷	1 (0.4)	0	0	0
サンバーン	0	0	1 (0.4)	1 (0.2)
腱断裂	1 (0.4)	1 (0.4)	0	1 (0.2)
上肢骨折	0	1 (0.4)	0	1 (0.2)
ワクチン接種合併症	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
臨床検査	18 (6.4)	32 (11.4)	39 (13.7)	71 (12.5)
アラニンアミノトランスフェラーゼ増加	2 (0.7)	2 (0.7)	5 (1.8)	7 (1.2)
アスパラギン酸アミノトランスフェラーゼ増加	0	2 (0.7)	4 (1.4)	6 (1.1)
B リンパ球数増加	0	1 (0.4)	0	1 (0.2)
血中アルカリホスファターゼ増加	0	1 (0.4)	0	1 (0.2)
血中ビリルビン増加	0	1 (0.4)	0	1 (0.2)
血中コレステロール増加	0	2 (0.7)	2 (0.7)	4 (0.7)
血中クレアチンホスホキナーゼ増加	7 (2.5)	16 (5.7)	16 (5.6)	32 (5.7)
血中クレアチニン増加	0	2 (0.7)	0	2 (0.4)
血中ブドウ糖増加	1 (0.4)	0	0	0
血中免疫グロブリン E 増加	3 (1.1)	3 (1.1)	0	3 (0.5)
血中カリウム増加	0	1 (0.4)	0	1 (0.2)
血圧上昇	0	1 (0.4)	0	1 (0.2)
血中ナトリウム増加	1 (0.4)	0	0	0
血中尿酸増加	1 (0.4)	0	1 (0.4)	1 (0.2)
尿中血陽性	0	1 (0.4)	0	1 (0.2)
CD4 リンパ球減少	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
臨床検査 (Cont.)				
CD8 リンパ球百分率減少	0	1 (0.4)	0	1 (0.2)
CD8 リンパ球減少	1 (0.4)	0	1 (0.4)	1 (0.2)
CD8 リンパ球増加	1 (0.4)	0	0	0
心雑音	0	0	1 (0.4)	1 (0.2)
尿中結晶陽性	0	0	1 (0.4)	1 (0.2)
好酸球百分率増加	0	1 (0.4)	0	1 (0.2)
ヘモグロビン減少	0	1 (0.4)	1 (0.4)	2 (0.4)
心拍数増加	0	0	1 (0.4)	1 (0.2)
肝酵素上昇	0	1 (0.4)	0	1 (0.2)
リンパ球数減少	1 (0.4)	0	0	0
ナチュラルキラー細胞数減少	0	1 (0.4)	0	1 (0.2)
好中球数減少	1 (0.4)	1 (0.4)	2 (0.7)	3 (0.5)
好中球数増加	1 (0.4)	0	0	0
尿蛋白	0	1 (0.4)	0	1 (0.2)
尿中蛋白陽性	2 (0.7)	0	1 (0.4)	1 (0.2)
T リンパ球数減少	1 (0.4)	1 (0.4)	0	1 (0.2)
トランスアミナーゼ上昇	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
臨床検査 (Cont.)				
尿中白血球エステラーゼ陽性	0	0	1 (0.4)	1 (0.2)
尿中シュウ酸塩	0	1 (0.4)	0	1 (0.2)
体重減少	0	0	2 (0.7)	2 (0.4)
体重増加	0	5 (1.8)	9 (3.2)	14 (2.5)
白血球数減少	1 (0.4)	0	2 (0.7)	2 (0.4)
尿中白血球陽性	1 (0.4)	0	0	0
代謝および栄養障害	6 (2.1)	9 (3.2)	12 (4.2)	21 (3.7)
食欲減退	2 (0.7)	2 (0.7)	2 (0.7)	4 (0.7)
脂質異常症	0	0	1 (0.4)	1 (0.2)
痛風	0	0	1 (0.4)	1 (0.2)
高コレステロール血症	0	1 (0.4)	2 (0.7)	3 (0.5)
高血糖	1 (0.4)	0	0	0
高脂血症	0	1 (0.4)	1 (0.4)	2 (0.4)
高トリグリセリド血症	0	2 (0.7)	1 (0.4)	3 (0.5)
高尿酸血症	3 (1.1)	1 (0.4)	1 (0.4)	2 (0.4)
低血糖	0	0	1 (0.4)	1 (0.2)
低カリウム血症	0	0	2 (0.7)	2 (0.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
代謝および栄養障害 (Cont.)				
低リン酸血症	0	1 (0.4)	0	1 (0.2)
食欲亢進	0	1 (0.4)	1 (0.4)	2 (0.4)
筋骨格系および結合組織障害	22 (7.8)	14 (5.0)	19 (6.7)	33 (5.8)
関節痛	3 (1.1)	3 (1.1)	4 (1.4)	7 (1.2)
腋窩腫瘤	0	0	1 (0.4)	1 (0.2)
背部痛	9 (3.2)	2 (0.7)	7 (2.5)	9 (1.6)
滑液包炎	0	1 (0.4)	0	1 (0.2)
側腹部痛	0	1 (0.4)	0	1 (0.2)
肢径部痛	1 (0.4)	0	0	0
筋痙縮	1 (0.4)	0	0	0
筋緊張	1 (0.4)	0	0	0
筋骨格痛	0	1 (0.4)	0	1 (0.2)
筋骨格硬直	1 (0.4)	0	0	0
筋肉痛	2 (0.7)	4 (1.4)	5 (1.8)	9 (1.6)
頚部痛	2 (0.7)	1 (0.4)	0	1 (0.2)
四肢痛	2 (0.7)	0	2 (0.7)	2 (0.4)
顎痛	0	1 (0.4)	1 (0.4)	2 (0.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
筋骨格系および結合組織障害 (Cont.)				
肩回旋筋腱板症候群	1 (0.4)	0	0	0
側弯症	0	1 (0.4)	0	1 (0.2)
変形性脊椎症	1 (0.4)	0	0	0
腱障害	0	1 (0.4)	0	1 (0.2)
腱炎	0	0	1 (0.4)	1 (0.2)
弾発指	1 (0.4)	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (0.4)	1 (0.4)	6 (2.1)	7 (1.2)
ボーエン病	0	1 (0.4)	0	1 (0.2)
真珠腫	0	0	1 (0.4)	1 (0.2)
胃癌	0	0	1 (0.4)	1 (0.2)
浸潤性乳管癌	0	0	1 (0.4)	1 (0.2)
皮膚乳頭腫	1 (0.4)	0	3 (1.1)	3 (0.5)
神経系障害	18 (6.4)	22 (7.8)	25 (8.8)	47 (8.3)
健忘	0	0	1 (0.4)	1 (0.2)
注意力障害	0	1 (0.4)	0	1 (0.2)
浮動性めまい	1 (0.4)	3 (1.1)	6 (2.1)	9 (1.6)
夢幻状態	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
神経系障害 (Cont.)				
味覚不全	0	0	1 (0.4)	1 (0.2)
錐体外路障害	0	1 (0.4)	0	1 (0.2)
頭痛	12 (4.3)	14 (5.0)	19 (6.7)	33 (5.8)
感覚鈍麻	1 (0.4)	0	0	0
片頭痛	2 (0.7)	0	1 (0.4)	1 (0.2)
前兆を伴う片頭痛	0	0	1 (0.4)	1 (0.2)
錯感覚	1 (0.4)	1 (0.4)	0	1 (0.2)
坐骨神経痛	1 (0.4)	0	0	0
副鼻腔炎に伴う頭痛	1 (0.4)	0	0	0
傾眠	1 (0.4)	2 (0.7)	0	2 (0.4)
緊張性頭痛	0	1 (0.4)	1 (0.4)	2 (0.4)
精神障害	6 (2.1)	11 (3.9)	4 (1.4)	15 (2.7)
抑うつ気分を伴う適応障害	1 (0.4)	0	0	0
不安	3 (1.1)	3 (1.1)	0	3 (0.5)
無感情	0	1 (0.4)	0	1 (0.2)
注意欠陥多動性障害	0	1 (0.4)	0	1 (0.2)
抑うつ気分	1 (0.4)	0	0	0

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
精神障害 (Cont.)				
うつ病	0	0	1 (0.4)	1 (0.2)
失見当識	0	0	1 (0.4)	1 (0.2)
不眠症	0	1 (0.4)	1 (0.4)	2 (0.4)
故意の自傷行為	0	1 (0.4)	0	1 (0.2)
リビドー減退	0	1 (0.4)	0	1 (0.2)
大うつ病	0	1 (0.4)	1 (0.4)	2 (0.4)
混合性不安抑うつ障害	0	1 (0.4)	0	1 (0.2)
パニック発作	1 (0.4)	0	0	0
睡眠障害	0	1 (0.4)	0	1 (0.2)
腎および尿路障害	2 (0.7)	3 (1.1)	6 (2.1)	9 (1.6)
アルブミン尿	0	1 (0.4)	2 (0.7)	3 (0.5)
排尿困難	0	1 (0.4)	2 (0.7)	3 (0.5)
血尿	1 (0.4)	1 (0.4)	0	1 (0.2)
蛋白尿	1 (0.4)	0	2 (0.7)	2 (0.4)
生殖系および乳房障害	5 (1.8)	2 (0.7)	5 (1.8)	7 (1.2)
腺筋症	1 (0.4)	0	0	0
無月経	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
生殖系および乳房障害 (Cont.)				
乳房腫大	0	0	1 (0.4)	1 (0.2)
乳房痛	1 (0.4)	0	0	0
乳房圧痛	0	0	1 (0.4)	1 (0.2)
月経困難症	1 (0.4)	1 (0.4)	0	1 (0.2)
精巣上体嚢胞	1 (0.4)	0	0	0
線維嚢胞性乳腺疾患	1 (0.4)	0	0	0
閉経期症状	0	0	1 (0.4)	1 (0.2)
月経過多	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
不規則月経	1 (0.4)	0	0	0
外陰腟乾燥	0	0	1 (0.4)	1 (0.2)
呼吸器、胸郭および縦隔障害	17 (6.0)	17 (6.0)	21 (7.4)	38 (6.7)
窒息	1 (0.4)	0	0	0
喘息	8 (2.8)	1 (0.4)	1 (0.4)	2 (0.4)
慢性閉塞性肺疾患	1 (0.4)	0	0	0
咳嗽	5 (1.8)	7 (2.5)	6 (2.1)	13 (2.3)
呼吸困難	1 (0.4)	2 (0.7)	0	2 (0.4)
鼻出血	0	1 (0.4)	4 (1.4)	5 (0.9)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Total (N=566) n (%)
呼吸器、胸郭および縦隔障害 (Cont.)				
鼻閉	0	1 (0.4)	2 (0.7)	3 (0.5)
鼻乾燥	0	0	1 (0.4)	1 (0.2)
鼻閉塞	1 (0.4)	0	0	0
口腔咽頭痛	2 (0.7)	6 (2.1)	6 (2.1)	12 (2.1)
湿性咳嗽	0	2 (0.7)	0	2 (0.4)
アレルギー性鼻炎	1 (0.4)	0	0	0
鼻漏	0	1 (0.4)	0	1 (0.2)
副鼻腔うっ血	0	0	2 (0.7)	2 (0.4)
咽喉刺激感	0	1 (0.4)	1 (0.4)	2 (0.4)
上気道咳症候群	1 (0.4)	0	0	0
皮膚および皮下組織障害	53 (18.9)	48 (17.1)	79 (27.7)	127 (22.4)
ざ瘡	6 (2.1)	19 (6.8)	49 (17.2)	68 (12.0)
光線角化症	0	1 (0.4)	1 (0.4)	2 (0.4)
脱毛症	0	1 (0.4)	1 (0.4)	2 (0.4)
円形脱毛症	0	0	1 (0.4)	1 (0.2)
血管浮腫	0	1 (0.4)	1 (0.4)	2 (0.4)
水疱	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
皮膚および皮下組織障害 (Cont.)				
皮膚嚢腫	0	0	1 (0.4)	1 (0.2)
皮膚炎	1 (0.4)	0	2 (0.7)	2 (0.4)
ざ瘡様皮膚炎	0	2 (0.7)	6 (2.1)	8 (1.4)
アトピー性皮膚炎	26 (9.3)	9 (3.2)	4 (1.4)	13 (2.3)
接触皮膚炎	1 (0.4)	1 (0.4)	3 (1.1)	4 (0.7)
全身性剥脱性皮膚炎	1 (0.4)	0	0	0
びまん性脱毛症	0	0	1 (0.4)	1 (0.2)
異汗性湿疹	0	0	1 (0.4)	1 (0.2)
斑状出血	0	1 (0.4)	0	1 (0.2)
湿疹	4 (1.4)	2 (0.7)	0	2 (0.4)
紅斑	1 (0.4)	1 (0.4)	2 (0.7)	3 (0.5)
毛髪成長異常	0	0	1 (0.4)	1 (0.2)
逆むけ	1 (0.4)	0	0	0
多汗症	0	0	1 (0.4)	1 (0.2)
過角化	1 (0.4)	0	0	0
機械性蕁麻疹	0	0	1 (0.4)	1 (0.2)
汗疹	1 (0.4)	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
皮膚および皮下組織障害 (Cont.)				
神経皮膚炎	0	1 (0.4)	0	1 (0.2)
寝汗	0	1 (0.4)	1 (0.4)	2 (0.4)
爪破損	0	0	1 (0.4)	1 (0.2)
皮膚疼痛	1 (0.4)	0	0	0
類乾癬	0	0	1 (0.4)	1 (0.2)
口囲皮膚炎	0	1 (0.4)	0	1 (0.2)
光線過敏性反応	0	0	1 (0.4)	1 (0.2)
炎症後色素沈着変化	0	1 (0.4)	0	1 (0.2)
そう痒症	3 (1.1)	2 (0.7)	2 (0.7)	4 (0.7)
紫斑	0	0	1 (0.4)	1 (0.2)
発疹	2 (0.7)	1 (0.4)	2 (0.7)	3 (0.5)
斑状丘疹状皮疹	0	1 (0.4)	1 (0.4)	2 (0.4)
丘疹性皮疹	0	1 (0.4)	0	1 (0.2)
小水疱性皮疹	1 (0.4)	0	0	0
酒さ	1 (0.4)	0	0	0
脂漏	0	1 (0.4)	0	1 (0.2)
皮膚障害	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
皮膚および皮下組織障害 (Cont.)				
皮膚亀裂	0	1 (0.4)	0	1 (0.2)
皮膚硬結	1 (0.4)	0	0	0
皮膚腫瘤	1 (0.4)	0	0	0
皮膚局面	1 (0.4)	0	0	0
皮膚腫脹	0	1 (0.4)	0	1 (0.2)
毛細血管拡張症	0	1 (0.4)	0	1 (0.2)
蕁麻疹	2 (0.7)	2 (0.7)	5 (1.8)	7 (1.2)
外科および内科処置	0	1 (0.4)	0	1 (0.2)
収れん薬療法	0	1 (0.4)	0	1 (0.2)
血管障害	7 (2.5)	3 (1.1)	3 (1.1)	6 (1.1)
血性分泌物	0	1 (0.4)	0	1 (0.2)
本態性高血圧症	1 (0.4)	0	0	0
潮紅	0	1 (0.4)	0	1 (0.2)
血腫	0	0	1 (0.4)	1 (0.2)
ほてり	1 (0.4)	0	0	0
高血圧	5 (1.8)	1 (0.4)	2 (0.7)	3 (0.5)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.6.1.1

表 2. 二重盲検投与期で有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（二重盲検投与期の安全性解析対象集団，青少年）

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=40) n (%)	Active UPA 15 mg QD (N=42) n (%)	Active UPA 30 mg QD (N=42) n (%)	Active Total (N=84) n (%)
Any adverse event	18 (45.0)	26 (61.9)	34 (81.0)	60 (71.4)
血液およびリンパ系障害	1 (2.5)	0	4 (9.5)	4 (4.8)
白血球減少症	0	0	1 (2.4)	1 (1.2)
好中球減少症	1 (2.5)	0	3 (7.1)	3 (3.6)
血小板減少症	0	0	1 (2.4)	1 (1.2)
眼障害	0	0	1 (2.4)	1 (1.2)
霧視	0	0	1 (2.4)	1 (1.2)
胃腸障害	0	3 (7.1)	5 (11.9)	8 (9.5)
上腹部痛	0	0	1 (2.4)	1 (1.2)
齲歯	0	1 (2.4)	1 (2.4)	2 (2.4)
下痢	0	1 (2.4)	2 (4.8)	3 (3.6)
食中毒	0	0	1 (2.4)	1 (1.2)
悪心	0	1 (2.4)	1 (2.4)	2 (2.4)
嘔吐	0	0	2 (4.8)	2 (2.4)
一般・全身障害および投与部位の状態	0	4 (9.5)	2 (4.8)	6 (7.1)
無力症	0	1 (2.4)	0	1 (1.2)
インフルエンザ様疾患	0	1 (2.4)	2 (4.8)	3 (3.6)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=40) n (%)	Active UPA 15 mg QD (N=42) n (%)	Active UPA 30 mg QD (N=42) n (%)	Total (N=84) n (%)
一般・全身障害および投与部位の状態 (Cont.)				
疼痛	0	1 (2.4)	0	1 (1.2)
発熱	0	1 (2.4)	0	1 (1.2)
免疫系障害	1 (2.5)	1 (2.4)	0	1 (1.2)
薬物過敏症	1 (2.5)	0	0	0
過敏症	0	1 (2.4)	0	1 (1.2)
感染症および寄生虫症	9 (22.5)	15 (35.7)	25 (59.5)	40 (47.6)
四肢膿瘍	1 (2.5)	0	1 (2.4)	1 (1.2)
細菌感染	1 (2.5)	0	0	0
結膜炎	0	0	1 (2.4)	1 (1.2)
耳感染	0	0	3 (7.1)	3 (3.6)
感染性湿疹	1 (2.5)	0	0	0
毛包炎	0	0	1 (2.4)	1 (1.2)
胃腸炎	1 (2.5)	0	1 (2.4)	1 (1.2)
単純ヘルペス	0	1 (2.4)	1 (2.4)	2 (2.4)
帯状疱疹	0	1 (2.4)	2 (4.8)	3 (3.6)
膿痂疹	0	2 (4.8)	1 (2.4)	3 (3.6)
インフルエンザ	0	0	3 (7.1)	3 (3.6)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=40) n (%)	Active UPA 15 mg QD (N=42) n (%)	Active UPA 30 mg QD (N=42) n (%)	Active Total (N=84) n (%)
感染症および寄生虫症 (Cont.)				
上咽頭炎	1 (2.5)	3 (7.1)	5 (11.9)	8 (9.5)
乳頭感染	0	1 (2.4)	0	1 (1.2)
口腔ヘルペス	0	0	2 (4.8)	2 (2.4)
咽頭炎	0	0	1 (2.4)	1 (1.2)
咽頭扁桃炎	0	1 (2.4)	0	1 (1.2)
気道感染	0	1 (2.4)	1 (2.4)	2 (2.4)
鼻炎	0	1 (2.4)	0	1 (1.2)
副鼻腔炎	0	1 (2.4)	0	1 (1.2)
皮膚細菌感染	2 (5.0)	1 (2.4)	0	1 (1.2)
皮下組織膿瘍	0	0	1 (2.4)	1 (1.2)
上気道感染	3 (7.5)	5 (11.9)	7 (16.7)	12 (14.3)
尿路感染	1 (2.5)	1 (2.4)	0	1 (1.2)
傷害、中毒および処置合併症	0	1 (2.4)	1 (2.4)	2 (2.4)
転倒	0	0	1 (2.4)	1 (1.2)
関節損傷	0	0	1 (2.4)	1 (1.2)
交通事故	0	0	1 (2.4)	1 (1.2)
皮膚擦過傷	0	1 (2.4)	0	1 (1.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=40) n (%)	Active UPA 15 mg QD (N=42) n (%)	Active UPA 30 mg QD (N=42) n (%)	Active Total (N=84) n (%)
臨床検査	4 (10.0)	6 (14.3)	8 (19.0)	14 (16.7)
アラニンアミノトランスフェラーゼ増加	0	1 (2.4)	0	1 (1.2)
アスパラギン酸アミノトランスフェラーゼ増加	0	1 (2.4)	0	1 (1.2)
血中アルカリホスファターゼ増加	0	1 (2.4)	0	1 (1.2)
血中ビリルビン増加	0	1 (2.4)	0	1 (1.2)
血中クレアチンホスホキナーゼ増加	2 (5.0)	4 (9.5)	5 (11.9)	9 (10.7)
血中免疫グロブリン E 増加	1 (2.5)	0	0	0
ヘモグロビン減少	0	1 (2.4)	0	1 (1.2)
心拍数増加	0	0	1 (2.4)	1 (1.2)
肝酵素上昇	0	1 (2.4)	0	1 (1.2)
尿中蛋白陽性	1 (2.5)	0	0	0
尿中シュウ酸塩	0	1 (2.4)	0	1 (1.2)
体重増加	0	0	2 (4.8)	2 (2.4)
代謝および栄養障害	0	2 (4.8)	0	2 (2.4)
食欲減退	0	1 (2.4)	0	1 (1.2)
食欲亢進	0	1 (2.4)	0	1 (1.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=40) n (%)	Active UPA 15 mg QD (N=42) n (%)	Active UPA 30 mg QD (N=42) n (%)	Active Total (N=84) n (%)
筋骨格系および結合組織障害	0	1 (2.4)	1 (2.4)	2 (2.4)
関節痛	0	0	1 (2.4)	1 (1.2)
顎痛	0	1 (2.4)	0	1 (1.2)
側弯症	0	1 (2.4)	0	1 (1.2)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	1 (2.4)	1 (1.2)
皮膚乳頭腫	0	0	1 (2.4)	1 (1.2)
神経系障害	2 (5.0)	4 (9.5)	3 (7.1)	7 (8.3)
錐体外路障害	0	1 (2.4)	0	1 (1.2)
頭痛	2 (5.0)	2 (4.8)	3 (7.1)	5 (6.0)
緊張性頭痛	0	1 (2.4)	0	1 (1.2)
精神障害	1 (2.5)	4 (9.5)	0	4 (4.8)
抑うつ気分を伴う適応障害	1 (2.5)	0	0	0
不安	0	2 (4.8)	0	2 (2.4)
故意の自傷行為	0	1 (2.4)	0	1 (1.2)
大うつ病	0	1 (2.4)	0	1 (1.2)
呼吸器、胸郭および縦隔障害	1 (2.5)	3 (7.1)	3 (7.1)	6 (7.1)
咳嗽	1 (2.5)	1 (2.4)	1 (2.4)	2 (2.4)
鼻出血	0	0	1 (2.4)	1 (1.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=40) n (%)	Active UPA 15 mg QD (N=42) n (%)	Active UPA 30 mg QD (N=42) n (%)	Active Total (N=84) n (%)
呼吸器、胸郭および縦隔障害 (Cont.)				
口腔咽頭痛	0	2 (4.8)	0	2 (2.4)
湿性咳嗽	0	1 (2.4)	0	1 (1.2)
鼻漏	0	1 (2.4)	0	1 (1.2)
副鼻腔うっ血	0	0	1 (2.4)	1 (1.2)
皮膚および皮下組織障害	6 (15.0)	8 (19.0)	12 (28.6)	20 (23.8)
ざ瘡	0	6 (14.3)	9 (21.4)	15 (17.9)
円形脱毛症	0	0	1 (2.4)	1 (1.2)
アトピー性皮膚炎	2 (5.0)	1 (2.4)	0	1 (1.2)
湿疹	1 (2.5)	1 (2.4)	0	1 (1.2)
紅斑	0	0	1 (2.4)	1 (1.2)
汗疹	1 (2.5)	0	0	0
炎症後色素沈着変化	0	1 (2.4)	0	1 (1.2)
そう痒症	0	0	1 (2.4)	1 (1.2)
発疹	1 (2.5)	0	1 (2.4)	1 (1.2)
斑状丘疹状皮疹	0	0	1 (2.4)	1 (1.2)
小水疱性皮疹	1 (2.5)	0	0	0
蕁麻疹	0	1 (2.4)	1 (2.4)	2 (2.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=40) n (%)	Active UPA 15 mg QD (N=42) n (%)	Active UPA 30 mg QD (N=42) n (%)	Active Total (N=84) n (%)
外科および内科処置	0	1 (2.4)	0	1 (1.2)
収れん薬療法	0	1 (2.4)	0	1 (1.2)
血管障害	0	0	1 (2.4)	1 (1.2)
血腫	0	0	1 (2.4)	1 (1.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.6.1.2

表 3. 二重盲検投与期で有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（二重盲検投与期の安全性解析対象集団，成人）

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
Any adverse event	148 (61.4)	150 (62.8)	175 (72.0)	325 (67.4)
血液およびリンパ系障害	5 (2.1)	5 (2.1)	14 (5.8)	19 (3.9)
貧血	1 (0.4)	0	4 (1.6)	4 (0.8)
白血球増加症	1 (0.4)	0	1 (0.4)	1 (0.2)
リンパ節症	2 (0.8)	1 (0.4)	1 (0.4)	2 (0.4)
リンパ球減少症	0	1 (0.4)	1 (0.4)	2 (0.4)
好中球減少症	0	3 (1.3)	10 (4.1)	13 (2.7)
好中球増加症	1 (0.4)	0	0	0
汎血球減少症	0	0	1 (0.4)	1 (0.2)
心臓障害	0	1 (0.4)	0	1 (0.2)
心血管障害	0	1 (0.4)	0	1 (0.2)
先天性、家族性および遺伝性障害	0	0	1 (0.4)	1 (0.2)
包茎	0	0	1 (0.4)	1 (0.2)
耳および迷路障害	3 (1.2)	1 (0.4)	1 (0.4)	2 (0.4)
耳垢栓塞	0	0	1 (0.4)	1 (0.2)
外耳の炎症	1 (0.4)	0	0	0
耳鳴	1 (0.4)	0	0	0

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
耳および迷路障害 (Cont.)				
回転性めまい	0	1 (0.4)	0	1 (0.2)
頭位性回転性めまい	1 (0.4)	0	0	0
内分泌障害	2 (0.8)	0	1 (0.4)	1 (0.2)
バセドウ病	0	0	1 (0.4)	1 (0.2)
甲状腺機能亢進症	1 (0.4)	0	0	0
甲状腺機能低下症	1 (0.4)	0	0	0
眼障害	9 (3.7)	5 (2.1)	6 (2.5)	11 (2.3)
眼瞼炎	0	0	1 (0.4)	1 (0.2)
白内障	1 (0.4)	1 (0.4)	0	1 (0.2)
アレルギー性結膜炎	4 (1.7)	1 (0.4)	2 (0.8)	3 (0.6)
ドライアイ	1 (0.4)	0	1 (0.4)	1 (0.2)
眼瞼湿疹	0	0	1 (0.4)	1 (0.2)
上強膜炎	1 (0.4)	0	0	0
眼そう痒症	0	0	1 (0.4)	1 (0.2)
緑内障	0	1 (0.4)	0	1 (0.2)
流涙増加	1 (0.4)	0	0	0
黄斑変性	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
眼障害 (Cont.)				
眼窩周囲腫脹	0	1 (0.4)	0	1 (0.2)
潰瘍性角膜炎	0	1 (0.4)	0	1 (0.2)
霧視	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
視力障害	0	1 (0.4)	0	1 (0.2)
胃腸障害	22 (9.1)	31 (13.0)	37 (15.2)	68 (14.1)
腹部不快感	1 (0.4)	0	0	0
腹部膨満	0	1 (0.4)	1 (0.4)	2 (0.4)
腹痛	2 (0.8)	0	2 (0.8)	2 (0.4)
上腹部痛	2 (0.8)	2 (0.8)	3 (1.2)	5 (1.0)
口角口唇炎	0	0	1 (0.4)	1 (0.2)
肛門直腸障害	1 (0.4)	0	0	0
アフタ性潰瘍	1 (0.4)	0	0	0
呼気臭	0	0	1 (0.4)	1 (0.2)
便秘	2 (0.8)	2 (0.8)	2 (0.8)	4 (0.8)
齲歯	3 (1.2)	1 (0.4)	0	1 (0.2)
下痢	7 (2.9)	7 (2.9)	8 (3.3)	15 (3.1)
口内乾燥	0	0	3 (1.2)	3 (0.6)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Total (N=482) n (%)
胃腸障害 (Cont.)				
消化不良	0	2 (0.8)	2 (0.8)	4 (0.8)
嚥下障害	1 (0.4)	0	0	0
軟便	0	0	2 (0.8)	2 (0.4)
鼓腸	0	3 (1.3)	2 (0.8)	5 (1.0)
食中毒	0	1 (0.4)	1 (0.4)	2 (0.4)
胃潰瘍	0	1 (0.4)	1 (0.4)	2 (0.4)
胃炎	0	2 (0.8)	0	2 (0.4)
びらん性胃炎	0	0	1 (0.4)	1 (0.2)
胃食道逆流性疾患	0	1 (0.4)	4 (1.6)	5 (1.0)
歯肉痛	0	0	1 (0.4)	1 (0.2)
血便排泄	1 (0.4)	0	0	0
痔核	0	0	1 (0.4)	1 (0.2)
歯の知覚過敏	0	0	1 (0.4)	1 (0.2)
悪心	2 (0.8)	9 (3.8)	9 (3.7)	18 (3.7)
歯の障害	1 (0.4)	0	0	0
埋伏歯	0	1 (0.4)	0	1 (0.2)
歯痛	1 (0.4)	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
胃腸障害 (Cont.)				
嘔吐	1 (0.4)	2 (0.8)	4 (1.6)	6 (1.2)
一般・全身障害および投与部位の状態	12 (5.0)	13 (5.4)	19 (7.8)	32 (6.6)
無力症	1 (0.4)	0	1 (0.4)	1 (0.2)
胸部不快感	0	1 (0.4)	1 (0.4)	2 (0.4)
胸痛	1 (0.4)	1 (0.4)	0	1 (0.2)
悪寒	0	0	1 (0.4)	1 (0.2)
不快感	1 (0.4)	0	1 (0.4)	1 (0.2)
薬物不耐性	0	0	1 (0.4)	1 (0.2)
顔面浮腫	0	0	1 (0.4)	1 (0.2)
疲労	3 (1.2)	3 (1.3)	3 (1.2)	6 (1.2)
びくびく感	0	0	1 (0.4)	1 (0.2)
インフルエンザ様疾患	3 (1.2)	4 (1.7)	4 (1.6)	8 (1.7)
倦怠感	1 (0.4)	0	0	0
腫瘤	0	1 (0.4)	0	1 (0.2)
粘膜乾燥	0	0	1 (0.4)	1 (0.2)
非心臓性胸痛	0	0	1 (0.4)	1 (0.2)
浮腫	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
一般・全身障害および投与部位の状態 (Cont.)				
末梢性浮腫	1 (0.4)	0	1 (0.4)	1 (0.2)
疼痛	0	0	1 (0.4)	1 (0.2)
発熱	3 (1.2)	4 (1.7)	4 (1.6)	8 (1.7)
腫脹	0	1 (0.4)	0	1 (0.2)
血管穿刺部位内出血	0	0	1 (0.4)	1 (0.2)
肝胆道系障害	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
胆石症	1 (0.4)	1 (0.4)	0	1 (0.2)
脂肪肝	0	0	1 (0.4)	1 (0.2)
免疫系障害	3 (1.2)	2 (0.8)	2 (0.8)	4 (0.8)
アナフィラキシー反応	0	0	1 (0.4)	1 (0.2)
アナフィラキシーショック	1 (0.4)	0	0	0
薬物過敏症	1 (0.4)	0	0	0
食物アレルギー	0	1 (0.4)	0	1 (0.2)
過敏症	0	1 (0.4)	0	1 (0.2)
季節性アレルギー	1 (0.4)	0	0	0
1 型過敏症	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
感染症および寄生虫症	68 (28.2)	93 (38.9)	117 (48.1)	210 (43.6)
膿疱性ざ瘡	0	1 (0.4)	0	1 (0.2)
虫垂炎	0	1 (0.4)	0	1 (0.2)
細菌感染	1 (0.4)	0	0	0
細菌性膣症	0	0	1 (0.4)	1 (0.2)
細菌尿	0	0	1 (0.4)	1 (0.2)
体部白癬	0	2 (0.8)	0	2 (0.4)
気管支炎	0	2 (0.8)	2 (0.8)	4 (0.8)
蜂巣炎	2 (0.8)	2 (0.8)	1 (0.4)	3 (0.6)
結膜炎	5 (2.1)	0	3 (1.2)	3 (0.6)
膀胱炎	1 (0.4)	0	0	0
感染性皮膚炎	0	1 (0.4)	0	1 (0.2)
皮膚糸状菌症	0	0	1 (0.4)	1 (0.2)
爪の皮膚糸状菌症	0	1 (0.4)	0	1 (0.2)
耳感染	2 (0.8)	0	3 (1.2)	3 (0.6)
膿瘡	0	1 (0.4)	0	1 (0.2)
ヘルペス性状湿疹	2 (0.8)	0	2 (0.8)	2 (0.4)
膿痂疹性湿疹	1 (0.4)	0	0	0

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
感染症および寄生虫症 (Cont.)				
丹毒	1 (0.4)	0	0	0
眼感染	0	1 (0.4)	0	1 (0.2)
毛包炎	5 (2.1)	4 (1.7)	7 (2.9)	11 (2.3)
せつ	0	2 (0.8)	0	2 (0.4)
胃腸炎	3 (1.2)	0	5 (2.1)	5 (1.0)
ウイルス性胃腸炎	0	1 (0.4)	1 (0.4)	2 (0.4)
ウイルス性消化管感染	0	0	1 (0.4)	1 (0.2)
陰部ヘルペス	1 (0.4)	1 (0.4)	0	1 (0.2)
陰部単純ヘルペス	0	0	2 (0.8)	2 (0.4)
蠕虫感染	0	0	1 (0.4)	1 (0.2)
ヘルパンギーナ	0	0	1 (0.4)	1 (0.2)
ヘルペス性皮膚炎	0	0	1 (0.4)	1 (0.2)
単純ヘルペス	3 (1.2)	5 (2.1)	6 (2.5)	11 (2.3)
ヘルペスウイルス感染	0	1 (0.4)	1 (0.4)	2 (0.4)
帯状疱疹	0	4 (1.7)	4 (1.6)	8 (1.7)
麦粒腫	1 (0.4)	0	5 (2.1)	5 (1.0)
膿痂疹	6 (2.5)	3 (1.3)	2 (0.8)	5 (1.0)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
感染症および寄生虫症 (Cont.)				
感染性嚢腫	1 (0.4)	0	0	0
感染性皮膚嚢腫	1 (0.4)	0	0	0
感染	1 (0.4)	0	0	0
インフルエンザ	0	3 (1.3)	2 (0.8)	5 (1.0)
カポジ水痘様発疹	2 (0.8)	0	1 (0.4)	1 (0.2)
喉頭炎	0	0	1 (0.4)	1 (0.2)
ウイルス性喉頭炎	0	1 (0.4)	0	1 (0.2)
限局性感染	1 (0.4)	0	0	0
下気道感染	0	1 (0.4)	0	1 (0.2)
伝染性軟属腫	0	1 (0.4)	1 (0.4)	2 (0.4)
上咽頭炎	15 (6.2)	19 (7.9)	28 (11.5)	47 (9.8)
眼部単純ヘルペス	0	1 (0.4)	1 (0.4)	2 (0.4)
口腔カンジダ症	0	0	3 (1.2)	3 (0.6)
口腔ヘルペス	3 (1.2)	5 (2.1)	12 (4.9)	17 (3.5)
中耳炎	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
急性中耳炎	0	0	1 (0.4)	1 (0.2)
爪囲炎	2 (0.8)	0	0	0

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Total (N=482) n (%)
感染症および寄生虫症 (Cont.)				
歯周炎	0	1 (0.4)	0	1 (0.2)
咽頭膿瘍	0	0	1 (0.4)	1 (0.2)
咽頭炎	0	1 (0.4)	1 (0.4)	2 (0.4)
肺炎	0	1 (0.4)	0	1 (0.2)
ブドウ球菌性肺炎	0	0	1 (0.4)	1 (0.2)
膿疱	1 (0.4)	0	1 (0.4)	1 (0.2)
膿皮症	0	1 (0.4)	0	1 (0.2)
膿疱性皮疹	0	1 (0.4)	0	1 (0.2)
気道感染	0	1 (0.4)	1 (0.4)	2 (0.4)
ウイルス性気道感染	0	1 (0.4)	0	1 (0.2)
鼻炎	0	0	2 (0.8)	2 (0.4)
ライノウイルス感染	0	0	1 (0.4)	1 (0.2)
副鼻腔炎	3 (1.2)	3 (1.3)	1 (0.4)	4 (0.8)
皮膚細菌感染	2 (0.8)	1 (0.4)	1 (0.4)	2 (0.4)
皮膚カンジダ	0	1 (0.4)	1 (0.4)	2 (0.4)
皮膚感染	2 (0.8)	2 (0.8)	3 (1.2)	5 (1.0)
ブドウ球菌感染	0	0	2 (0.8)	2 (0.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
感染症および寄生虫症 (Cont.)				
ブドウ球菌皮膚感染	0	1 (0.4)	0	1 (0.2)
皮下組織膿瘍	0	1 (0.4)	0	1 (0.2)
細菌重複感染	0	1 (0.4)	0	1 (0.2)
股部白癬	0	0	2 (0.8)	2 (0.4)
足部白癬	0	1 (0.4)	0	1 (0.2)
癜風	0	2 (0.8)	0	2 (0.4)
扁桃炎	1 (0.4)	2 (0.8)	1 (0.4)	3 (0.6)
細菌性扁桃炎	0	0	1 (0.4)	1 (0.2)
歯膿瘍	0	1 (0.4)	2 (0.8)	3 (0.6)
歯感染	1 (0.4)	0	1 (0.4)	1 (0.2)
上気道感染	17 (7.1)	20 (8.4)	31 (12.8)	51 (10.6)
クラミジア性尿道炎	0	1 (0.4)	0	1 (0.2)
尿路感染	2 (0.8)	3 (1.3)	6 (2.5)	9 (1.9)
水痘	0	0	1 (0.4)	1 (0.2)
ウイルス感染	2 (0.8)	1 (0.4)	0	1 (0.2)
ウイルス性咽頭炎	0	1 (0.4)	0	1 (0.2)
ウイルス性発疹	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
感染症および寄生虫症 (Cont.)				
ウイルス性上気道感染	2 (0.8)	5 (2.1)	5 (2.1)	10 (2.1)
外陰部腟カンジダ症	1 (0.4)	2 (0.8)	2 (0.8)	4 (0.8)
外陰腟真菌感染	1 (0.4)	1 (0.4)	0	1 (0.2)
創傷感染	0	0	1 (0.4)	1 (0.2)
ブドウ球菌性創感染	0	0	1 (0.4)	1 (0.2)
傷害、中毒および処置合併症	6 (2.5)	13 (5.4)	8 (3.3)	21 (4.4)
節足動物咬傷	0	1 (0.4)	1 (0.4)	2 (0.4)
節足動物刺傷	0	0	1 (0.4)	1 (0.2)
背部損傷	0	1 (0.4)	0	1 (0.2)
第２度熱傷	0	1 (0.4)	0	1 (0.2)
軟骨損傷	0	1 (0.4)	0	1 (0.2)
挫傷	0	1 (0.4)	0	1 (0.2)
転倒	1 (0.4)	2 (0.8)	0	2 (0.4)
足骨折	0	1 (0.4)	1 (0.4)	2 (0.4)
損傷	1 (0.4)	1 (0.4)	0	1 (0.2)
関節脱臼	0	1 (0.4)	0	1 (0.2)
靭帯捻挫	1 (0.4)	2 (0.8)	0	2 (0.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
傷害、中毒および処置合併症 (Cont.)				
四肢損傷	0	2 (0.8)	0	2 (0.4)
肉離れ	0	0	2 (0.8)	2 (0.4)
交通事故	0	1 (0.4)	0	1 (0.2)
皮膚擦過傷	0	0	1 (0.4)	1 (0.2)
皮膚裂傷	1 (0.4)	0	0	0
軟部組織損傷	1 (0.4)	0	0	0
サンバーン	0	0	1 (0.4)	1 (0.2)
腱断裂	1 (0.4)	1 (0.4)	0	1 (0.2)
上肢骨折	0	1 (0.4)	0	1 (0.2)
ワクチン接種合併症	0	0	1 (0.4)	1 (0.2)
臨床検査	14 (5.8)	26 (10.9)	31 (12.8)	57 (11.8)
アラニンアミノトランスフェラーゼ増加	2 (0.8)	1 (0.4)	5 (2.1)	6 (1.2)
アスパラギン酸アミノトランスフェラーゼ増加	0	1 (0.4)	4 (1.6)	5 (1.0)
B リンパ球数増加	0	1 (0.4)	0	1 (0.2)
血中コレステロール増加	0	2 (0.8)	2 (0.8)	4 (0.8)
血中クレアチンホスホキナーゼ増加	5 (2.1)	12 (5.0)	11 (4.5)	23 (4.8)
血中クレアチニン増加	0	2 (0.8)	0	2 (0.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
臨床検査 (Cont.)				
血中ブドウ糖増加	1 (0.4)	0	0	0
血中免疫グロブリン E 増加	2 (0.8)	3 (1.3)	0	3 (0.6)
血中カリウム増加	0	1 (0.4)	0	1 (0.2)
血圧上昇	0	1 (0.4)	0	1 (0.2)
血中ナトリウム増加	1 (0.4)	0	0	0
血中尿酸増加	1 (0.4)	0	1 (0.4)	1 (0.2)
尿中血陽性	0	1 (0.4)	0	1 (0.2)
CD4 リンパ球減少	0	1 (0.4)	0	1 (0.2)
CD8 リンパ球百分率減少	0	1 (0.4)	0	1 (0.2)
CD8 リンパ球減少	1 (0.4)	0	1 (0.4)	1 (0.2)
CD8 リンパ球増加	1 (0.4)	0	0	0
心雑音	0	0	1 (0.4)	1 (0.2)
尿中結晶陽性	0	0	1 (0.4)	1 (0.2)
好酸球百分率増加	0	1 (0.4)	0	1 (0.2)
ヘモグロビン減少	0	0	1 (0.4)	1 (0.2)
リンパ球数減少	1 (0.4)	0	0	0
ナチュラルキラー細胞数減少	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
臨床検査 (Cont.)				
好中球数減少	1 (0.4)	1 (0.4)	2 (0.8)	3 (0.6)
好中球数増加	1 (0.4)	0	0	0
尿蛋白	0	1 (0.4)	0	1 (0.2)
尿中蛋白陽性	1 (0.4)	0	1 (0.4)	1 (0.2)
T リンパ球数減少	1 (0.4)	1 (0.4)	0	1 (0.2)
トランスアミナーゼ上昇	0	0	1 (0.4)	1 (0.2)
尿中白血球エステラーゼ陽性	0	0	1 (0.4)	1 (0.2)
体重減少	0	0	2 (0.8)	2 (0.4)
体重増加	0	5 (2.1)	7 (2.9)	12 (2.5)
白血球数減少	1 (0.4)	0	2 (0.8)	2 (0.4)
尿中白血球陽性	1 (0.4)	0	0	0
代謝および栄養障害	6 (2.5)	7 (2.9)	12 (4.9)	19 (3.9)
食欲減退	2 (0.8)	1 (0.4)	2 (0.8)	3 (0.6)
脂質異常症	0	0	1 (0.4)	1 (0.2)
痛風	0	0	1 (0.4)	1 (0.2)
高コレステロール血症	0	1 (0.4)	2 (0.8)	3 (0.6)
高血糖	1 (0.4)	0	0	0

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
代謝および栄養障害 (Cont.)				
高脂血症	0	1 (0.4)	1 (0.4)	2 (0.4)
高トリグリセリド血症	0	2 (0.8)	1 (0.4)	3 (0.6)
高尿酸血症	3 (1.2)	1 (0.4)	1 (0.4)	2 (0.4)
低血糖	0	0	1 (0.4)	1 (0.2)
低カリウム血症	0	0	2 (0.8)	2 (0.4)
低リン酸血症	0	1 (0.4)	0	1 (0.2)
食欲亢進	0	0	1 (0.4)	1 (0.2)
筋骨格系および結合組織障害	22 (9.1)	13 (5.4)	18 (7.4)	31 (6.4)
関節痛	3 (1.2)	3 (1.3)	3 (1.2)	6 (1.2)
腋窩腫瘤	0	0	1 (0.4)	1 (0.2)
背部痛	9 (3.7)	2 (0.8)	7 (2.9)	9 (1.9)
滑液包炎	0	1 (0.4)	0	1 (0.2)
側腹部痛	0	1 (0.4)	0	1 (0.2)
単径部痛	1 (0.4)	0	0	0
筋痙縮	1 (0.4)	0	0	0
筋緊張	1 (0.4)	0	0	0
筋骨格痛	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
筋骨格系および結合組織障害 (Cont.)				
筋骨格硬直	1 (0.4)	0	0	0
筋肉痛	2 (0.8)	4 (1.7)	5 (2.1)	9 (1.9)
頚部痛	2 (0.8)	1 (0.4)	0	1 (0.2)
四肢痛	2 (0.8)	0	2 (0.8)	2 (0.4)
顎痛	0	0	1 (0.4)	1 (0.2)
肩回旋筋腱板症候群	1 (0.4)	0	0	0
変形性脊椎症	1 (0.4)	0	0	0
腱障害	0	1 (0.4)	0	1 (0.2)
腱炎	0	0	1 (0.4)	1 (0.2)
弾発指	1 (0.4)	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (0.4)	1 (0.4)	5 (2.1)	6 (1.2)
ボーエン病	0	1 (0.4)	0	1 (0.2)
真珠腫	0	0	1 (0.4)	1 (0.2)
胃癌	0	0	1 (0.4)	1 (0.2)
浸潤性乳管癌	0	0	1 (0.4)	1 (0.2)
皮膚乳頭腫	1 (0.4)	0	2 (0.8)	2 (0.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
神経系障害	16 (6.6)	18 (7.5)	22 (9.1)	40 (8.3)
健忘	0	0	1 (0.4)	1 (0.2)
注意力障害	0	1 (0.4)	0	1 (0.2)
浮動性めまい	1 (0.4)	3 (1.3)	6 (2.5)	9 (1.9)
夢幻状態	0	1 (0.4)	0	1 (0.2)
味覚不全	0	0	1 (0.4)	1 (0.2)
頭痛	10 (4.1)	12 (5.0)	16 (6.6)	28 (5.8)
感覚鈍麻	1 (0.4)	0	0	0
片頭痛	2 (0.8)	0	1 (0.4)	1 (0.2)
前兆を伴う片頭痛	0	0	1 (0.4)	1 (0.2)
錯感覚	1 (0.4)	1 (0.4)	0	1 (0.2)
坐骨神経痛	1 (0.4)	0	0	0
副鼻腔炎に伴う頭痛	1 (0.4)	0	0	0
傾眠	1 (0.4)	2 (0.8)	0	2 (0.4)
緊張性頭痛	0	0	1 (0.4)	1 (0.2)
精神障害	5 (2.1)	7 (2.9)	4 (1.6)	11 (2.3)
不安	3 (1.2)	1 (0.4)	0	1 (0.2)
無感情	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
精神障害 (Cont.)				
注意欠陥多動性障害	0	1 (0.4)	0	1 (0.2)
抑うつ気分	1 (0.4)	0	0	0
うつ病	0	0	1 (0.4)	1 (0.2)
失見当識	0	0	1 (0.4)	1 (0.2)
不眠症	0	1 (0.4)	1 (0.4)	2 (0.4)
リビドー減退	0	1 (0.4)	0	1 (0.2)
大うつ病	0	0	1 (0.4)	1 (0.2)
混合性不安抑うつ障害	0	1 (0.4)	0	1 (0.2)
パニック発作	1 (0.4)	0	0	0
睡眠障害	0	1 (0.4)	0	1 (0.2)
腎および尿路障害	2 (0.8)	3 (1.3)	6 (2.5)	9 (1.9)
アルブミン尿	0	1 (0.4)	2 (0.8)	3 (0.6)
排尿困難	0	1 (0.4)	2 (0.8)	3 (0.6)
血尿	1 (0.4)	1 (0.4)	0	1 (0.2)
蛋白尿	1 (0.4)	0	2 (0.8)	2 (0.4)
生殖系および乳房障害	5 (2.1)	2 (0.8)	5 (2.1)	7 (1.5)
腺筋症	1 (0.4)	0	0	0

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
生殖系および乳房障害 (Cont.)				
無月経	0	0	1 (0.4)	1 (0.2)
乳房腫大	0	0	1 (0.4)	1 (0.2)
乳房痛	1 (0.4)	0	0	0
乳房圧痛	0	0	1 (0.4)	1 (0.2)
月経困難症	1 (0.4)	1 (0.4)	0	1 (0.2)
精巣上体嚢胞	1 (0.4)	0	0	0
線維嚢胞性乳腺疾患	1 (0.4)	0	0	0
閉経期症状	0	0	1 (0.4)	1 (0.2)
月経過多	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
不規則月経	1 (0.4)	0	0	0
外陰腟乾燥	0	0	1 (0.4)	1 (0.2)
呼吸器、胸郭および縦隔障害	16 (6.6)	14 (5.9)	18 (7.4)	32 (6.6)
窒息	1 (0.4)	0	0	0
喘息	8 (3.3)	1 (0.4)	1 (0.4)	2 (0.4)
慢性閉塞性肺疾患	1 (0.4)	0	0	0
咳嗽	4 (1.7)	6 (2.5)	5 (2.1)	11 (2.3)
呼吸困難	1 (0.4)	2 (0.8)	0	2 (0.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
呼吸器、胸郭および縦隔障害 (Cont.)				
鼻出血	0	1 (0.4)	3 (1.2)	4 (0.8)
鼻閉	0	1 (0.4)	2 (0.8)	3 (0.6)
鼻乾燥	0	0	1 (0.4)	1 (0.2)
鼻閉塞	1 (0.4)	0	0	0
口腔咽頭痛	2 (0.8)	4 (1.7)	6 (2.5)	10 (2.1)
湿性咳嗽	0	1 (0.4)	0	1 (0.2)
アレルギー性鼻炎	1 (0.4)	0	0	0
副鼻腔うっ血	0	0	1 (0.4)	1 (0.2)
咽喉刺激感	0	1 (0.4)	1 (0.4)	2 (0.4)
上気道咳症候群	1 (0.4)	0	0	0
皮膚および皮下組織障害	47 (19.5)	40 (16.7)	67 (27.6)	107 (22.2)
ざ瘡	6 (2.5)	13 (5.4)	40 (16.5)	53 (11.0)
光線角化症	0	1 (0.4)	1 (0.4)	2 (0.4)
脱毛症	0	1 (0.4)	1 (0.4)	2 (0.4)
血管浮腫	0	1 (0.4)	1 (0.4)	2 (0.4)
水疱	0	1 (0.4)	0	1 (0.2)
皮膚嚢腫	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
皮膚および皮下組織障害 (Cont.)				
皮膚炎	1 (0.4)	0	2 (0.8)	2 (0.4)
ざ瘡様皮膚炎	0	2 (0.8)	6 (2.5)	8 (1.7)
アトピー性皮膚炎	24 (10.0)	8 (3.3)	4 (1.6)	12 (2.5)
接触皮膚炎	1 (0.4)	1 (0.4)	3 (1.2)	4 (0.8)
全身性剥脱性皮膚炎	1 (0.4)	0	0	0
びまん性脱毛症	0	0	1 (0.4)	1 (0.2)
異汗性湿疹	0	0	1 (0.4)	1 (0.2)
斑状出血	0	1 (0.4)	0	1 (0.2)
湿疹	3 (1.2)	1 (0.4)	0	1 (0.2)
紅斑	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
毛髪成長異常	0	0	1 (0.4)	1 (0.2)
逆むけ	1 (0.4)	0	0	0
多汗症	0	0	1 (0.4)	1 (0.2)
過角化	1 (0.4)	0	0	0
機械性蕁麻疹	0	0	1 (0.4)	1 (0.2)
汗疹	0	1 (0.4)	0	1 (0.2)
神経皮膚炎	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
皮膚および皮下組織障害 (Cont.)				
寝汗	0	1 (0.4)	1 (0.4)	2 (0.4)
爪破損	0	0	1 (0.4)	1 (0.2)
皮膚疼痛	1 (0.4)	0	0	0
類乾癬	0	0	1 (0.4)	1 (0.2)
口囲皮膚炎	0	1 (0.4)	0	1 (0.2)
光線過敏性反応	0	0	1 (0.4)	1 (0.2)
そう痒症	3 (1.2)	2 (0.8)	1 (0.4)	3 (0.6)
紫斑	0	0	1 (0.4)	1 (0.2)
発疹	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
斑状丘疹状皮疹	0	1 (0.4)	0	1 (0.2)
丘疹性皮疹	0	1 (0.4)	0	1 (0.2)
酒さ	1 (0.4)	0	0	0
脂漏	0	1 (0.4)	0	1 (0.2)
皮膚障害	0	0	1 (0.4)	1 (0.2)
皮膚亀裂	0	1 (0.4)	0	1 (0.2)
皮膚硬結	1 (0.4)	0	0	0
皮膚腫瘤	1 (0.4)	0	0	0

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=241) n (%)	Active UPA 15 mg QD (N=239) n (%)	Active UPA 30 mg QD (N=243) n (%)	Active Total (N=482) n (%)
皮膚および皮下組織障害 (Cont.)				
皮膚局面	1 (0.4)	0	0	0
皮膚腫脹	0	1 (0.4)	0	1 (0.2)
毛細血管拡張症	0	1 (0.4)	0	1 (0.2)
蕁麻疹	2 (0.8)	1 (0.4)	4 (1.6)	5 (1.0)
血管障害	7 (2.9)	3 (1.3)	2 (0.8)	5 (1.0)
血性分泌物	0	1 (0.4)	0	1 (0.2)
本態性高血圧症	1 (0.4)	0	0	0
潮紅	0	1 (0.4)	0	1 (0.2)
ほてり	1 (0.4)	0	0	0
高血圧	5 (2.1)	1 (0.4)	2 (0.8)	3 (0.6)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.6.1.3

表 4. ウパダシチニブ投与期間中で有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
Any adverse event	267 (67.1)	306 (75.4)	573 (71.3)
血液およびリンパ系障害	12 (3.0)	20 (4.9)	32 (4.0)
貧血	0	5 (1.2)	5 (0.6)
白血球増加症	1 (0.3)	1 (0.2)	2 (0.2)
白血球減少症	0	1 (0.2)	1 (0.1)
リンパ節症	3 (0.8)	2 (0.5)	5 (0.6)
リンパ球減少症	1 (0.3)	1 (0.2)	2 (0.2)
好中球減少症	7 (1.8)	13 (3.2)	20 (2.5)
好中球増加症	2 (0.5)	0	2 (0.2)
汎血球減少症	0	1 (0.2)	1 (0.1)
血小板減少症	0	1 (0.2)	1 (0.1)
心臓障害	1 (0.3)	3 (0.7)	4 (0.5)
心房細動	0	1 (0.2)	1 (0.1)
徐脈	0	1 (0.2)	1 (0.1)
心血管障害	1 (0.3)	0	1 (0.1)
冠動脈疾患	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
先天性、家族性および遺伝性障害	0	1 (0.2)	1 (0.1)
包茎	0	1 (0.2)	1 (0.1)
耳および迷路障害	2 (0.5)	6 (1.5)	8 (1.0)
耳垢栓塞	0	2 (0.5)	2 (0.2)
突発性難聴	0	1 (0.2)	1 (0.1)
鼓膜障害	0	1 (0.2)	1 (0.1)
回転性めまい	2 (0.5)	2 (0.5)	4 (0.5)
内分泌障害	1 (0.3)	2 (0.5)	3 (0.4)
バセドウ病	0	1 (0.2)	1 (0.1)
甲状腺機能低下症	1 (0.3)	0	1 (0.1)
甲状腺腫瘤	0	1 (0.2)	1 (0.1)
眼障害	8 (2.0)	14 (3.4)	22 (2.7)
眼瞼炎	0	2 (0.5)	2 (0.2)
白内障	1 (0.3)	0	1 (0.1)
結膜出血	0	1 (0.2)	1 (0.1)
アレルギー性結膜炎	1 (0.3)	2 (0.5)	3 (0.4)
ドライアイ	1 (0.3)	2 (0.5)	3 (0.4)
眼瞼湿疹	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of
upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
眼障害 (Cont.)			
眼そう痒症	0	1 (0.2)	1 (0.1)
眼部腫脹	0	1 (0.2)	1 (0.1)
緑内障	1 (0.3)	0	1 (0.1)
流涙増加	1 (0.3)	1 (0.2)	2 (0.2)
黄斑変性	1 (0.3)	0	1 (0.1)
眼窩周囲腫脹	1 (0.3)	1 (0.2)	2 (0.2)
網膜剥離	1 (0.3)	0	1 (0.1)
潰瘍性角膜炎	1 (0.3)	0	1 (0.1)
霧視	1 (0.3)	3 (0.7)	4 (0.5)
視力障害	1 (0.3)	0	1 (0.1)
胃腸障害	44 (11.1)	61 (15.0)	105 (13.1)
腹部不快感	1 (0.3)	1 (0.2)	2 (0.2)
腹部膨満	1 (0.3)	1 (0.2)	2 (0.2)
腹痛	1 (0.3)	6 (1.5)	7 (0.9)
上腹部痛	4 (1.0)	5 (1.2)	9 (1.1)
口角口唇炎	0	1 (0.2)	1 (0.1)
呼気臭	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
胃腸障害 (Cont.)			
便秘	3 (0.8)	2 (0.5)	5 (0.6)
齲歯	2 (0.5)	3 (0.7)	5 (0.6)
下痢	12 (3.0)	14 (3.4)	26 (3.2)
腸憩室	1 (0.3)	0	1 (0.1)
口内乾燥	0	3 (0.7)	3 (0.4)
消化不良	2 (0.5)	2 (0.5)	4 (0.5)
軟便	0	2 (0.5)	2 (0.2)
鼓腸	3 (0.8)	2 (0.5)	5 (0.6)
食中毒	1 (0.3)	2 (0.5)	3 (0.4)
胃潰瘍	1 (0.3)	1 (0.2)	2 (0.2)
胃炎	4 (1.0)	0	4 (0.5)
びらん性胃炎	0	1 (0.2)	1 (0.1)
消化器痛	1 (0.3)	0	1 (0.1)
胃食道逆流性疾患	1 (0.3)	5 (1.2)	6 (0.7)
歯肉痛	0	1 (0.2)	1 (0.1)
痔核	0	2 (0.5)	2 (0.2)
歯の知覚過敏	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
胃腸障害 (Cont.)			
過敏性腸症候群	0	1 (0.2)	1 (0.1)
口唇腫脹	0	1 (0.2)	1 (0.1)
口腔内潰瘍形成	0	1 (0.2)	1 (0.1)
悪心	12 (3.0)	14 (3.4)	26 (3.2)
食道狭窄	1 (0.3)	0	1 (0.1)
大網壊死	0	1 (0.2)	1 (0.1)
口腔障害	0	1 (0.2)	1 (0.1)
膵炎	0	1 (0.2)	1 (0.1)
埋伏歯	1 (0.3)	0	1 (0.1)
歯痛	1 (0.3)	2 (0.5)	3 (0.4)
嘔吐	4 (1.0)	8 (2.0)	12 (1.5)
一般・全身障害および投与部位の状態	31 (7.8)	30 (7.4)	61 (7.6)
無力症	1 (0.3)	1 (0.2)	2 (0.2)
胸部不快感	1 (0.3)	1 (0.2)	2 (0.2)
胸痛	1 (0.3)	0	1 (0.1)
悪寒	0	2 (0.5)	2 (0.2)
嚢胞	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
一般・全身障害および投与部位の状態 (Cont.)			
不快感	0	1 (0.2)	1 (0.1)
薬物不耐性	0	1 (0.2)	1 (0.1)
顔面浮腫	1 (0.3)	1 (0.2)	2 (0.2)
疲労	4 (1.0)	3 (0.7)	7 (0.9)
びくびく感	0	1 (0.2)	1 (0.1)
インフルエンザ様疾患	7 (1.8)	10 (2.5)	17 (2.1)
倦怠感	0	1 (0.2)	1 (0.1)
腫瘤	1 (0.3)	0	1 (0.1)
粘膜乾燥	0	1 (0.2)	1 (0.1)
小結節	0	1 (0.2)	1 (0.1)
非心臓性胸痛	0	1 (0.2)	1 (0.1)
浮腫	0	1 (0.2)	1 (0.1)
末梢性浮腫	1 (0.3)	1 (0.2)	2 (0.2)
疼痛	2 (0.5)	2 (0.5)	4 (0.5)
発熱	12 (3.0)	7 (1.7)	19 (2.4)
腫脹	1 (0.3)	0	1 (0.1)
顔面腫脹	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
一般・全身障害および投与部位の状態 (Cont.)			
血管穿刺部位内出血	0	1 (0.2)	1 (0.1)
肝胆道系障害	2 (0.5)	6 (1.5)	8 (1.0)
胆嚢炎	0	1 (0.2)	1 (0.1)
胆石症	1 (0.3)	0	1 (0.1)
胆嚢ポリープ	0	1 (0.2)	1 (0.1)
肝機能異常	1 (0.3)	0	1 (0.1)
脂肪肝	0	3 (0.7)	3 (0.4)
肝腫大	0	1 (0.2)	1 (0.1)
免疫系障害	6 (1.5)	6 (1.5)	12 (1.5)
化学物質アレルギー	1 (0.3)	0	1 (0.1)
ワクチンアレルギー	1 (0.3)	0	1 (0.1)
アナフィラキシー反応	0	2 (0.5)	2 (0.2)
薬物過敏症	0	1 (0.2)	1 (0.1)
食物アレルギー	2 (0.5)	1 (0.2)	3 (0.4)
過敏症	2 (0.5)	0	2 (0.2)
乳アレルギー	0	1 (0.2)	1 (0.1)
1 型過敏症	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症	189 (47.5)	215 (53.0)	404 (50.2)
四肢膿瘍	0	1 (0.2)	1 (0.1)
ダニ皮膚炎	1 (0.3)	1 (0.2)	2 (0.2)
膿疱性ざ瘡	1 (0.3)	0	1 (0.1)
虫垂炎	2 (0.5)	0	2 (0.2)
細菌感染	1 (0.3)	1 (0.2)	2 (0.2)
細菌性膣症	0	2 (0.5)	2 (0.2)
細菌尿	0	1 (0.2)	1 (0.1)
体部白癬	3 (0.8)	2 (0.5)	5 (0.6)
気管支炎	6 (1.5)	10 (2.5)	16 (2.0)
ウイルス性気管支炎	1 (0.3)	0	1 (0.1)
カンジダ感染	1 (0.3)	0	1 (0.1)
蜂巣炎	3 (0.8)	2 (0.5)	5 (0.6)
結膜炎	3 (0.8)	7 (1.7)	10 (1.2)
コロナウイルス感染	1 (0.3)	1 (0.2)	2 (0.2)
感染性クループ	1 (0.3)	0	1 (0.1)
膀胱炎	0	2 (0.5)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
感染性皮膚炎	1 (0.3)	0	1 (0.1)
皮膚糸状菌症	1 (0.3)	1 (0.2)	2 (0.2)
爪の皮膚糸状菌症	1 (0.3)	0	1 (0.1)
憩室炎	0	1 (0.2)	1 (0.1)
耳感染	2 (0.5)	9 (2.2)	11 (1.4)
膿瘡	2 (0.5)	0	2 (0.2)
ヘルペス性状湿疹	1 (0.3)	2 (0.5)	3 (0.4)
感染性湿疹	0	1 (0.2)	1 (0.1)
丹毒	0	1 (0.2)	1 (0.1)
大腸菌性尿路感染	0	1 (0.2)	1 (0.1)
外耳蜂巣炎	1 (0.3)	0	1 (0.1)
眼感染	1 (0.3)	0	1 (0.1)
毛包炎	7 (1.8)	16 (3.9)	23 (2.9)
真菌感染	2 (0.5)	0	2 (0.2)
せつ	3 (0.8)	3 (0.7)	6 (0.7)
胃腸炎	4 (1.0)	12 (3.0)	16 (2.0)
ウイルス性胃腸炎	1 (0.3)	2 (0.5)	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
ウイルス性消化管感染	0	1 (0.2)	1 (0.1)
陰部ヘルペス	2 (0.5)	0	2 (0.2)
陰部単純ヘルペス	0	2 (0.5)	2 (0.2)
手足口病	1 (0.3)	0	1 (0.1)
蠕虫感染	0	1 (0.2)	1 (0.1)
B 型肝炎	0	1 (0.2)	1 (0.1)
ヘルパンギーナ	0	1 (0.2)	1 (0.1)
ヘルペス性皮膚炎	0	2 (0.5)	2 (0.2)
ヘルペス眼感染	0	2 (0.5)	2 (0.2)
単純ヘルペス	11 (2.8)	15 (3.7)	26 (3.2)
ヘルペスウイルス感染	2 (0.5)	1 (0.2)	3 (0.4)
帯状疱疹	8 (2.0)	11 (2.7)	19 (2.4)
麦粒腫	4 (1.0)	8 (2.0)	12 (1.5)
膿痂疹	10 (2.5)	6 (1.5)	16 (2.0)
インフルエンザ	3 (0.8)	9 (2.2)	12 (1.5)
椎間板炎	1 (0.3)	0	1 (0.1)
カポジ水痘様発疹	1 (0.3)	4 (1.0)	5 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
喉頭炎	2 (0.5)	3 (0.7)	5 (0.6)
ウイルス性喉頭炎	1 (0.3)	0	1 (0.1)
潜伏結核	0	2 (0.5)	2 (0.2)
限局性感染	1 (0.3)	0	1 (0.1)
下気道感染	1 (0.3)	0	1 (0.1)
細菌性リンパ節炎	0	1 (0.2)	1 (0.1)
伝染性軟属腫	2 (0.5)	3 (0.7)	5 (0.6)
マイコプラズマ感染	0	1 (0.2)	1 (0.1)
上咽頭炎	43 (10.8)	47 (11.6)	90 (11.2)
乳頭感染	1 (0.3)	0	1 (0.1)
爪真菌症	1 (0.3)	0	1 (0.1)
眼部単純ヘルペス	1 (0.3)	2 (0.5)	3 (0.4)
口腔カンジダ症	1 (0.3)	4 (1.0)	5 (0.6)
口腔ヘルペス	7 (1.8)	23 (5.7)	30 (3.7)
骨髄炎	0	1 (0.2)	1 (0.1)
外耳炎	2 (0.5)	1 (0.2)	3 (0.4)
中耳炎	1 (0.3)	2 (0.5)	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
急性中耳炎	1 (0.3)	1 (0.2)	2 (0.2)
爪囲炎	2 (0.5)	6 (1.5)	8 (1.0)
歯周炎	1 (0.3)	0	1 (0.1)
咽頭膿瘍	0	1 (0.2)	1 (0.1)
咽頭炎	6 (1.5)	4 (1.0)	10 (1.2)
レンサ球菌性咽頭炎	1 (0.3)	0	1 (0.1)
咽頭扁桃炎	1 (0.3)	1 (0.2)	2 (0.2)
肺炎	3 (0.8)	3 (0.7)	6 (0.7)
細菌性肺炎	0	1 (0.2)	1 (0.1)
ブドウ球菌性肺炎	0	1 (0.2)	1 (0.1)
ウイルス性肺炎	1 (0.3)	0	1 (0.1)
術後創感染	0	1 (0.2)	1 (0.1)
膿疱	0	1 (0.2)	1 (0.1)
腎盂腎炎	0	1 (0.2)	1 (0.1)
膿皮症	1 (0.3)	0	1 (0.1)
膿疱性皮疹	1 (0.3)	0	1 (0.1)
RS ウイルス感染	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
気道感染	3 (0.8)	2 (0.5)	5 (0.6)
ウイルス性気道感染	1 (0.3)	0	1 (0.1)
鼻炎	4 (1.0)	6 (1.5)	10 (1.2)
ライノウイルス感染	0	1 (0.2)	1 (0.1)
根管感染	0	1 (0.2)	1 (0.1)
敗血症	0	2 (0.5)	2 (0.2)
副鼻腔炎	7 (1.8)	5 (1.2)	12 (1.5)
皮膚細菌感染	2 (0.5)	2 (0.5)	4 (0.5)
皮膚カンジダ	1 (0.3)	1 (0.2)	2 (0.2)
植皮感染	0	1 (0.2)	1 (0.1)
皮膚感染	4 (1.0)	4 (1.0)	8 (1.0)
ブドウ球菌感染	1 (0.3)	5 (1.2)	6 (0.7)
ブドウ球菌性敗血症	0	1 (0.2)	1 (0.1)
ブドウ球菌皮膚感染	1 (0.3)	0	1 (0.1)
皮下組織膿瘍	1 (0.3)	1 (0.2)	2 (0.2)
細菌重複感染	1 (0.3)	0	1 (0.1)
股部白癬	0	3 (0.7)	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
足部白癬	2 (0.5)	2 (0.5)	4 (0.5)
癜風	2 (0.5)	0	2 (0.2)
扁桃炎	2 (0.5)	3 (0.7)	5 (0.6)
細菌性扁桃炎	0	1 (0.2)	1 (0.1)
歯膿瘍	2 (0.5)	2 (0.5)	4 (0.5)
歯感染	0	2 (0.5)	2 (0.2)
上気道感染	45 (11.3)	54 (13.3)	99 (12.3)
クラミジア性尿道炎	1 (0.3)	0	1 (0.1)
尿路感染	10 (2.5)	12 (3.0)	22 (2.7)
水痘	0	1 (0.2)	1 (0.1)
ウイルス性下痢	0	1 (0.2)	1 (0.1)
ウイルス感染	2 (0.5)	1 (0.2)	3 (0.4)
ウイルス性咽頭炎	1 (0.3)	0	1 (0.1)
ウイルス性発疹	1 (0.3)	0	1 (0.1)
ウイルス性上気道感染	7 (1.8)	13 (3.2)	20 (2.5)
外陰部腟カンジダ症	2 (0.5)	2 (0.5)	4 (0.5)
外陰腟真菌感染	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
創傷感染	0	1 (0.2)	1 (0.1)
ブドウ球菌性創感染	0	1 (0.2)	1 (0.1)
傷害、中毒および処置合併症	27 (6.8)	27 (6.7)	54 (6.7)
偶発的過量投与	0	1 (0.2)	1 (0.1)
アルコール中毒	0	1 (0.2)	1 (0.1)
節足動物咬傷	1 (0.3)	1 (0.2)	2 (0.2)
節足動物刺傷	0	1 (0.2)	1 (0.1)
背部損傷	1 (0.3)	0	1 (0.1)
第１度熱傷	0	1 (0.2)	1 (0.1)
第２度熱傷	1 (0.3)	0	1 (0.1)
第３度熱傷	0	1 (0.2)	1 (0.1)
軟骨損傷	1 (0.3)	0	1 (0.1)
脳振盪	2 (0.5)	0	2 (0.2)
挫傷	3 (0.8)	1 (0.2)	4 (0.5)
転倒	3 (0.8)	3 (0.7)	6 (0.7)
足骨折	1 (0.3)	3 (0.7)	4 (0.5)
体内異物	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
傷害、中毒および処置合併症 (Cont.)			
手骨折	0	1 (0.2)	1 (0.1)
頭部損傷	1 (0.3)	1 (0.2)	2 (0.2)
熱疲労	1 (0.3)	0	1 (0.1)
損傷	1 (0.3)	0	1 (0.1)
関節脱臼	1 (0.3)	0	1 (0.1)
関節損傷	1 (0.3)	1 (0.2)	2 (0.2)
靭帯断裂	1 (0.3)	1 (0.2)	2 (0.2)
靭帯捻挫	3 (0.8)	0	3 (0.4)
四肢損傷	3 (0.8)	1 (0.2)	4 (0.5)
口唇損傷	0	1 (0.2)	1 (0.1)
半月板損傷	0	1 (0.2)	1 (0.1)
肉離れ	2 (0.5)	3 (0.7)	5 (0.6)
筋骨格系損傷	0	1 (0.2)	1 (0.1)
膝蓋骨骨折	1 (0.3)	0	1 (0.1)
処置による疼痛	0	1 (0.2)	1 (0.1)
交通事故	1 (0.3)	1 (0.2)	2 (0.2)
瘢痕	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
傷害、中毒および処置合併症 (Cont.)			
皮膚擦過傷	1 (0.3)	1 (0.2)	2 (0.2)
皮膚裂傷	0	1 (0.2)	1 (0.1)
サンバーン	1 (0.3)	1 (0.2)	2 (0.2)
腱断裂	1 (0.3)	1 (0.2)	2 (0.2)
熱傷	0	1 (0.2)	1 (0.1)
上肢骨折	1 (0.3)	0	1 (0.1)
ワクチン接種合併症	0	1 (0.2)	1 (0.1)
臨床検査	46 (11.6)	64 (15.8)	110 (13.7)
アラニンアミノトランスフェラーゼ増加	7 (1.8)	9 (2.2)	16 (2.0)
アスパラギン酸アミノトランスフェラーゼ増加	4 (1.0)	7 (1.7)	11 (1.4)
B リンパ球数増加	1 (0.3)	0	1 (0.1)
血中アルカリホスファターゼ増加	1 (0.3)	0	1 (0.1)
血中ビリルビン増加	1 (0.3)	0	1 (0.1)
血中コレステロール増加	2 (0.5)	3 (0.7)	5 (0.6)
血中クレアチンホスホキナーゼ増加	19 (4.8)	31 (7.6)	50 (6.2)
血中クレアチニン増加	2 (0.5)	0	2 (0.2)
血液培養陽性	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
臨床検査 (Cont.)			
血中ブドウ糖増加	0	2 (0.5)	2 (0.2)
血中免疫グロブリン E 増加	6 (1.5)	0	6 (0.7)
血中乳酸脱水素酵素増加	0	1 (0.2)	1 (0.1)
血中カリウム増加	1 (0.3)	0	1 (0.1)
血圧上昇	1 (0.3)	0	1 (0.1)
血中トリグリセリド増加	1 (0.3)	0	1 (0.1)
血中尿酸増加	0	3 (0.7)	3 (0.4)
尿中血陽性	2 (0.5)	1 (0.2)	3 (0.4)
CD4 リンパ球減少	1 (0.3)	0	1 (0.1)
CD8 リンパ球百分率減少	1 (0.3)	0	1 (0.1)
CD8 リンパ球減少	0	1 (0.2)	1 (0.1)
心雑音	0	2 (0.5)	2 (0.2)
ケモカイン増加	1 (0.3)	0	1 (0.1)
尿中結晶陽性	1 (0.3)	1 (0.2)	2 (0.2)
尿培養陽性	0	1 (0.2)	1 (0.1)
好酸球百分率増加	1 (0.3)	0	1 (0.1)
ヘモグロビン減少	1 (0.3)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
臨床検査 (Cont.)			
心拍数増加	0	2 (0.5)	2 (0.2)
肝酵素上昇	1 (0.3)	0	1 (0.1)
高比重リポ蛋白増加	0	1 (0.2)	1 (0.1)
肝機能検査値上昇	1 (0.3)	0	1 (0.1)
低比重リポ蛋白増加	0	1 (0.2)	1 (0.1)
リンパ球数減少	0	2 (0.5)	2 (0.2)
ナチュラルキラー細胞数減少	1 (0.3)	0	1 (0.1)
好中球数減少	1 (0.3)	2 (0.5)	3 (0.4)
血小板数増加	0	1 (0.2)	1 (0.1)
尿妊娠反応陽性	1 (0.3)	0	1 (0.1)
尿蛋白	1 (0.3)	0	1 (0.1)
尿中蛋白陽性	2 (0.5)	2 (0.5)	4 (0.5)
T リンパ球数減少	1 (0.3)	0	1 (0.1)
トランスアミナーゼ上昇	1 (0.3)	4 (1.0)	5 (0.6)
尿円柱	1 (0.3)	0	1 (0.1)
尿中ケトン体陽性	1 (0.3)	0	1 (0.1)
尿中白血球エステラーゼ陽性	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
臨床検査 (Cont.)			
尿中シュウ酸塩	1 (0.3)	0	1 (0.1)
体重減少	0	3 (0.7)	3 (0.4)
体重増加	8 (2.0)	14 (3.4)	22 (2.7)
白血球数減少	0	2 (0.5)	2 (0.2)
代謝および栄養障害	15 (3.8)	18 (4.4)	33 (4.1)
食欲減退	2 (0.5)	3 (0.7)	5 (0.6)
脂質異常症	0	1 (0.2)	1 (0.1)
痛風	0	1 (0.2)	1 (0.1)
高コレステロール血症	1 (0.3)	5 (1.2)	6 (0.7)
高脂血症	1 (0.3)	1 (0.2)	2 (0.2)
高トリグリセリド血症	2 (0.5)	1 (0.2)	3 (0.4)
高尿酸血症	4 (1.0)	1 (0.2)	5 (0.6)
低血糖	0	1 (0.2)	1 (0.1)
低カリウム血症	0	3 (0.7)	3 (0.4)
低リン酸血症	1 (0.3)	0	1 (0.1)
食欲亢進	2 (0.5)	1 (0.2)	3 (0.4)
2 型糖尿病	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
代謝および栄養障害 (Cont.)			
ビタミンD欠乏	2 (0.5)	0	2 (0.2)
筋骨格系および結合組織障害	25 (6.3)	32 (7.9)	57 (7.1)
関節痛	4 (1.0)	6 (1.5)	10 (1.2)
関節炎	1 (0.3)	0	1 (0.1)
腋窩腫瘤	0	1 (0.2)	1 (0.1)
背部痛	6 (1.5)	12 (3.0)	18 (2.2)
滑液包炎	1 (0.3)	0	1 (0.1)
側腹部痛	1 (0.3)	0	1 (0.1)
足変形	1 (0.3)	0	1 (0.1)
椎間板変性症	0	1 (0.2)	1 (0.1)
椎間板突出	1 (0.3)	0	1 (0.1)
筋骨格系胸痛	0	1 (0.2)	1 (0.1)
筋骨格痛	2 (0.5)	2 (0.5)	4 (0.5)
筋肉痛	5 (1.3)	6 (1.5)	11 (1.4)
頚部痛	1 (0.3)	0	1 (0.1)
変形性関節症	1 (0.3)	1 (0.2)	2 (0.2)
骨端症	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
筋骨格系および結合組織障害 (Cont.)			
四肢痛	0	5 (1.2)	5 (0.6)
顎痛	1 (0.3)	1 (0.2)	2 (0.2)
骨膜炎	0	1 (0.2)	1 (0.1)
肩回旋筋腱板症候群	0	1 (0.2)	1 (0.1)
側弯症	1 (0.3)	0	1 (0.1)
腱障害	1 (0.3)	0	1 (0.1)
腱炎	1 (0.3)	1 (0.2)	2 (0.2)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	5 (1.3)	11 (2.7)	16 (2.0)
肛門性器疣贅	1 (0.3)	0	1 (0.1)
ボーエン病	1 (0.3)	0	1 (0.1)
真珠腫	0	1 (0.2)	1 (0.1)
胃癌	0	1 (0.2)	1 (0.1)
浸潤性乳管癌	0	1 (0.2)	1 (0.1)
メラノサイト性母斑	0	1 (0.2)	1 (0.1)
脂漏性角化症	0	1 (0.2)	1 (0.1)
皮膚乳頭腫	3 (0.8)	5 (1.2)	8 (1.0)
扁平上皮癌	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
神経系障害	30 (7.5)	33 (8.1)	63 (7.8)
健忘	0	1 (0.2)	1 (0.1)
手根管症候群	1 (0.3)	0	1 (0.1)
注意力障害	1 (0.3)	0	1 (0.1)
浮動性めまい	4 (1.0)	6 (1.5)	10 (1.2)
夢幻状態	1 (0.3)	0	1 (0.1)
味覚不全	0	1 (0.2)	1 (0.1)
錐体外路障害	1 (0.3)	0	1 (0.1)
頭痛	18 (4.5)	23 (5.7)	41 (5.1)
虚血性脳卒中	1 (0.3)	0	1 (0.1)
片頭痛	0	2 (0.5)	2 (0.2)
前兆を伴う片頭痛	0	1 (0.2)	1 (0.1)
錯感覚	1 (0.3)	0	1 (0.1)
神経根障害	0	1 (0.2)	1 (0.1)
坐骨神経痛	1 (0.3)	0	1 (0.1)
傾眠	2 (0.5)	0	2 (0.2)
失神	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
神経系障害 (Cont.)			
緊張性頭痛	1 (0.3)	2 (0.5)	3 (0.4)
精神障害	18 (4.5)	11 (2.7)	29 (3.6)
不安	5 (1.3)	4 (1.0)	9 (1.1)
不安障害	0	1 (0.2)	1 (0.1)
無感情	1 (0.3)	0	1 (0.1)
注意欠陥多動性障害	1 (0.3)	0	1 (0.1)
抑うつ気分	0	1 (0.2)	1 (0.1)
うつ病	1 (0.3)	2 (0.5)	3 (0.4)
失見当識	0	1 (0.2)	1 (0.1)
不眠症	2 (0.5)	1 (0.2)	3 (0.4)
故意の自傷行為	1 (0.3)	0	1 (0.1)
リビドー減退	1 (0.3)	0	1 (0.1)
大うつ病	1 (0.3)	1 (0.2)	2 (0.2)
躁病	1 (0.3)	0	1 (0.1)
混合性不安抑うつ障害	1 (0.3)	0	1 (0.1)
パニック発作	0	1 (0.2)	1 (0.1)
睡眠障害	3 (0.8)	0	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
精神障害 (Cont.)			
ストレス	1 (0.3)	0	1 (0.1)
腎および尿路障害	4 (1.0)	11 (2.7)	15 (1.9)
急性腎障害	0	1 (0.2)	1 (0.1)
アルブミン尿	1 (0.3)	2 (0.5)	3 (0.4)
排尿困難	1 (0.3)	3 (0.7)	4 (0.5)
血尿	1 (0.3)	1 (0.2)	2 (0.2)
緊張性膀胱	0	1 (0.2)	1 (0.1)
頻尿	0	1 (0.2)	1 (0.1)
蛋白尿	1 (0.3)	2 (0.5)	3 (0.4)
生殖系および乳房障害	4 (1.0)	8 (2.0)	12 (1.5)
無月経	1 (0.3)	3 (0.7)	4 (0.5)
乳房腫大	0	1 (0.2)	1 (0.1)
乳房圧痛	0	1 (0.2)	1 (0.1)
月経困難症	2 (0.5)	0	2 (0.2)
閉経期症状	0	1 (0.2)	1 (0.1)
月経過多	1 (0.3)	1 (0.2)	2 (0.2)
精巣痛	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
生殖系および乳房障害 (Cont.)			
外陰腟乾燥	0	1 (0.2)	1 (0.1)
呼吸器、胸郭および縦隔障害	34 (8.5)	34 (8.4)	68 (8.5)
喘息	6 (1.5)	4 (1.0)	10 (1.2)
気管支反応性亢進	1 (0.3)	0	1 (0.1)
慢性閉塞性肺疾患	0	1 (0.2)	1 (0.1)
咳嗽	16 (4.0)	9 (2.2)	25 (3.1)
発声障害	1 (0.3)	0	1 (0.1)
呼吸困難	2 (0.5)	1 (0.2)	3 (0.4)
鼻出血	2 (0.5)	6 (1.5)	8 (1.0)
鼻閉	1 (0.3)	3 (0.7)	4 (0.5)
鼻乾燥	0	1 (0.2)	1 (0.1)
口腔咽頭痛	9 (2.3)	10 (2.5)	19 (2.4)
湿性咳嗽	2 (0.5)	0	2 (0.2)
アレルギー性鼻炎	2 (0.5)	1 (0.2)	3 (0.4)
鼻漏	1 (0.3)	1 (0.2)	2 (0.2)
副鼻腔うっ血	1 (0.3)	2 (0.5)	3 (0.4)
咽喉刺激感	1 (0.3)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
呼吸器、胸郭および縦隔障害 (Cont.)			
上気道の炎症	0	1 (0.2)	1 (0.1)
皮膚および皮下組織障害	81 (20.4)	135 (33.3)	216 (26.9)
ざ瘡	28 (7.0)	81 (20.0)	109 (13.6)
光線角化症	2 (0.5)	1 (0.2)	3 (0.4)
脱毛症	1 (0.3)	1 (0.2)	2 (0.2)
円形脱毛症	0	1 (0.2)	1 (0.1)
血管浮腫	1 (0.3)	1 (0.2)	2 (0.2)
水疱	1 (0.3)	0	1 (0.1)
皮膚嚢腫	0	1 (0.2)	1 (0.1)
皮膚炎	1 (0.3)	3 (0.7)	4 (0.5)
ざ瘡様皮膚炎	3 (0.8)	15 (3.7)	18 (2.2)
アレルギー性皮膚炎	0	1 (0.2)	1 (0.1)
アトピー性皮膚炎	22 (5.5)	19 (4.7)	41 (5.1)
接触皮膚炎	2 (0.5)	9 (2.2)	11 (1.4)
びまん性脱毛症	0	1 (0.2)	1 (0.1)
薬疹	1 (0.3)	0	1 (0.1)
異汗性湿疹	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
皮膚および皮下組織障害 (Cont.)			
斑状出血	1 (0.3)	0	1 (0.1)
湿疹	4 (1.0)	2 (0.5)	6 (0.7)
紅斑	2 (0.5)	2 (0.5)	4 (0.5)
毛包性ムチン沈着症	0	1 (0.2)	1 (0.1)
毛髪成長異常	0	1 (0.2)	1 (0.1)
逆むけ	0	1 (0.2)	1 (0.1)
汗腺炎	0	1 (0.2)	1 (0.1)
多汗症	0	2 (0.5)	2 (0.2)
嵌入爪	1 (0.3)	0	1 (0.1)
機械性蕁麻疹	0	1 (0.2)	1 (0.1)
汗疹	1 (0.3)	1 (0.2)	2 (0.2)
神経皮膚炎	1 (0.3)	0	1 (0.1)
寝汗	1 (0.3)	1 (0.2)	2 (0.2)
爪破損	0	1 (0.2)	1 (0.1)
類乾癬	0	1 (0.2)	1 (0.1)
口囲皮膚炎	1 (0.3)	0	1 (0.1)
光線過敏性反応	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
皮膚および皮下組織障害 (Cont.)			
炎症後色素沈着変化	1 (0.3)	0	1 (0.1)
そう痒症	5 (1.3)	2 (0.5)	7 (0.9)
紫斑	0	1 (0.2)	1 (0.1)
発疹	2 (0.5)	2 (0.5)	4 (0.5)
斑状丘疹状皮疹	1 (0.3)	1 (0.2)	2 (0.2)
丘疹性皮疹	1 (0.3)	0	1 (0.1)
酒さ	0	2 (0.5)	2 (0.2)
脂漏	1 (0.3)	0	1 (0.1)
脂漏性皮膚炎	0	2 (0.5)	2 (0.2)
皮膚障害	0	1 (0.2)	1 (0.1)
皮膚亀裂	1 (0.3)	0	1 (0.1)
皮膚腫脹	1 (0.3)	0	1 (0.1)
日光黒子	0	1 (0.2)	1 (0.1)
毛細血管拡張症	1 (0.3)	0	1 (0.1)
中毒性表皮壊死融解症	1 (0.3)	0	1 (0.1)
蕁麻疹	6 (1.5)	7 (1.7)	13 (1.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
外科および内科処置	2 (0.5)	0	2 (0.2)
人工流産	1 (0.3)	0	1 (0.1)
収れん薬療法	1 (0.3)	0	1 (0.1)
血管障害	8 (2.0)	5 (1.2)	13 (1.6)
血性分泌物	1 (0.3)	0	1 (0.1)
潮紅	1 (0.3)	0	1 (0.1)
血腫	1 (0.3)	1 (0.2)	2 (0.2)
ほてり	0	1 (0.2)	1 (0.1)
高血圧	5 (1.3)	2 (0.5)	7 (0.9)
血栓性静脈炎	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.6.2.1

表 5. ウパダシチニブ投与期間中に有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団，青少年）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=59) n (%)	Total (N=119) n (%)
Any adverse event	37 (61.7)	47 (79.7)	84 (70.6)
血液およびリンパ系障害	1 (1.7)	4 (6.8)	5 (4.2)
白血球減少症	0	1 (1.7)	1 (0.8)
好中球減少症	0	3 (5.1)	3 (2.5)
好中球増加症	1 (1.7)	0	1 (0.8)
血小板減少症	0	1 (1.7)	1 (0.8)
眼障害	0	2 (3.4)	2 (1.7)
流涙増加	0	1 (1.7)	1 (0.8)
霧視	0	1 (1.7)	1 (0.8)
胃腸障害	4 (6.7)	8 (13.6)	12 (10.1)
腹痛	0	1 (1.7)	1 (0.8)
上腹部痛	1 (1.7)	2 (3.4)	3 (2.5)
齲歯	1 (1.7)	1 (1.7)	2 (1.7)
下痢	1 (1.7)	5 (8.5)	6 (5.0)
食中毒	0	1 (1.7)	1 (0.8)
胃食道逆流性疾患	0	1 (1.7)	1 (0.8)
口唇腫脹	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=59) n (%)	Total (N=119) n (%)
胃腸障害 (Cont.)			
悪心	1 (1.7)	1 (1.7)	2 (1.7)
嘔吐	0	2 (3.4)	2 (1.7)
一般・全身障害および投与部位の状態	6 (10.0)	4 (6.8)	10 (8.4)
無力症	1 (1.7)	0	1 (0.8)
インフルエンザ様疾患	1 (1.7)	2 (3.4)	3 (2.5)
疼痛	1 (1.7)	0	1 (0.8)
発熱	3 (5.0)	2 (3.4)	5 (4.2)
免疫系障害	1 (1.7)	2 (3.4)	3 (2.5)
アナフィラキシー反応	0	1 (1.7)	1 (0.8)
薬物過敏症	0	1 (1.7)	1 (0.8)
過敏症	1 (1.7)	0	1 (0.8)
感染症および寄生虫症	26 (43.3)	36 (61.0)	62 (52.1)
四肢膿瘍	0	1 (1.7)	1 (0.8)
体部白癬	0	1 (1.7)	1 (0.8)
気管支炎	1 (1.7)	1 (1.7)	2 (1.7)
結膜炎	1 (1.7)	3 (5.1)	4 (3.4)
感染性クループ	1 (1.7)	0	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=59) n (%)	Total (N=119) n (%)
感染症および寄生虫症 (Cont.)			
膀胱炎	0	1 (1.7)	1 (0.8)
耳感染	0	3 (5.1)	3 (2.5)
毛包炎	0	1 (1.7)	1 (0.8)
胃腸炎	0	2 (3.4)	2 (1.7)
手足口病	1 (1.7)	0	1 (0.8)
単純ヘルペス	1 (1.7)	3 (5.1)	4 (3.4)
帯状疱疹	1 (1.7)	2 (3.4)	3 (2.5)
麦粒腫	0	1 (1.7)	1 (0.8)
膿痂疹	4 (6.7)	3 (5.1)	7 (5.9)
インフルエンザ	0	3 (5.1)	3 (2.5)
上咽頭炎	5 (8.3)	5 (8.5)	10 (8.4)
乳頭感染	1 (1.7)	0	1 (0.8)
口腔ヘルペス	0	2 (3.4)	2 (1.7)
骨髄炎	0	1 (1.7)	1 (0.8)
爪囲炎	0	1 (1.7)	1 (0.8)
咽頭炎	0	1 (1.7)	1 (0.8)
咽頭扁桃炎	1 (1.7)	0	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=59) n (%)	Total (N=119) n (%)
感染症および寄生虫症 (Cont.)			
肺炎	0	1 (1.7)	1 (0.8)
腎盂腎炎	0	1 (1.7)	1 (0.8)
気道感染	2 (3.3)	1 (1.7)	3 (2.5)
鼻炎	1 (1.7)	2 (3.4)	3 (2.5)
敗血症	0	1 (1.7)	1 (0.8)
副鼻腔炎	1 (1.7)	0	1 (0.8)
皮膚細菌感染	1 (1.7)	0	1 (0.8)
皮膚感染	1 (1.7)	0	1 (0.8)
ブドウ球菌感染	1 (1.7)	0	1 (0.8)
ブドウ球菌性敗血症	0	1 (1.7)	1 (0.8)
皮下組織膿瘍	0	1 (1.7)	1 (0.8)
上気道感染	8 (13.3)	11 (18.6)	19 (16.0)
尿路感染	1 (1.7)	2 (3.4)	3 (2.5)
ウイルス性下痢	0	1 (1.7)	1 (0.8)
ウイルス性上気道感染	0	1 (1.7)	1 (0.8)
傷害、中毒および処置合併症	4 (6.7)	2 (3.4)	6 (5.0)
脳振盪	1 (1.7)	0	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=59) n (%)	Total (N=119) n (%)
傷害、中毒および処置合併症 (Cont.)			
転倒	0	1 (1.7)	1 (0.8)
頭部損傷	1 (1.7)	0	1 (0.8)
熱疲労	1 (1.7)	0	1 (0.8)
関節損傷	0	1 (1.7)	1 (0.8)
靱帯断裂	0	1 (1.7)	1 (0.8)
半月板損傷	0	1 (1.7)	1 (0.8)
交通事故	0	1 (1.7)	1 (0.8)
皮膚擦過傷	1 (1.7)	0	1 (0.8)
臨床検査	8 (13.3)	12 (20.3)	20 (16.8)
アラニンアミノトランスフェラーゼ増加	1 (1.7)	0	1 (0.8)
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.7)	0	1 (0.8)
血中アルカリホスファターゼ増加	1 (1.7)	0	1 (0.8)
血中ビリルビン増加	1 (1.7)	0	1 (0.8)
血中クレアチンホスホキナーゼ増加	5 (8.3)	7 (11.9)	12 (10.1)
血液培養陽性	0	1 (1.7)	1 (0.8)
心雑音	0	1 (1.7)	1 (0.8)
尿培養陽性	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=59) n (%)	Total (N=119) n (%)
臨床検査 (Cont.)			
ヘモグロビン減少	1 (1.7)	0	1 (0.8)
心拍数増加	0	2 (3.4)	2 (1.7)
肝酵素上昇	1 (1.7)	0	1 (0.8)
トランスアミナーゼ上昇	1 (1.7)	0	1 (0.8)
尿中シュウ酸塩	1 (1.7)	0	1 (0.8)
体重増加	1 (1.7)	3 (5.1)	4 (3.4)
代謝および栄養障害	3 (5.0)	0	3 (2.5)
食欲減退	1 (1.7)	0	1 (0.8)
食欲亢進	1 (1.7)	0	1 (0.8)
ビタミン D 欠乏	1 (1.7)	0	1 (0.8)
筋骨格系および結合組織障害	2 (3.3)	2 (3.4)	4 (3.4)
関節痛	0	1 (1.7)	1 (0.8)
筋肉痛	1 (1.7)	0	1 (0.8)
骨端症	0	1 (1.7)	1 (0.8)
顎痛	1 (1.7)	0	1 (0.8)
側弯症	1 (1.7)	0	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=59) n (%)	Total (N=119) n (%)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.7)	1 (1.7)	2 (1.7)
皮膚乳頭腫	1 (1.7)	1 (1.7)	2 (1.7)
神経系障害	6 (10.0)	4 (6.8)	10 (8.4)
錐体外路障害	1 (1.7)	0	1 (0.8)
頭痛	4 (6.7)	3 (5.1)	7 (5.9)
失神	0	1 (1.7)	1 (0.8)
緊張性頭痛	1 (1.7)	0	1 (0.8)
精神障害	6 (10.0)	1 (1.7)	7 (5.9)
不安	2 (3.3)	0	2 (1.7)
不安障害	0	1 (1.7)	1 (0.8)
うつ病	1 (1.7)	0	1 (0.8)
故意の自傷行為	1 (1.7)	0	1 (0.8)
大うつ病	1 (1.7)	0	1 (0.8)
パニック発作	0	1 (1.7)	1 (0.8)
睡眠障害	1 (1.7)	0	1 (0.8)
腎および尿路障害	0	1 (1.7)	1 (0.8)
排尿困難	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=59) n (%)	Total (N=119) n (%)
生殖系および乳房障害	1 (1.7)	1 (1.7)	2 (1.7)
無月経	0	1 (1.7)	1 (0.8)
月経困難症	1 (1.7)	0	1 (0.8)
呼吸器、胸郭および縦隔障害	6 (10.0)	7 (11.9)	13 (10.9)
咳嗽	5 (8.3)	1 (1.7)	6 (5.0)
呼吸困難	0	1 (1.7)	1 (0.8)
鼻出血	0	2 (3.4)	2 (1.7)
口腔咽頭痛	2 (3.3)	2 (3.4)	4 (3.4)
湿性咳嗽	1 (1.7)	0	1 (0.8)
鼻漏	1 (1.7)	0	1 (0.8)
副鼻腔うっ血	1 (1.7)	1 (1.7)	2 (1.7)
皮膚および皮下組織障害	12 (20.0)	25 (42.4)	37 (31.1)
ざ瘡	6 (10.0)	19 (32.2)	25 (21.0)
円形脱毛症	0	1 (1.7)	1 (0.8)
皮膚炎	0	1 (1.7)	1 (0.8)
ざ瘡様皮膚炎	0	1 (1.7)	1 (0.8)
アレルギー性皮膚炎	0	1 (1.7)	1 (0.8)
アトピー性皮膚炎	2 (3.3)	1 (1.7)	3 (2.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=59) n (%)	Total (N=119) n (%)
皮膚および皮下組織障害 (Cont.)			
接触皮膚炎	0	2 (3.4)	2 (1.7)
湿疹	2 (3.3)	0	2 (1.7)
紅斑	0	1 (1.7)	1 (0.8)
汗腺炎	0	1 (1.7)	1 (0.8)
多汗症	0	1 (1.7)	1 (0.8)
汗疹	0	1 (1.7)	1 (0.8)
炎症後色素沈着変化	1 (1.7)	0	1 (0.8)
そう痒症	0	1 (1.7)	1 (0.8)
発疹	0	1 (1.7)	1 (0.8)
斑状丘疹状皮疹	0	1 (1.7)	1 (0.8)
脂漏性皮膚炎	0	1 (1.7)	1 (0.8)
蕁麻疹	3 (5.0)	1 (1.7)	4 (3.4)
外科および内科処置	1 (1.7)	0	1 (0.8)
収れん薬療法	1 (1.7)	0	1 (0.8)
血管障害	0	1 (1.7)	1 (0.8)
血腫	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.6.2.2

表 6. ウパダシチニブ投与期間中に有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団，成人）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
Any adverse event	230 (68.0)	259 (74.6)	489 (71.4)
血液およびリンパ系障害	11 (3.3)	16 (4.6)	27 (3.9)
貧血	0	5 (1.4)	5 (0.7)
白血球増加症	1 (0.3)	1 (0.3)	2 (0.3)
リンパ節症	3 (0.9)	2 (0.6)	5 (0.7)
リンパ球減少症	1 (0.3)	1 (0.3)	2 (0.3)
好中球減少症	7 (2.1)	10 (2.9)	17 (2.5)
好中球増加症	1 (0.3)	0	1 (0.1)
汎血球減少症	0	1 (0.3)	1 (0.1)
心臓障害	1 (0.3)	3 (0.9)	4 (0.6)
心房細動	0	1 (0.3)	1 (0.1)
徐脈	0	1 (0.3)	1 (0.1)
心血管障害	1 (0.3)	0	1 (0.1)
冠動脈疾患	0	1 (0.3)	1 (0.1)
先天性、家族性および遺伝性障害	0	1 (0.3)	1 (0.1)
包茎	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
耳および迷路障害	2 (0.6)	6 (1.7)	8 (1.2)
耳垢栓塞	0	2 (0.6)	2 (0.3)
突発性難聴	0	1 (0.3)	1 (0.1)
鼓膜障害	0	1 (0.3)	1 (0.1)
回転性めまい	2 (0.6)	2 (0.6)	4 (0.6)
内分泌障害	1 (0.3)	2 (0.6)	3 (0.4)
バセドウ病	0	1 (0.3)	1 (0.1)
甲状腺機能低下症	1 (0.3)	0	1 (0.1)
甲状腺腫瘤	0	1 (0.3)	1 (0.1)
眼障害	8 (2.4)	12 (3.5)	20 (2.9)
眼瞼炎	0	2 (0.6)	2 (0.3)
白内障	1 (0.3)	0	1 (0.1)
結膜出血	0	1 (0.3)	1 (0.1)
アレルギー性結膜炎	1 (0.3)	2 (0.6)	3 (0.4)
ドライアイ	1 (0.3)	2 (0.6)	3 (0.4)
眼瞼湿疹	0	1 (0.3)	1 (0.1)
眼そう痒症	0	1 (0.3)	1 (0.1)
眼部腫脹	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
眼障害 (Cont.)			
緑内障	1 (0.3)	0	1 (0.1)
流涙増加	1 (0.3)	0	1 (0.1)
黄斑変性	1 (0.3)	0	1 (0.1)
眼窩周囲腫脹	1 (0.3)	1 (0.3)	2 (0.3)
網膜剥離	1 (0.3)	0	1 (0.1)
潰瘍性角膜炎	1 (0.3)	0	1 (0.1)
霧視	1 (0.3)	2 (0.6)	3 (0.4)
視力障害	1 (0.3)	0	1 (0.1)
胃腸障害	40 (11.8)	53 (15.3)	93 (13.6)
腹部不快感	1 (0.3)	1 (0.3)	2 (0.3)
腹部膨満	1 (0.3)	1 (0.3)	2 (0.3)
腹痛	1 (0.3)	5 (1.4)	6 (0.9)
上腹部痛	3 (0.9)	3 (0.9)	6 (0.9)
口角口唇炎	0	1 (0.3)	1 (0.1)
呼気臭	0	1 (0.3)	1 (0.1)
便秘	3 (0.9)	2 (0.6)	5 (0.7)
齲歯	1 (0.3)	2 (0.6)	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
胃腸障害 (Cont.)			
下痢	11 (3.3)	9 (2.6)	20 (2.9)
腸憩室	1 (0.3)	0	1 (0.1)
口内乾燥	0	3 (0.9)	3 (0.4)
消化不良	2 (0.6)	2 (0.6)	4 (0.6)
軟便	0	2 (0.6)	2 (0.3)
鼓腸	3 (0.9)	2 (0.6)	5 (0.7)
食中毒	1 (0.3)	1 (0.3)	2 (0.3)
胃潰瘍	1 (0.3)	1 (0.3)	2 (0.3)
胃炎	4 (1.2)	0	4 (0.6)
びらん性胃炎	0	1 (0.3)	1 (0.1)
消化器痛	1 (0.3)	0	1 (0.1)
胃食道逆流性疾患	1 (0.3)	4 (1.2)	5 (0.7)
歯肉痛	0	1 (0.3)	1 (0.1)
痔核	0	2 (0.6)	2 (0.3)
歯の知覚過敏	0	1 (0.3)	1 (0.1)
過敏性腸症候群	0	1 (0.3)	1 (0.1)
口腔内潰瘍形成	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
胃腸障害 (Cont.)			
悪心	11 (3.3)	13 (3.7)	24 (3.5)
食道狭窄	1 (0.3)	0	1 (0.1)
大網壊死	0	1 (0.3)	1 (0.1)
口腔障害	0	1 (0.3)	1 (0.1)
膵炎	0	1 (0.3)	1 (0.1)
埋伏歯	1 (0.3)	0	1 (0.1)
歯痛	1 (0.3)	2 (0.6)	3 (0.4)
嘔吐	4 (1.2)	6 (1.7)	10 (1.5)
一般・全身障害および投与部位の状態	25 (7.4)	26 (7.5)	51 (7.4)
無力症	0	1 (0.3)	1 (0.1)
胸部不快感	1 (0.3)	1 (0.3)	2 (0.3)
胸痛	1 (0.3)	0	1 (0.1)
悪寒	0	2 (0.6)	2 (0.3)
嚢胞	1 (0.3)	0	1 (0.1)
不快感	0	1 (0.3)	1 (0.1)
薬物不耐性	0	1 (0.3)	1 (0.1)
顔面浮腫	1 (0.3)	1 (0.3)	2 (0.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
一般・全身障害および投与部位の状態 (Cont.)			
疲労	4 (1.2)	3 (0.9)	7 (1.0)
びくびく感	0	1 (0.3)	1 (0.1)
インフルエンザ様疾患	6 (1.8)	8 (2.3)	14 (2.0)
倦怠感	0	1 (0.3)	1 (0.1)
腫瘤	1 (0.3)	0	1 (0.1)
粘膜乾燥	0	1 (0.3)	1 (0.1)
小結節	0	1 (0.3)	1 (0.1)
非心臓性胸痛	0	1 (0.3)	1 (0.1)
浮腫	0	1 (0.3)	1 (0.1)
末梢性浮腫	1 (0.3)	1 (0.3)	2 (0.3)
疼痛	1 (0.3)	2 (0.6)	3 (0.4)
発熱	9 (2.7)	5 (1.4)	14 (2.0)
腫脹	1 (0.3)	0	1 (0.1)
顔面腫脹	1 (0.3)	0	1 (0.1)
血管穿刺部位内出血	0	1 (0.3)	1 (0.1)
肝胆道系障害	2 (0.6)	6 (1.7)	8 (1.2)
胆嚢炎	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
肝胆道系障害 (Cont.)			
胆石症	1 (0.3)	0	1 (0.1)
胆嚢ポリープ	0	1 (0.3)	1 (0.1)
肝機能異常	1 (0.3)	0	1 (0.1)
脂肪肝	0	3 (0.9)	3 (0.4)
肝腫大	0	1 (0.3)	1 (0.1)
免疫系障害	5 (1.5)	4 (1.2)	9 (1.3)
化学物質アレルギー	1 (0.3)	0	1 (0.1)
ワクチンアレルギー	1 (0.3)	0	1 (0.1)
アナフィラキシー反応	0	1 (0.3)	1 (0.1)
食物アレルギー	2 (0.6)	1 (0.3)	3 (0.4)
過敏症	1 (0.3)	0	1 (0.1)
乳アレルギー	0	1 (0.3)	1 (0.1)
1 型過敏症	0	1 (0.3)	1 (0.1)
感染症および寄生虫症	163 (48.2)	179 (51.6)	342 (49.9)
ダニ皮膚炎	1 (0.3)	1 (0.3)	2 (0.3)
膿疱性ざ瘡	1 (0.3)	0	1 (0.1)
虫垂炎	2 (0.6)	0	2 (0.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
感染症および寄生虫症 (Cont.)			
細菌感染	1 (0.3)	1 (0.3)	2 (0.3)
細菌性膣症	0	2 (0.6)	2 (0.3)
細菌尿	0	1 (0.3)	1 (0.1)
体部白癬	3 (0.9)	1 (0.3)	4 (0.6)
気管支炎	5 (1.5)	9 (2.6)	14 (2.0)
ウイルス性気管支炎	1 (0.3)	0	1 (0.1)
カンジダ感染	1 (0.3)	0	1 (0.1)
蜂巣炎	3 (0.9)	2 (0.6)	5 (0.7)
結膜炎	2 (0.6)	4 (1.2)	6 (0.9)
コロナウイルス感染	1 (0.3)	1 (0.3)	2 (0.3)
膀胱炎	0	1 (0.3)	1 (0.1)
感染性皮膚炎	1 (0.3)	0	1 (0.1)
皮膚糸状菌症	1 (0.3)	1 (0.3)	2 (0.3)
爪の皮膚糸状菌症	1 (0.3)	0	1 (0.1)
憩室炎	0	1 (0.3)	1 (0.1)
耳感染	2 (0.6)	6 (1.7)	8 (1.2)
膿瘡	2 (0.6)	0	2 (0.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
感染症および寄生虫症 (Cont.)			
ヘルペス性状湿疹	1 (0.3)	2 (0.6)	3 (0.4)
感染性湿疹	0	1 (0.3)	1 (0.1)
丹毒	0	1 (0.3)	1 (0.1)
大腸菌性尿路感染	0	1 (0.3)	1 (0.1)
外耳蜂巣炎	1 (0.3)	0	1 (0.1)
眼感染	1 (0.3)	0	1 (0.1)
毛包炎	7 (2.1)	15 (4.3)	22 (3.2)
真菌感染	2 (0.6)	0	2 (0.3)
せつ	3 (0.9)	3 (0.9)	6 (0.9)
胃腸炎	4 (1.2)	10 (2.9)	14 (2.0)
ウイルス性胃腸炎	1 (0.3)	2 (0.6)	3 (0.4)
ウイルス性消化管感染	0	1 (0.3)	1 (0.1)
陰部ヘルペス	2 (0.6)	0	2 (0.3)
陰部単純ヘルペス	0	2 (0.6)	2 (0.3)
蠕虫感染	0	1 (0.3)	1 (0.1)
B 型肝炎	0	1 (0.3)	1 (0.1)
ヘルパンギーナ	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
感染症および寄生虫症 (Cont.)			
ヘルペス性皮膚炎	0	2 (0.6)	2 (0.3)
ヘルペス眼感染	0	2 (0.6)	2 (0.3)
単純ヘルペス	10 (3.0)	12 (3.5)	22 (3.2)
ヘルペスウイルス感染	2 (0.6)	1 (0.3)	3 (0.4)
帯状疱疹	7 (2.1)	9 (2.6)	16 (2.3)
麦粒腫	4 (1.2)	7 (2.0)	11 (1.6)
膿痂疹	6 (1.8)	3 (0.9)	9 (1.3)
インフルエンザ	3 (0.9)	6 (1.7)	9 (1.3)
椎間板炎	1 (0.3)	0	1 (0.1)
カポジ水痘様発疹	1 (0.3)	4 (1.2)	5 (0.7)
喉頭炎	2 (0.6)	3 (0.9)	5 (0.7)
ウイルス性喉頭炎	1 (0.3)	0	1 (0.1)
潜伏結核	0	2 (0.6)	2 (0.3)
限局性感染	1 (0.3)	0	1 (0.1)
下気道感染	1 (0.3)	0	1 (0.1)
細菌性リンパ節炎	0	1 (0.3)	1 (0.1)
伝染性軟属腫	2 (0.6)	3 (0.9)	5 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
感染症および寄生虫症 (Cont.)			
マイコプラズマ感染	0	1 (0.3)	1 (0.1)
上咽頭炎	38 (11.2)	42 (12.1)	80 (11.7)
爪真菌症	1 (0.3)	0	1 (0.1)
眼部単純ヘルペス	1 (0.3)	2 (0.6)	3 (0.4)
口腔カンジダ症	1 (0.3)	4 (1.2)	5 (0.7)
口腔ヘルペス	7 (2.1)	21 (6.1)	28 (4.1)
外耳炎	2 (0.6)	1 (0.3)	3 (0.4)
中耳炎	1 (0.3)	2 (0.6)	3 (0.4)
急性中耳炎	1 (0.3)	1 (0.3)	2 (0.3)
爪囲炎	2 (0.6)	5 (1.4)	7 (1.0)
歯周炎	1 (0.3)	0	1 (0.1)
咽頭膿瘍	0	1 (0.3)	1 (0.1)
咽頭炎	6 (1.8)	3 (0.9)	9 (1.3)
レンサ球菌性咽頭炎	1 (0.3)	0	1 (0.1)
咽頭扁桃炎	0	1 (0.3)	1 (0.1)
肺炎	3 (0.9)	2 (0.6)	5 (0.7)
細菌性肺炎	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
感染症および寄生虫症 (Cont.)			
ブドウ球菌性肺炎	0	1 (0.3)	1 (0.1)
ウイルス性肺炎	1 (0.3)	0	1 (0.1)
術後創感染	0	1 (0.3)	1 (0.1)
膿疱	0	1 (0.3)	1 (0.1)
膿皮症	1 (0.3)	0	1 (0.1)
膿疱性皮疹	1 (0.3)	0	1 (0.1)
RS ウイルス感染	0	1 (0.3)	1 (0.1)
気道感染	1 (0.3)	1 (0.3)	2 (0.3)
ウイルス性気道感染	1 (0.3)	0	1 (0.1)
鼻炎	3 (0.9)	4 (1.2)	7 (1.0)
ライノウイルス感染	0	1 (0.3)	1 (0.1)
根管感染	0	1 (0.3)	1 (0.1)
敗血症	0	1 (0.3)	1 (0.1)
副鼻腔炎	6 (1.8)	5 (1.4)	11 (1.6)
皮膚細菌感染	1 (0.3)	2 (0.6)	3 (0.4)
皮膚カンジダ	1 (0.3)	1 (0.3)	2 (0.3)
植皮感染	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
感染症および寄生虫症 (Cont.)			
皮膚感染	3 (0.9)	4 (1.2)	7 (1.0)
ブドウ球菌感染	0	5 (1.4)	5 (0.7)
ブドウ球菌皮膚感染	1 (0.3)	0	1 (0.1)
皮下組織膿瘍	1 (0.3)	0	1 (0.1)
細菌重複感染	1 (0.3)	0	1 (0.1)
股部白癬	0	3 (0.9)	3 (0.4)
足部白癬	2 (0.6)	2 (0.6)	4 (0.6)
癜風	2 (0.6)	0	2 (0.3)
扁桃炎	2 (0.6)	3 (0.9)	5 (0.7)
細菌性扁桃炎	0	1 (0.3)	1 (0.1)
歯膿瘍	2 (0.6)	2 (0.6)	4 (0.6)
歯感染	0	2 (0.6)	2 (0.3)
上気道感染	37 (10.9)	43 (12.4)	80 (11.7)
クラミジア性尿道炎	1 (0.3)	0	1 (0.1)
尿路感染	9 (2.7)	10 (2.9)	19 (2.8)
水痘	0	1 (0.3)	1 (0.1)
ウイルス感染	2 (0.6)	1 (0.3)	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
感染症および寄生虫症 (Cont.)			
ウイルス性咽頭炎	1 (0.3)	0	1 (0.1)
ウイルス性発疹	1 (0.3)	0	1 (0.1)
ウイルス性上気道感染	7 (2.1)	12 (3.5)	19 (2.8)
外陰部腟カンジダ症	2 (0.6)	2 (0.6)	4 (0.6)
外陰腟真菌感染	1 (0.3)	0	1 (0.1)
創傷感染	0	1 (0.3)	1 (0.1)
ブドウ球菌性創感染	0	1 (0.3)	1 (0.1)
傷害、中毒および処置合併症	23 (6.8)	25 (7.2)	48 (7.0)
偶発的過量投与	0	1 (0.3)	1 (0.1)
アルコール中毒	0	1 (0.3)	1 (0.1)
節足動物咬傷	1 (0.3)	1 (0.3)	2 (0.3)
節足動物刺傷	0	1 (0.3)	1 (0.1)
背部損傷	1 (0.3)	0	1 (0.1)
第 1 度熱傷	0	1 (0.3)	1 (0.1)
第 2 度熱傷	1 (0.3)	0	1 (0.1)
第 3 度熱傷	0	1 (0.3)	1 (0.1)
軟骨損傷	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
傷害、中毒および処置合併症 (Cont.)			
脳振盪	1 (0.3)	0	1 (0.1)
挫傷	3 (0.9)	1 (0.3)	4 (0.6)
転倒	3 (0.9)	2 (0.6)	5 (0.7)
足骨折	1 (0.3)	3 (0.9)	4 (0.6)
体内異物	0	1 (0.3)	1 (0.1)
手骨折	0	1 (0.3)	1 (0.1)
頭部損傷	0	1 (0.3)	1 (0.1)
損傷	1 (0.3)	0	1 (0.1)
関節脱臼	1 (0.3)	0	1 (0.1)
関節損傷	1 (0.3)	0	1 (0.1)
靭帯断裂	1 (0.3)	0	1 (0.1)
靭帯捻挫	3 (0.9)	0	3 (0.4)
四肢損傷	3 (0.9)	1 (0.3)	4 (0.6)
口唇損傷	0	1 (0.3)	1 (0.1)
肉離れ	2 (0.6)	3 (0.9)	5 (0.7)
筋骨格系損傷	0	1 (0.3)	1 (0.1)
膝蓋骨骨折	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
傷害、中毒および処置合併症 (Cont.)			
処置による疼痛	0	1 (0.3)	1 (0.1)
交通事故	1 (0.3)	0	1 (0.1)
瘢痕	1 (0.3)	0	1 (0.1)
皮膚擦過傷	0	1 (0.3)	1 (0.1)
皮膚裂傷	0	1 (0.3)	1 (0.1)
サンバーン	1 (0.3)	1 (0.3)	2 (0.3)
腱断裂	1 (0.3)	1 (0.3)	2 (0.3)
熱傷	0	1 (0.3)	1 (0.1)
上肢骨折	1 (0.3)	0	1 (0.1)
ワクチン接種合併症	0	1 (0.3)	1 (0.1)
臨床検査	38 (11.2)	52 (15.0)	90 (13.1)
アラニンアミノトランスフェラーゼ増加	6 (1.8)	9 (2.6)	15 (2.2)
アスパラギン酸アミノトランスフェラーゼ増加	3 (0.9)	7 (2.0)	10 (1.5)
B リンパ球数増加	1 (0.3)	0	1 (0.1)
血中コレステロール増加	2 (0.6)	3 (0.9)	5 (0.7)
血中クレアチンホスホキナーゼ増加	14 (4.1)	24 (6.9)	38 (5.5)
血中クレアチニン増加	2 (0.6)	0	2 (0.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
臨床検査 (Cont.)			
血中ブドウ糖増加	0	2 (0.6)	2 (0.3)
血中免疫グロブリンＥ増加	6 (1.8)	0	6 (0.9)
血中乳酸脱水素酵素増加	0	1 (0.3)	1 (0.1)
血中カリウム増加	1 (0.3)	0	1 (0.1)
血圧上昇	1 (0.3)	0	1 (0.1)
血中トリグリセリド増加	1 (0.3)	0	1 (0.1)
血中尿酸増加	0	3 (0.9)	3 (0.4)
尿中血陽性	2 (0.6)	1 (0.3)	3 (0.4)
CD4 リンパ球減少	1 (0.3)	0	1 (0.1)
CD8 リンパ球百分率減少	1 (0.3)	0	1 (0.1)
CD8 リンパ球減少	0	1 (0.3)	1 (0.1)
心雑音	0	1 (0.3)	1 (0.1)
ケモカイン増加	1 (0.3)	0	1 (0.1)
尿中結晶陽性	1 (0.3)	1 (0.3)	2 (0.3)
好酸球百分率増加	1 (0.3)	0	1 (0.1)
ヘモグロビン減少	0	1 (0.3)	1 (0.1)
高比重リポ蛋白増加	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
臨床検査 (Cont.)			
肝機能検査値上昇	1 (0.3)	0	1 (0.1)
低比重リポ蛋白増加	0	1 (0.3)	1 (0.1)
リンパ球数減少	0	2 (0.6)	2 (0.3)
ナチュラルキラー細胞数減少	1 (0.3)	0	1 (0.1)
好中球数減少	1 (0.3)	2 (0.6)	3 (0.4)
血小板数増加	0	1 (0.3)	1 (0.1)
尿妊娠反応陽性	1 (0.3)	0	1 (0.1)
尿蛋白	1 (0.3)	0	1 (0.1)
尿中蛋白陽性	2 (0.6)	2 (0.6)	4 (0.6)
T リンパ球数減少	1 (0.3)	0	1 (0.1)
トランスアミナーゼ上昇	0	4 (1.2)	4 (0.6)
尿円柱	1 (0.3)	0	1 (0.1)
尿中ケトン体陽性	1 (0.3)	0	1 (0.1)
尿中白血球エステラーゼ陽性	0	1 (0.3)	1 (0.1)
体重減少	0	3 (0.9)	3 (0.4)
体重増加	7 (2.1)	11 (3.2)	18 (2.6)
白血球数減少	0	2 (0.6)	2 (0.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
代謝および栄養障害	12 (3.6)	18 (5.2)	30 (4.4)
食欲減退	1 (0.3)	3 (0.9)	4 (0.6)
脂質異常症	0	1 (0.3)	1 (0.1)
痛風	0	1 (0.3)	1 (0.1)
高コレステロール血症	1 (0.3)	5 (1.4)	6 (0.9)
高脂血症	1 (0.3)	1 (0.3)	2 (0.3)
高トリグリセリド血症	2 (0.6)	1 (0.3)	3 (0.4)
高尿酸血症	4 (1.2)	1 (0.3)	5 (0.7)
低血糖	0	1 (0.3)	1 (0.1)
低カリウム血症	0	3 (0.9)	3 (0.4)
低リン酸血症	1 (0.3)	0	1 (0.1)
食欲亢進	1 (0.3)	1 (0.3)	2 (0.3)
2 型糖尿病	0	1 (0.3)	1 (0.1)
ビタミン D 欠乏	1 (0.3)	0	1 (0.1)
筋骨格系および結合組織障害	23 (6.8)	30 (8.6)	53 (7.7)
関節痛	4 (1.2)	5 (1.4)	9 (1.3)
関節炎	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
筋骨格系および結合組織障害 (Cont.)			
腋窩腫瘤	0	1 (0.3)	1 (0.1)
背部痛	6 (1.8)	12 (3.5)	18 (2.6)
滑液包炎	1 (0.3)	0	1 (0.1)
側腹部痛	1 (0.3)	0	1 (0.1)
足変形	1 (0.3)	0	1 (0.1)
椎間板変性症	0	1 (0.3)	1 (0.1)
椎間板突出	1 (0.3)	0	1 (0.1)
筋骨格系胸痛	0	1 (0.3)	1 (0.1)
筋骨格痛	2 (0.6)	2 (0.6)	4 (0.6)
筋肉痛	4 (1.2)	6 (1.7)	10 (1.5)
頚部痛	1 (0.3)	0	1 (0.1)
変形性関節症	1 (0.3)	1 (0.3)	2 (0.3)
四肢痛	0	5 (1.4)	5 (0.7)
顎痛	0	1 (0.3)	1 (0.1)
骨膜炎	0	1 (0.3)	1 (0.1)
肩回旋筋腱板症候群	0	1 (0.3)	1 (0.1)
腱障害	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
筋骨格系および結合組織障害 (Cont.)			
腱炎	1 (0.3)	1 (0.3)	2 (0.3)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	4 (1.2)	10 (2.9)	14 (2.0)
肛門性器疣贅	1 (0.3)	0	1 (0.1)
ボーエン病	1 (0.3)	0	1 (0.1)
真珠腫	0	1 (0.3)	1 (0.1)
胃癌	0	1 (0.3)	1 (0.1)
浸潤性乳管癌	0	1 (0.3)	1 (0.1)
メラノサイト性母斑	0	1 (0.3)	1 (0.1)
脂漏性角化症	0	1 (0.3)	1 (0.1)
皮膚乳頭腫	2 (0.6)	4 (1.2)	6 (0.9)
扁平上皮癌	0	1 (0.3)	1 (0.1)
神経系障害	24 (7.1)	29 (8.4)	53 (7.7)
健忘	0	1 (0.3)	1 (0.1)
手根管症候群	1 (0.3)	0	1 (0.1)
注意力障害	1 (0.3)	0	1 (0.1)
浮動性めまい	4 (1.2)	6 (1.7)	10 (1.5)
夢幻状態	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
神経系障害 (Cont.)			
味覚不全	0	1 (0.3)	1 (0.1)
頭痛	14 (4.1)	20 (5.8)	34 (5.0)
虚血性脳卒中	1 (0.3)	0	1 (0.1)
片頭痛	0	2 (0.6)	2 (0.3)
前兆を伴う片頭痛	0	1 (0.3)	1 (0.1)
錯感覚	1 (0.3)	0	1 (0.1)
神経根障害	0	1 (0.3)	1 (0.1)
坐骨神経痛	1 (0.3)	0	1 (0.1)
傾眠	2 (0.6)	0	2 (0.3)
緊張性頭痛	0	2 (0.6)	2 (0.3)
精神障害	12 (3.6)	10 (2.9)	22 (3.2)
不安	3 (0.9)	4 (1.2)	7 (1.0)
無感情	1 (0.3)	0	1 (0.1)
注意欠陥多動性障害	1 (0.3)	0	1 (0.1)
抑うつ気分	0	1 (0.3)	1 (0.1)
うつ病	0	2 (0.6)	2 (0.3)
失見当識	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
精神障害 (Cont.)			
不眠症	2 (0.6)	1 (0.3)	3 (0.4)
リビドー減退	1 (0.3)	0	1 (0.1)
大うつ病	0	1 (0.3)	1 (0.1)
躁病	1 (0.3)	0	1 (0.1)
混合性不安抑うつ障害	1 (0.3)	0	1 (0.1)
睡眠障害	2 (0.6)	0	2 (0.3)
ストレス	1 (0.3)	0	1 (0.1)
腎および尿路障害	4 (1.2)	10 (2.9)	14 (2.0)
急性腎障害	0	1 (0.3)	1 (0.1)
アルブミン尿	1 (0.3)	2 (0.6)	3 (0.4)
排尿困難	1 (0.3)	2 (0.6)	3 (0.4)
血尿	1 (0.3)	1 (0.3)	2 (0.3)
緊張性膀胱	0	1 (0.3)	1 (0.1)
頻尿	0	1 (0.3)	1 (0.1)
蛋白尿	1 (0.3)	2 (0.6)	3 (0.4)
生殖系および乳房障害	3 (0.9)	7 (2.0)	10 (1.5)
無月経	1 (0.3)	2 (0.6)	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
生殖系および乳房障害 (Cont.)			
乳房腫大	0	1 (0.3)	1 (0.1)
乳房圧痛	0	1 (0.3)	1 (0.1)
月経困難症	1 (0.3)	0	1 (0.1)
閉経期症状	0	1 (0.3)	1 (0.1)
月経過多	1 (0.3)	1 (0.3)	2 (0.3)
精巣痛	0	1 (0.3)	1 (0.1)
外陰腟乾燥	0	1 (0.3)	1 (0.1)
呼吸器、胸郭および縦隔障害	28 (8.3)	27 (7.8)	55 (8.0)
喘息	6 (1.8)	4 (1.2)	10 (1.5)
気管支反応性亢進	1 (0.3)	0	1 (0.1)
慢性閉塞性肺疾患	0	1 (0.3)	1 (0.1)
咳嗽	11 (3.3)	8 (2.3)	19 (2.8)
発声障害	1 (0.3)	0	1 (0.1)
呼吸困難	2 (0.6)	0	2 (0.3)
鼻出血	2 (0.6)	4 (1.2)	6 (0.9)
鼻閉	1 (0.3)	3 (0.9)	4 (0.6)
鼻乾燥	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
呼吸器、胸郭および縦隔障害 (Cont.)			
口腔咽頭痛	7 (2.1)	8 (2.3)	15 (2.2)
湿性咳嗽	1 (0.3)	0	1 (0.1)
アレルギー性鼻炎	2 (0.6)	1 (0.3)	3 (0.4)
鼻漏	0	1 (0.3)	1 (0.1)
副鼻腔うっ血	0	1 (0.3)	1 (0.1)
咽喉刺激感	1 (0.3)	1 (0.3)	2 (0.3)
上気道の炎症	0	1 (0.3)	1 (0.1)
皮膚および皮下組織障害	69 (20.4)	110 (31.7)	179 (26.1)
ざ瘡	22 (6.5)	62 (17.9)	84 (12.3)
光線角化症	2 (0.6)	1 (0.3)	3 (0.4)
脱毛症	1 (0.3)	1 (0.3)	2 (0.3)
血管浮腫	1 (0.3)	1 (0.3)	2 (0.3)
水疱	1 (0.3)	0	1 (0.1)
皮膚嚢腫	0	1 (0.3)	1 (0.1)
皮膚炎	1 (0.3)	2 (0.6)	3 (0.4)
ざ瘡様皮膚炎	3 (0.9)	14 (4.0)	17 (2.5)
アトピー性皮膚炎	20 (5.9)	18 (5.2)	38 (5.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
皮膚および皮下組織障害 (Cont.)			
接触皮膚炎	2 (0.6)	7 (2.0)	9 (1.3)
びまん性脱毛症	0	1 (0.3)	1 (0.1)
薬疹	1 (0.3)	0	1 (0.1)
異汗性湿疹	0	1 (0.3)	1 (0.1)
斑状出血	1 (0.3)	0	1 (0.1)
湿疹	2 (0.6)	2 (0.6)	4 (0.6)
紅斑	2 (0.6)	1 (0.3)	3 (0.4)
毛包性ムチン沈着症	0	1 (0.3)	1 (0.1)
毛髪成長異常	0	1 (0.3)	1 (0.1)
逆むけ	0	1 (0.3)	1 (0.1)
多汗症	0	1 (0.3)	1 (0.1)
嵌入爪	1 (0.3)	0	1 (0.1)
機械性蕁麻疹	0	1 (0.3)	1 (0.1)
汗疹	1 (0.3)	0	1 (0.1)
神経皮膚炎	1 (0.3)	0	1 (0.1)
寝汗	1 (0.3)	1 (0.3)	2 (0.3)
爪破損	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
皮膚および皮下組織障害 (Cont.)			
類乾癬	0	1 (0.3)	1 (0.1)
口囲皮膚炎	1 (0.3)	0	1 (0.1)
光線過敏性反応	0	1 (0.3)	1 (0.1)
そう痒症	5 (1.5)	1 (0.3)	6 (0.9)
紫斑	0	1 (0.3)	1 (0.1)
発疹	2 (0.6)	1 (0.3)	3 (0.4)
斑状丘疹状皮疹	1 (0.3)	0	1 (0.1)
丘疹性皮疹	1 (0.3)	0	1 (0.1)
酒さ	0	2 (0.6)	2 (0.3)
脂漏	1 (0.3)	0	1 (0.1)
脂漏性皮膚炎	0	1 (0.3)	1 (0.1)
皮膚障害	0	1 (0.3)	1 (0.1)
皮膚亀裂	1 (0.3)	0	1 (0.1)
皮膚腫脹	1 (0.3)	0	1 (0.1)
日光黒子	0	1 (0.3)	1 (0.1)
毛細血管拡張症	1 (0.3)	0	1 (0.1)
中毒性表皮壊死融解症	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) n (%)	UPA 30 mg QD (N=347) n (%)	Total (N=685) n (%)
皮膚および皮下組織障害 (Cont.)			
蕁麻疹	3 (0.9)	6 (1.7)	9 (1.3)
外科および内科処置	1 (0.3)	0	1 (0.1)
人工流産	1 (0.3)	0	1 (0.1)
血管障害	8 (2.4)	4 (1.2)	12 (1.8)
血性分泌物	1 (0.3)	0	1 (0.1)
潮紅	1 (0.3)	0	1 (0.1)
血腫	1 (0.3)	0	1 (0.1)
ほてり	0	1 (0.3)	1 (0.1)
高血圧	5 (1.5)	2 (0.6)	7 (1.0)
血栓性静脈炎	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.6.2.3

表 7. ウパダシチニブ投与期間中の有害事象の 100 人年あたりの発現率：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
Any adverse event	850 (335.0)	1170 (454.9)	20[redacted] (395.4)
血液およびリンパ系障害	16 (6.3)	34 (13.2)	50 (9.8)
貧血	0	8 (3.1)	8 (1.6)
白血球増加症	1 (0.4)	1 (0.4)	2 (0.4)
白血球減少症	0	1 (0.4)	1 (0.2)
リンパ節症	3 (1.2)	2 (0.8)	5 (1.0)
リンパ球減少症	2 (0.8)	1 (0.4)	3 (0.6)
好中球減少症	8 (3.2)	19 (7.4)	27 (5.3)
好中球増加症	2 (0.8)	0	2 (0.4)
汎血球減少症	0	1 (0.4)	1 (0.2)
血小板減少症	0	1 (0.4)	1 (0.2)
心臓障害	1 (0.4)	3 (1.2)	4 (0.8)
心房細動	0	1 (0.4)	1 (0.2)
徐脈	0	1 (0.4)	1 (0.2)
心血管障害	1 (0.4)	0	1 (0.2)
冠動脈疾患	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
先天性、家族性および遺伝性障害	0	1 (0.4)	1 (0.2)
包茎	0	1 (0.4)	1 (0.2)
耳および迷路障害	4 (1.6)	6 (2.3)	10 (2.0)
耳垢栓塞	0	2 (0.8)	2 (0.4)
突発性難聴	0	1 (0.4)	1 (0.2)
鼓膜障害	0	1 (0.4)	1 (0.2)
回転性めまい	4 (1.6)	2 (0.8)	6 (1.2)
内分泌障害	1 (0.4)	2 (0.8)	3 (0.6)
バセドウ病	0	1 (0.4)	1 (0.2)
甲状腺機能低下症	1 (0.4)	0	1 (0.2)
甲状腺腫瘤	0	1 (0.4)	1 (0.2)
眼障害	11 (4.3)	15 (5.8)	26 (5.1)
眼瞼炎	0	2 (0.8)	2 (0.4)
白内障	1 (0.4)	0	1 (0.2)
結膜出血	0	1 (0.4)	1 (0.2)
アレルギー性結膜炎	1 (0.4)	2 (0.8)	3 (0.6)
ドライアイ	1 (0.4)	2 (0.8)	3 (0.6)
眼瞼湿疹	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
眼障害 (Cont.)			
眼そう痒症	0	1 (0.4)	1 (0.2)
眼部腫脹	0	1 (0.4)	1 (0.2)
緑内障	1 (0.4)	0	1 (0.2)
流涙増加	1 (0.4)	1 (0.4)	2 (0.4)
黄斑変性	1 (0.4)	0	1 (0.2)
眼窩周囲腫脹	1 (0.4)	1 (0.4)	2 (0.4)
網膜剥離	1 (0.4)	0	1 (0.2)
潰瘍性角膜炎	1 (0.4)	0	1 (0.2)
霧視	1 (0.4)	3 (1.2)	4 (0.8)
視力障害	1 (0.4)	0	1 (0.2)
胃腸障害	59 (23.3)	90 (35.0)	149 (29.2)
腹部不快感	1 (0.4)	1 (0.4)	2 (0.4)
腹部膨満	1 (0.4)	1 (0.4)	2 (0.4)
腹痛	1 (0.4)	6 (2.3)	7 (1.4)
上腹部痛	5 (2.0)	5 (1.9)	10 (2.0)
口角口唇炎	0	1 (0.4)	1 (0.2)
呼気臭	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
胃腸障害 (Cont.)			
便秘	3 (1.2)	2 (0.8)	5 (1.0)
齲歯	2 (0.8)	4 (1.6)	6 (1.2)
下痢	12 (4.7)	16 (6.2)	28 (5.5)
腸憩室	1 (0.4)	0	1 (0.2)
口内乾燥	0	3 (1.2)	3 (0.6)
消化不良	2 (0.8)	2 (0.8)	4 (0.8)
軟便	0	2 (0.8)	2 (0.4)
鼓腸	3 (1.2)	2 (0.8)	5 (1.0)
食中毒	1 (0.4)	2 (0.8)	3 (0.6)
胃潰瘍	1 (0.4)	1 (0.4)	2 (0.4)
胃炎	4 (1.6)	0	4 (0.8)
びらん性胃炎	0	1 (0.4)	1 (0.2)
消化器痛	1 (0.4)	0	1 (0.2)
胃食道逆流性疾患	1 (0.4)	5 (1.9)	6 (1.2)
歯肉痛	0	1 (0.4)	1 (0.2)
痔核	0	2 (0.8)	2 (0.4)
歯の知覚過敏	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
胃腸障害 (Cont.)			
過敏性腸症候群	0	1 (0.4)	1 (0.2)
口唇腫脹	0	1 (0.4)	1 (0.2)
口腔内潰瘍形成	0	1 (0.4)	1 (0.2)
悪心	13 (5.1)	15 (5.8)	28 (5.5)
食道狭窄	1 (0.4)	0	1 (0.2)
大網壊死	0	1 (0.4)	1 (0.2)
口腔障害	0	1 (0.4)	1 (0.2)
膵炎	0	1 (0.4)	1 (0.2)
埋伏歯	1 (0.4)	0	1 (0.2)
歯痛	1 (0.4)	2 (0.8)	3 (0.6)
嘔吐	4 (1.6)	8 (3.1)	12 (2.3)
一般・全身障害および投与部位の状態	35 (13.8)	40 (15.6)	75 (14.7)
無力症	1 (0.4)	1 (0.4)	2 (0.4)
胸部不快感	1 (0.4)	1 (0.4)	2 (0.4)
胸痛	1 (0.4)	0	1 (0.2)
悪寒	0	2 (0.8)	2 (0.4)
嚢胞	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
一般・全身障害および投与部位の状態 (Cont.)			
不快感	0	1 (0.4)	1 (0.2)
薬物不耐性	0	1 (0.4)	1 (0.2)
顔面浮腫	1 (0.4)	1 (0.4)	2 (0.4)
疲労	4 (1.6)	3 (1.2)	7 (1.4)
びくびく感	0	1 (0.4)	1 (0.2)
インフルエンザ様疾患	7 (2.8)	11 (4.3)	18 (3.5)
倦怠感	0	1 (0.4)	1 (0.2)
腫瘤	1 (0.4)	0	1 (0.2)
粘膜乾燥	0	1 (0.4)	1 (0.2)
小結節	0	1 (0.4)	1 (0.2)
非心臓性胸痛	0	1 (0.4)	1 (0.2)
浮腫	0	1 (0.4)	1 (0.2)
末梢性浮腫	1 (0.4)	1 (0.4)	2 (0.4)
疼痛	2 (0.8)	2 (0.8)	4 (0.8)
発熱	13 (5.1)	9 (3.5)	22 (4.3)
腫脹	1 (0.4)	0	1 (0.2)
顔面腫脹	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
一般・全身障害および投与部位の状態 (Cont.)			
血管穿刺部位内出血	0	1 (0.4)	1 (0.2)
肝胆道系障害	2 (0.8)	6 (2.3)	8 (1.6)
胆嚢炎	0	1 (0.4)	1 (0.2)
胆石症	1 (0.4)	0	1 (0.2)
胆嚢ポリープ	0	1 (0.4)	1 (0.2)
肝機能異常	1 (0.4)	0	1 (0.2)
脂肪肝	0	3 (1.2)	3 (0.6)
肝腫大	0	1 (0.4)	1 (0.2)
免疫系障害	6 (2.4)	8 (3.1)	14 (2.7)
化学物質アレルギー	1 (0.4)	0	1 (0.2)
ワクチンアレルギー	1 (0.4)	0	1 (0.2)
アナフィラキシー反応	0	2 (0.8)	2 (0.4)
薬物過敏症	0	1 (0.4)	1 (0.2)
食物アレルギー	2 (0.8)	2 (0.8)	4 (0.8)
過敏症	2 (0.8)	0	2 (0.4)
乳アレルギー	0	1 (0.4)	1 (0.2)
1 型過敏症	0	2 (0.8)	2 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症	313 (123.4)	440 (171.1)	753 (147.4)
四肢膿瘍	0	1 (0.4)	1 (0.2)
ダニ皮膚炎	1 (0.4)	1 (0.4)	2 (0.4)
膿疱性ざ瘡	1 (0.4)	0	1 (0.2)
虫垂炎	2 (0.8)	0	2 (0.4)
細菌感染	1 (0.4)	1 (0.4)	2 (0.4)
細菌性膣症	0	2 (0.8)	2 (0.4)
細菌尿	0	1 (0.4)	1 (0.2)
体部白癬	3 (1.2)	2 (0.8)	5 (1.0)
気管支炎	7 (2.8)	10 (3.9)	17 (3.3)
ウイルス性気管支炎	1 (0.4)	0	1 (0.2)
カンジダ感染	1 (0.4)	0	1 (0.2)
蜂巣炎	4 (1.6)	2 (0.8)	6 (1.2)
結膜炎	3 (1.2)	7 (2.7)	10 (2.0)
コロナウイルス感染	1 (0.4)	1 (0.4)	2 (0.4)
感染性クループ	1 (0.4)	0	1 (0.2)
膀胱炎	0	2 (0.8)	2 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
感染性皮膚炎	1 (0.4)	0	1 (0.2)
皮膚糸状菌症	1 (0.4)	1 (0.4)	2 (0.4)
爪の皮膚糸状菌症	1 (0.4)	0	1 (0.2)
憩室炎	0	1 (0.4)	1 (0.2)
耳感染	3 (1.2)	9 (3.5)	12 (2.3)
膿瘡	2 (0.8)	0	2 (0.4)
ヘルペス性状湿疹	1 (0.4)	3 (1.2)	4 (0.8)
感染性湿疹	0	1 (0.4)	1 (0.2)
丹毒	0	1 (0.4)	1 (0.2)
大腸菌性尿路感染	0	1 (0.4)	1 (0.2)
外耳蜂巣炎	1 (0.4)	0	1 (0.2)
眼感染	1 (0.4)	0	1 (0.2)
毛包炎	8 (3.2)	16 (6.2)	24 (4.7)
真菌感染	2 (0.8)	0	2 (0.4)
せつ	4 (1.6)	4 (1.6)	8 (1.6)
胃腸炎	4 (1.6)	12 (4.7)	16 (3.1)
ウイルス性胃腸炎	1 (0.4)	2 (0.8)	3 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
ウイルス性消化管感染	0	1 (0.4)	1 (0.2)
陰部ヘルペス	2 (0.8)	0	2 (0.4)
陰部単純ヘルペス	0	3 (1.2)	3 (0.6)
手足口病	1 (0.4)	0	1 (0.2)
蠕虫感染	0	1 (0.4)	1 (0.2)
B 型肝炎	0	1 (0.4)	1 (0.2)
ヘルパンギーナ	0	1 (0.4)	1 (0.2)
ヘルペス性皮膚炎	0	2 (0.8)	2 (0.4)
ヘルペス眼感染	0	4 (1.6)	4 (0.8)
単純ヘルペス	12 (4.7)	17 (6.6)	29 (5.7)
ヘルペスウイルス感染	2 (0.8)	1 (0.4)	3 (0.6)
帯状疱疹	8 (3.2)	12 (4.7)	20 (3.9)
麦粒腫	4 (1.6)	10 (3.9)	14 (2.7)
膿痂疹	14 (5.5)	6 (2.3)	20 (3.9)
インフルエンザ	3 (1.2)	10 (3.9)	13 (2.5)
椎間板炎	1 (0.4)	0	1 (0.2)
カポジ水痘様発疹	1 (0.4)	5 (1.9)	6 (1.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
喉頭炎	2 (0.8)	3 (1.2)	5 (1.0)
ウイルス性喉頭炎	1 (0.4)	0	1 (0.2)
潜伏結核	0	2 (0.8)	2 (0.4)
限局性感染	1 (0.4)	0	1 (0.2)
下気道感染	1 (0.4)	0	1 (0.2)
細菌性リンパ節炎	0	1 (0.4)	1 (0.2)
伝染性軟属腫	2 (0.8)	3 (1.2)	5 (1.0)
マイコプラズマ感染	0	1 (0.4)	1 (0.2)
上咽頭炎	48 (18.9)	62 (24.1)	110 (21.5)
乳頭感染	1 (0.4)	0	1 (0.2)
爪真菌症	1 (0.4)	0	1 (0.2)
眼部単純ヘルペス	1 (0.4)	2 (0.8)	3 (0.6)
口腔カンジダ症	1 (0.4)	5 (1.9)	6 (1.2)
口腔ヘルペス	8 (3.2)	29 (11.3)	37 (7.2)
骨髄炎	0	1 (0.4)	1 (0.2)
外耳炎	2 (0.8)	1 (0.4)	3 (0.6)
中耳炎	1 (0.4)	2 (0.8)	3 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
急性中耳炎	1 (0.4)	1 (0.4)	2 (0.4)
爪囲炎	2 (0.8)	6 (2.3)	8 (1.6)
歯周炎	1 (0.4)	0	1 (0.2)
咽頭膿瘍	0	1 (0.4)	1 (0.2)
咽頭炎	7 (2.8)	5 (1.9)	12 (2.3)
レンサ球菌性咽頭炎	1 (0.4)	0	1 (0.2)
咽頭扁桃炎	2 (0.8)	1 (0.4)	3 (0.6)
肺炎	3 (1.2)	3 (1.2)	6 (1.2)
細菌性肺炎	0	1 (0.4)	1 (0.2)
ブドウ球菌性肺炎	0	1 (0.4)	1 (0.2)
ウイルス性肺炎	1 (0.4)	0	1 (0.2)
術後創感染	0	1 (0.4)	1 (0.2)
膿疱	0	1 (0.4)	1 (0.2)
腎盂腎炎	0	1 (0.4)	1 (0.2)
膿皮症	1 (0.4)	0	1 (0.2)
膿疱性皮疹	1 (0.4)	0	1 (0.2)
RS ウイルス感染	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
気道感染	4 (1.6)	2 (0.8)	6 (1.2)
ウイルス性気道感染	1 (0.4)	0	1 (0.2)
鼻炎	4 (1.6)	6 (2.3)	10 (2.0)
ライノウイルス感染	0	1 (0.4)	1 (0.2)
根管感染	0	1 (0.4)	1 (0.2)
敗血症	0	2 (0.8)	2 (0.4)
副鼻腔炎	7 (2.8)	5 (1.9)	12 (2.3)
皮膚細菌感染	2 (0.8)	2 (0.8)	4 (0.8)
皮膚カンジダ	1 (0.4)	1 (0.4)	2 (0.4)
植皮感染	0	1 (0.4)	1 (0.2)
皮膚感染	4 (1.6)	4 (1.6)	8 (1.6)
ブドウ球菌感染	1 (0.4)	5 (1.9)	6 (1.2)
ブドウ球菌性敗血症	0	1 (0.4)	1 (0.2)
ブドウ球菌皮膚感染	1 (0.4)	0	1 (0.2)
皮下組織膿瘍	1 (0.4)	1 (0.4)	2 (0.4)
細菌重複感染	1 (0.4)	0	1 (0.2)
股部白癬	0	3 (1.2)	3 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
足部白癬	2 (0.8)	2 (0.8)	4 (0.8)
癜風	2 (0.8)	0	2 (0.4)
扁桃炎	3 (1.2)	4 (1.6)	7 (1.4)
細菌性扁桃炎	0	1 (0.4)	1 (0.2)
歯膿瘍	3 (1.2)	2 (0.8)	5 (1.0)
歯感染	0	2 (0.8)	2 (0.4)
上気道感染	55 (21.7)	69 (26.8)	124 (24.3)
クラミジア性尿道炎	1 (0.4)	0	1 (0.2)
尿路感染	10 (3.9)	13 (5.1)	23 (4.5)
水痘	0	1 (0.4)	1 (0.2)
ウイルス性下痢	0	1 (0.4)	1 (0.2)
ウイルス感染	2 (0.8)	1 (0.4)	3 (0.6)
ウイルス性咽頭炎	2 (0.8)	0	2 (0.4)
ウイルス性発疹	1 (0.4)	0	1 (0.2)
ウイルス性上気道感染	8 (3.2)	15 (5.8)	23 (4.5)
外陰部腟カンジダ症	2 (0.8)	2 (0.8)	4 (0.8)
外陰腟真菌感染	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
創傷感染	0	1 (0.4)	1 (0.2)
ブドウ球菌性創感染	0	1 (0.4)	1 (0.2)
傷害、中毒および処置合併症	34 (13.4)	33 (12.8)	67 (13.1)
偶発的過量投与	0	1 (0.4)	1 (0.2)
アルコール中毒	0	1 (0.4)	1 (0.2)
節足動物咬傷	1 (0.4)	1 (0.4)	2 (0.4)
節足動物刺傷	0	1 (0.4)	1 (0.2)
背部損傷	1 (0.4)	0	1 (0.2)
第 1 度熱傷	0	1 (0.4)	1 (0.2)
第 2 度熱傷	1 (0.4)	0	1 (0.2)
第 3 度熱傷	0	1 (0.4)	1 (0.2)
軟骨損傷	1 (0.4)	0	1 (0.2)
脳振盪	2 (0.8)	0	2 (0.4)
挫傷	3 (1.2)	1 (0.4)	4 (0.8)
転倒	3 (1.2)	3 (1.2)	6 (1.2)
足骨折	1 (0.4)	3 (1.2)	4 (0.8)
体内異物	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
手骨折	0	1 (0.4)	1 (0.2)
頭部損傷	1 (0.4)	1 (0.4)	2 (0.4)
熱疲労	1 (0.4)	0	1 (0.2)
損傷	1 (0.4)	0	1 (0.2)
関節脱臼	1 (0.4)	0	1 (0.2)
関節損傷	1 (0.4)	1 (0.4)	2 (0.4)
靱帯断裂	1 (0.4)	1 (0.4)	2 (0.4)
靱帯捻挫	3 (1.2)	0	3 (0.6)
四肢損傷	3 (1.2)	1 (0.4)	4 (0.8)
口唇損傷	0	1 (0.4)	1 (0.2)
半月板損傷	0	1 (0.4)	1 (0.2)
肉離れ	2 (0.8)	3 (1.2)	5 (1.0)
筋骨格系損傷	0	1 (0.4)	1 (0.2)
膝蓋骨骨折	1 (0.4)	0	1 (0.2)
処置による疼痛	0	1 (0.4)	1 (0.2)
交通事故	1 (0.4)	1 (0.4)	2 (0.4)
瘢痕	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
皮膚擦過傷	1 (0.4)	1 (0.4)	2 (0.4)
皮膚裂傷	0	1 (0.4)	1 (0.2)
サンバーン	1 (0.4)	1 (0.4)	2 (0.4)
腱断裂	1 (0.4)	1 (0.4)	2 (0.4)
熱傷	0	1 (0.4)	1 (0.2)
上肢骨折	1 (0.4)	0	1 (0.2)
ワクチン接種合併症	0	1 (0.4)	1 (0.2)
臨床検査	91 (35.9)	109 (42.4)	200 (39.1)
アラニンアミノトランスフェラーゼ増加	8 (3.2)	10 (3.9)	18 (3.5)
アスパラギン酸アミノトランスフェラーゼ増加	4 (1.6)	7 (2.7)	11 (2.2)
B リンパ球数増加	1 (0.4)	0	1 (0.2)
血中アルカリホスファターゼ増加	1 (0.4)	0	1 (0.2)
血中ビリルビン増加	1 (0.4)	0	1 (0.2)
血中コレステロール増加	3 (1.2)	4 (1.6)	7 (1.4)
血中クレアチンホスホキナーゼ増加	30 (11.8)	37 (14.4)	67 (13.1)
血中クレアチニン増加	3 (1.2)	0	3 (0.6)
血液培養陽性	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
臨床検査 (Cont.)			
血中ブドウ糖増加	0	2 (0.8)	2 (0.4)
血中免疫グロブリン E 増加	6 (2.4)	0	6 (1.2)
血中乳酸脱水素酵素増加	0	1 (0.4)	1 (0.2)
血中カリウム増加	1 (0.4)	0	1 (0.2)
血圧上昇	1 (0.4)	0	1 (0.2)
血中トリグリセリド増加	1 (0.4)	0	1 (0.2)
血中尿酸増加	0	3 (1.2)	3 (0.6)
尿中血陽性	2 (0.8)	1 (0.4)	3 (0.6)
CD4 リンパ球減少	1 (0.4)	0	1 (0.2)
CD8 リンパ球百分率減少	1 (0.4)	0	1 (0.2)
CD8 リンパ球減少	0	1 (0.4)	1 (0.2)
心雑音	0	2 (0.8)	2 (0.4)
ケモカイン増加	1 (0.4)	0	1 (0.2)
尿中結晶陽性	1 (0.4)	1 (0.4)	2 (0.4)
尿培養陽性	0	1 (0.4)	1 (0.2)
好酸球百分率増加	1 (0.4)	0	1 (0.2)
ヘモグロビン減少	2 (0.8)	1 (0.4)	3 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
臨床検査 (Cont.)			
心拍数増加	0	2 (0.8)	2 (0.4)
肝酵素上昇	1 (0.4)	0	1 (0.2)
高比重リポ蛋白増加	0	1 (0.4)	1 (0.2)
肝機能検査値上昇	1 (0.4)	0	1 (0.2)
低比重リポ蛋白増加	0	1 (0.4)	1 (0.2)
リンパ球数減少	0	2 (0.8)	2 (0.4)
ナチュラルキラー細胞数減少	1 (0.4)	0	1 (0.2)
好中球数減少	1 (0.4)	2 (0.8)	3 (0.6)
血小板数増加	0	1 (0.4)	1 (0.2)
尿妊娠反応陽性	1 (0.4)	0	1 (0.2)
尿蛋白	1 (0.4)	0	1 (0.2)
尿中蛋白陽性	2 (0.8)	2 (0.8)	4 (0.8)
T リンパ球数減少	1 (0.4)	0	1 (0.2)
トランスアミナーゼ上昇	1 (0.4)	4 (1.6)	5 (1.0)
尿円柱	1 (0.4)	0	1 (0.2)
尿中ケトン体陽性	1 (0.4)	0	1 (0.2)
尿中白血球エステラーゼ陽性	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
臨床検査 (Cont.)			
尿中シュウ酸塩	1 (0.4)	0	1 (0.2)
体重減少	0	3 (1.2)	3 (0.6)
体重増加	9 (3.5)	15 (5.8)	24 (4.7)
白血球数減少	0	3 (1.2)	3 (0.6)
代謝および栄養障害	15 (5.9)	19 (7.4)	34 (6.7)
食欲減退	2 (0.8)	3 (1.2)	5 (1.0)
脂質異常症	0	1 (0.4)	1 (0.2)
痛風	0	1 (0.4)	1 (0.2)
高コレステロール血症	1 (0.4)	5 (1.9)	6 (1.2)
高脂血症	1 (0.4)	1 (0.4)	2 (0.4)
高トリグリセリド血症	2 (0.8)	1 (0.4)	3 (0.6)
高尿酸血症	4 (1.6)	1 (0.4)	5 (1.0)
低血糖	0	1 (0.4)	1 (0.2)
低カリウム血症	0	3 (1.2)	3 (0.6)
低リン酸血症	1 (0.4)	0	1 (0.2)
食欲亢進	2 (0.8)	1 (0.4)	3 (0.6)
2 型糖尿病	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
代謝および栄養障害 (Cont.)			
ビタミンD欠乏	2 (0.8)	0	2 (0.4)
筋骨格系および結合組織障害	29 (11.4)	45 (17.5)	74 (14.5)
関節痛	4 (1.6)	7 (2.7)	11 (2.2)
関節炎	1 (0.4)	0	1 (0.2)
腋窩腫瘤	0	1 (0.4)	1 (0.2)
背部痛	7 (2.8)	15 (5.8)	22 (4.3)
滑液包炎	1 (0.4)	0	1 (0.2)
側腹部痛	1 (0.4)	0	1 (0.2)
足変形	1 (0.4)	0	1 (0.2)
椎間板変性症	0	1 (0.4)	1 (0.2)
椎間板突出	1 (0.4)	0	1 (0.2)
筋骨格系胸痛	0	1 (0.4)	1 (0.2)
筋骨格痛	2 (0.8)	2 (0.8)	4 (0.8)
筋肉痛	5 (2.0)	6 (2.3)	11 (2.2)
頚部痛	1 (0.4)	0	1 (0.2)
変形性関節症	1 (0.4)	1 (0.4)	2 (0.4)
骨端症	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
筋骨格系および結合組織障害 (Cont.)			
四肢痛	0	6 (2.3)	6 (1.2)
顎痛	1 (0.4)	1 (0.4)	2 (0.4)
骨膜炎	0	1 (0.4)	1 (0.2)
肩回旋筋腱板症候群	0	1 (0.4)	1 (0.2)
側弯症	1 (0.4)	0	1 (0.2)
腱障害	1 (0.4)	0	1 (0.2)
腱炎	1 (0.4)	1 (0.4)	2 (0.4)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	5 (2.0)	11 (4.3)	16 (3.1)
肛門性器疣贅	1 (0.4)	0	1 (0.2)
ボーエン病	1 (0.4)	0	1 (0.2)
真珠腫	0	1 (0.4)	1 (0.2)
胃癌	0	1 (0.4)	1 (0.2)
浸潤性乳管癌	0	1 (0.4)	1 (0.2)
メラノサイト性母斑	0	1 (0.4)	1 (0.2)
脂漏性角化症	0	1 (0.4)	1 (0.2)
皮膚乳頭腫	3 (1.2)	5 (1.9)	8 (1.6)
扁平上皮癌	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
神経系障害	35 (13.8)	40 (15.6)	75 (14.7)
健忘	0	1 (0.4)	1 (0.2)
手根管症候群	1 (0.4)	0	1 (0.2)
注意力障害	1 (0.4)	0	1 (0.2)
浮動性めまい	4 (1.6)	6 (2.3)	10 (2.0)
夢幻状態	1 (0.4)	0	1 (0.2)
味覚不全	0	1 (0.4)	1 (0.2)
錐体外路障害	1 (0.4)	0	1 (0.2)
頭痛	20 (7.9)	25 (9.7)	45 (8.8)
虚血性脳卒中	1 (0.4)	0	1 (0.2)
片頭痛	0	2 (0.8)	2 (0.4)
前兆を伴う片頭痛	0	1 (0.4)	1 (0.2)
錯感覚	1 (0.4)	0	1 (0.2)
神経根障害	0	1 (0.4)	1 (0.2)
坐骨神経痛	1 (0.4)	0	1 (0.2)
傾眠	3 (1.2)	0	3 (0.6)
失神	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
神経系障害 (Cont.)			
緊張性頭痛	1 (0.4)	2 (0.8)	3 (0.6)
精神障害	19 (7.5)	13 (5.1)	32 (6.3)
不安	5 (2.0)	4 (1.6)	9 (1.8)
不安障害	0	1 (0.4)	1 (0.2)
無感情	1 (0.4)	0	1 (0.2)
注意欠陥多動性障害	1 (0.4)	0	1 (0.2)
抑うつ気分	0	1 (0.4)	1 (0.2)
うつ病	1 (0.4)	2 (0.8)	3 (0.6)
失見当識	0	1 (0.4)	1 (0.2)
不眠症	2 (0.8)	2 (0.8)	4 (0.8)
故意の自傷行為	1 (0.4)	0	1 (0.2)
リビドー減退	1 (0.4)	0	1 (0.2)
大うつ病	1 (0.4)	1 (0.4)	2 (0.4)
躁病	1 (0.4)	0	1 (0.2)
混合性不安抑うつ障害	1 (0.4)	0	1 (0.2)
パニック発作	0	1 (0.4)	1 (0.2)
睡眠障害	3 (1.2)	0	3 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
精神障害 (Cont.)			
ストレス	1 (0.4)	0	1 (0.2)
腎および尿路障害	4 (1.6)	13 (5.1)	17 (3.3)
急性腎障害	0	1 (0.4)	1 (0.2)
アルブミン尿	1 (0.4)	4 (1.6)	5 (1.0)
排尿困難	1 (0.4)	3 (1.2)	4 (0.8)
血尿	1 (0.4)	1 (0.4)	2 (0.4)
緊張性膀胱	0	1 (0.4)	1 (0.2)
頻尿	0	1 (0.4)	1 (0.2)
蛋白尿	1 (0.4)	2 (0.8)	3 (0.6)
生殖系および乳房障害	4 (1.6)	9 (3.5)	13 (2.5)
無月経	1 (0.4)	3 (1.2)	4 (0.8)
乳房腫大	0	1 (0.4)	1 (0.2)
乳房圧痛	0	1 (0.4)	1 (0.2)
月経困難症	2 (0.8)	0	2 (0.4)
閉経期症状	0	1 (0.4)	1 (0.2)
月経過多	1 (0.4)	1 (0.4)	2 (0.4)
精巣痛	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
生殖系および乳房障害 (Cont.)			
外陰腟乾燥	0	1 (0.4)	1 (0.2)
呼吸器、胸郭および縦隔障害	54 (21.3)	43 (16.7)	97 (19.0)
喘息	9 (3.5)	4 (1.6)	13 (2.5)
気管支反応性亢進	1 (0.4)	0	1 (0.2)
慢性閉塞性肺疾患	0	1 (0.4)	1 (0.2)
咳嗽	17 (6.7)	9 (3.5)	26 (5.1)
発声障害	1 (0.4)	0	1 (0.2)
呼吸困難	2 (0.8)	2 (0.8)	4 (0.8)
鼻出血	2 (0.8)	6 (2.3)	8 (1.6)
鼻閉	1 (0.4)	3 (1.2)	4 (0.8)
鼻乾燥	0	2 (0.8)	2 (0.4)
口腔咽頭痛	13 (5.1)	10 (3.9)	23 (4.5)
湿性咳嗽	2 (0.8)	0	2 (0.4)
アレルギー性鼻炎	2 (0.8)	1 (0.4)	3 (0.6)
鼻漏	2 (0.8)	1 (0.4)	3 (0.6)
副鼻腔うっ血	1 (0.4)	2 (0.8)	3 (0.6)
咽喉刺激感	1 (0.4)	1 (0.4)	2 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
呼吸器、胸郭および縦隔障害 (Cont.)			
上気道の炎症	0	1 (0.4)	1 (0.2)
皮膚および皮下組織障害	102 (40.2)	185 (71.9)	287 (56.2)
ざ瘡	30 (11.8)	91 (35.4)	121 (23.7)
光線角化症	2 (0.8)	1 (0.4)	3 (0.6)
脱毛症	1 (0.4)	1 (0.4)	2 (0.4)
円形脱毛症	0	1 (0.4)	1 (0.2)
血管浮腫	1 (0.4)	1 (0.4)	2 (0.4)
水疱	1 (0.4)	0	1 (0.2)
皮膚嚢腫	0	1 (0.4)	1 (0.2)
皮膚炎	1 (0.4)	3 (1.2)	4 (0.8)
ざ瘡様皮膚炎	3 (1.2)	16 (6.2)	19 (3.7)
アレルギー性皮膚炎	0	1 (0.4)	1 (0.2)
アトピー性皮膚炎	25 (9.9)	20 (7.8)	45 (8.8)
接触皮膚炎	2 (0.8)	10 (3.9)	12 (2.3)
びまん性脱毛症	0	1 (0.4)	1 (0.2)
薬疹	1 (0.4)	0	1 (0.2)
異汗性湿疹	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
斑状出血	1 (0.4)	0	1 (0.2)
湿疹	4 (1.6)	2 (0.8)	6 (1.2)
紅斑	2 (0.8)	2 (0.8)	4 (0.8)
毛包性ムチン沈着症	0	1 (0.4)	1 (0.2)
毛髪成長異常	0	1 (0.4)	1 (0.2)
逆むけ	0	1 (0.4)	1 (0.2)
汗腺炎	0	1 (0.4)	1 (0.2)
多汗症	0	3 (1.2)	3 (0.6)
嵌入爪	1 (0.4)	0	1 (0.2)
機械性蕁麻疹	0	1 (0.4)	1 (0.2)
汗疹	1 (0.4)	1 (0.4)	2 (0.4)
神経皮膚炎	1 (0.4)	0	1 (0.2)
寝汗	1 (0.4)	1 (0.4)	2 (0.4)
爪破損	0	1 (0.4)	1 (0.2)
類乾癬	0	1 (0.4)	1 (0.2)
口囲皮膚炎	1 (0.4)	0	1 (0.2)
光線過敏性反応	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
炎症後色素沈着変化	1 (0.4)	0	1 (0.2)
そう痒症	5 (2.0)	2 (0.8)	7 (1.4)
紫斑	0	1 (0.4)	1 (0.2)
発疹	2 (0.8)	2 (0.8)	4 (0.8)
斑状丘疹状皮疹	1 (0.4)	1 (0.4)	2 (0.4)
丘疹性皮疹	1 (0.4)	0	1 (0.2)
酒さ	0	2 (0.8)	2 (0.4)
脂漏	1 (0.4)	0	1 (0.2)
脂漏性皮膚炎	0	2 (0.8)	2 (0.4)
皮膚障害	0	1 (0.4)	1 (0.2)
皮膚亀裂	1 (0.4)	0	1 (0.2)
皮膚腫脹	1 (0.4)	0	1 (0.2)
日光黒子	0	1 (0.4)	1 (0.2)
毛細血管拡張症	1 (0.4)	0	1 (0.2)
中毒性表皮壊死融解症	1 (0.4)	0	1 (0.2)
蕁麻疹	8 (3.2)	8 (3.1)	16 (3.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
外科および内科処置	2 (0.8)	0	2 (0.4)
人工流産	1 (0.4)	0	1 (0.2)
収れん薬療法	1 (0.4)	0	1 (0.2)
血管障害	8 (3.2)	5 (1.9)	13 (2.5)
血性分泌物	1 (0.4)	0	1 (0.2)
潮紅	1 (0.4)	0	1 (0.2)
血腫	1 (0.4)	1 (0.4)	2 (0.4)
ほてり	0	1 (0.4)	1 (0.2)
高血圧	5 (2.0)	2 (0.8)	7 (1.4)
血栓性静脈炎	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.7.2.1

表 8. ウパダシチニブ投与期間中の有害事象の 100 人年あたりの発現率：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団，青少年）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=38.0) Events (E/100PY)	UPA 30 mg QD (N=59) (PYS=39.6) Events (E/100PY)	Total (N=119) (PYS=77.6) Events (E/100PY)
Any adverse event	133 (350.4)	173 (436.4)	306 (394.3)
血液およびリンパ系障害	1 (2.6)	6 (15.1)	7 (9.0)
白血球減少症	0	1 (2.5)	1 (1.3)
好中球減少症	0	4 (10.1)	4 (5.2)
好中球増加症	1 (2.6)	0	1 (1.3)
血小板減少症	0	1 (2.5)	1 (1.3)
眼障害	0	2 (5.0)	2 (2.6)
流涙増加	0	1 (2.5)	1 (1.3)
霧視	0	1 (2.5)	1 (1.3)
胃腸障害	4 (10.5)	15 (37.8)	19 (24.5)
腹痛	0	1 (2.5)	1 (1.3)
上腹部痛	1 (2.6)	2 (5.0)	3 (3.9)
齲歯	1 (2.6)	1 (2.5)	2 (2.6)
下痢	1 (2.6)	5 (12.6)	6 (7.7)
食中毒	0	1 (2.5)	1 (1.3)
胃食道逆流性疾患	0	1 (2.5)	1 (1.3)
口唇腫脹	0	1 (2.5)	1 (1.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=38.0) Events (E/100PY)	UPA 30 mg QD (N=59) (PYS=39.6) Events (E/100PY)	Total (N=119) (PYS=77.6) Events (E/100PY)
胃腸障害 (Cont.)			
悪心	1 (2.6)	1 (2.5)	2 (2.6)
嘔吐	0	2 (5.0)	2 (2.6)
一般・全身障害および投与部位の状態	6 (15.8)	5 (12.6)	11 (14.2)
無力症	1 (2.6)	0	1 (1.3)
インフルエンザ様疾患	1 (2.6)	3 (7.6)	4 (5.2)
疼痛	1 (2.6)	0	1 (1.3)
発熱	3 (7.9)	2 (5.0)	5 (6.4)
免疫系障害	1 (2.6)	2 (5.0)	3 (3.9)
アナフィラキシー反応	0	1 (2.5)	1 (1.3)
薬物過敏症	0	1 (2.5)	1 (1.3)
過敏症	1 (2.6)	0	1 (1.3)
感染症および寄生虫症	43 (113.3)	64 (161.4)	107 (137.9)
四肢膿瘍	0	1 (2.5)	1 (1.3)
体部白癬	0	1 (2.5)	1 (1.3)
気管支炎	1 (2.6)	1 (2.5)	2 (2.6)
結膜炎	1 (2.6)	3 (7.6)	4 (5.2)
感染性クループ	1 (2.6)	0	1 (1.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=38.0) Events (E/100PY)	UPA 30 mg QD (N=59) (PYS=39.6) Events (E/100PY)	Total (N=119) (PYS=77.6) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
膀胱炎	0	1 (2.5)	1 (1.3)
耳感染	0	3 (7.6)	3 (3.9)
毛包炎	0	1 (2.5)	1 (1.3)
胃腸炎	0	2 (5.0)	2 (2.6)
手足口病	1 (2.6)	0	1 (1.3)
単純ヘルペス	2 (5.3)	3 (7.6)	5 (6.4)
帯状疱疹	1 (2.6)	3 (7.6)	4 (5.2)
麦粒腫	0	1 (2.5)	1 (1.3)
膿痂疹	6 (15.8)	3 (7.6)	9 (11.6)
インフルエンザ	0	3 (7.6)	3 (3.9)
上咽頭炎	5 (13.2)	6 (15.1)	11 (14.2)
乳頭感染	1 (2.6)	0	1 (1.3)
口腔ヘルペス	0	3 (7.6)	3 (3.9)
骨髄炎	0	1 (2.5)	1 (1.3)
爪囲炎	0	1 (2.5)	1 (1.3)
咽頭炎	0	1 (2.5)	1 (1.3)
咽頭扁桃炎	2 (5.3)	0	2 (2.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=38.0) Events (E/100PY)	UPA 30 mg QD (N=59) (PYS=39.6) Events (E/100PY)	Total (N=119) (PYS=77.6) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
肺炎	0	1 (2.5)	1 (1.3)
腎盂腎炎	0	1 (2.5)	1 (1.3)
気道感染	3 (7.9)	1 (2.5)	4 (5.2)
鼻炎	1 (2.6)	2 (5.0)	3 (3.9)
敗血症	0	1 (2.5)	1 (1.3)
副鼻腔炎	1 (2.6)	0	1 (1.3)
皮膚細菌感染	1 (2.6)	0	1 (1.3)
皮膚感染	1 (2.6)	0	1 (1.3)
ブドウ球菌感染	1 (2.6)	0	1 (1.3)
ブドウ球菌性敗血症	0	1 (2.5)	1 (1.3)
皮下組織膿瘍	0	1 (2.5)	1 (1.3)
上気道感染	13 (34.3)	14 (35.3)	27 (34.8)
尿路感染	1 (2.6)	2 (5.0)	3 (3.9)
ウイルス性下痢	0	1 (2.5)	1 (1.3)
ウイルス性上気道感染	0	1 (2.5)	1 (1.3)
傷害、中毒および処置合併症	4 (10.5)	5 (12.6)	9 (11.6)
脳振盪	1 (2.6)	0	1 (1.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=38.0) Events (E/100PY)	UPA 30 mg QD (N=59) (PYS=39.6) Events (E/100PY)	Total (N=119) (PYS=77.6) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
転倒	0	1 (2.5)	1 (1.3)
頭部損傷	1 (2.6)	0	1 (1.3)
熱疲労	1 (2.6)	0	1 (1.3)
関節損傷	0	1 (2.5)	1 (1.3)
靱帯断裂	0	1 (2.5)	1 (1.3)
半月板損傷	0	1 (2.5)	1 (1.3)
交通事故	0	1 (2.5)	1 (1.3)
皮膚擦過傷	1 (2.6)	0	1 (1.3)
臨床検査	22 (58.0)	15 (37.8)	37 (47.7)
アラニンアミノトランスフェラーゼ増加	1 (2.6)	0	1 (1.3)
アスパラギン酸アミノトランスフェラーゼ増加	1 (2.6)	0	1 (1.3)
血中アルカリホスファターゼ増加	1 (2.6)	0	1 (1.3)
血中ビリルビン増加	1 (2.6)	0	1 (1.3)
血中クレアチンホスホキナーゼ増加	12 (31.6)	7 (17.7)	19 (24.5)
血液培養陽性	0	1 (2.5)	1 (1.3)
心雑音	0	1 (2.5)	1 (1.3)
尿培養陽性	0	1 (2.5)	1 (1.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=38.0) Events (E/100PY)	UPA 30 mg QD (N=59) (PYS=39.6) Events (E/100PY)	Total (N=119) (PYS=77.6) Events (E/100PY)
臨床検査 (Cont.)			
ヘモグロビン減少	2 (5.3)	0	2 (2.6)
心拍数増加	0	2 (5.0)	2 (2.6)
肝酵素上昇	1 (2.6)	0	1 (1.3)
トランスアミナーゼ上昇	1 (2.6)	0	1 (1.3)
尿中シュウ酸塩	1 (2.6)	0	1 (1.3)
体重増加	1 (2.6)	3 (7.6)	4 (5.2)
代謝および栄養障害	3 (7.9)	0	3 (3.9)
食欲減退	1 (2.6)	0	1 (1.3)
食欲亢進	1 (2.6)	0	1 (1.3)
ビタミン D 欠乏	1 (2.6)	0	1 (1.3)
筋骨格系および結合組織障害	3 (7.9)	2 (5.0)	5 (6.4)
関節痛	0	1 (2.5)	1 (1.3)
筋肉痛	1 (2.6)	0	1 (1.3)
骨端症	0	1 (2.5)	1 (1.3)
顎痛	1 (2.6)	0	1 (1.3)
側弯症	1 (2.6)	0	1 (1.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=38.0) Events (E/100PY)	UPA 30 mg QD (N=59) (PYS=39.6) Events (E/100PY)	Total (N=119) (PYS=77.6) Events (E/100PY)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (2.6)	1 (2.5)	2 (2.6)
皮膚乳頭腫	1 (2.6)	1 (2.5)	2 (2.6)
神経系障害	7 (18.4)	5 (12.6)	12 (15.5)
錐体外路障害	1 (2.6)	0	1 (1.3)
頭痛	5 (13.2)	4 (10.1)	9 (11.6)
失神	0	1 (2.5)	1 (1.3)
緊張性頭痛	1 (2.6)	0	1 (1.3)
精神障害	6 (15.8)	2 (5.0)	8 (10.3)
不安	2 (5.3)	0	2 (2.6)
不安障害	0	1 (2.5)	1 (1.3)
うつ病	1 (2.6)	0	1 (1.3)
故意の自傷行為	1 (2.6)	0	1 (1.3)
大うつ病	1 (2.6)	0	1 (1.3)
パニック発作	0	1 (2.5)	1 (1.3)
睡眠障害	1 (2.6)	0	1 (1.3)
腎および尿路障害	0	1 (2.5)	1 (1.3)
排尿困難	0	1 (2.5)	1 (1.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=38.0) Events (E/100PY)	UPA 30 mg QD (N=59) (PYS=39.6) Events (E/100PY)	Total (N=119) (PYS=77.6) Events (E/100PY)
生殖系および乳房障害	1 (2.6)	1 (2.5)	2 (2.6)
無月経	0	1 (2.5)	1 (1.3)
月経困難症	1 (2.6)	0	1 (1.3)
呼吸器、胸郭および縦隔障害	14 (36.9)	8 (20.2)	22 (28.4)
咳嗽	5 (13.2)	1 (2.5)	6 (7.7)
呼吸困難	0	2 (5.0)	2 (2.6)
鼻出血	0	2 (5.0)	2 (2.6)
口腔咽頭痛	5 (13.2)	2 (5.0)	7 (9.0)
湿性咳嗽	1 (2.6)	0	1 (1.3)
鼻漏	2 (5.3)	0	2 (2.6)
副鼻腔うっ血	1 (2.6)	1 (2.5)	2 (2.6)
皮膚および皮下組織障害	16 (42.2)	38 (95.9)	54 (69.6)
ざ瘡	6 (15.8)	20 (50.4)	26 (33.5)
円形脱毛症	0	1 (2.5)	1 (1.3)
皮膚炎	0	1 (2.5)	1 (1.3)
ざ瘡様皮膚炎	0	1 (2.5)	1 (1.3)
アレルギー性皮膚炎	0	1 (2.5)	1 (1.3)
アトピー性皮膚炎	3 (7.9)	1 (2.5)	4 (5.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=38.0) Events (E/100PY)	UPA 30 mg QD (N=59) (PYS=39.6) Events (E/100PY)	Total (N=119) (PYS=77.6) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
接触皮膚炎	0	2 (5.0)	2 (2.6)
湿疹	2 (5.3)	0	2 (2.6)
紅斑	0	1 (2.5)	1 (1.3)
汗腺炎	0	1 (2.5)	1 (1.3)
多汗症	0	2 (5.0)	2 (2.6)
汗疹	0	1 (2.5)	1 (1.3)
炎症後色素沈着変化	1 (2.6)	0	1 (1.3)
そう痒症	0	1 (2.5)	1 (1.3)
発疹	0	1 (2.5)	1 (1.3)
斑状丘疹状皮疹	0	1 (2.5)	1 (1.3)
脂漏性皮膚炎	0	1 (2.5)	1 (1.3)
蕁麻疹	4 (10.5)	2 (5.0)	6 (7.7)
外科および内科処置	1 (2.6)	0	1 (1.3)
収れん薬療法	1 (2.6)	0	1 (1.3)
血管障害	0	1 (2.5)	1 (1.3)
血腫	0	1 (2.5)	1 (1.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.7.2.2

表 9. ウパダシチニブ投与期間中の有害事象の 100 人年あたりの発現率：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団, 成人）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
Any adverse event	717 (332.3)	997 (458.3)	1714 (395.6)
血液およびリンパ系障害	15 (7.0)	28 (12.9)	43 (9.9)
貧血	0	8 (3.7)	8 (1.8)
白血球増加症	1 (0.5)	1 (0.5)	2 (0.5)
リンパ節症	3 (1.4)	2 (0.9)	5 (1.2)
リンパ球減少症	2 (0.9)	1 (0.5)	3 (0.7)
好中球減少症	8 (3.7)	15 (6.9)	23 (5.3)
好中球増加症	1 (0.5)	0	1 (0.2)
汎血球減少症	0	1 (0.5)	1 (0.2)
心臓障害	1 (0.5)	3 (1.4)	4 (0.9)
心房細動	0	1 (0.5)	1 (0.2)
徐脈	0	1 (0.5)	1 (0.2)
心血管障害	1 (0.5)	0	1 (0.2)
冠動脈疾患	0	1 (0.5)	1 (0.2)
先天性、家族性および遺伝性障害	0	1 (0.5)	1 (0.2)
包茎	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
耳および迷路障害	4 (1.9)	6 (2.8)	10 (2.3)
耳垢栓塞	0	2 (0.9)	2 (0.5)
突発性難聴	0	1 (0.5)	1 (0.2)
鼓膜障害	0	1 (0.5)	1 (0.2)
回転性めまい	4 (1.9)	2 (0.9)	6 (1.4)
内分泌障害	1 (0.5)	2 (0.9)	3 (0.7)
バセドウ病	0	1 (0.5)	1 (0.2)
甲状腺機能低下症	1 (0.5)	0	1 (0.2)
甲状腺腫瘤	0	1 (0.5)	1 (0.2)
眼障害	11 (5.1)	13 (6.0)	24 (5.5)
眼瞼炎	0	2 (0.9)	2 (0.5)
白内障	1 (0.5)	0	1 (0.2)
結膜出血	0	1 (0.5)	1 (0.2)
アレルギー性結膜炎	1 (0.5)	2 (0.9)	3 (0.7)
ドライアイ	1 (0.5)	2 (0.9)	3 (0.7)
眼瞼湿疹	0	1 (0.5)	1 (0.2)
眼そう痒症	0	1 (0.5)	1 (0.2)
眼部腫脹	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
眼障害 (Cont.)			
緑内障	1 (0.5)	0	1 (0.2)
流涙増加	1 (0.5)	0	1 (0.2)
黄斑変性	1 (0.5)	0	1 (0.2)
眼窩周囲腫脹	1 (0.5)	1 (0.5)	2 (0.5)
網膜剥離	1 (0.5)	0	1 (0.2)
潰瘍性角膜炎	1 (0.5)	0	1 (0.2)
霧視	1 (0.5)	2 (0.9)	3 (0.7)
視力障害	1 (0.5)	0	1 (0.2)
胃腸障害	55 (25.5)	75 (34.5)	130 (30.0)
腹部不快感	1 (0.5)	1 (0.5)	2 (0.5)
腹部膨満	1 (0.5)	1 (0.5)	2 (0.5)
腹痛	1 (0.5)	5 (2.3)	6 (1.4)
上腹部痛	4 (1.9)	3 (1.4)	7 (1.6)
口角口唇炎	0	1 (0.5)	1 (0.2)
呼気臭	0	1 (0.5)	1 (0.2)
便秘	3 (1.4)	2 (0.9)	5 (1.2)
齲歯	1 (0.5)	3 (1.4)	4 (0.9)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
胃腸障害 (Cont.)			
下痢	11 (5.1)	11 (5.1)	22 (5.1)
腸憩室	1 (0.5)	0	1 (0.2)
口内乾燥	0	3 (1.4)	3 (0.7)
消化不良	2 (0.9)	2 (0.9)	4 (0.9)
軟便	0	2 (0.9)	2 (0.5)
鼓腸	3 (1.4)	2 (0.9)	5 (1.2)
食中毒	1 (0.5)	1 (0.5)	2 (0.5)
胃潰瘍	1 (0.5)	1 (0.5)	2 (0.5)
胃炎	4 (1.9)	0	4 (0.9)
びらん性胃炎	0	1 (0.5)	1 (0.2)
消化器痛	1 (0.5)	0	1 (0.2)
胃食道逆流性疾患	1 (0.5)	4 (1.8)	5 (1.2)
歯肉痛	0	1 (0.5)	1 (0.2)
痔核	0	2 (0.9)	2 (0.5)
歯の知覚過敏	0	1 (0.5)	1 (0.2)
過敏性腸症候群	0	1 (0.5)	1 (0.2)
口腔内潰瘍形成	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
胃腸障害 (Cont.)			
悪心	12 (5.6)	14 (6.4)	26 (6.0)
食道狭窄	1 (0.5)	0	1 (0.2)
大網壊死	0	1 (0.5)	1 (0.2)
口腔障害	0	1 (0.5)	1 (0.2)
膵炎	0	1 (0.5)	1 (0.2)
埋伏歯	1 (0.5)	0	1 (0.2)
歯痛	1 (0.5)	2 (0.9)	3 (0.7)
嘔吐	4 (1.9)	6 (2.8)	10 (2.3)
一般・全身障害および投与部位の状態	29 (13.4)	35 (16.1)	64 (14.8)
無力症	0	1 (0.5)	1 (0.2)
胸部不快感	1 (0.5)	1 (0.5)	2 (0.5)
胸痛	1 (0.5)	0	1 (0.2)
悪寒	0	2 (0.9)	2 (0.5)
嚢胞	1 (0.5)	0	1 (0.2)
不快感	0	1 (0.5)	1 (0.2)
薬物不耐性	0	1 (0.5)	1 (0.2)
顔面浮腫	1 (0.5)	1 (0.5)	2 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
一般・全身障害および投与部位の状態 (Cont.)			
疲労	4 (1.9)	3 (1.4)	7 (1.6)
びくびく感	0	1 (0.5)	1 (0.2)
インフルエンザ様疾患	6 (2.8)	8 (3.7)	14 (3.2)
倦怠感	0	1 (0.5)	1 (0.2)
腫瘤	1 (0.5)	0	1 (0.2)
粘膜乾燥	0	1 (0.5)	1 (0.2)
小結節	0	1 (0.5)	1 (0.2)
非心臓性胸痛	0	1 (0.5)	1 (0.2)
浮腫	0	1 (0.5)	1 (0.2)
末梢性浮腫	1 (0.5)	1 (0.5)	2 (0.5)
疼痛	1 (0.5)	2 (0.9)	3 (0.7)
発熱	10 (4.6)	7 (3.2)	17 (3.9)
腫脹	1 (0.5)	0	1 (0.2)
顔面腫脹	1 (0.5)	0	1 (0.2)
血管穿刺部位内出血	0	1 (0.5)	1 (0.2)
肝胆道系障害	2 (0.9)	6 (2.8)	8 (1.8)
胆嚢炎	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
肝胆道系障害 (Cont.)			
胆石症	1 (0.5)	0	1 (0.2)
胆嚢ポリープ	0	1 (0.5)	1 (0.2)
肝機能異常	1 (0.5)	0	1 (0.2)
脂肪肝	0	3 (1.4)	3 (0.7)
肝腫大	0	1 (0.5)	1 (0.2)
免疫系障害	5 (2.3)	6 (2.8)	11 (2.5)
化学物質アレルギー	1 (0.5)	0	1 (0.2)
ワクチンアレルギー	1 (0.5)	0	1 (0.2)
アナフィラキシー反応	0	1 (0.5)	1 (0.2)
食物アレルギー	2 (0.9)	2 (0.9)	4 (0.9)
過敏症	1 (0.5)	0	1 (0.2)
乳アレルギー	0	1 (0.5)	1 (0.2)
1 型過敏症	0	2 (0.9)	2 (0.5)
感染症および寄生虫症	270 (125.1)	376 (172.8)	646 (149.1)
ダニ皮膚炎	1 (0.5)	1 (0.5)	2 (0.5)
膿疱性ざ瘡	1 (0.5)	0	1 (0.2)
虫垂炎	2 (0.9)	0	2 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
細菌感染	1 (0.5)	1 (0.5)	2 (0.5)
細菌性膣症	0	2 (0.9)	2 (0.5)
細菌尿	0	1 (0.5)	1 (0.2)
体部白癬	3 (1.4)	1 (0.5)	4 (0.9)
気管支炎	6 (2.8)	9 (4.1)	15 (3.5)
ウイルス性気管支炎	1 (0.5)	0	1 (0.2)
カンジダ感染	1 (0.5)	0	1 (0.2)
蜂巣炎	4 (1.9)	2 (0.9)	6 (1.4)
結膜炎	2 (0.9)	4 (1.8)	6 (1.4)
コロナウイルス感染	1 (0.5)	1 (0.5)	2 (0.5)
膀胱炎	0	1 (0.5)	1 (0.2)
感染性皮膚炎	1 (0.5)	0	1 (0.2)
皮膚糸状菌症	1 (0.5)	1 (0.5)	2 (0.5)
爪の皮膚糸状菌症	1 (0.5)	0	1 (0.2)
憩室炎	0	1 (0.5)	1 (0.2)
耳感染	3 (1.4)	6 (2.8)	9 (2.1)
膿瘡	2 (0.9)	0	2 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
ヘルペス性状湿疹	1 (0.5)	3 (1.4)	4 (0.9)
感染性湿疹	0	1 (0.5)	1 (0.2)
丹毒	0	1 (0.5)	1 (0.2)
大腸菌性尿路感染	0	1 (0.5)	1 (0.2)
外耳蜂巣炎	1 (0.5)	0	1 (0.2)
眼感染	1 (0.5)	0	1 (0.2)
毛包炎	8 (3.7)	15 (6.9)	23 (5.3)
真菌感染	2 (0.9)	0	2 (0.5)
せつ	4 (1.9)	4 (1.8)	8 (1.8)
胃腸炎	4 (1.9)	10 (4.6)	14 (3.2)
ウイルス性胃腸炎	1 (0.5)	2 (0.9)	3 (0.7)
ウイルス性消化管感染	0	1 (0.5)	1 (0.2)
陰部ヘルペス	2 (0.9)	0	2 (0.5)
陰部単純ヘルペス	0	3 (1.4)	3 (0.7)
蠕虫感染	0	1 (0.5)	1 (0.2)
B 型肝炎	0	1 (0.5)	1 (0.2)
ヘルパンギーナ	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
ヘルペス性皮膚炎	0	2 (0.9)	2 (0.5)
ヘルペス眼感染	0	4 (1.8)	4 (0.9)
単純ヘルペス	10 (4.6)	14 (6.4)	24 (5.5)
ヘルペスウイルス感染	2 (0.9)	1 (0.5)	3 (0.7)
帯状疱疹	7 (3.2)	9 (4.1)	16 (3.7)
麦粒腫	4 (1.9)	9 (4.1)	13 (3.0)
膿痂疹	8 (3.7)	3 (1.4)	11 (2.5)
インフルエンザ	3 (1.4)	7 (3.2)	10 (2.3)
椎間板炎	1 (0.5)	0	1 (0.2)
カポジ水痘様発疹	1 (0.5)	5 (2.3)	6 (1.4)
喉頭炎	2 (0.9)	3 (1.4)	5 (1.2)
ウイルス性喉頭炎	1 (0.5)	0	1 (0.2)
潜伏結核	0	2 (0.9)	2 (0.5)
限局性感染	1 (0.5)	0	1 (0.2)
下気道感染	1 (0.5)	0	1 (0.2)
細菌性リンパ節炎	0	1 (0.5)	1 (0.2)
伝染性軟属腫	2 (0.9)	3 (1.4)	5 (1.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
マイコプラズマ感染	0	1 (0.5)	1 (0.2)
上咽頭炎	43 (19.9)	56 (25.7)	99 (22.8)
爪真菌症	1 (0.5)	0	1 (0.2)
眼部単純ヘルペス	1 (0.5)	2 (0.9)	3 (0.7)
口腔カンジダ症	1 (0.5)	5 (2.3)	6 (1.4)
口腔ヘルペス	8 (3.7)	26 (12.0)	34 (7.8)
外耳炎	2 (0.9)	1 (0.5)	3 (0.7)
中耳炎	1 (0.5)	2 (0.9)	3 (0.7)
急性中耳炎	1 (0.5)	1 (0.5)	2 (0.5)
爪囲炎	2 (0.9)	5 (2.3)	7 (1.6)
歯周炎	1 (0.5)	0	1 (0.2)
咽頭膿瘍	0	1 (0.5)	1 (0.2)
咽頭炎	7 (3.2)	4 (1.8)	11 (2.5)
レンサ球菌性咽頭炎	1 (0.5)	0	1 (0.2)
咽頭扁桃炎	0	1 (0.5)	1 (0.2)
肺炎	3 (1.4)	2 (0.9)	5 (1.2)
細菌性肺炎	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
ブドウ球菌性肺炎	0	1 (0.5)	1 (0.2)
ウイルス性肺炎	1 (0.5)	0	1 (0.2)
術後創感染	0	1 (0.5)	1 (0.2)
膿疱	0	1 (0.5)	1 (0.2)
膿皮症	1 (0.5)	0	1 (0.2)
膿疱性皮疹	1 (0.5)	0	1 (0.2)
RS ウイルス感染	0	1 (0.5)	1 (0.2)
気道感染	1 (0.5)	1 (0.5)	2 (0.5)
ウイルス性気道感染	1 (0.5)	0	1 (0.2)
鼻炎	3 (1.4)	4 (1.8)	7 (1.6)
ライノウイルス感染	0	1 (0.5)	1 (0.2)
根管感染	0	1 (0.5)	1 (0.2)
敗血症	0	1 (0.5)	1 (0.2)
副鼻腔炎	6 (2.8)	5 (2.3)	11 (2.5)
皮膚細菌感染	1 (0.5)	2 (0.9)	3 (0.7)
皮膚カンジダ	1 (0.5)	1 (0.5)	2 (0.5)
植皮感染	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
皮膚感染	3 (1.4)	4 (1.8)	7 (1.6)
ブドウ球菌感染	0	5 (2.3)	5 (1.2)
ブドウ球菌皮膚感染	1 (0.5)	0	1 (0.2)
皮下組織膿瘍	1 (0.5)	0	1 (0.2)
細菌重複感染	1 (0.5)	0	1 (0.2)
股部白癬	0	3 (1.4)	3 (0.7)
足部白癬	2 (0.9)	2 (0.9)	4 (0.9)
癜風	2 (0.9)	0	2 (0.5)
扁桃炎	3 (1.4)	4 (1.8)	7 (1.6)
細菌性扁桃炎	0	1 (0.5)	1 (0.2)
歯膿瘍	3 (1.4)	2 (0.9)	5 (1.2)
歯感染	0	2 (0.9)	2 (0.5)
上気道感染	42 (19.5)	55 (25.3)	97 (22.4)
クラミジア性尿道炎	1 (0.5)	0	1 (0.2)
尿路感染	9 (4.2)	11 (5.1)	20 (4.6)
水痘	0	1 (0.5)	1 (0.2)
ウイルス感染	2 (0.9)	1 (0.5)	3 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
ウイルス性咽頭炎	2 (0.9)	0	2 (0.5)
ウイルス性発疹	1 (0.5)	0	1 (0.2)
ウイルス性上気道感染	8 (3.7)	14 (6.4)	22 (5.1)
外陰部腟カンジダ症	2 (0.9)	2 (0.9)	4 (0.9)
外陰腟真菌感染	1 (0.5)	0	1 (0.2)
創傷感染	0	1 (0.5)	1 (0.2)
ブドウ球菌性創感染	0	1 (0.5)	1 (0.2)
傷害、中毒および処置合併症	30 (13.9)	28 (12.9)	58 (13.4)
偶発的過量投与	0	1 (0.5)	1 (0.2)
アルコール中毒	0	1 (0.5)	1 (0.2)
節足動物咬傷	1 (0.5)	1 (0.5)	2 (0.5)
節足動物刺傷	0	1 (0.5)	1 (0.2)
背部損傷	1 (0.5)	0	1 (0.2)
第 1 度熱傷	0	1 (0.5)	1 (0.2)
第 2 度熱傷	1 (0.5)	0	1 (0.2)
第 3 度熱傷	0	1 (0.5)	1 (0.2)
軟骨損傷	1 (0.5)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
脳振盪	1 (0.5)	0	1 (0.2)
挫傷	3 (1.4)	1 (0.5)	4 (0.9)
転倒	3 (1.4)	2 (0.9)	5 (1.2)
足骨折	1 (0.5)	3 (1.4)	4 (0.9)
体内異物	0	1 (0.5)	1 (0.2)
手骨折	0	1 (0.5)	1 (0.2)
頭部損傷	0	1 (0.5)	1 (0.2)
損傷	1 (0.5)	0	1 (0.2)
関節脱臼	1 (0.5)	0	1 (0.2)
関節損傷	1 (0.5)	0	1 (0.2)
靱帯断裂	1 (0.5)	0	1 (0.2)
靱帯捻挫	3 (1.4)	0	3 (0.7)
四肢損傷	3 (1.4)	1 (0.5)	4 (0.9)
口唇損傷	0	1 (0.5)	1 (0.2)
肉離れ	2 (0.9)	3 (1.4)	5 (1.2)
筋骨格系損傷	0	1 (0.5)	1 (0.2)
膝蓋骨骨折	1 (0.5)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
処置による疼痛	0	1 (0.5)	1 (0.2)
交通事故	1 (0.5)	0	1 (0.2)
瘢痕	1 (0.5)	0	1 (0.2)
皮膚擦過傷	0	1 (0.5)	1 (0.2)
皮膚裂傷	0	1 (0.5)	1 (0.2)
サンバーン	1 (0.5)	1 (0.5)	2 (0.5)
腱断裂	1 (0.5)	1 (0.5)	2 (0.5)
熱傷	0	1 (0.5)	1 (0.2)
上肢骨折	1 (0.5)	0	1 (0.2)
ワクチン接種合併症	0	1 (0.5)	1 (0.2)
臨床検査	69 (32.0)	94 (43.2)	163 (37.6)
アラニンアミノトランスフェラーゼ増加	7 (3.2)	10 (4.6)	17 (3.9)
アスパラギン酸アミノトランスフェラーゼ増加	3 (1.4)	7 (3.2)	10 (2.3)
B リンパ球数増加	1 (0.5)	0	1 (0.2)
血中コレステロール増加	3 (1.4)	4 (1.8)	7 (1.6)
血中クレアチンホスホキナーゼ増加	18 (8.3)	30 (13.8)	48 (11.1)
血中クレアチニン増加	3 (1.4)	0	3 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
臨床検査 (Cont.)			
血中ブドウ糖増加	0	2 (0.9)	2 (0.5)
血中免疫グロブリン E 増加	6 (2.8)	0	6 (1.4)
血中乳酸脱水素酵素増加	0	1 (0.5)	1 (0.2)
血中カリウム増加	1 (0.5)	0	1 (0.2)
血圧上昇	1 (0.5)	0	1 (0.2)
血中トリグリセリド増加	1 (0.5)	0	1 (0.2)
血中尿酸増加	0	3 (1.4)	3 (0.7)
尿中血陽性	2 (0.9)	1 (0.5)	3 (0.7)
CD4 リンパ球減少	1 (0.5)	0	1 (0.2)
CD8 リンパ球百分率減少	1 (0.5)	0	1 (0.2)
CD8 リンパ球減少	0	1 (0.5)	1 (0.2)
心雑音	0	1 (0.5)	1 (0.2)
ケモカイン増加	1 (0.5)	0	1 (0.2)
尿中結晶陽性	1 (0.5)	1 (0.5)	2 (0.5)
好酸球百分率増加	1 (0.5)	0	1 (0.2)
ヘモグロビン減少	0	1 (0.5)	1 (0.2)
高比重リポ蛋白増加	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
臨床検査 (Cont.)			
肝機能検査値上昇	1 (0.5)	0	1 (0.2)
低比重リポ蛋白増加	0	1 (0.5)	1 (0.2)
リンパ球数減少	0	2 (0.9)	2 (0.5)
ナチュラルキラー細胞数減少	1 (0.5)	0	1 (0.2)
好中球数減少	1 (0.5)	2 (0.9)	3 (0.7)
血小板数増加	0	1 (0.5)	1 (0.2)
尿妊娠反応陽性	1 (0.5)	0	1 (0.2)
尿蛋白	1 (0.5)	0	1 (0.2)
尿中蛋白陽性	2 (0.9)	2 (0.9)	4 (0.9)
T リンパ球数減少	1 (0.5)	0	1 (0.2)
トランスアミナーゼ上昇	0	4 (1.8)	4 (0.9)
尿円柱	1 (0.5)	0	1 (0.2)
尿中ケトン体陽性	1 (0.5)	0	1 (0.2)
尿中白血球エステラーゼ陽性	0	1 (0.5)	1 (0.2)
体重減少	0	3 (1.4)	3 (0.7)
体重増加	8 (3.7)	12 (5.5)	20 (4.6)
白血球数減少	0	3 (1.4)	3 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
代謝および栄養障害	12 (5.6)	19 (8.7)	31 (7.2)
食欲減退	1 (0.5)	3 (1.4)	4 (0.9)
脂質異常症	0	1 (0.5)	1 (0.2)
痛風	0	1 (0.5)	1 (0.2)
高コレステロール血症	1 (0.5)	5 (2.3)	6 (1.4)
高脂血症	1 (0.5)	1 (0.5)	2 (0.5)
高トリグリセリド血症	2 (0.9)	1 (0.5)	3 (0.7)
高尿酸血症	4 (1.9)	1 (0.5)	5 (1.2)
低血糖	0	1 (0.5)	1 (0.2)
低カリウム血症	0	3 (1.4)	3 (0.7)
低リン酸血症	1 (0.5)	0	1 (0.2)
食欲亢進	1 (0.5)	1 (0.5)	2 (0.5)
2 型糖尿病	0	1 (0.5)	1 (0.2)
ビタミン D 欠乏	1 (0.5)	0	1 (0.2)
筋骨格系および結合組織障害	26 (12.1)	43 (19.8)	69 (15.9)
関節痛	4 (1.9)	6 (2.8)	10 (2.3)
関節炎	1 (0.5)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
筋骨格系および結合組織障害 (Cont.)			
腋窩腫瘤	0	1 (0.5)	1 (0.2)
背部痛	7 (3.2)	15 (6.9)	22 (5.1)
滑液包炎	1 (0.5)	0	1 (0.2)
側腹部痛	1 (0.5)	0	1 (0.2)
足変形	1 (0.5)	0	1 (0.2)
椎間板変性症	0	1 (0.5)	1 (0.2)
椎間板突出	1 (0.5)	0	1 (0.2)
筋骨格系胸痛	0	1 (0.5)	1 (0.2)
筋骨格痛	2 (0.9)	2 (0.9)	4 (0.9)
筋肉痛	4 (1.9)	6 (2.8)	10 (2.3)
頚部痛	1 (0.5)	0	1 (0.2)
変形性関節症	1 (0.5)	1 (0.5)	2 (0.5)
四肢痛	0	6 (2.8)	6 (1.4)
顎痛	0	1 (0.5)	1 (0.2)
骨膜炎	0	1 (0.5)	1 (0.2)
肩回旋筋腱板症候群	0	1 (0.5)	1 (0.2)
腱障害	1 (0.5)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
筋骨格系および結合組織障害 (Cont.)			
腱炎	1 (0.5)	1 (0.5)	2 (0.5)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	4 (1.9)	10 (4.6)	14 (3.2)
肛門性器疣贅	1 (0.5)	0	1 (0.2)
ボーエン病	1 (0.5)	0	1 (0.2)
真珠腫	0	1 (0.5)	1 (0.2)
胃癌	0	1 (0.5)	1 (0.2)
浸潤性乳管癌	0	1 (0.5)	1 (0.2)
メラノサイト性母斑	0	1 (0.5)	1 (0.2)
脂漏性角化症	0	1 (0.5)	1 (0.2)
皮膚乳頭腫	2 (0.9)	4 (1.8)	6 (1.4)
扁平上皮癌	0	1 (0.5)	1 (0.2)
神経系障害	28 (13.0)	35 (16.1)	63 (14.5)
健忘	0	1 (0.5)	1 (0.2)
手根管症候群	1 (0.5)	0	1 (0.2)
注意力障害	1 (0.5)	0	1 (0.2)
浮動性めまい	4 (1.9)	6 (2.8)	10 (2.3)
夢幻状態	1 (0.5)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
神経系障害 (Cont.)			
味覚不全	0	1 (0.5)	1 (0.2)
頭痛	15 (7.0)	21 (9.7)	36 (8.3)
虚血性脳卒中	1 (0.5)	0	1 (0.2)
片頭痛	0	2 (0.9)	2 (0.5)
前兆を伴う片頭痛	0	1 (0.5)	1 (0.2)
錯感覚	1 (0.5)	0	1 (0.2)
神経根障害	0	1 (0.5)	1 (0.2)
坐骨神経痛	1 (0.5)	0	1 (0.2)
傾眠	3 (1.4)	0	3 (0.7)
緊張性頭痛	0	2 (0.9)	2 (0.5)
精神障害	13 (6.0)	11 (5.1)	24 (5.5)
不安	3 (1.4)	4 (1.8)	7 (1.6)
無感情	1 (0.5)	0	1 (0.2)
注意欠陥多動性障害	1 (0.5)	0	1 (0.2)
抑うつ気分	0	1 (0.5)	1 (0.2)
うつ病	0	2 (0.9)	2 (0.5)
失見当識	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
精神障害 (Cont.)			
不眠症	2 (0.9)	2 (0.9)	4 (0.9)
リビドー減退	1 (0.5)	0	1 (0.2)
大うつ病	0	1 (0.5)	1 (0.2)
躁病	1 (0.5)	0	1 (0.2)
混合性不安抑うつ障害	1 (0.5)	0	1 (0.2)
睡眠障害	2 (0.9)	0	2 (0.5)
ストレス	1 (0.5)	0	1 (0.2)
腎および尿路障害	4 (1.9)	12 (5.5)	16 (3.7)
急性腎障害	0	1 (0.5)	1 (0.2)
アルブミン尿	1 (0.5)	4 (1.8)	5 (1.2)
排尿困難	1 (0.5)	2 (0.9)	3 (0.7)
血尿	1 (0.5)	1 (0.5)	2 (0.5)
緊張性膀胱	0	1 (0.5)	1 (0.2)
頻尿	0	1 (0.5)	1 (0.2)
蛋白尿	1 (0.5)	2 (0.9)	3 (0.7)
生殖系および乳房障害	3 (1.4)	8 (3.7)	11 (2.5)
無月経	1 (0.5)	2 (0.9)	3 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
生殖系および乳房障害 (Cont.)			
乳房腫大	0	1 (0.5)	1 (0.2)
乳房圧痛	0	1 (0.5)	1 (0.2)
月経困難症	1 (0.5)	0	1 (0.2)
閉経期症状	0	1 (0.5)	1 (0.2)
月経過多	1 (0.5)	1 (0.5)	2 (0.5)
精巣痛	0	1 (0.5)	1 (0.2)
外陰腟乾燥	0	1 (0.5)	1 (0.2)
呼吸器、胸郭および縦隔障害	40 (18.5)	35 (16.1)	75 (17.3)
喘息	9 (4.2)	4 (1.8)	13 (3.0)
気管支反応性亢進	1 (0.5)	0	1 (0.2)
慢性閉塞性肺疾患	0	1 (0.5)	1 (0.2)
咳嗽	12 (5.6)	8 (3.7)	20 (4.6)
発声障害	1 (0.5)	0	1 (0.2)
呼吸困難	2 (0.9)	0	2 (0.5)
鼻出血	2 (0.9)	4 (1.8)	6 (1.4)
鼻閉	1 (0.5)	3 (1.4)	4 (0.9)
鼻乾燥	0	2 (0.9)	2 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
呼吸器、胸郭および縦隔障害 (Cont.)			
口腔咽頭痛	8 (3.7)	8 (3.7)	16 (3.7)
湿性咳嗽	1 (0.5)	0	1 (0.2)
アレルギー性鼻炎	2 (0.9)	1 (0.5)	3 (0.7)
鼻漏	0	1 (0.5)	1 (0.2)
副鼻腔うっ血	0	1 (0.5)	1 (0.2)
咽喉刺激感	1 (0.5)	1 (0.5)	2 (0.5)
上気道の炎症	0	1 (0.5)	1 (0.2)
皮膚および皮下組織障害	86 (39.9)	147 (67.6)	233 (53.8)
ざ瘡	24 (11.1)	71 (32.6)	95 (21.9)
光線角化症	2 (0.9)	1 (0.5)	3 (0.7)
脱毛症	1 (0.5)	1 (0.5)	2 (0.5)
血管浮腫	1 (0.5)	1 (0.5)	2 (0.5)
水疱	1 (0.5)	0	1 (0.2)
皮膚嚢腫	0	1 (0.5)	1 (0.2)
皮膚炎	1 (0.5)	2 (0.9)	3 (0.7)
ざ瘡様皮膚炎	3 (1.4)	15 (6.9)	18 (4.2)
アトピー性皮膚炎	22 (10.2)	19 (8.7)	41 (9.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
接触皮膚炎	2 (0.9)	8 (3.7)	10 (2.3)
びまん性脱毛症	0	1 (0.5)	1 (0.2)
薬疹	1 (0.5)	0	1 (0.2)
異汗性湿疹	0	1 (0.5)	1 (0.2)
斑状出血	1 (0.5)	0	1 (0.2)
湿疹	2 (0.9)	2 (0.9)	4 (0.9)
紅斑	2 (0.9)	1 (0.5)	3 (0.7)
毛包性ムチン沈着症	0	1 (0.5)	1 (0.2)
毛髪成長異常	0	1 (0.5)	1 (0.2)
逆むけ	0	1 (0.5)	1 (0.2)
多汗症	0	1 (0.5)	1 (0.2)
嵌入爪	1 (0.5)	0	1 (0.2)
機械性蕁麻疹	0	1 (0.5)	1 (0.2)
汗疹	1 (0.5)	0	1 (0.2)
神経皮膚炎	1 (0.5)	0	1 (0.2)
寝汗	1 (0.5)	1 (0.5)	2 (0.5)
爪破損	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
類乾癬	0	1 (0.5)	1 (0.2)
口囲皮膚炎	1 (0.5)	0	1 (0.2)
光線過敏性反応	0	1 (0.5)	1 (0.2)
そう痒症	5 (2.3)	1 (0.5)	6 (1.4)
紫斑	0	1 (0.5)	1 (0.2)
発疹	2 (0.9)	1 (0.5)	3 (0.7)
斑状丘疹状皮疹	1 (0.5)	0	1 (0.2)
丘疹性皮疹	1 (0.5)	0	1 (0.2)
酒さ	0	2 (0.9)	2 (0.5)
脂漏	1 (0.5)	0	1 (0.2)
脂漏性皮膚炎	0	1 (0.5)	1 (0.2)
皮膚障害	0	1 (0.5)	1 (0.2)
皮膚亀裂	1 (0.5)	0	1 (0.2)
皮膚腫脹	1 (0.5)	0	1 (0.2)
日光黒子	0	1 (0.5)	1 (0.2)
毛細血管拡張症	1 (0.5)	0	1 (0.2)
中毒性表皮壊死融解症	1 (0.5)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=338) (PYS=215.8) Events (E/100PY)	UPA 30 mg QD (N=347) (PYS=217.5) Events (E/100PY)	Total (N=685) (PYS=433.3) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
蕁麻疹	4 (1.9)	6 (2.8)	10 (2.3)
外科および内科処置	1 (0.5)	0	1 (0.2)
人工流産	1 (0.5)	0	1 (0.2)
血管障害	8 (3.7)	4 (1.8)	12 (2.8)
血性分泌物	1 (0.5)	0	1 (0.2)
潮紅	1 (0.5)	0	1 (0.2)
血腫	1 (0.5)	0	1 (0.2)
ほてり	0	1 (0.5)	1 (0.2)
高血圧	5 (2.3)	2 (0.9)	7 (1.6)
血栓性静脈炎	0	1 (0.5)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.7.2.3

表 10. 二重盲検投与期で治験薬と関連ありの有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（二重盲検投与期の安全性解析対象集団）

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Total (N=566) n (%)
Any adverse event	55 (19.6)	86 (30.6)	123 (43.2)	209 (36.9)
血液およびリンパ系障害	3 (1.1)	4 (1.4)	13 (4.6)	17 (3.0)
貧血	0	0	3 (1.1)	3 (0.5)
白血球増加症	1 (0.4)	0	0	0
白血球減少症	0	0	1 (0.4)	1 (0.2)
リンパ球減少症	0	1 (0.4)	1 (0.4)	2 (0.4)
好中球減少症	1 (0.4)	3 (1.1)	12 (4.2)	15 (2.7)
好中球増加症	1 (0.4)	0	0	0
汎血球減少症	0	0	1 (0.4)	1 (0.2)
耳および迷路障害	0	1 (0.4)	0	1 (0.2)
回転性めまい	0	1 (0.4)	0	1 (0.2)
眼障害	1 (0.4)	1 (0.4)	4 (1.4)	5 (0.9)
眼瞼炎	0	0	1 (0.4)	1 (0.2)
ドライアイ	0	0	1 (0.4)	1 (0.2)
眼瞼湿疹	0	0	1 (0.4)	1 (0.2)
霧視	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
視力障害	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
胃腸障害	4 (1.4)	12 (4.3)	15 (5.3)	27 (4.8)
腹部膨満	0	1 (0.4)	0	1 (0.2)
腹痛	1 (0.4)	0	1 (0.4)	1 (0.2)
上腹部痛	0	1 (0.4)	1 (0.4)	2 (0.4)
便秘	0	0	1 (0.4)	1 (0.2)
齲歯	0	1 (0.4)	0	1 (0.2)
下痢	0	2 (0.7)	4 (1.4)	6 (1.1)
口内乾燥	0	0	1 (0.4)	1 (0.2)
消化不良	0	1 (0.4)	1 (0.4)	2 (0.4)
嚥下障害	1 (0.4)	0	0	0
軟便	0	0	2 (0.7)	2 (0.4)
鼓腸	0	1 (0.4)	1 (0.4)	2 (0.4)
血便排泄	1 (0.4)	0	0	0
悪心	1 (0.4)	7 (2.5)	6 (2.1)	13 (2.3)
嘔吐	1 (0.4)	1 (0.4)	1 (0.4)	2 (0.4)
一般・全身障害および投与部位の状態	7 (2.5)	7 (2.5)	9 (3.2)	16 (2.8)
無力症	1 (0.4)	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Total (N=566) n (%)
一般・全身障害および投与部位の状態 (Cont.)				
胸痛	0	1 (0.4)	0	1 (0.2)
悪寒	0	0	1 (0.4)	1 (0.2)
顔面浮腫	0	0	1 (0.4)	1 (0.2)
疲労	2 (0.7)	1 (0.4)	1 (0.4)	2 (0.4)
びくびく感	0	0	1 (0.4)	1 (0.2)
インフルエンザ様疾患	2 (0.7)	3 (1.1)	3 (1.1)	6 (1.1)
倦怠感	1 (0.4)	0	0	0
末梢性浮腫	0	0	1 (0.4)	1 (0.2)
疼痛	0	0	1 (0.4)	1 (0.2)
発熱	1 (0.4)	1 (0.4)	2 (0.7)	3 (0.5)
免疫系障害	2 (0.7)	1 (0.4)	0	1 (0.2)
薬物過敏症	2 (0.7)	0	0	0
過敏症	0	1 (0.4)	0	1 (0.2)
感染症および寄生虫症	22 (7.8)	43 (15.3)	62 (21.8)	105 (18.6)
細菌尿	0	0	1 (0.4)	1 (0.2)
気管支炎	0	1 (0.4)	0	1 (0.2)
蜂巣炎	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
感染症および寄生虫症 (Cont.)				
結膜炎	1 (0.4)	0	4 (1.4)	4 (0.7)
感染性皮膚炎	0	1 (0.4)	0	1 (0.2)
皮膚糸状菌症	0	0	1 (0.4)	1 (0.2)
爪の皮膚糸状菌症	0	1 (0.4)	0	1 (0.2)
耳感染	0	0	2 (0.7)	2 (0.4)
膿瘡	0	1 (0.4)	0	1 (0.2)
ヘルペス性状湿疹	2 (0.7)	0	2 (0.7)	2 (0.4)
眼感染	0	1 (0.4)	0	1 (0.2)
毛包炎	2 (0.7)	2 (0.7)	4 (1.4)	6 (1.1)
せつ	0	1 (0.4)	0	1 (0.2)
ウイルス性胃腸炎	0	1 (0.4)	0	1 (0.2)
陰部ヘルペス	1 (0.4)	1 (0.4)	0	1 (0.2)
陰部単純ヘルペス	0	0	1 (0.4)	1 (0.2)
ヘルパンギーナ	0	0	1 (0.4)	1 (0.2)
ヘルペス性皮膚炎	0	0	1 (0.4)	1 (0.2)
単純ヘルペス	1 (0.4)	3 (1.1)	5 (1.8)	8 (1.4)
ヘルペスウイルス感染	0	1 (0.4)	1 (0.4)	2 (0.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
感染症および寄生虫症 (Cont.)				
帯状疱疹	0	5 (1.8)	6 (2.1)	11 (1.9)
麦粒腫	0	0	2 (0.7)	2 (0.4)
膿痂疹	2 (0.7)	2 (0.7)	2 (0.7)	4 (0.7)
感染	1 (0.4)	0	0	0
インフルエンザ	0	0	1 (0.4)	1 (0.2)
カポジ水痘様発疹	1 (0.4)	0	1 (0.4)	1 (0.2)
下気道感染	0	1 (0.4)	0	1 (0.2)
伝染性軟属腫	0	0	1 (0.4)	1 (0.2)
上咽頭炎	5 (1.8)	2 (0.7)	6 (2.1)	8 (1.4)
眼部単純ヘルペス	0	0	1 (0.4)	1 (0.2)
口腔カンジダ症	0	0	3 (1.1)	3 (0.5)
口腔ヘルペス	2 (0.7)	3 (1.1)	8 (2.8)	11 (1.9)
急性中耳炎	0	0	1 (0.4)	1 (0.2)
咽頭膿瘍	0	0	1 (0.4)	1 (0.2)
咽頭炎	0	0	1 (0.4)	1 (0.2)
肺炎	0	1 (0.4)	0	1 (0.2)
気道感染	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
感染症および寄生虫症 (Cont.)				
鼻炎	0	1 (0.4)	1 (0.4)	2 (0.4)
副鼻腔炎	1 (0.4)	1 (0.4)	0	1 (0.2)
皮膚細菌感染	2 (0.7)	0	1 (0.4)	1 (0.2)
皮膚カンジダ	0	0	1 (0.4)	1 (0.2)
皮膚感染	0	1 (0.4)	0	1 (0.2)
ブドウ球菌感染	0	0	1 (0.4)	1 (0.2)
股部白癬	0	0	1 (0.4)	1 (0.2)
癜風	0	1 (0.4)	0	1 (0.2)
扁桃炎	1 (0.4)	0	0	0
歯膿瘍	0	0	2 (0.7)	2 (0.4)
上気道感染	3 (1.1)	10 (3.6)	10 (3.5)	20 (3.5)
尿路感染	0	1 (0.4)	2 (0.7)	3 (0.5)
水痘	0	0	1 (0.4)	1 (0.2)
ウイルス感染	1 (0.4)	1 (0.4)	0	1 (0.2)
ウイルス性咽頭炎	0	1 (0.4)	0	1 (0.2)
ウイルス性上気道感染	0	1 (0.4)	2 (0.7)	3 (0.5)
外陰部腟カンジダ症	0	1 (0.4)	1 (0.4)	2 (0.4)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Total (N=566) n (%)
感染症および寄生虫症 (Cont.)				
外陰膣真菌感染	1 (0.4)	0	0	0
ブドウ球菌性創感染	0	0	1 (0.4)	1 (0.2)
傷害、中毒および処置合併症	0	0	2 (0.7)	2 (0.4)
節足動物咬傷	0	0	1 (0.4)	1 (0.2)
ワクチン接種合併症	0	0	1 (0.4)	1 (0.2)
臨床検査	9 (3.2)	22 (7.8)	23 (8.1)	45 (8.0)
アラニンアミノトランスフェラーゼ増加	1 (0.4)	1 (0.4)	3 (1.1)	4 (0.7)
アスパラギン酸アミノトランスフェラーゼ増加	0	1 (0.4)	3 (1.1)	4 (0.7)
B リンパ球数増加	0	1 (0.4)	0	1 (0.2)
血中コレステロール増加	0	2 (0.7)	1 (0.4)	3 (0.5)
血中クレアチンホスホキナーゼ増加	4 (1.4)	12 (4.3)	11 (3.9)	23 (4.1)
血中クレアチニン増加	0	2 (0.7)	0	2 (0.4)
血中免疫グロブリン E 増加	0	1 (0.4)	0	1 (0.2)
尿中血陽性	0	1 (0.4)	0	1 (0.2)
CD4 リンパ球減少	0	1 (0.4)	0	1 (0.2)
CD8 リンパ球百分率減少	0	1 (0.4)	0	1 (0.2)
CD8 リンパ球減少	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
臨床検査 (Cont.)				
CD8 リンパ球増加	1 (0.4)	0	0	0
尿中結晶陽性	0	0	1 (0.4)	1 (0.2)
好酸球百分率増加	0	1 (0.4)	0	1 (0.2)
ヘモグロビン減少	0	1 (0.4)	1 (0.4)	2 (0.4)
肝酵素上昇	0	1 (0.4)	0	1 (0.2)
リンパ球数減少	1 (0.4)	0	0	0
ナチュラルキラー細胞数減少	0	1 (0.4)	0	1 (0.2)
好中球数減少	1 (0.4)	1 (0.4)	2 (0.7)	3 (0.5)
好中球数増加	1 (0.4)	0	0	0
尿蛋白	0	1 (0.4)	0	1 (0.2)
T リンパ球数減少	0	1 (0.4)	0	1 (0.2)
トランスアミナーゼ上昇	0	0	1 (0.4)	1 (0.2)
体重増加	0	4 (1.4)	6 (2.1)	10 (1.8)
白血球数減少	1 (0.4)	0	1 (0.4)	1 (0.2)
代謝および栄養障害	3 (1.1)	5 (1.8)	5 (1.8)	10 (1.8)
食欲減退	1 (0.4)	2 (0.7)	1 (0.4)	3 (0.5)
脂質異常症	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
代謝および栄養障害 (Cont.)				
痛風	0	0	1 (0.4)	1 (0.2)
高コレステロール血症	0	1 (0.4)	2 (0.7)	3 (0.5)
高トリグリセリド血症	0	1 (0.4)	1 (0.4)	2 (0.4)
高尿酸血症	2 (0.7)	1 (0.4)	0	1 (0.2)
筋骨格系および結合組織障害	2 (0.7)	3 (1.1)	4 (1.4)	7 (1.2)
腋窩腫瘤	0	0	1 (0.4)	1 (0.2)
背部痛	1 (0.4)	0	1 (0.4)	1 (0.2)
滑液包炎	0	1 (0.4)	0	1 (0.2)
尺骨部痛	1 (0.4)	0	0	0
筋骨格痛	0	1 (0.4)	0	1 (0.2)
筋肉痛	2 (0.7)	1 (0.4)	3 (1.1)	4 (0.7)
頚部痛	1 (0.4)	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	1 (0.4)	1 (0.2)
皮膚乳頭腫	0	0	1 (0.4)	1 (0.2)
神経系障害	4 (1.4)	7 (2.5)	14 (4.9)	21 (3.7)
健忘	0	0	1 (0.4)	1 (0.2)
注意力障害	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
神経系障害 (Cont.)				
浮動性めまい	1 (0.4)	2 (0.7)	2 (0.7)	4 (0.7)
味覚不全	0	0	1 (0.4)	1 (0.2)
頭痛	2 (0.7)	5 (1.8)	9 (3.2)	14 (2.5)
片頭痛	1 (0.4)	0	1 (0.4)	1 (0.2)
前兆を伴う片頭痛	0	0	1 (0.4)	1 (0.2)
錯感覚	1 (0.4)	0	0	0
傾眠	1 (0.4)	1 (0.4)	0	1 (0.2)
緊張性頭痛	0	0	1 (0.4)	1 (0.2)
精神障害	0	2 (0.7)	0	2 (0.4)
無感情	0	1 (0.4)	0	1 (0.2)
リビドー減退	0	1 (0.4)	0	1 (0.2)
腎および尿路障害	0	1 (0.4)	3 (1.1)	4 (0.7)
アルブミン尿	0	1 (0.4)	1 (0.4)	2 (0.4)
排尿困難	0	0	1 (0.4)	1 (0.2)
蛋白尿	0	0	1 (0.4)	1 (0.2)
生殖系および乳房障害	2 (0.7)	0	3 (1.1)	3 (0.5)
乳房腫大	0	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
生殖系および乳房障害 (Cont.)				
乳房痛	1 (0.4)	0	0	0
乳房圧痛	0	0	1 (0.4)	1 (0.2)
月経困難症	1 (0.4)	0	0	0
閉経期症状	0	0	1 (0.4)	1 (0.2)
月経過多	1 (0.4)	0	0	0
不規則月経	1 (0.4)	0	0	0
呼吸器、胸郭および縦隔障害	1 (0.4)	5 (1.8)	11 (3.9)	16 (2.8)
咳嗽	0	2 (0.7)	1 (0.4)	3 (0.5)
呼吸困難	0	1 (0.4)	0	1 (0.2)
鼻出血	0	0	2 (0.7)	2 (0.4)
鼻閉	0	0	1 (0.4)	1 (0.2)
口腔咽頭痛	0	2 (0.7)	5 (1.8)	7 (1.2)
湿性咳嗽	0	1 (0.4)	0	1 (0.2)
アレルギー性鼻炎	1 (0.4)	0	0	0
副鼻腔うっ血	0	0	2 (0.7)	2 (0.4)
皮膚および皮下組織障害	15 (5.3)	21 (7.5)	48 (16.8)	69 (12.2)
ざ瘡	4 (1.4)	15 (5.3)	36 (12.6)	51 (9.0)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
皮膚および皮下組織障害 (Cont.)				
脱毛症	0	0	1 (0.4)	1 (0.2)
円形脱毛症	0	0	1 (0.4)	1 (0.2)
皮膚嚢腫	0	0	1 (0.4)	1 (0.2)
皮膚炎	0	0	1 (0.4)	1 (0.2)
ざ瘡様皮膚炎	0	1 (0.4)	1 (0.4)	2 (0.4)
アトピー性皮膚炎	6 (2.1)	4 (1.4)	2 (0.7)	6 (1.1)
全身性剥脱性皮膚炎	1 (0.4)	0	0	0
湿疹	2 (0.7)	2 (0.7)	0	2 (0.4)
紅斑	1 (0.4)	0	1 (0.4)	1 (0.2)
毛髪成長異常	0	0	1 (0.4)	1 (0.2)
機械性蕁麻疹	0	0	1 (0.4)	1 (0.2)
神経皮膚炎	0	1 (0.4)	0	1 (0.2)
爪破損	0	0	1 (0.4)	1 (0.2)
炎症後色素沈着変化	0	1 (0.4)	0	1 (0.2)
紫斑	0	0	1 (0.4)	1 (0.2)
発疹	1 (0.4)	0	0	0
酒さ	1 (0.4)	0	0	0

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	Placebo (N=281) n (%)	Active UPA 15 mg QD (N=281) n (%)	Active UPA 30 mg QD (N=285) n (%)	Active Total (N=566) n (%)
皮膚および皮下組織障害 (Cont.)				
脂漏	0	1 (0.4)	0	1 (0.2)
皮膚障害	0	0	1 (0.4)	1 (0.2)
蕁麻疹	0	0	2 (0.7)	2 (0.4)
血管障害	0	1 (0.4)	0	1 (0.2)
潮紅	0	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events in DB Period are defined as any adverse events with an onset or worsening date on or after the first dose of study drug and prior to the first dose of study drug in BE Period or no more than 30 days after the last dose of study drug in DB Period, whichever occurs firstly.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]
相互参照：M16-045 試験 CSR W16 Table 14.3__1.10.1

表 11. ウパダシチニブ投与期間中に治験薬と関連ありの有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
Any adverse event	134 (33.7)	189 (46.6)	323 (40.2)
血液およびリンパ系障害	8 (2.0)	16 (3.9)	24 (3.0)
貧血	0	4 (1.0)	4 (0.5)
白血球増加症	1 (0.3)	0	1 (0.1)
白血球減少症	0	1 (0.2)	1 (0.1)
リンパ節症	1 (0.3)	1 (0.2)	2 (0.2)
リンパ球減少症	1 (0.3)	1 (0.2)	2 (0.2)
好中球減少症	6 (1.5)	13 (3.2)	19 (2.4)
好中球増加症	1 (0.3)	0	1 (0.1)
汎血球減少症	0	1 (0.2)	1 (0.1)
耳および迷路障害	1 (0.3)	1 (0.2)	2 (0.2)
突発性難聴	0	1 (0.2)	1 (0.1)
回転性めまい	1 (0.3)	0	1 (0.1)
眼障害	2 (0.5)	4 (1.0)	6 (0.7)
眼瞼炎	0	1 (0.2)	1 (0.1)
ドライアイ	1 (0.3)	1 (0.2)	2 (0.2)
眼瞼湿疹	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
眼障害 (Cont.)			
霧視	1 (0.3)	1 (0.2)	2 (0.2)
視力障害	1 (0.3)	0	1 (0.1)
胃腸障害	14 (3.5)	20 (4.9)	34 (4.2)
腹部膨満	1 (0.3)	0	1 (0.1)
腹痛	0	2 (0.5)	2 (0.2)
上腹部痛	2 (0.5)	1 (0.2)	3 (0.4)
便秘	0	1 (0.2)	1 (0.1)
齲歯	1 (0.3)	0	1 (0.1)
下痢	2 (0.5)	5 (1.2)	7 (0.9)
腸憩室	1 (0.3)	0	1 (0.1)
口内乾燥	0	1 (0.2)	1 (0.1)
消化不良	1 (0.3)	1 (0.2)	2 (0.2)
軟便	0	2 (0.5)	2 (0.2)
鼓腸	1 (0.3)	1 (0.2)	2 (0.2)
胃炎	1 (0.3)	0	1 (0.1)
消化器痛	1 (0.3)	0	1 (0.1)
胃食道逆流性疾患	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
胃腸障害 (Cont.)			
口唇腫脹	0	1 (0.2)	1 (0.1)
悪心	7 (1.8)	8 (2.0)	15 (1.9)
大網壊死	0	1 (0.2)	1 (0.1)
嘔吐	1 (0.3)	2 (0.5)	3 (0.4)
一般・全身障害および投与部位の状態	11 (2.8)	14 (3.4)	25 (3.1)
無力症	1 (0.3)	0	1 (0.1)
胸痛	1 (0.3)	0	1 (0.1)
悪寒	0	2 (0.5)	2 (0.2)
顔面浮腫	0	1 (0.2)	1 (0.1)
疲労	1 (0.3)	1 (0.2)	2 (0.2)
びくびく感	0	1 (0.2)	1 (0.1)
インフルエンザ様疾患	3 (0.8)	6 (1.5)	9 (1.1)
末梢性浮腫	1 (0.3)	1 (0.2)	2 (0.2)
疼痛	1 (0.3)	1 (0.2)	2 (0.2)
発熱	3 (0.8)	3 (0.7)	6 (0.7)
免疫系障害	1 (0.3)	2 (0.5)	3 (0.4)
アナフィラキシー反応	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
免疫系障害 (Cont.)			
食物アレルギー	0	1 (0.2)	1 (0.1)
過敏症	1 (0.3)	0	1 (0.1)
感染症および寄生虫症	76 (19.1)	103 (25.4)	179 (22.3)
虫垂炎	1 (0.3)	0	1 (0.1)
細菌感染	1 (0.3)	0	1 (0.1)
細菌性膣症	0	1 (0.2)	1 (0.1)
細菌尿	0	1 (0.2)	1 (0.1)
体部白癬	1 (0.3)	1 (0.2)	2 (0.2)
気管支炎	2 (0.5)	3 (0.7)	5 (0.6)
蜂巣炎	1 (0.3)	0	1 (0.1)
結膜炎	0	5 (1.2)	5 (0.6)
コロナウイルス感染	1 (0.3)	1 (0.2)	2 (0.2)
膀胱炎	0	1 (0.2)	1 (0.1)
感染性皮膚炎	1 (0.3)	0	1 (0.1)
皮膚糸状菌症	1 (0.3)	1 (0.2)	2 (0.2)
爪の皮膚糸状菌症	1 (0.3)	0	1 (0.1)
耳感染	1 (0.3)	3 (0.7)	4 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
膿瘡	1 (0.3)	0	1 (0.1)
ヘルペス性状湿疹	1 (0.3)	2 (0.5)	3 (0.4)
丹毒	0	1 (0.2)	1 (0.1)
大腸菌性尿路感染	0	1 (0.2)	1 (0.1)
眼感染	1 (0.3)	0	1 (0.1)
毛包炎	3 (0.8)	7 (1.7)	10 (1.2)
せつ	2 (0.5)	2 (0.5)	4 (0.5)
胃腸炎	0	1 (0.2)	1 (0.1)
ウイルス性胃腸炎	1 (0.3)	0	1 (0.1)
陰部ヘルペス	1 (0.3)	0	1 (0.1)
陰部単純ヘルペス	0	1 (0.2)	1 (0.1)
手足口病	1 (0.3)	0	1 (0.1)
ヘルパンギーナ	0	1 (0.2)	1 (0.1)
ヘルペス性皮膚炎	0	2 (0.5)	2 (0.2)
ヘルペス眼感染	0	1 (0.2)	1 (0.1)
単純ヘルペス	6 (1.5)	8 (2.0)	14 (1.7)
ヘルペスウイルス感染	1 (0.3)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
帯状疱疹	6 (1.5)	11 (2.7)	17 (2.1)
麦粒腫	2 (0.5)	3 (0.7)	5 (0.6)
膿痂疹	4 (1.0)	3 (0.7)	7 (0.9)
インフルエンザ	0	1 (0.2)	1 (0.1)
椎間板炎	1 (0.3)	0	1 (0.1)
カポジ水痘様発疹	1 (0.3)	4 (1.0)	5 (0.6)
潜伏結核	0	2 (0.5)	2 (0.2)
限局性感染	1 (0.3)	0	1 (0.1)
下気道感染	1 (0.3)	0	1 (0.1)
細菌性リンパ節炎	0	1 (0.2)	1 (0.1)
伝染性軟属腫	0	3 (0.7)	3 (0.4)
上咽頭炎	7 (1.8)	8 (2.0)	15 (1.9)
爪真菌症	1 (0.3)	0	1 (0.1)
眼部単純ヘルペス	0	2 (0.5)	2 (0.2)
口腔カンジダ症	0	4 (1.0)	4 (0.5)
口腔ヘルペス	5 (1.3)	14 (3.4)	19 (2.4)
外耳炎	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
中耳炎	0	1 (0.2)	1 (0.1)
急性中耳炎	0	1 (0.2)	1 (0.1)
咽頭膿瘍	0	1 (0.2)	1 (0.1)
咽頭炎	1 (0.3)	1 (0.2)	2 (0.2)
レンサ球菌性咽頭炎	1 (0.3)	0	1 (0.1)
咽頭扁桃炎	1 (0.3)	0	1 (0.1)
肺炎	3 (0.8)	2 (0.5)	5 (0.6)
ウイルス性肺炎	1 (0.3)	0	1 (0.1)
腎盂腎炎	0	1 (0.2)	1 (0.1)
RS ウイルス感染	0	1 (0.2)	1 (0.1)
気道感染	1 (0.3)	0	1 (0.1)
鼻炎	1 (0.3)	2 (0.5)	3 (0.4)
敗血症	0	1 (0.2)	1 (0.1)
副鼻腔炎	1 (0.3)	1 (0.2)	2 (0.2)
皮膚細菌感染	0	1 (0.2)	1 (0.1)
皮膚カンジダ	0	1 (0.2)	1 (0.1)
皮膚感染	1 (0.3)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
感染症および寄生虫症 (Cont.)			
ブドウ球菌感染	0	1 (0.2)	1 (0.1)
ブドウ球菌性敗血症	0	1 (0.2)	1 (0.1)
股部白癬	0	2 (0.5)	2 (0.2)
足部白癬	1 (0.3)	1 (0.2)	2 (0.2)
癜風	1 (0.3)	0	1 (0.1)
歯膿瘍	0	2 (0.5)	2 (0.2)
上気道感染	19 (4.8)	15 (3.7)	34 (4.2)
尿路感染	3 (0.8)	4 (1.0)	7 (0.9)
水痘	0	1 (0.2)	1 (0.1)
ウイルス感染	1 (0.3)	1 (0.2)	2 (0.2)
ウイルス性咽頭炎	1 (0.3)	0	1 (0.1)
ウイルス性上気道感染	1 (0.3)	6 (1.5)	7 (0.9)
外陰部腟カンジダ症	1 (0.3)	1 (0.2)	2 (0.2)
ブドウ球菌性創感染	0	1 (0.2)	1 (0.1)
傷害、中毒および処置合併症	0	2 (0.5)	2 (0.2)
節足動物咬傷	0	1 (0.2)	1 (0.1)
ワクチン接種合併症	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
臨床検査	33 (8.3)	42 (10.3)	75 (9.3)
アラニンアミノトランスフェラーゼ増加	4 (1.0)	7 (1.7)	11 (1.4)
アスパラギン酸アミノトランスフェラーゼ増加	2 (0.5)	6 (1.5)	8 (1.0)
B リンパ球数増加	1 (0.3)	0	1 (0.1)
血中コレステロール増加	2 (0.5)	1 (0.2)	3 (0.4)
血中クレアチンホスホキナーゼ増加	15 (3.8)	19 (4.7)	34 (4.2)
血中クレアチニン増加	2 (0.5)	0	2 (0.2)
血液培養陽性	0	1 (0.2)	1 (0.1)
血中免疫グロブリン E 増加	3 (0.8)	0	3 (0.4)
血中トリグリセリド増加	1 (0.3)	0	1 (0.1)
血中尿酸増加	0	1 (0.2)	1 (0.1)
尿中血陽性	1 (0.3)	0	1 (0.1)
CD4 リンパ球減少	1 (0.3)	0	1 (0.1)
CD8 リンパ球百分率減少	1 (0.3)	0	1 (0.1)
CD8 リンパ球減少	0	1 (0.2)	1 (0.1)
心雑音	0	1 (0.2)	1 (0.1)
尿中結晶陽性	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
臨床検査 (Cont.)			
尿培養陽性	0	1 (0.2)	1 (0.1)
好酸球百分率増加	1 (0.3)	0	1 (0.1)
ヘモグロビン減少	1 (0.3)	1 (0.2)	2 (0.2)
心拍数増加	0	1 (0.2)	1 (0.1)
肝酵素上昇	1 (0.3)	0	1 (0.1)
肝機能検査値上昇	1 (0.3)	0	1 (0.1)
リンパ球数減少	0	2 (0.5)	2 (0.2)
ナチュラルキラー細胞数減少	1 (0.3)	0	1 (0.1)
好中球数減少	1 (0.3)	2 (0.5)	3 (0.4)
血小板数増加	0	1 (0.2)	1 (0.1)
尿蛋白	1 (0.3)	0	1 (0.1)
T リンパ球数減少	1 (0.3)	0	1 (0.1)
トランスアミナーゼ上昇	1 (0.3)	3 (0.7)	4 (0.5)
体重増加	7 (1.8)	10 (2.5)	17 (2.1)
白血球数減少	0	1 (0.2)	1 (0.1)
代謝および栄養障害	6 (1.5)	8 (2.0)	14 (1.7)
食欲減退	2 (0.5)	2 (0.5)	4 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
代謝および栄養障害 (Cont.)			
脂質異常症	0	1 (0.2)	1 (0.1)
痛風	0	1 (0.2)	1 (0.1)
高コレステロール血症	1 (0.3)	4 (1.0)	5 (0.6)
高トリグリセリド血症	1 (0.3)	1 (0.2)	2 (0.2)
高尿酸血症	2 (0.5)	0	2 (0.2)
筋骨格系および結合組織障害	4 (1.0)	5 (1.2)	9 (1.1)
腋窩腫瘤	0	1 (0.2)	1 (0.1)
背部痛	0	1 (0.2)	1 (0.1)
滑液包炎	1 (0.3)	0	1 (0.1)
筋骨格痛	1 (0.3)	0	1 (0.1)
筋肉痛	2 (0.5)	4 (1.0)	6 (0.7)
四肢痛	0	1 (0.2)	1 (0.1)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (0.3)	2 (0.5)	3 (0.4)
皮膚乳頭腫	1 (0.3)	2 (0.5)	3 (0.4)
神経系障害	8 (2.0)	15 (3.7)	23 (2.9)
健忘	0	1 (0.2)	1 (0.1)
注意力障害	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
神経系障害 (Cont.)			
浮動性めまい	2 (0.5)	2 (0.5)	4 (0.5)
味覚不全	0	1 (0.2)	1 (0.1)
頭痛	5 (1.3)	10 (2.5)	15 (1.9)
虚血性脳卒中	1 (0.3)	0	1 (0.1)
片頭痛	0	1 (0.2)	1 (0.1)
前兆を伴う片頭痛	0	1 (0.2)	1 (0.1)
傾眠	1 (0.3)	0	1 (0.1)
緊張性頭痛	0	1 (0.2)	1 (0.1)
精神障害	4 (1.0)	0	4 (0.5)
不安	1 (0.3)	0	1 (0.1)
無感情	1 (0.3)	0	1 (0.1)
リビドー減退	1 (0.3)	0	1 (0.1)
睡眠障害	1 (0.3)	0	1 (0.1)
腎および尿路障害	1 (0.3)	3 (0.7)	4 (0.5)
アルブミン尿	1 (0.3)	1 (0.2)	2 (0.2)
排尿困難	0	1 (0.2)	1 (0.1)
蛋白尿	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
生殖系および乳房障害	1 (0.3)	4 (1.0)	5 (0.6)
無月経	1 (0.3)	1 (0.2)	2 (0.2)
乳房腫大	0	1 (0.2)	1 (0.1)
乳房圧痛	0	1 (0.2)	1 (0.1)
閉経期症状	0	1 (0.2)	1 (0.1)
呼吸器、胸郭および縦隔障害	9 (2.3)	13 (3.2)	22 (2.7)
喘息	0	1 (0.2)	1 (0.1)
咳嗽	5 (1.3)	1 (0.2)	6 (0.7)
呼吸困難	1 (0.3)	1 (0.2)	2 (0.2)
鼻出血	0	2 (0.5)	2 (0.2)
鼻閉	0	1 (0.2)	1 (0.1)
口腔咽頭痛	4 (1.0)	5 (1.2)	9 (1.1)
湿性咳嗽	1 (0.3)	0	1 (0.1)
副鼻腔うっ血	1 (0.3)	2 (0.5)	3 (0.4)
皮膚および皮下組織障害	41 (10.3)	85 (20.9)	126 (15.7)
ざ瘡	24 (6.0)	65 (16.0)	89 (11.1)
脱毛症	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
皮膚および皮下組織障害 (Cont.)			
円形脱毛症	0	1 (0.2)	1 (0.1)
皮膚嚢腫	0	1 (0.2)	1 (0.1)
皮膚炎	0	2 (0.5)	2 (0.2)
ざ瘡様皮膚炎	2 (0.5)	6 (1.5)	8 (1.0)
アトピー性皮膚炎	11 (2.8)	6 (1.5)	17 (2.1)
接触皮膚炎	0	1 (0.2)	1 (0.1)
湿疹	4 (1.0)	0	4 (0.5)
紅斑	1 (0.3)	1 (0.2)	2 (0.2)
毛髪成長異常	0	1 (0.2)	1 (0.1)
多汗症	0	1 (0.2)	1 (0.1)
機械性蕁麻疹	0	1 (0.2)	1 (0.1)
神経皮膚炎	1 (0.3)	0	1 (0.1)
爪破損	0	1 (0.2)	1 (0.1)
炎症後色素沈着変化	1 (0.3)	0	1 (0.1)
そう痒症	1 (0.3)	0	1 (0.1)
紫斑	0	1 (0.2)	1 (0.1)
脂漏	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) n (%)	UPA 30 mg QD (N=406) n (%)	Total (N=804) n (%)
皮膚および皮下組織障害 (Cont.)			
脂漏性皮膚炎	0	1 (0.2)	1 (0.1)
皮膚障害	0	1 (0.2)	1 (0.1)
日光黒子	0	1 (0.2)	1 (0.1)
蕁麻疹	0	2 (0.5)	2 (0.2)
血管障害	1 (0.3)	0	1 (0.1)
潮紅	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.10.2

表 12. ウパダシチニブ投与期間中の治験薬と関連ありの有害事象の 100 人年あたりの発現率：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
Any adverse event	310 (122.2)	475 (184.7)	785 (153.6)
血液およびリンパ系障害	12 (4.7)	27 (10.5)	39 (7.6)
貧血	0	5 (1.9)	5 (1.0)
白血球増加症	1 (0.4)	0	1 (0.2)
白血球減少症	0	1 (0.4)	1 (0.2)
リンパ節症	1 (0.4)	1 (0.4)	2 (0.4)
リンパ球減少症	2 (0.8)	1 (0.4)	3 (0.6)
好中球減少症	7 (2.8)	18 (7.0)	25 (4.9)
好中球増加症	1 (0.4)	0	1 (0.2)
汎血球減少症	0	1 (0.4)	1 (0.2)
耳および迷路障害	1 (0.4)	1 (0.4)	2 (0.4)
突発性難聴	0	1 (0.4)	1 (0.2)
回転性めまい	1 (0.4)	0	1 (0.2)
眼障害	3 (1.2)	4 (1.6)	7 (1.4)
眼瞼炎	0	1 (0.4)	1 (0.2)
ドライアイ	1 (0.4)	1 (0.4)	2 (0.4)
眼瞼湿疹	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
眼障害 (Cont.)			
霧視	1 (0.4)	1 (0.4)	2 (0.4)
視力障害	1 (0.4)	0	1 (0.2)
胃腸障害	21 (8.3)	27 (10.5)	48 (9.4)
腹部膨満	1 (0.4)	0	1 (0.2)
腹痛	0	2 (0.8)	2 (0.4)
上腹部痛	3 (1.2)	1 (0.4)	4 (0.8)
便秘	0	1 (0.4)	1 (0.2)
齲歯	1 (0.4)	0	1 (0.2)
下痢	2 (0.8)	5 (1.9)	7 (1.4)
腸憩室	1 (0.4)	0	1 (0.2)
口内乾燥	0	1 (0.4)	1 (0.2)
消化不良	1 (0.4)	1 (0.4)	2 (0.4)
軟便	0	2 (0.8)	2 (0.4)
鼓腸	1 (0.4)	1 (0.4)	2 (0.4)
胃炎	1 (0.4)	0	1 (0.2)
消化器痛	1 (0.4)	0	1 (0.2)
胃食道逆流性疾患	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
胃腸障害 (Cont.)			
口唇腫脹	0	1 (0.4)	1 (0.2)
悪心	8 (3.2)	8 (3.1)	16 (3.1)
大網壊死	0	1 (0.4)	1 (0.2)
嘔吐	1 (0.4)	2 (0.8)	3 (0.6)
一般・全身障害および投与部位の状態	11 (4.3)	17 (6.6)	28 (5.5)
無力症	1 (0.4)	0	1 (0.2)
胸痛	1 (0.4)	0	1 (0.2)
悪寒	0	2 (0.8)	2 (0.4)
顔面浮腫	0	1 (0.4)	1 (0.2)
疲労	1 (0.4)	1 (0.4)	2 (0.4)
びくびく感	0	1 (0.4)	1 (0.2)
インフルエンザ様疾患	3 (1.2)	6 (2.3)	9 (1.8)
末梢性浮腫	1 (0.4)	1 (0.4)	2 (0.4)
疼痛	1 (0.4)	1 (0.4)	2 (0.4)
発熱	3 (1.2)	4 (1.6)	7 (1.4)
免疫系障害	1 (0.4)	2 (0.8)	3 (0.6)
アナフィラキシー反応	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
免疫系障害 (Cont.)			
食物アレルギー	0	1 (0.4)	1 (0.2)
過敏症	1 (0.4)	0	1 (0.2)
感染症および寄生虫症	105 (41.4)	166 (64.5)	271 (53.0)
虫垂炎	1 (0.4)	0	1 (0.2)
細菌感染	1 (0.4)	0	1 (0.2)
細菌性膣症	0	1 (0.4)	1 (0.2)
細菌尿	0	1 (0.4)	1 (0.2)
体部白癬	1 (0.4)	1 (0.4)	2 (0.4)
気管支炎	2 (0.8)	3 (1.2)	5 (1.0)
蜂巣炎	1 (0.4)	0	1 (0.2)
結膜炎	0	5 (1.9)	5 (1.0)
コロナウイルス感染	1 (0.4)	1 (0.4)	2 (0.4)
膀胱炎	0	1 (0.4)	1 (0.2)
感染性皮膚炎	1 (0.4)	0	1 (0.2)
皮膚糸状菌症	1 (0.4)	1 (0.4)	2 (0.4)
爪の皮膚糸状菌症	1 (0.4)	0	1 (0.2)
耳感染	1 (0.4)	3 (1.2)	4 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
膿瘡	1 (0.4)	0	1 (0.2)
ヘルペス性状湿疹	1 (0.4)	3 (1.2)	4 (0.8)
丹毒	0	1 (0.4)	1 (0.2)
大腸菌性尿路感染	0	1 (0.4)	1 (0.2)
眼感染	1 (0.4)	0	1 (0.2)
毛包炎	3 (1.2)	7 (2.7)	10 (2.0)
せつ	2 (0.8)	2 (0.8)	4 (0.8)
胃腸炎	0	1 (0.4)	1 (0.2)
ウイルス性胃腸炎	1 (0.4)	0	1 (0.2)
陰部ヘルペス	1 (0.4)	0	1 (0.2)
陰部単純ヘルペス	0	1 (0.4)	1 (0.2)
手足口病	1 (0.4)	0	1 (0.2)
ヘルパンギーナ	0	1 (0.4)	1 (0.2)
ヘルペス性皮膚炎	0	2 (0.8)	2 (0.4)
ヘルペス眼感染	0	1 (0.4)	1 (0.2)
単純ヘルペス	6 (2.4)	8 (3.1)	14 (2.7)
ヘルペスウイルス感染	1 (0.4)	1 (0.4)	2 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
帯状疱疹	6 (2.4)	12 (4.7)	18 (3.5)
麦粒腫	2 (0.8)	4 (1.6)	6 (1.2)
膿痂疹	6 (2.4)	3 (1.2)	9 (1.8)
インフルエンザ	0	1 (0.4)	1 (0.2)
椎間板炎	1 (0.4)	0	1 (0.2)
カポジ水痘様発疹	1 (0.4)	5 (1.9)	6 (1.2)
潜伏結核	0	2 (0.8)	2 (0.4)
限局性感染	1 (0.4)	0	1 (0.2)
下気道感染	1 (0.4)	0	1 (0.2)
細菌性リンパ節炎	0	1 (0.4)	1 (0.2)
伝染性軟属腫	0	3 (1.2)	3 (0.6)
上咽頭炎	7 (2.8)	9 (3.5)	16 (3.1)
爪真菌症	1 (0.4)	0	1 (0.2)
眼部単純ヘルペス	0	2 (0.8)	2 (0.4)
口腔カンジダ症	0	4 (1.6)	4 (0.8)
口腔ヘルペス	6 (2.4)	17 (6.6)	23 (4.5)
外耳炎	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
中耳炎	0	1 (0.4)	1 (0.2)
急性中耳炎	0	1 (0.4)	1 (0.2)
咽頭膿瘍	0	1 (0.4)	1 (0.2)
咽頭炎	1 (0.4)	1 (0.4)	2 (0.4)
レンサ球菌性咽頭炎	1 (0.4)	0	1 (0.2)
咽頭扁桃炎	1 (0.4)	0	1 (0.2)
肺炎	3 (1.2)	2 (0.8)	5 (1.0)
ウイルス性肺炎	1 (0.4)	0	1 (0.2)
腎盂腎炎	0	1 (0.4)	1 (0.2)
RS ウイルス感染	0	1 (0.4)	1 (0.2)
気道感染	1 (0.4)	0	1 (0.2)
鼻炎	1 (0.4)	2 (0.8)	3 (0.6)
敗血症	0	1 (0.4)	1 (0.2)
副鼻腔炎	1 (0.4)	1 (0.4)	2 (0.4)
皮膚細菌感染	0	1 (0.4)	1 (0.2)
皮膚カンジダ	0	1 (0.4)	1 (0.2)
皮膚感染	1 (0.4)	1 (0.4)	2 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
ブドウ球菌感染	0	1 (0.4)	1 (0.2)
ブドウ球菌性敗血症	0	1 (0.4)	1 (0.2)
股部白癬	0	2 (0.8)	2 (0.4)
足部白癬	1 (0.4)	1 (0.4)	2 (0.4)
癜風	1 (0.4)	0	1 (0.2)
歯膿瘍	0	2 (0.8)	2 (0.4)
上気道感染	22 (8.7)	21 (8.2)	43 (8.4)
尿路感染	3 (1.2)	4 (1.6)	7 (1.4)
水痘	0	1 (0.4)	1 (0.2)
ウイルス感染	1 (0.4)	1 (0.4)	2 (0.4)
ウイルス性咽頭炎	2 (0.8)	0	2 (0.4)
ウイルス性上気道感染	1 (0.4)	6 (2.3)	7 (1.4)
外陰部腟カンジダ症	1 (0.4)	1 (0.4)	2 (0.4)
ブドウ球菌性創感染	0	1 (0.4)	1 (0.2)
傷害、中毒および処置合併症	0	2 (0.8)	2 (0.4)
節足動物咬傷	0	1 (0.4)	1 (0.2)
ワクチン接種合併症	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
臨床検査	63 (24.8)	65 (25.3)	128 (25.1)
アラニンアミノトランスフェラーゼ増加	4 (1.6)	8 (3.1)	12 (2.3)
アスパラギン酸アミノトランスフェラーゼ増加	2 (0.8)	6 (2.3)	8 (1.6)
B リンパ球数増加	1 (0.4)	0	1 (0.2)
血中コレステロール増加	3 (1.2)	2 (0.8)	5 (1.0)
血中クレアチンホスホキナーゼ増加	25 (9.9)	21 (8.2)	46 (9.0)
血中クレアチニン増加	3 (1.2)	0	3 (0.6)
血液培養陽性	0	1 (0.4)	1 (0.2)
血中免疫グロブリン E 増加	3 (1.2)	0	3 (0.6)
血中トリグリセリド増加	1 (0.4)	0	1 (0.2)
血中尿酸増加	0	1 (0.4)	1 (0.2)
尿中血陽性	1 (0.4)	0	1 (0.2)
CD4 リンパ球減少	1 (0.4)	0	1 (0.2)
CD8 リンパ球百分率減少	1 (0.4)	0	1 (0.2)
CD8 リンパ球減少	0	1 (0.4)	1 (0.2)
心雑音	0	1 (0.4)	1 (0.2)
尿中結晶陽性	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
臨床検査 (Cont.)			
尿培養陽性	0	1 (0.4)	1 (0.2)
好酸球百分率増加	1 (0.4)	0	1 (0.2)
ヘモグロビン減少	2 (0.8)	1 (0.4)	3 (0.6)
心拍数増加	0	1 (0.4)	1 (0.2)
肝酵素上昇	1 (0.4)	0	1 (0.2)
肝機能検査値上昇	1 (0.4)	0	1 (0.2)
リンパ球数減少	0	2 (0.8)	2 (0.4)
ナチュラルキラー細胞数減少	1 (0.4)	0	1 (0.2)
好中球数減少	1 (0.4)	2 (0.8)	3 (0.6)
血小板数増加	0	1 (0.4)	1 (0.2)
尿蛋白	1 (0.4)	0	1 (0.2)
T リンパ球数減少	1 (0.4)	0	1 (0.2)
トランスアミナーゼ上昇	1 (0.4)	3 (1.2)	4 (0.8)
体重増加	8 (3.2)	11 (4.3)	19 (3.7)
白血球数減少	0	1 (0.4)	1 (0.2)
代謝および栄養障害	6 (2.4)	9 (3.5)	15 (2.9)
食欲減退	2 (0.8)	2 (0.8)	4 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
代謝および栄養障害 (Cont.)			
脂質異常症	0	1 (0.4)	1 (0.2)
痛風	0	1 (0.4)	1 (0.2)
高コレステロール血症	1 (0.4)	4 (1.6)	5 (1.0)
高トリグリセリド血症	1 (0.4)	1 (0.4)	2 (0.4)
高尿酸血症	2 (0.8)	0	2 (0.4)
筋骨格系および結合組織障害	4 (1.6)	8 (3.1)	12 (2.3)
腋窩腫瘤	0	1 (0.4)	1 (0.2)
背部痛	0	2 (0.8)	2 (0.4)
滑液包炎	1 (0.4)	0	1 (0.2)
筋骨格痛	1 (0.4)	0	1 (0.2)
筋肉痛	2 (0.8)	4 (1.6)	6 (1.2)
四肢痛	0	1 (0.4)	1 (0.2)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (0.4)	2 (0.8)	3 (0.6)
皮膚乳頭腫	1 (0.4)	2 (0.8)	3 (0.6)
神経系障害	12 (4.7)	18 (7.0)	30 (5.9)
健忘	0	1 (0.4)	1 (0.2)
注意力障害	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
神経系障害 (Cont.)			
浮動性めまい	2 (0.8)	2 (0.8)	4 (0.8)
味覚不全	0	1 (0.4)	1 (0.2)
頭痛	6 (2.4)	11 (4.3)	17 (3.3)
虚血性脳卒中	1 (0.4)	0	1 (0.2)
片頭痛	0	1 (0.4)	1 (0.2)
前兆を伴う片頭痛	0	1 (0.4)	1 (0.2)
傾眠	2 (0.8)	0	2 (0.4)
緊張性頭痛	0	1 (0.4)	1 (0.2)
精神障害	4 (1.6)	0	4 (0.8)
不安	1 (0.4)	0	1 (0.2)
無感情	1 (0.4)	0	1 (0.2)
リビドー減退	1 (0.4)	0	1 (0.2)
睡眠障害	1 (0.4)	0	1 (0.2)
腎および尿路障害	1 (0.4)	4 (1.6)	5 (1.0)
アルブミン尿	1 (0.4)	2 (0.8)	3 (0.6)
排尿困難	0	1 (0.4)	1 (0.2)
蛋白尿	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
生殖系および乳房障害	1 (0.4)	4 (1.6)	5 (1.0)
無月経	1 (0.4)	1 (0.4)	2 (0.4)
乳房腫大	0	1 (0.4)	1 (0.2)
乳房圧痛	0	1 (0.4)	1 (0.2)
閉経期症状	0	1 (0.4)	1 (0.2)
呼吸器、胸郭および縦隔障害	12 (4.7)	14 (5.4)	26 (5.1)
喘息	0	1 (0.4)	1 (0.2)
咳嗽	5 (2.0)	1 (0.4)	6 (1.2)
呼吸困難	1 (0.4)	2 (0.8)	3 (0.6)
鼻出血	0	2 (0.8)	2 (0.4)
鼻閉	0	1 (0.4)	1 (0.2)
口腔咽頭痛	4 (1.6)	5 (1.9)	9 (1.8)
湿性咳嗽	1 (0.4)	0	1 (0.2)
副鼻腔うっ血	1 (0.4)	2 (0.8)	3 (0.6)
皮膚および皮下組織障害	51 (20.1)	105 (40.8)	156 (30.5)
ざ瘡	26 (10.2)	73 (28.4)	99 (19.4)
脱毛症	0	1 (0.4)	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
円形脱毛症	0	1 (0.4)	1 (0.2)
皮膚嚢腫	0	1 (0.4)	1 (0.2)
皮膚炎	0	2 (0.8)	2 (0.4)
ざ瘡様皮膚炎	2 (0.8)	7 (2.7)	9 (1.8)
アトピー性皮膚炎	14 (5.5)	6 (2.3)	20 (3.9)
接触皮膚炎	0	1 (0.4)	1 (0.2)
湿疹	4 (1.6)	0	4 (0.8)
紅斑	1 (0.4)	1 (0.4)	2 (0.4)
毛髪成長異常	0	1 (0.4)	1 (0.2)
多汗症	0	2 (0.8)	2 (0.4)
機械性蕁麻疹	0	1 (0.4)	1 (0.2)
神経皮膚炎	1 (0.4)	0	1 (0.2)
爪破損	0	1 (0.4)	1 (0.2)
炎症後色素沈着変化	1 (0.4)	0	1 (0.2)
そう痒症	1 (0.4)	0	1 (0.2)
紫斑	0	1 (0.4)	1 (0.2)
脂漏	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=398) (PYS=253.7) Events (E/100PY)	UPA 30 mg QD (N=406) (PYS=257.2) Events (E/100PY)	Total (N=804) (PYS=510.9) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
脂漏性皮膚炎	0	1 (0.4)	1 (0.2)
皮膚障害	0	1 (0.4)	1 (0.2)
日光黒子	0	1 (0.4)	1 (0.2)
蕁麻疹	0	3 (1.2)	3 (0.6)
血管障害	1 (0.4)	0	1 (0.2)
潮紅	1 (0.4)	0	1 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W16 Table 14.3__1.10.3

重篤な有害事象の叙述

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
虚血性脳卒中	X	X		X

Treatment Group	Age at Study Start	Sex	Race
PLACEBO/UPA 15 MG QD	6[redacted]	MALE	WHITE

Medical History	Onset Year
HYPERTENSION	19[redacted]
PSUEDOGOUT	20[redacted]
RHEUMATOID ARTHRITIS	20[redacted]
OBSTRUCTIVE SLEEP APNEA	20[redacted]
ATOPIC DERMATITIS	20[redacted]
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	20[redacted]
ATOPIC DERMATITIS	20[redacted]
HIDRADENITIS SUPPURATIVA	20[redacted]
SCARRING OF THE LEFT LUNG	20[redacted]
SMALL HIATAL HERNIA	20[redacted]

Prior Procedures	Procedure Year
PRIOR PROCEDURES: RIGHT INGUINAL HERNIA REPAIR	20[redacted]
PRIOR PROCEDURES: BILATERAL CATARACT SURGERY	20[redacted]
PRIOR PROCEDURES: TOTAL LEFT KNEE REPLACEMENT	20[redacted]
PRIOR PROCEDURES: VENOUS LASER ABLATION	20[redacted]
PRIOR PROCEDURES: CT CHEST	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	20 CIGARETTE	54	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 109	109

UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 141	[redacted]20[redacted] / 150	10

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
AMLODIPINE	10 mg	QD	Y-M: 20[redacted]
LOSARTAN	50 mg	QD	Y-M: 20[redacted]
IBUPROFEN	600 mg	QD	Y-M: 20[redacted]
HERPES ZOSTER IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
ERGOCALCIFEROL	400 IU	QD	Y-M: 20[redacted]
LEFLUNOMIDE	20 mg	QD	Y-M: 20[redacted]
CLINDAMYCIN	1 %	PRN	Y-M: 20[redacted]
TRIAMCINOLONE	01 %	BID	Y-M: 20[redacted]
BETAMETHASONE	0.05 %	BID	Y-M: 20[redacted]
MUPIROCIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
TRIAMCINOLONE	2.5 OTHER: MG/ML	OTHER: ONCE	Y-M: 20[redacted]
CETIRIZINE	10 mg	QD	Y-M: 20[redacted]
FEXOFENADINE	180 mg	QD	Y-M: 20[redacted]
FLUOCINONIDE	0.05 %	BID	Y-M: 20[redacted]
LORATADINE	10 mg	QD	Y-M: 20[redacted]
OTHER EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
PREDNISONE	40MG X 3 DAYS, 30MG X 3 DAYS, 20MG X 3 DAYS, 10MG X 3 DAYS mg	QD	Y-M: 20[redacted] / -306
HYDROXYZINE	25 mg	OTHER: HS	Y-M: 20[redacted] / -250
HONEY	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -222
TRIAMCINOLONE	2.5 OTHER: MG/ML	OTHER: ONCE	Y-M: 20[redacted] / -145
PREDNISONE	10 mg	QD	Y-M: 20[redacted] / -31

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
AMLODIPINE	10 mg	QD	Y-M: 20[redacted]	ONGOING
ERGOCALCIFEROL	400 IU	QD	Y-M: 20[redacted]	ONGOING
LEFLUNOMIDE	20 mg	QD	Y-M: 20[redacted]	ONGOING
CLINDAMYCIN	1 %	PRN	Y-M: 20[redacted]	ONGOING
MUPIROCIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]	ONGOING
OTHER EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]	ONGOING
LOSARTAN	100 mg	QD	Y-M: 20[redacted] / 56	ONGOING
PARACETAMOL	650MG mg	BID	Y-M: 20[redacted] / 83	ONGOING

UMECLIDINIUM	62.5MCG OTHER: MCG	QD	Y-M: 20[redacted]- / 130	ONGOING
NEBIVOLOL	5MG mg	QD	Y-M: 20[redacted]- / 130	Y-M: 20[redacted]- / 144
NEBIVOLOL	10 mg	QD	Y-M: 20[redacted]- / 144	ONGOING
POTASSIUM	10MG mg	QD	Y-M: 20[redacted]- / 149	ONGOING
ACETYLSALICYLIC ACID	81MG mg	QD	Y-M: 20[redacted]- / 150	ONGOING
CHLORTALIDONE	25MG mg	QD	Y-M: 20[redacted]- / 150	ONGOING
NICOTINE	21 mg	QD	Y-M: 20[redacted]- / 151	ONGOING
ATORVASTATIN	10MG mg	QD	Y-M: 20[redacted]- / 159	ONGOING

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Event of Interest - MACE

Event Description	ISCHEMIC STROKE
Preferred term	虚血性脳卒中
AE Onset Date / Rx Day	[redacted]20[redacted] / 149
Age at AE Onset	6[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 149): CHEST XRAY: NODULAR DENSITY PROJECTS LEFT LUNG BASE, INTERSTITIAL PROMINENCE BILATERALLY MAY REPRESENT SCARRING OR EDEMA/INFILTRATE. CT CHEST RECOMMENDED; CT CHEST WITHOUT CONTRAST: 1. AREAS OF ATELECTASIS IN LOWER LUNGS 2. ELONGATED THORACIC AORTA W FOCAL DILATION OF THE AORTIC ARCH. MAY REPRESENT A SACCULAR ANEURYSM VERSUS A DUCTUS DIVERTICULUM 3. COPD; CT HEAD WITHOUT CONTRAST: NO ACUTE INTRACRANIAL ABNORMALITIES; ECG: SINUS BRADYCARDIA, NONSPECIFIC ST & T WAVE CHANGES; [redacted]20[redacted] (RX DAY 150): MRI BRAIN WITHOUT AND WITH CONTRAST: ACUTE LUNAR INFARCTS IN THE LEFT PERIVENTRICULAR WHITE MATTER AND RIGHT BASAL GANGLIA. ADVANCE MICROVASCULAR DISEASE. NO ACUTE INTRACRANIAL HEMMORHAGE.; TRANS THORACIC ECHOCARDIOGRAM: LEFT VENTRICULAR EJECTION FRACTION, BY VISUAL ESTIMATION, IS 50 TO 55%. MILD DIASTOLIC DYSFUNCTION OF THE LEFT VENTRICLE. MODERATE SEPTAL LEFT VENTRICULAR HYPERTROPHY. NO FOCAL LEFT VENTRICULAR WALL MOTION ABNORMALITIES. MILDLY THICKENED MITRAL VALVE. MILD AORTIC REGURGITATION. MODERATE AORTIC VALVE SCLEROSIS/CALCIFICATION WITHOUT ANY EVIDENCE OF AORTIC STENOSIS. SALINE CONTRAST BUBBLE STUDY WAS NEGATIVE, WITH NO EVIDENCE OF ANY INTRACARDIAC SHUNT.; ULTRASOUND CAROTID DUPLEX: NO EVIDENCE OF HEMODYNAMICALLY SIGNIFICANT STENOSIS INVOLVING THE INTERNAL CAROTID ARTERIES BILATERALLY; [redacted]20[redacted] (RX DAY 151): CT ANGIOGRAPHY HEAD AND NECK: NO VASCULAR ABNORMALITY IDENTIFIED IN THE HEAD AND NECK
AE Stopped Rx Day	163 (13 DAYS AFTER LAST TREATMENT)
Duration of AE	15 DAYS
Toxicity Grade	3

Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	SMALL VESSEL DISEASE RELATED TO UNCONTROLLED HYPERTENSION
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 6[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，虚血性脳卒中を発現した。被験者は紙巻タバコ喫煙者（1 箱／日，54 年間）かつ飲酒者（2 杯未満／日）で，関連する病歴は高血圧，関節リウマチ，閉塞性睡眠時無呼吸（夜間に持続陽圧呼吸装置を使用），化膿性汗腺炎及びアトピー性皮膚炎であった。血管内レーザー焼灼術（下肢静脈逆流）による治療歴があり，家族歴に脳卒中（両親及び兄又は弟）があった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は虚血性脳卒中を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，虚血性脳卒中は消失した。

本事象発現前の数ヵ月間，被験者の血圧コントロールはやや難渋していた。無症状であったものの，被験者には本試験開始前から長期にわたる高血圧の病歴があった。かかりつけ医が降圧薬を調整しており，試験開始以降に大きな血圧上昇はなかった。家庭血圧は収縮期が 160 mmHg 台，拡張期が 100 mmHg 台を継続していた。本事象発現の 2 ヵ月前，losartan が増量され，Bystolic の投与が上乗せされた。これまで正常値であったクレアチニン値が上昇したため，慢性疼痛に対する非ステロイド系抗炎症薬の使用は中止された。被験者によれば，胸痛，息切れ，新規の咳嗽，発熱，悪寒，悪心，嘔吐，腹痛，排尿困難，下痢及び便秘はなかった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は初めて神経学的症状を自覚した。眼瞼から顔面下部にかけて，顔面右側が垂れ下がっているような感覚が生じた。被験者は幾分かの霧視及び軽度の会話障害を訴えたが，嚥下のトラブルや錯乱はなかった。被験者は断続的な軽度の頭痛を発現していた。翌日の 20[redacted] 年 [redacted] 月 [redacted] 日，症状は顔面非対称に持続していた。被験者は救急治療室を受診することにした。ほとんどの症状は救急治療室到着前に消失していた。

救急治療室にて神経科医が身体所見を診察したが，局所神経障害は認められなかった。症状は改善していった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院した。臨床検査結果に特筆すべき所見はほとんどなく，頭部コンピュータ断層撮影の所見は正常であり，神経学的診察の所見も正常であった。入院時の血圧は 150/98 mmHg であった（血圧連続測定結果は収縮期が 140～150 mmHg 台，拡張期が 80～100 mmHg 台）。核磁気共鳴画像の所見として，左脳室周囲の白質に急性ラクナ梗塞，右大脳基底核に進行した微小血管疾患が認められた。入院時の最初の診断は，構語障害を伴う顔面麻痺であった。アスピリンが投与された。被験者によれば，顔面のしびれ感，四肢の脱力，しびれ感又はピリピリ感，並びに歩行障害はなかった。（米）国立衛生研究所脳卒中スケールに関する記録はなかった。総合的に被験者の自覚として，会話は正常に復しつつあり，顔が垂れ下がる感覚は軽減し，正常に戻ったように見えた。入院中，被験者の血圧は 146～155/87～102 mmHg の範囲を推移した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者はアスピリン及び心イベントモニター装置の使用を継続しながら退院し，退院時モニター所見は心機能完全回復であった。被験者は本事象を理由に試験を中止した。

関連するリスク因子には家族歴の脳卒中（両親及び兄又は弟），及び本人の病歴の高血圧があり，後者については血圧上昇に対し降圧薬を追加投与したが反応しなかった。被験者は脳卒中や神経疾患の既往歴はないと申告した。

chlorthalidone，カリウム及びアスピリンが投与された。

The patient's past medications include:

IBUPROFEN for RHEUMATOID ARTHRITIS ([redacted] [redacted]20[redacted] - [redacted] [redacted]20[redacted])

PREDNISONE for ATOPIC DERMATITIS ([redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted], [redacted] [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Ischemic stroke (10055221) (Ischaemic stroke (10061256)) [v.22.1] [10055221]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of ISCHEMIC STROKE

- Investigator: SMALL VESSEL DISEASE RELATED TO UNCONTROLLED HYPERTENSION

- AbbVie: Risk factors include pre-existing hypertension, current long term smoking status, family history of strokes, and advanced age.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BLOOD PRESSURE:** on admission was 150/98 mmHg (continued readings of 140s-150s/80s-100s mmHg on day of admission)

[redacted] **20[redacted] CHEST X-RAY:** NODULAR DENSITY PROJECTS LEFT LUNG BASE, INTERSTITIAL PROMINENCE BILATERALLY MAY REPRESENT SCARRING OR EDEMA/INFILTRATE. CT CHEST RECOMMENDED

[redacted] **20[redacted] CHEST X-RAY (SCREENING):** ABNORMAL: SMALL HIATAL HERNIA AND AORTIC UNFOLDING, NO CARDIOMEGALY OR MEDIASTINAL LYMPHADENOPATHY. SCARRING THE LEFT LUNG MID ZONE AND LEFT BASE BUT NO ACUTE OR FOCAL DOMINANT CARDIOPULMONARY ABNORMALITY.

[redacted] **20[redacted] CT ANGIOGRAPHY HEAD AND NECK:** NO VASCULAR ABNORMALITY IDENTIFIED IN THE HEAD AND NECK

[redacted] **20[redacted] CT CHEST (PRIOR TO STUDY):** SMALL RIGHT LOWER LOBE PULMONARY NODULE APPEARS TO HAVE DEVELOPED CENTRAL BENIGN APPEARING CALCIFICATION

[redacted] **20[redacted] CT CHEST WITHOUT CONTRAST:** 1. AREAS OF ATELECTASIS IN LOWER LUNGS. 2. ELONGATED THORACIC AORTA WITH FOCAL DILATION OF THE AORTIC ARCH. MAY REPRESENT A SACCULAR ANEURYSM VERSUS A DUCTUS DIVERTICULUM. 3. COPD.

[redacted] **20[redacted] CT HEAD WITHOUT CONTRAST:** NO ACUTE INTRACRANIAL ABNORMALITIES

[redacted] **20[redacted] ECG:** SINUS BRADYCARDIA, NONSPECIFIC ST & T WAVE CHANGES

[redacted] **20[redacted] MRI BRAIN WITHOUT AND WITH CONTRAST:** ACUTE LUNAR INFARCTS IN THE LEFT PERIVENTRICULAR WHITE MATTER AND RIGHT BASAL GANGLIA. ADVANCE MICROVASCULAR DISEASE. NO ACUTE INTRACRANIAL HEMMORHAGE.

[redacted] **20[redacted] TRANSTHORACIC ECHOCARDIOGRAM:** LEFT VENTRICULAR EJECTION FRACTION, BY VISUAL ESTIMATION, IS 50 TO 55%. MILD DIASTOLIC DYSFUNCTION OF THE LEFT VENTRICLE. MODERATE SEPTAL LEFT VENTRICULAR HYPERTROPHY. NO FOCAL LEFT VENTRICULAR WALL MOTION ABNORMALITIES. MILDLY THICKENED MITRAL VALVE. MILD AORTIC REGURGITATION. MODERATE AORTIC VALVE SCLEROSIS/CALCIFICATION WITHOUT ANY EVIDENCE OF AORTIC STENOSIS. SALINE CONTRAST BUBBLE STUDY WAS NEGATIVE, WITH NO EVIDENCE OF ANY INTRACARDIAC SHUNT.

[redacted] **20[redacted] ULTRASOUND CAROTID DUPLEX:** NO EVIDENCE OF HEMODYNAMICALLY SIGNIFICANT STENOSIS INVOLVING THE INTERNAL CAROTID ARTERIES BILATERALLY

Subject [redacted]([redacted]

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
ウイルス性肺炎	X			X

Treatment Group	Age at Study Start	Sex	Race
UPA 15 MG QD/UPA 15 MG QD	4[redacted]	MALE	BLACK OR AFRICAN AMERICAN

Medical History	Onset Year
ALLERGY TO SHELLFISH	19[redacted]
ATOPIC DERMATITIS	19[redacted]
ATOPIC DERMATITIS	19[redacted]
SEASONAL ALLERGIES	19[redacted]
ALLERGIC RHINITIS	NOT REPORTED
FOOD ALLERGY	NOT REPORTED

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 118	118
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 119		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	NOT REPORTED
EUCERIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]-[redacted]

CLOBETASOL	0.05 %	QD	Y-M: 20[redacted]-[redacted] / -132

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
HYDROXYCHLOROQUINE	UNKNOWN		NOT REPORTED	NOT REPORTED
EUCERIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]-[redacted]	NOT REPORTED

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	VIRAL PNEUMONIA
Preferred term	ウイルス性肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 368
Age at AE Onset	4[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	NOT REPORTED
AE Stopped Rx Day	400
Duration of AE	33 DAYS
Toxicity Grade	4
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	COVID-19
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 4[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，ウイルス性肺炎を発現した。被験者は非喫煙者かつ飲酒者（2 杯未満／日）であり，関連する病歴はアトピー性皮膚炎であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者はウイルス性肺炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，ウイルス性肺炎は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は息切れ，片頭痛及び下痢の症状で入院した。同日，被験者は新型コロナウイルス感染症（非重篤）を発現した。息切れが悪化し，20[redacted] 年 [redacted] 月 [redacted] 日に気管挿管を行った。

hydroxychloroquine が投与された。

The patient's past medications include:

CLOBETASOL for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Viral pneumonia (10047474) (Pneumonia viral (10035737)) [v.23.0] [10047474]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of VIRAL PNEUMONIA

- Investigator: COVID-19.

- AbbVie: Event is more likely related to the COVID-19 pandemic outbreak.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] WEIGHT:** 88 KG

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
虫垂炎	X			X

Treatment Group	Age at Study Start	Sex	Race
PLACEBO/UPA 15 MG QD	3[redacted]	MALE	WHITE

Medical History	Onset Year
ACNE	19[redacted]
ANDROGENETEIC ALOPECIA	20[redacted]
ATOPIC DERMATITIS	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	2 - 4

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 112	112
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 113		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y: 19[redacted]
EUCERIN	1 OTHER: APPLICATION	BID	Y: 20[redacted]
FINASTERIDE	1 mg	QD	Y: 20[redacted]
TRIAMCINOLONE	0.1 %	BID	Y-M: 20[redacted]-[redacted]
ALL OTHER NON-THERAPEUTIC PRODUCTS	1 OTHER: TREATMENT	OTHER: 3 X PER WEEK	Y-M: 20[redacted]-[redacted] / -128

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
EUCERIN	1 OTHER: APPLICATION	BID	Y: 20[redacted]	NOT REPORTED
FINASTERIDE	1 mg	QD	Y: 20[redacted]	NOT REPORTED
CEFALEXIN	500 mg	BID	Y-M: 20[redacted]-[redacted] / 175	Y-M: 20[redacted]-[redacted] / 185
METRONIDAZOLE	500 mg	TID	Y-M: 20[redacted]-[redacted] / 175	Y-M: 20[redacted]-[redacted] / 185
METRONIDAZOLE	500 mg	OTHER: Q8H	Y-M: 20[redacted]-[redacted] / 176	Y-M: 20[redacted]-[redacted] / 176
OXYCOCET	5/325 mg	PRN	Y-M: 20[redacted]-[redacted] / 208	Y-M: 20[redacted]-[redacted] / 210

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	APPENDICITIS
Preferred term	虫垂炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 173
Age at AE Onset	3[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 175): Leukocytes: 15.1 [3.1 - 8.4] 10^9/L; [redacted]20[redacted] (RX DAY 176): Leukocytes: 8.9 [3.1 - 8.4] 10^9/L
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 175): ABDOMINAL CT SCAN: FINDINGS CONSISTENT WITH ACUTE APPENDICITIS;[redacted]20[redacted] (RX DAY 208): APPENDECTOMY: NA
AE Stopped Rx Day	208
Duration of AE	36 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 3[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，虫垂炎を発現した。被験者は非喫煙者かつ飲酒者（2～4 杯／日）であり，関連する病歴はアトピー性皮膚炎であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は虫垂炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，虫垂炎は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は 2 日間持続する腹痛のため救急治療室を受診し，入院した。身体的診察の所見は，腹部が軟であり，腹部膨満はなく，圧痛，McBurney 点の圧痛，及びロブシング徴候が認められた。治療薬として，抗生物質の静脈内投与が 24 時間行われた。被験者の症状は消失し，経口薬による治療が開始された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。20[redacted] 年 [redacted] 月 1 日，被験者は外来で虫垂切除を受けた。

PERCOCET，メトロニダゾール及び cephalexin が投与された。

The patient's past medications include:

TRIAMCINOLONE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Appendicitis (10003011) (Appendicitis (10003011)) [v.22.1] [10003011]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of APPENDICITIS

- Investigator: Not applicable

- AbbVie: Event is common in the general population; lifetime incidence is 8.6 percent in males and 6.7 percent in females.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ABDOMINAL CT SCAN:** Findings consistent with acute appendicitis

[redacted] **20[redacted] WHITE BLOOD CELLS:** 15.11 X10**3/MCL (normal 3.12 to 8.44)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 8.87 X10**3/MCL (normal 3.12 to 8.44)

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
肺炎	X			X

Treatment Group	Age at Study Start	Sex	Race
UPA 15 MG QD/UPA 15 MG QD	4[redacted]	FEMALE	WHITE

Medical History	Onset Year
FOOD ALLERGY (LAMB)	19[redacted]
ATOPIC DERMATITIS	20[redacted]
TONSILLITIS	20[redacted]
APPENDICITIS	20[redacted]
HEARTBURN	20[redacted]
PNEUMONIA	20[redacted]
ATOPIC DERMATITIS	20[redacted]
ANTERIOR CRUCIATE LIGAMENT KNEE REPLACEMENT	20[redacted]
DIABETES	20[redacted]
HIGH CHOLESTEROL	20[redacted]
HYPERTENSION	20[redacted]
FOOD ALLERGY	NOT REPORTED

Prior Procedures	Procedure Year
PRIOR PROCEDURES: TONSILLECTOMY	20[redacted]
PRIOR PROCEDURES: APPENDECTOMY	20[redacted]
PRIOR PROCEDURES: ANTERIOR CRUCIATE LIGAMENT KNEE REPLACEMENT	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	5 CIGARETTE	25	20[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 113	113
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 114		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
PREDNISONE	30 mg	QD	Y-M: 20[redacted]
OMEPRAZOLE	20 mg	QD	Y: 20[redacted] / -281
CLOBETASOL	0.05 %	OTHER: BID PRN	Y-M: 20[redacted] / -234
ZESTORETIC	20/25 mg	QD	Y-M: 20[redacted] / -191
PREDNISONE	20 mg	QD	Y-M: 20[redacted] / -125
ATORVASTATIN	40 mg	QD	Y-M: 20[redacted] / -100
METFORMIN	500 mg	QD	Y-M: 20[redacted] / -100
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -69
BETAMETHASONE	0.05 %	OTHER: BID PRN	Y-M: 20[redacted] / -64
PREDNISONE	20 mg	OTHER: EVERY OTHER DAY	Y-M: 20[redacted] / -64
HYDROCODONE	5/500 mg	PRN	Y-M: 20[redacted] / -28
NAPROXEN	375 mg	BID	Y-M: 20[redacted] / -28
TRAMADOL	50 mg	PRN	Y-M: 20[redacted] / -19
IBUPROFEN	800 mg	PRN	Y-M: 20[redacted] / -15
PARACETAMOL	500 mg	PRN	Y-M: 20[redacted] / -15
AQUAPHOR	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -7

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
OMEPRAZOLE	20 mg	QD	Y: 20[redacted] / -281	NOT REPORTED
ZESTORETIC	20/25 mg	QD	Y-M: 20[redacted] / -191	Y-M: 20[redacted] / 159
ATORVASTATIN	40 mg	QD	Y-M: 20[redacted] / -100	Y-M: 20[redacted] / 159
METFORMIN	500 mg	QD	Y-M: 20[redacted] / -100	Y-M: 20[redacted] / 159
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -69	NOT REPORTED
PARACETAMOL	500 mg	PRN	Y-M: 20[redacted] / -15	NOT REPORTED
IBUPROFEN	800 mg	PRN	Y-M: 20[redacted] / -15	Y-M: 20[redacted] / 418
AQUAPHOR	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -7	NOT REPORTED
SALBUTAMOL	90 OTHER: MCG	PRN	Y-M: 20[redacted] / 222	NOT REPORTED
CLARITHROMYCIN	500 mg	OTHER: EVERY 12 HOURS	Y-M: 20[redacted] / 222	Y-M: 20[redacted] / 231

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	PNEUMONIA
Preferred term	肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 175
Age at AE Onset	4[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 222): Leukocytes: 10.6 [4 - 11] 10^9/L; Lymphocytes: 2.2 [0.9 - 3.9] 10^9/L; Neutrophils: 7.7 [1.5 - 7.8] 10^9/L
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 222): CHEST PA + LAT: NO RADIOGRAPHIC EVIDENCE OF ACUTE CARDIOPULMONARY ABNORMALITY. STABLE APPEARING EXAMINATION.; ELECTROCARDIOGRAM: NORMAL SINUS RHYTHM
AE Stopped Rx Day	231
Duration of AE	57 DAYS
Toxicity Grade	2
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 4[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，肺炎を発現した。被験者は元喫煙者（紙巻タバコ 5 本／日，25 年間）かつ飲酒者（2 杯未満／日）であり，関連する病歴は肺炎，アトピー性皮膚炎，高血圧，糖尿病及びコレステロール高値であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月，被験者は肺炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，肺炎は消失した。

被験者は 3 週間続く咳嗽のため救急治療室を受診した。被験者は肺炎と診断され，Biaxin 及び albuterol を処方されて救急治療室から帰宅した。

ALBUTEROL HFA 及び BIAXIN が投与された。

The patient's past medications include:

PREDNISONE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

CLOBETASOL CREAM for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

CLOBETASOL OINTMENT for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

BETAMETHASONE CREAM for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Pneumonia (10035664) (Pneumonia (10035664)) [v.22.1] [10035664]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of PNEUMONIA

- Investigator: Not applicable

- AbbVie: Risk factors include diabetes, prior history of pneumonia, long term prior tobacco use of 5 cigarettes per day for 25 years

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] CHEST X-RAY:** No radiographic evidence of acute cardiopulmonary abnormality. Stable appearing examination.

[redacted] **20[redacted] ELECTROCARDIOGRAM:** normal sinus rhythm

[redacted] **20[redacted] SCREENING CHEST X-RAY:** normal

[redacted] **20[redacted] WBC:** 10.6 K/MM3 (normal 4.0 to 11.0)

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
膿痂疹	X			X

Treatment Group	Age at Study Start	Sex	Race
UPA 15 MG QD/UPA 15 MG QD	1[redacted]	FEMALE	BLACK OR AFRICAN AMERICAN

Medical History	Onset Year
ASTHMA	20[redacted]
ATOPIC DERMATITIS	20[redacted]
BENIGN HEART MURMUR	20[redacted]
ENVIRONMENTAL ALLERGIES	20[redacted]
BLEPHARITIS	20[redacted]
OBESITY	20[redacted]
MENSTRUAL CRAMPS	20[redacted]
ANGULAR CHELITIS	20[redacted]
ANXIETY	20[redacted]
ALLERGIC RHINITIS	NOT REPORTED
ASTHMA	NOT REPORTED

Prior Procedures	Procedure Year
PRIOR PROCEDURES: BLEACH BATH	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 112	112
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 113	[redacted]20[redacted] / 138	26

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
HYDROCORTISONE	2.5 %	BID	Y: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
HYDROXYZINE	5 mg	PRN	Y: 20[redacted]
HYPOCHLOROUS ACID	N/A OTHER: UNK	QD	Y: 20[redacted]
SALBUTAMOL	1 OTHER: VIAL	OTHER: Q4-6 HRS, PRN	Y-M: 20[redacted]
CETIRIZINE	10 mg	PRN	Y: 20[redacted]
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	PRN	Y: 20[redacted]
TRIAMCINOLONE	0.1 %	PRN	Y: 20[redacted]
BETAMETHASONE	1 OTHER: APPLLICATION	BID	Y: 20[redacted]
IBUPROFEN	400 mg	QD	Y: 20[redacted]
METHOTREXATE	15 mg	OTHER: EVERY WEEK	Y-M: 20[redacted]
KETOCONAZOLE	1 OTHER: APP	OTHER: BID, PRN	Y-M: 20[redacted] / -346
OLOPATADINE	1 DROP, BOTH EYES gtt	QD	Y-M: 20[redacted] / -344
METHOTREXATE	25 mg	OTHER: EVERY WEEK	Y-M: 20[redacted] / -329
CLOBETASOL	0.05 %	PRN	Y: 20[redacted] / -191
MENINGOCOCCAL VACCINE	0.5 mL	OTHER: X1	Y-M: 20[redacted] / -48
EMOLLIENTS AND PROTECTIVES	N/A OTHER: UNKNOWN	BID	Y-M: 20[redacted] / -14

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
HYDROXYZINE	5 mg	PRN	Y: 20[redacted]	ONGOING
SALBUTAMOL	1 OTHER: VIAL	OTHER: Q4-6 HRS, PRN	Y-M: 20[redacted]	ONGOING
CETIRIZINE	10 mg	PRN	Y: 20[redacted]	ONGOING
IBUPROFEN	400 mg	QD	Y: 20[redacted]	ONGOING
KETOCONAZOLE	1 OTHER: APP	OTHER: BID, PRN	Y-M: 20[redacted] / -346	ONGOING
OLOPATADINE	1 DROP, BOTH EYES gtt	QD	Y-M: 20[redacted] / -344	ONGOING
EMOLLIENTS AND PROTECTIVES	N/A OTHER: UNKNOWN	BID	Y-M: 20[redacted] / -14	ONGOING
MUPIROCIN	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 25	Y-M: 20[redacted] / 56
CEFALEXIN	500 mg	BID	Y-M: 20[redacted] / 68	Y-M: 20[redacted] / 75
CLINDAMYCIN	300 mg	TID	Y-M: 20[redacted] / 76	Y-M: 20[redacted] / 82
MUPIROCIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 78	ONGOING
ESCITALOPRAM	5 mg	QD	Y-M: 20[redacted] / 78	Y-M: 20[redacted] / 91

HYDROCORTISONE	2.5 %	TID	Y-M: 20[redacted] / 83	ONGOING
VANCOMYCIN	1 g	OTHER: EVERY 8 HOURS	Y-M: 20[redacted] / 83	Y-M: 20[redacted] / 83
CLINDAMYCIN	900 mg	OTHER: EVERY 6 HOURS	Y-M: 20[redacted] / 83	Y-M: 20[redacted] / 84
CLINDAMYCIN	600 mg	TID	Y-M: 20[redacted] / 85	Y-M: 20[redacted] / 95
ESCITALOPRAM	10 mg	QD	Y-M: 20[redacted] / 92	Y-M: 20[redacted] / 112
ESCITALOPRAM	15 mg	QD	Y-M: 20[redacted] / 113	ONGOING
INFLUENZA VACCINE	0.5 mL	OTHER: ONCE	Y-M: 20[redacted] / 125	Y-M: 20[redacted] / 125
CLINDAMYCIN	600 mg	TID	Y-M: 20[redacted] / 125	Y-M: 20[redacted] / 128
TRIAMCINOLONE	0.1 %	QD	Y-M: 20[redacted] / 141	ONGOING

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	WORSENING IMPETIGO AROUND LIPS
Preferred term	膿痂疹
AE Onset Date / Rx Day	[redacted]20[redacted] / 82
Age at AE Onset	1[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 83): Leukocytes: 8.6 [3.5 - 10.6] 10^9/L; Lymphocytes: 2.8 [1 - 3.8] UNIT NOT REPORTED; Neutrophils: 5.0 [1.58 - 7.13] UNIT NOT REPORTED
Microbiology	[redacted]20[redacted] (RX DAY 82): WOUND NPTST026-CULTURE: POSITIVE-RARE CORYNEBACTERIUM SPECIES; [redacted]20[redacted] (RX DAY 83): BLOOD NPTST026-CULTURE: NEGATIVE; WOUND NPTST045-HERPES SIMPLEX VIRUS 1/2: NEGATIVE
SAE Supplemental Procedure	NOT REPORTED
AE Stopped Rx Day	155 (17 DAYS AFTER LAST TREATMENT)
Duration of AE	74 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 1[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，口唇周囲の膿痂疹増悪を発現した。被験者は非喫煙者かつ非飲酒者であり，関連する病歴はアトピー性皮膚炎，環境アレルギー及び口角口唇炎であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は口唇周囲の膿痂疹増悪を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，口唇周囲の膿痂疹増悪は消失した。

本事象発現に先行し，被験者は 20[redacted] 年 [redacted] 月に膿痂疹（非重篤）を 2 回発現していた。1 回目の患部は下唇，2 回目の患部は口周囲及び前額部であった。外来治療として mupirocin の外用軟膏，並びに Keflex 及び clindamycin の経口薬が投与されたが，全体的な改善が得られなかった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院し，症状として口唇乾燥，1 ヵ月持続する口周囲の漿液性痂皮病変及び漿液性排液，中等度のそう痒を伴うびまん性湿疹性顔面皮疹，皮膚乾燥，及び皮膚剥離を呈していた。治療薬として，vancomycin の静脈内投与及び静脈内補液が行われた。その後，clindamycin の静脈内投与に変更された。創部検体培養の結果はコリネバクテリウム属菌陽性であった。バイタルサインは安定しており，入院期間中の発熱はなかった。20[redacted] 年 [redacted] 月 [redacted] 日，口周囲の病変は軽快して漿液性排液もなく，被験者は退院した。

BACTROBAN，clindamycin，vancomycin 及びヒドロコルチゾンが投与された。

The patient's past medications include:

HYDROCORTISONE for ATOPIC DERMATITIS (20[redacted] - [redacted] 20[redacted])

TRIAMCINOLONE for ATOPIC DERMATITIS (20[redacted] - [redacted] 20[redacted])

BETAMETHASONE DIPROPIONATE for ATOPIC DERMATITIS (20[redacted] - [redacted] 20[redacted])

METHOTREXATE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted]20[redacted])

CLOBETASOL for ATOPIC DERMATITIS (20[redacted] - [redacted] 20[redacted])

KEFLEX for IMPETIGO ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Impetigo (10021531) (Impetigo (10021531)) [v.22.1] [10021531]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of WORSENING IMPETIGO AROUND LIPS

- Investigator: Not applicable

- AbbVie: Risk factors include pre-existing angular cheilitis and atopic dermatitis.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BLOOD TEST:** Negative

[redacted] **20[redacted] WHITE BLOOD CELLS:** 8.6 K/CUMM (normal 3.5 to 10.6)

[redacted] **20[redacted] WOUND CULTURES:** Negative for HERPES SIMPLEX VIRUS 1/2.

[redacted] **20[redacted] WOUND CULTURES:** Positive for rare Corynebacterium species.

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
コロナウイルス感染	X			X
急性腎障害				X
細菌性肺炎	X			X

Treatment Group	Age at Study Start	Sex	Race
PLACEBO/UPA 30 MG QD	5[redacted]	MALE	BLACK OR AFRICAN AMERICAN

Medical History	Onset Year
ASTHMA	19[redacted]
ATOPIC DERMATITIS	19[redacted]
CHRONIC KIDNEY DISEASE	19[redacted]
ATOPIC DERMATITIS	19[redacted]
FOOD ALLERGIES: FISH	19[redacted]
GOUT	20[redacted]
CARDIOVASCULAR DISEASE - MYOCARDIAL INFARCTION	20[redacted]
CORONARY ARTERY DISEASE	20[redacted]
HYPERCHOLESTEROLEMIA	20[redacted]
HYPERTENSION	20[redacted]
KERATOCONUS	20[redacted]
ALLERGIC RHINITIS	20[redacted]
ACUTE OTITIS MEDIA	20[redacted]
ALLERGIC RHINITIS	NOT REPORTED
ANEMIA	NOT REPORTED
ASTHMA	NOT REPORTED
FOOD ALLERGY	NOT REPORTED
OBSTRUCTIVE SLEEP APNEA	NOT REPORTED

Prior Procedures	Procedure Year
PRIOR PROCEDURES: HIP REPLACEMENT- RIGHT	19[redacted]
PRIOR PROCEDURES: EXCISION OF GOUT NODULE	20[redacted]
PRIOR PROCEDURES: CORONARY ANGIOPLASTY	20[redacted]
PRIOR PROCEDURES: CORONARY STENT	20[redacted]
PRIOR PROCEDURES: HIP REPLACEMENT - RIGHT	20[redacted]
PRIOR PROCEDURES: BUNIONECTOMY	20[redacted]
PRIOR PROCEDURES: HIP REPLACEMENT - LEFT	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	5 CIGARETTE	13	19[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 112	112
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 113		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
PARAFFIN SOFT	4 g	BID	Y: 19[redacted]
ATORVASTATIN	80 mg	QD	Y: 20[redacted]
CLOPIDOGREL	75 mg	QD	Y: 20[redacted]
METOPROLOL	50 mg	BID	Y: 20[redacted]
ALLOPURINOL	100 mg	QD	Y-M: 20[redacted]
FLUOCINONIDE	0.05 %	BID	Y: 20[redacted]
CRISABOROLE	2 %	BID	Y-M: 20[redacted]
HYDROXYZINE	25 mg	QD	Y-M: 20[redacted] / -148
FLUTICASONE	88 ug	BID	Y-M: 20[redacted] / -35
MONTELUKAST	10 mg	QD	Y-M: 20[redacted] / -30
AUGMENTIN	875-125 mg	BID	Y-M: 20[redacted] / -13
AUGMENTIN	875/125 mg	BID	Y-M: 20[redacted] / -13
COLCHICINE	0.6 mg	QD	Y-M: 20[redacted] / -13

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
PARAFFIN SOFT	4 g	BID	Y: 19[redacted]	NOT REPORTED

ATORVASTATIN	80 mg	QD	Y: 20[redacted]	ONGOING
CLOPIDOGREL	75 mg	QD	Y: 20[redacted]	ONGOING
METOPROLOL	50 mg	BID	Y: 20[redacted]	ONGOING
HYDROXYZINE	25 mg	QD	Y-M: 20[redacted] / - 148	NOT REPORTED
FLUTICASONE	88 ug	BID	Y-M: 20[redacted] / -35	ONGOING
MONTELUKAST	10 mg	QD	Y-M: 20[redacted] / -30	ONGOING
COLCHICINE	0.6 mg	QD	Y-M: 20[redacted] / -13	ONGOING
TRIAMCINOLONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 57	NOT REPORTED
ULOBETASOL	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 57	NOT REPORTED
MUPIROCIN	1 OTHER: APPLICATION	TID	Y-M: 20[redacted] / 67	NOT REPORTED
HEPARIN	5000 OTHER: UNITS	OTHER: Q8H	Y-M: 20[redacted] / 294	Y-M: 20[redacted] / 299
SODIUM CHLORIDE	100 OTHER: ML/HR	OTHER: CONTINIOUS	Y-M: 20[redacted] / 294	Y-M: 20[redacted] / 299
PARACETAMOL	650 mg	OTHER: Q6H	Y-M: 20[redacted] / 294	Y-M: 20[redacted] / 308
VANCOMYCIN	1500 mg	OTHER: ONCE	Y-M: 20[redacted] / 295	Y-M: 20[redacted] / 295
HYDROXYCHLOROQUINE	400 mg	BID	Y-M: 20[redacted] / 295	Y-M: 20[redacted] / 296
LEVETIRACETAM	1000 mg	QD	Y-M: 20[redacted] / 296	Y-M: 20[redacted] / 296
CEFTRIAXONE	1 g	QD	Y-M: 20[redacted] / 296	Y-M: 20[redacted] / 297
HYDROXYCHLOROQUINE	400 mg	QD	Y-M: 20[redacted] / 296	Y-M: 20[redacted] / 299
PIP/TAZO	2.25 g	QID	Y-M: 20[redacted] / 297	Y-M: 20[redacted] / 299
VANCOMYCIN	1500 mg	QD	Y-M: 20[redacted] / 297	Y-M: 20[redacted] / 299
POTASSIUM	40 mEq	PRN	Y-M: 20[redacted] / 298	Y-M: 20[redacted] / 299

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	COVID-19 INFECTION
Preferred term	コロナウイルス感染
AE Onset Date / Rx Day	[redacted]20[redacted] / 292
Age at AE Onset	5[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 294): Basophils: 0.0 [0 - 0.05] UNIT NOT REPORTED; Basophils/Leukocytes: 0 [0 - 2] %; Blood Urea Nitrogen: 9.3 [1.8 - 7.1] MMOL/L; Calcium: 2.07 [2.12 - 2.62] MMOL/L; Chloride: 94 [98 - 108] MMOL/L; Creatinine: 233 [0 - 133] UMOL/L; Eosinophils: 0.0 [0.1 - 0.3] UNIT NOT REPORTED; Eosinophils/Leukocytes: 0 [1 - 4] %; Erythrocytes: 4.29 [4.5 - 5.9] UNIT NOT REPORTED; Glucose: 7 [3.9 - 7.8] MMOL/L; Hematocrit: 0.38 [0.42 - 0.5] FRACTION OF 1; Hemoglobin: 127 [140 - 174] G/L; Leukocytes: 5.3 [4.8 - 10.8] UNIT NOT REPORTED; Lymphocytes: 0.6 [1 - 4.8] UNIT NOT REPORTED; Lymphocytes/Leukocytes: 11 [20 - 44] %; NPTST022-CO2: 26 [20 - 30] MEQ/L; NPTST060-MCH: 29.6 [27 - 33] PG; NPTST061-MCV: 88.6 [80 - 96] FL; NPTST077-RDW: 15.5 [12.2 - 16.1] %; Neutrophils: 4.4 [1.8 - 7.7] UNIT NOT

	REPORTED; Neutrophils/Leukocytes: 84 [50 - 70] %; Platelets: 119 [150 - 400] UNIT NOT REPORTED; Potassium: 3.5 [3.5 - 5] MMOL/L; Sodium: 136 [135 - 145] MMOL/L; [redacted]20[redacted] (RX DAY 295): Alanine Aminotransferase: 50 [0 - 40] U/L; Albumin: 38 [35 - 50] G/L; Alkaline Phosphatase: 38 [0 - 130] U/L; Aspartate Aminotransferase: 104 [0 - 50] U/L; Basophils: 0.01 [0 - 0.05] UNIT NOT REPORTED; Basophils/Leukocytes: 0 [0 - 2] %; Bilirubin: 12 [0 - 21] UMOL/L; Blood Urea Nitrogen: 9.6 [1.8 - 7.1] MMOL/L; Calcium: 1.72 [2.12 - 2.62] MMOL/L; Chloride: 94 [98 - 108] MMOL/L; Creatine Kinase: 1575 [0 - 200] U/L; Creatinine: 201 [0 - 133] UMOL/L; Eosinophils: 0.0 [0.1 - 0.3] UNIT NOT REPORTED; Eosinophils/Leukocytes: 0 [1 - 4] %; Erythrocytes: 4.18 [4.5 - 5.9] UNIT NOT REPORTED; Glucose: 6.7 [3.9 - 7.8] MMOL/L; Hematocrit: 0.37 [0.42 - 0.5] FRACTION OF 1; Hemoglobin: 125 [140 - 174] G/L; Leukocytes: 3.8 [4.8 - 10.8] UNIT NOT REPORTED; Lymphocytes: 0.7 [1 - 4.8] UNIT NOT REPORTED; Lymphocytes/Leukocytes: 19 [20 - 44] %; Monocytes: 0.1 [0.3 - 0.5] UNIT NOT REPORTED; Monocytes/Leukocytes: 2 [2 - 9] %; NPTST011-BILLIRUBIN - CONJUGATED: 0.2 [0 - 0.3] MG/DL; NPTST022-CO2: 21 [20 - 30] MEQ/L; NPTST053-LDH: 518 [0 - 240] U/L; NPTST059-MAGNESIUM: 1.2 [1.7 - 2.8] MG/DL; NPTST060-MCH: 29.9 [27 - 33] PG; NPTST061-MCV: 87.6 [80 - 96] FL; NPTST072-PHOSPHORUS: 2.5 [2.5 - 4.5] MG/DL; NPTST077-RDW: 15.6 [12.2 - 16.1] %; Neutrophils: 3.0 [1.8 - 7.7] UNIT NOT REPORTED; Neutrophils/Leukocytes: 78 [50 - 70] %; Platelets: 99 [150 - 400] UNIT NOT REPORTED; Potassium: 3.1 [3.5 - 5] MMOL/L; Protein: 62 [60 - 80] G/L; Sodium: 131 [135 - 145] MMOL/L; [redacted]20[redacted] (RX DAY 296): Basophils: 0.01 [0 - 0.05] UNIT NOT REPORTED; Basophils/Leukocytes: 0 [0 - 2] %; Blood Urea Nitrogen: 10.4 [1.8 - 7.1] MMOL/L; Calcium: 1.75 [2.12 - 2.62] MMOL/L; Chloride: 98 [98 - 108] MMOL/L; Creatine Kinase: 1863 [0 - 200] U/L; Creatinine: 210 [0 - 133] UMOL/L; Eosinophils: 0.0 [0.1 - 0.3] UNIT NOT REPORTED; Eosinophils/Leukocytes: 0 [1 - 4] %; Erythrocytes: 4.33 [4.5 - 5.9] UNIT NOT REPORTED; Glucose: 7.3 [3.9 - 7.8] MMOL/L; Hematocrit: 0.38 [0.42 - 0.5] FRACTION OF 1; Hemoglobin: 126 [140 - 174] G/L; Leukocytes: 3.7 [4.8 - 10.8] UNIT NOT REPORTED; Lymphocytes: 0.8 [1 - 4.8] UNIT NOT REPORTED; Lymphocytes/Leukocytes: 20 [20 - 44] %; Monocytes: 0.1 [0.3 - 0.5] UNIT NOT REPORTED; Monocytes/Leukocytes: 4 [2 - 9] %; NPTST022-CO2: 16 [20 - 30] MEQ/L; NPTST059-MAGNESIUM: 1.5 [1.7 - 2.8] MG/DL; NPTST060-MCH: 29.1 [27 - 33] PG; NPTST061-MCV: 87.8 [80 - 96] FL; NPTST072-PHOSPHORUS: 2.5 [2.5 - 4.5] MG/DL; NPTST077-RDW: 15.6 [12.2 - 16.1] %; NPTST089-TROPONIN: 0.01 [0 - 0.1] NG/ML; Neutrophils: 2.8 [1.8 - 7.7] UNIT NOT REPORTED; Neutrophils/Leukocytes: 75 [50 - 70] %; Platelets: 115 [150 - 400] UNIT NOT REPORTED; Potassium: 3.1 [3.5 - 5] MMOL/L; Sodium: 132 [135 - 145] MMOL/L; [redacted]20[redacted] (RX DAY 297): NPTST074-PROCALCITONIN: 3.6 [0 - 0.1] NG/ML; [redacted]20[redacted] (RX DAY 298): Basophils: 0.00 [0 - 0.05] UNIT NOT REPORTED; Blood Urea Nitrogen: 7.5 [1.8 - 7.1] MMOL/L; Calcium: 1.62 [2.12 - 2.62] MMOL/L; Chloride: 99 [98 - 108] MMOL/L; Creatinine: 197 [0 - 133] UMOL/L; Eosinophils: 0.0 [0.1 - 0.3] UNIT NOT REPORTED; Eosinophils/Leukocytes: 0 [1 - 4] %; Erythrocytes: 3.80 [4.5 - 5.9] UNIT NOT REPORTED; Glucose: 5.7 [3.9 - 7.8] MMOL/L; Hematocrit: 0.33 [0.42 - 0.5] FRACTION OF 1; Hemoglobin: 111 [140 - 174] G/L; Leukocytes: 3.8 [4.8 - 10.8] UNIT NOT REPORTED; Lymphocytes: 0.6 [1 - 4.8] UNIT NOT REPORTED; Lymphocytes/Leukocytes: 16 [20 - 44] %; Monocytes: 0.3 [0.3 - 0.5] UNIT NOT REPORTED; Monocytes/Leukocytes: 7 [2 - 9] %; NPTST022-CO2: 21 [20 - 30] MEQ/L; NPTST059-MAGNESIUM: 1.5 [1.7 - 2.8] MG/DL; NPTST060-MCH: 29.2 [27 - 33] PG; NPTST061-MCV: 87.4 [80 - 96] FL; NPTST072-PHOSPHORUS: 2 [2.5 - 4.5] MG/DL; NPTST077-RDW: 15.7 [12.2 - 16.1] %; Neutrophils: 2.9 [1.8 - 7.7] UNIT NOT REPORTED; Neutrophils/Leukocytes: 76 [50 - 70] %; Platelets: 108 [150 - 400] UNIT NOT REPORTED; Potassium: 3 [3.5 - 5] MMOL/L; Sodium: 138 [135 - 145] MMOL/L; [redacted]20[redacted] (RX DAY 299): Basophils: 0.01 [0 - 0.05] UNIT NOT REPORTED; Basophils/Leukocytes: 0 [0 - 2] %; Eosinophils: 0.0 [0.1 - 0.3] UNIT NOT REPORTED; Eosinophils/Leukocytes: 0 [1 - 4] %; Erythrocytes: 3.72 [4.5 - 5.9] UNIT NOT REPORTED; Hematocrit: 0.33 [0.42 - 0.5] FRACTION OF 1; Hemoglobin: 111 [140 - 174] G/L; Leukocytes: 3.3 [4.8 - 10.8] UNIT NOT REPORTED; Lymphocytes: 0.3 [1 - 4.8] UNIT NOT REPORTED; Lymphocytes/Leukocytes: 10 [20 - 44] %; Monocytes: 0.4 [0.3 - 0.5] UNIT NOT REPORTED; Monocytes/Leukocytes: 12 [2 - 9] %; NPTST060-MCH: 29.8 [27 - 33] PG; NPTST061-MCV: 88.4 [80 - 96] FL; NPTST077-RDW: 15.6 [12.2 - 16.1] %; Neutrophils: 2.5 [1.8 - 7.7] UNIT NOT REPORTED; Neutrophils/Leukocytes: 76 [50 - 70] %; Platelets: 131 [150 - 400] UNIT NOT REPORTED
Microbiology	[redacted]20[redacted] (RX DAY 294): BLOOD NPTST012-BLOOD CULTURE: POSITIVE-STAPHYLOCOCCUS EPIDERMIDIS; OTHER NASOPHARYNGEAL SWAB NPTST023-COVID-19 PCR: POSITIVE-NOVEL CORONAVIRUS; OTHER NASOPHARYNGEAL SWAB NPTST050-INFLUENZA A/B: NEGATIVE-INFLUENZA A/B; OTHER NASOPHARYNGEAL SWAB

	NPTST079-RESPIRATORY SYNCYTIAL VIRUS: NEGATIVE-RESPIRATORY SYNCYTIAL VIRUS; [redacted]20[redacted] (RX DAY 295): BLOOD NPTST012-BLOOD CULTURE: NEGATIVE-NO GROWTH AT 48 HRS
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 294): ELECTROCARDIOGRAM: NORMAL; PORTABLE AP CHEST X RAY: CLEAR LUNGS; VITAL SIGNS: TEMPERATURE(F): 102.4 PULSE: 115 BP: 103/67 RR: 22 SP02(%):100 ROOM AIR; VITAL SIGNS: TEMPERATURE(F):102.4 PULSE: 87 BP: 102/68 RR:18 SP02(%):97% ROOM AIR; VITAL SIGNS: TEMPERATURE(F): 99.2 PULSE: 85 BP: 113/74 RR: 18 SP02(%): 99 ROOM AIR; [redacted]20[redacted] (RX DAY 295): VITAL SIGNS: TEMPERATURE(F): 101.3 PULSE: 93 BP: 111/72 RR: 18 SP02(%): 99 ROOM AIR; [redacted]20[redacted] (RX DAY 296): CT HEAD: NORMAL CT OF BRAIN; PARTIAL RIGHT-SIDED PARANASAL SINUS OPACIFICATION; VITAL SIGNS: TEMPERATURE(F): 102 PULSE: 93 BP: 109/52 RR: NA SP02(%): 95 ON 02 2 LITERS NASAL CANNULA; VITAL SIGNS: TEMPERATURE(F): 100.7 PULSE: 103 BP: 107/70 RR: 22 SP02(%): 99 ROOM AIR; XR CHEST- PORTABLE AP: BILATERAL PATCHY PERIPHERAL AND LEFT PERIHILIAR INFILTRATES WITH AIR BRONCHOGRAMS ARE NOTED, NOT VISUALIZED ON THE MOST RECENT PREVIOUS EXAMINATION; [redacted]20[redacted] (RX DAY 297): VITAL SIGNS: TEMPERATURE(F): 99.8 PULSE: 96 BP: 106/66 RR: 20 SPO2(%):97 ON 02 2 LITERS ON NASAL CANNULA; VITAL SIGNS: TEMPERATURE(F): 99.2 PULSE: 86 BP: 87/49 RR: 20 SP02(%): 93 ON 02 2 LITERS NASAL CANUNLA; [redacted]20[redacted] (RX DAY 298): VITAL SIGNS: TEMPERATURE(F): 98.2 PULSE: 87 BP: 119/70 RR: 20 SPO2(%):100 ON 02 2 LITERS ON NASAL CANNULA; VITAL SIGNS: TEMPERATURE(F): 99.4 PULSE: 74 BP: 136/95 RR: 20 SPO2(%):92 ON 02 2 LITERS ON NASAL CANNULA; [redacted]20[redacted] (RX DAY 299): VITAL SIGNS: TEMPERATURE(F): 102.1 PULSE: 107 BP: 107/59 RR: 20 SPO2(%):99 ROOM AIR; VITAL SIGNS: TEMPERATURE(F): 97.9 PULSE: 98 BP: 121/76 RR: 20 SPO2(%):98 ON 02 2 LITERS ON NASAL CANNULA
AE Stopped Rx Day	328
Duration of AE	37 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Event #2: Event of Interest - Renal Dysfunction

Event Description	ACUTE KIDNEY INJURY
Preferred term	急性腎障害
AE Onset Date / Rx Day	[redacted]20[redacted] / 294
Age at AE Onset	5[redacted]
Laboratory Testing	NOT APPLICABLE
Microbiology	NOT APPLICABLE
SAE Supplemental Procedure	NOT APPLICABLE
AE Stopped Rx Day	299
Duration of AE	6 DAYS
Toxicity Grade	2
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT APPLICABLE

Discontinued Study Drug Due to the Event	NO
SAE Criteria	NONE

Event #3: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	BACTERIAL PNEUMONIA
Preferred term	細菌性肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 296
Age at AE Onset	5[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 294): Basophils: 0.0 [0 - 0.05] UNIT NOT REPORTED; Basophils/Leukocytes: 0 [0 - 2] %; Blood Urea Nitrogen: 9.3 [1.8 - 7.1] MMOL/L; Calcium: 2.07 [2.12 - 2.62] MMOL/L; Chloride: 94 [98 - 108] MMOL/L; Creatinine: 233 [0 - 133] UMOL/L; Eosinophils: 0.0 [0.1 - 0.3] UNIT NOT REPORTED; Eosinophils/Leukocytes: 0 [1 - 4] %; Erythrocytes: 4.29 [4.5 - 5.9] UNIT NOT REPORTED; Glucose: 7 [3.9 - 7.8] MMOL/L; Hematocrit: 0.38 [0.42 - 0.5] FRACTION OF 1; Hemoglobin: 127 [140 - 174] G/L; Leukocytes: 5.3 [4.8 - 10.8] UNIT NOT REPORTED; Lymphocytes: 0.6 [1 - 4.8] UNIT NOT REPORTED; Lymphocytes/Leukocytes: 11 [20 - 44] %; NPTST022-CO2: 26 [20 - 30] MEQ/L; NPTST060-MCH: 29.6 [27 - 33] PG; NPTST061-MCV: 88.6 [80 - 96] FL; NPTST077-RDW: 15.5 [12.2 - 16.1] %; Neutrophils: 4.4 [1.8 - 7.7] UNIT NOT REPORTED; Neutrophils/Leukocytes: 84 [50 - 70] %; Platelets: 119 [150 - 400] UNIT NOT REPORTED; Potassium: 3.5 [3.5 - 5] MMOL/L; Sodium: 136 [135 - 145] MMOL/L; [redacted]20[redacted] (RX DAY 295): Alanine Aminotransferase: 50 [0 - 40] U/L; Albumin: 38 [35 - 50] G/L; Alkaline Phosphatase: 38 [0 - 130] U/L; Aspartate Aminotransferase: 104 [0 - 50] U/L; Basophils: 0.01 [0 - 0.05] UNIT NOT REPORTED; Basophils/Leukocytes: 0 [0 - 2] %; Bilirubin: 12 [0 - 21] UMOL/L; Blood Urea Nitrogen: 9.6 [1.8 - 7.1] MMOL/L; Calcium: 1.72 [2.12 - 2.62] MMOL/L; Chloride: 94 [98 - 108] MMOL/L; Creatine Kinase: 1575 [0 - 200] U/L; Creatinine: 201 [0 - 133] UMOL/L; Eosinophils: 0.0 [0.1 - 0.3] UNIT NOT REPORTED; Eosinophils/Leukocytes: 0 [1 - 4] %; Erythrocytes: 4.18 [4.5 - 5.9] UNIT NOT REPORTED; Glucose: 6.7 [3.9 - 7.8] MMOL/L; Hematocrit: 0.37 [0.42 - 0.5] FRACTION OF 1; Hemoglobin: 125 [140 - 174] G/L; Leukocytes: 3.8 [4.8 - 10.8] UNIT NOT REPORTED; Lymphocytes: 0.7 [1 - 4.8] UNIT NOT REPORTED; Lymphocytes/Leukocytes: 19 [20 - 44] %; Monocytes: 0.1 [0.3 - 0.5] UNIT NOT REPORTED; Monocytes/Leukocytes: 2 [2 - 9] %; NPTST011-BILLIRUBIN - CONJUGATED: 0.2 [0 - 0.3] MG/DL; NPTST022-CO2: 21 [20 - 30] MEQ/L; NPTST053-LDH: 518 [0 - 240] U/L; NPTST059-MAGNESIUM: 1.2 [1.7 - 2.8] MG/DL; NPTST060-MCH: 29.9 [27 - 33] PG; NPTST061-MCV: 87.6 [80 - 96] FL; NPTST072-PHOSPHORUS: 2.5 [2.5 - 4.5] MG/DL; NPTST077-RDW: 15.6 [12.2 - 16.1] %; Neutrophils: 3.0 [1.8 - 7.7] UNIT NOT REPORTED; Neutrophils/Leukocytes: 78 [50 - 70] %; Platelets: 99 [150 - 400] UNIT NOT REPORTED; Potassium: 3.1 [3.5 - 5] MMOL/L; Protein: 62 [60 - 80] G/L; Sodium: 131 [135 - 145] MMOL/L; [redacted]20[redacted] (RX DAY 296): Basophils: 0.01 [0 - 0.05] UNIT NOT REPORTED; Basophils/Leukocytes: 0 [0 - 2] %; Blood Urea Nitrogen: 10.4 [1.8 - 7.1] MMOL/L; Calcium: 1.75 [2.12 - 2.62] MMOL/L; Chloride: 98 [98 - 108] MMOL/L; Creatine Kinase: 1863 [0 - 200] U/L; Creatinine: 210 [0 - 133] UMOL/L; Eosinophils: 0.0 [0.1 - 0.3] UNIT NOT REPORTED; Eosinophils/Leukocytes: 0 [1 - 4] %; Erythrocytes: 4.33 [4.5 - 5.9] UNIT NOT REPORTED; Glucose: 7.3 [3.9 - 7.8] MMOL/L; Hematocrit: 0.38 [0.42 - 0.5] FRACTION OF 1; Hemoglobin: 126 [140 - 174] G/L; Leukocytes: 3.7 [4.8 - 10.8] UNIT NOT REPORTED; Lymphocytes: 0.8 [1 - 4.8] UNIT NOT REPORTED; Lymphocytes/Leukocytes: 20 [20 - 44] %; Monocytes: 0.1 [0.3 - 0.5] UNIT NOT REPORTED; Monocytes/Leukocytes: 4 [2 - 9] %; NPTST022-CO2: 16 [20 - 30] MEQ/L; NPTST059-MAGNESIUM: 1.5 [1.7 - 2.8] MG/DL; NPTST060-MCH: 29.1 [27 - 33] PG; NPTST061-MCV: 87.8 [80 - 96] FL; NPTST072-PHOSPHORUS: 2.5 [2.5 - 4.5] MG/DL; NPTST077-RDW: 15.6 [12.2 - 16.1] %; NPTST089-TROPONIN: 0.01 [0 - 0.1] NG/ML; Neutrophils: 2.8 [1.8 - 7.7] UNIT NOT REPORTED; Neutrophils/Leukocytes: 75 [50 - 70] %; Platelets: 115 [150 - 400] UNIT NOT REPORTED; Potassium: 3.1 [3.5 - 5] MMOL/L; Sodium: 132 [135 - 145] MMOL/L; [redacted]20[redacted] (RX DAY 297): NPTST074-PROCALCITONIN: 3.6 [0 - 0.1] NG/ML; [redacted]20[redacted] (RX DAY 298): Basophils: 0.00 [0 - 0.05] UNIT NOT REPORTED; Blood Urea Nitrogen: 7.5 [1.8 - 7.1] MMOL/L; Calcium: 1.62 [2.12 - 2.62] MMOL/L; Chloride: 99 [98 - 108] MMOL/L; Creatinine: 197 [0 - 133] UMOL/L; Eosinophils: 0.0 [0.1 - 0.3] UNIT NOT REPORTED; Eosinophils/Leukocytes: 0 [1 - 4] %; Erythrocytes: 3.80 [4.5 - 5.9] UNIT NOT REPORTED; Glucose: 5.7 [3.9 - 7.8] MMOL/L; Hematocrit:

	0.33 [0.42 - 0.5] FRACTION OF 1; Hemoglobin: 111 [140 - 174] G/L; Leukocytes: 3.8 [4.8 - 10.8] UNIT NOT REPORTED; Lymphocytes: 0.6 [1 - 4.8] UNIT NOT REPORTED; Lymphocytes/Leukocytes: 16 [20 - 44] %; Monocytes: 0.3 [0.3 - 0.5] UNIT NOT REPORTED; Monocytes/Leukocytes: 7 [2 - 9] %; NPTST022-CO2: 21 [20 - 30] MEQ/L; NPTST059-MAGNESIUM: 1.5 [1.7 - 2.8] MG/DL; NPTST060-MCH: 29.2 [27 - 33] PG; NPTST061-MCV: 87.4 [80 - 96] FL; NPTST072-PHOSPHORUS: 2 [2.5 - 4.5] MG/DL; NPTST077-RDW: 15.7 [12.2 - 16.1] %; Neutrophils: 2.9 [1.8 - 7.7] UNIT NOT REPORTED; Neutrophils/Leukocytes: 76 [50 - 70] %; Platelets: 108 [150 - 400] UNIT NOT REPORTED; Potassium: 3 [3.5 - 5] MMOL/L; Sodium: 138 [135 - 145] MMOL/L; [redacted]20[redacted] (RX DAY 299): Basophils: 0.01 [0 - 0.05] UNIT NOT REPORTED; Basophils/Leukocytes: 0 [0 - 2] %; Eosinophils: 0.0 [0.1 - 0.3] UNIT NOT REPORTED; Eosinophils/Leukocytes: 0 [1 - 4] %; Erythrocytes: 3.72 [4.5 - 5.9] UNIT NOT REPORTED; Hematocrit: 0.33 [0.42 - 0.5] FRACTION OF 1; Hemoglobin: 111 [140 - 174] G/L; Leukocytes: 3.3 [4.8 - 10.8] UNIT NOT REPORTED; Lymphocytes: 0.3 [1 - 4.8] UNIT NOT REPORTED; Lymphocytes/Leukocytes: 10 [20 - 44] %; Monocytes: 0.4 [0.3 - 0.5] UNIT NOT REPORTED; Monocytes/Leukocytes: 12 [2 - 9] %; NPTST060-MCH: 29.8 [27 - 33] PG; NPTST061-MCV: 88.4 [80 - 96] FL; NPTST077-RDW: 15.6 [12.2 - 16.1] %; Neutrophils: 2.5 [1.8 - 7.7] UNIT NOT REPORTED; Neutrophils/Leukocytes: 76 [50 - 70] %; Platelets: 131 [150 - 400] UNIT NOT REPORTED
Microbiology	[redacted]20[redacted] (RX DAY 294): BLOOD NPTST012-BLOOD CULTURE: POSITIVE-STAPHYLOCOCCUS EPIDERMIDIS; OTHER NASOPHARYNGEAL SWAB NPTST023-COVID-19 PCR: POSITIVE-NOVEL CORONAVIRUS; OTHER NASOPHARYNGEAL SWAB NPTST050-INFLUENZA A/B: NEGATIVE-INFLUENZA A/B; OTHER NASOPHARYNGEAL SWAB NPTST079-RESPIRATORY SYNCYTIAL VIRUS: NEGATIVE-RESPIRATORY SYNCYTIAL VIRUS; [redacted]20[redacted] (RX DAY 295): BLOOD NPTST012-BLOOD CULTURE: NEGATIVE-NO GROWTH AT 48 HRS
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 294): ELECTROCARDIOGRAM: NORMAL; PORTABLE AP CHEST X RAY: CLEAR LUNGS; VITAL SIGNS: TEMPERATURE(F): 102.4 PULSE: 115 BP: 103/67 RR: 22 SP02(%):100 ROOM AIR; VITAL SIGNS: TEMPERATURE(F):102.4 PULSE: 87 BP: 102/68 RR:18 SP02(%):97% ROOM AIR; VITAL SIGNS: TEMPERATURE(F): 99.2 PULSE: 85 BP: 113/74 RR: 18 SP02(%): 99 ROOM AIR; [redacted]20[redacted] (RX DAY 295): VITAL SIGNS: TEMPERATURE(F): 101.3 PULSE: 93 BP: 111/72 RR: 18 SP02(%): 99 ROOM AIR; [redacted]20[redacted] (RX DAY 296): CT HEAD: NORMAL CT OF BRAIN; PARTIAL RIGHT-SIDED PARANASAL SINUS OPACIFICATION; VITAL SIGNS: TEMPERATURE(F): 102 PULSE: 93 BP: 109/52 RR: NA SP02(%): 95 ON 02 2 LITERS NASAL CANNULA; VITAL SIGNS: TEMPERATURE(F): 100.7 PULSE: 103 BP: 107/70 RR: 22 SP02(%): 99 ROOM AIR; XR CHEST- PORTABLE AP: BILATERAL PATCHY PERIPHERAL AND LEFT PERIHILIAR INFILTRATES WITH AIR BRONCHOGRAMS ARE NOTED, NOT VISUALIZED ON THE MOST RECENT PREVIOUS EXAMINATION; [redacted]20[redacted] (RX DAY 297): VITAL SIGNS: TEMPERATURE(F): 99.8 PULSE: 96 BP: 106/66 RR: 20 SPO2(%):97 ON 02 2 LITERS ON NASAL CANNULA; VITAL SIGNS: TEMPERATURE(F): 99.2 PULSE: 86 BP: 87/49 RR: 20 SP02(%): 93 ON 02 2 LITERS NASAL CANUNLA; [redacted]20[redacted] (RX DAY 298): VITAL SIGNS: TEMPERATURE(F): 98.2 PULSE: 87 BP: 119/70 RR: 20 SPO2(%):100 ON 02 2 LITERS ON NASAL CANNULA; VITAL SIGNS: TEMPERATURE(F): 99.4 PULSE: 74 BP: 136/95 RR: 20 SPO2(%):92 ON 02 2 LITERS ON NASAL CANNULA; [redacted]20[redacted] (RX DAY 299): VITAL SIGNS: TEMPERATURE(F): 102.1 PULSE: 107 BP: 107/59 RR: 20 SPO2(%):99 ROOM AIR; VITAL SIGNS: TEMPERATURE(F): 97.9 PULSE: 98 BP: 121/76 RR: 20 SPO2(%):98 ON 02 2 LITERS ON NASAL CANNULA
AE Stopped Rx Day	299
Duration of AE	4 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	SOCONDARY INFECTION DUE TO COVID 19

Discontinued Study Drug Due to the Event NO
SAE Criteria REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 5[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，新型コロナウイルス感染症（以下，「COVID-19」）及び細菌性肺炎を発現した。被験者は元喫煙者（紙巻タバコ 5 本／日，13 年間）かつ飲酒者（2 杯未満／日）であり，関連する病歴は喘息，慢性腎臓病，アトピー性皮膚炎，心血管疾患（心筋梗塞），冠動脈疾患，高コレステロール血症，高血圧，アレルギー性鼻炎，貧血及び閉塞性睡眠時無呼吸であり，冠動脈形成及び冠動脈ステントによる治療歴があった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は COVID-19 を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は細菌性肺炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，細菌性肺炎は消失した。20[redacted] 年 [redacted] 月 [redacted] 日，COVID-19 は消失した。

入院前，被験者は COVID-19 のホットラインに電話して症状について相談し，検査のため受診するよう指導された。

20[redacted] 年 [redacted] 月 [redacted] 日，1 日間続く発熱（40°C）の自覚，筋肉痛，及び乾性咳嗽に関連した頭痛があり，被験者は入院した。身体的診察で発達及び発育良好な男性と確認され，急性窮迫症状はなかった。呼吸器の診察所見は断続性ラ音なし，低音性連続性ラ音なし，喘鳴なしであった。循環器の診察所見は正常であり，心拍数及び心調律正常で，心雑音なし，心膜摩擦音なし，ギャロップ・リズムなしであった。バイタルサインは体温 39.1°C，心拍数 115 bpm，呼吸数 22 回／分，血圧 103/67 mmHg，酸素飽和度 100%（室内気）であった。20[redacted] 年 [redacted] 月に発現した感冒／RS ウイルス感染（非重篤）と類似した症状であったが，最近流行している COVID-19 を除外する必要があった。COVID-19 を検査するため検体を採取した。被験者は急性腎障害（非重篤）も発現しており，敗血症の続発症と考えられた。クレアチニン値は 2.63 mg/dL であり，ベースラインの 1.8 から上昇していた。被験者は内科病棟に入院し，発熱に対しアセトアミノフェンを 6 時間ごとに投与され，静脈内補液を受けた。

20[redacted] 年 [redacted] 月 [redacted] 日，COVID-19 検査の結果は陽性であり，隔離が継続された。hydroxychloroquine の経口投与が開始され，始めの 2 回は 400 mg を 12 時間ごとに，その後は 400 mg を 24 時間ごとに 4 日間投与した。被験者の発熱は持続したが，その他の状態は安定した。バイタルサイン

は体温 39.8°C，心拍数 92 bpm，呼吸数 19 回／分，血圧 103/67 mmHg，酸素飽和度 100%（室内気）であった。血液培養で *Staphylococcus epidermidis* の増殖が認められた。医療チームは検体が汚染されていたのではないかと考えたが，vancomycin 1500 mg の経験的投与を 1 回行った。vancomycin の再投与を要する状態悪化を感知できるよう，臨床症状をモニターした。被験者が常用していた薬剤の投与は，いずれも適宜再開された。

20[redacted] 年 [redacted] 月 [redacted] 日，症状軽減のためにアセトアミノフェンの投与が継続され，食事は経口摂取であった。被験者は洗面所に行った際に浮動性めまいを発現して転倒し，頭部に外傷を負い，尿失禁で汚れた床の上で発見された。看護師によると，被験者に異常な身体活動が認められ，院内急変対応チームが呼ばれた。血圧 107/68 mmHg，酸素飽和度 90%台後半（室内気），ブドウ糖値 104 であった。Keppra の導入用量が投与され，心電図検査及び頭部コンピュータ断層撮影（以下「CT」）が行われた。心電図では洞調律が認められ，頭部 CT 像に急性所見はなかった。後の被験者の訴えによると，入浴後に浮動性めまいを自覚し，意識を失うような感覚があり，床に座り込んで気絶した。このときは，発熱，悪寒，息切れ，脱力及び胸痛はなかった。痙攣発作に対する血管迷走神経性失神であり心原性ではなさそうだと医療チームは考えたが，持続的遠隔モニタリングを開始し，軽度洞性頻脈を確認した。被験者は発熱，悪寒，息切れ及び脱力が持続しており，必要に応じて酸素が投与された。胸部 X 線像に透過性の更なる低下及び間質の肺紋理増強が認められた。ceftriaxone の投与が開始された。プロカルシトニン値は 3.6 であり，細菌性肺炎の併発が示された。vancomycin（血中濃度により調整）及び Zosyn を含む広域抗生物質に変更した。2 回目の血液培養検査で微生物の増殖は認められなかった。被験者は低酸素状態が持続していたものの，酸素要求量は 2 L/min に減少した。その後，血行動態は安定し，被験者は胸痛を否定した。息切れ及び酸素飽和度は改善した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

この他のリスク因子として，被験者に喘息の病歴があり，COVID-19 が流行する人口密度の高い地域に居住していたことが挙げられた。

アセトアミノフェン，生理食塩液，hydroxychloroquine，ceftriaxone，vancomycin 及び ZOSYN が投与された。

The patient's past medications include:

FLUOCINONIDE for ATOPIC DERMATITIS and ATOPIC DERMATITIS RESCUE THERAPY (20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

EUCRISA for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

PREDNISONE for ATOPIC DERMATITIS RESCUE THERAPY [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

ATROVENT for COMMON COLD ([redacted] 20[redacted] - [redacted] 20[redacted])

TAMILFLU for INITIAL FLU-LIKE SYMPTOMS ([redacted] 20[redacted] - [redacted] 20[redacted])

TESSALON PERLE for COMMON COLD ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Coronavirus infection (10051905) (Coronavirus infection (10051905)) [v.23.0] [10051905]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

2) Pneumonia bacterial (10060946) (Pneumonia bacterial (10060946)) [v.23.0] [10060946]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of COVID-19 INFECTION

- Investigator: Not applicable.

- AbbVie: Event is more likely related to the COVID-19 pandemic outbreak.

Event of BACTERIAL PNEUMONIA

- Investigator: Secondary infection due to COVID 19.

- AbbVie: Event is more likely related to concurrt COVID-19 infection.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 50 U/L (normal 0 to 40)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 104 U/L (normal 0 to 50)

[redacted] **20[redacted] BASOPHILS %:** 0 %

[redacted] **20[redacted] BASOPHILS %:** 0 %

[redacted] **20[redacted] BASOPHILS ABS:** 0.0 K/UL (normal 0.0 to 0.05)

[redacted] **20[redacted] BASOPHILS ABS:** 0.00 K/UL (normal 0.0 to 0.05)

[redacted] **20[redacted] BLOOD CULTURE:** Positive; Staphylococcus epidermidis

[redacted] **20[redacted] BLOOD CULTURE:** Negative

[redacted] **20[redacted] BLOOD PRESSURE:** 103/70 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 103/67 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 121/75 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 113/74 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 111/72 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 109/52 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 111/72 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:**107/68 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 87/49 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 106/66 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 136/95 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 119/70 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 121/76 mmHg

[redacted] **20[redacted] BLOOD PRESSURE:** 107/59 mmHg

[redacted] **20[redacted] BLOOD UREA NITROGEN:** 26 mg/dL (normal 5 to 20)

[redacted] **20[redacted] BLOOD UREA NITROGEN:** 27 mg/dL (normal 5 to 20)

[redacted] **20[redacted] BLOOD UREA NITROGEN:** 29 mg/dL (normal 5 to 20)

[redacted] **20[redacted] BLOOD UREA NITROGEN:** 21 mg/dL (normal 5 to 20)

[redacted] **20[redacted] BODY TEMPERATURE:** 104 F

[redacted] **20[redacted] BODY TEMPERATURE:** 102.4 F

[redacted] **20[redacted] BODY TEMPERATURE:** 103.7 F

[redacted] **20[redacted] BODY TEMPERATURE:** 102 F

[redacted] **20[redacted] BODY TEMPERATURE:** 101.3 F

[redacted] **20[redacted] CALCIUM:** 8.3 mg/dL (normal 8.5 to 10.5)

[redacted] **20[redacted] CALCIUM:** 6.9 mg/dL (normal 8.5 to 10.5)

[redacted] **20[redacted] CALCIUM:** 6.5 mg/dL (normal 8.5 to 10.5)

[redacted] **20[redacted] CHLORIDE:** 94 MEQ/L (normal 98 to 108)

[redacted] **20[redacted] CHLORIDE:** 99 MEQ/L (normal 98 to 108)

[redacted] **20[redacted] CO2:** 26 MEQ/L (normal 20 to 30)

[redacted] **20[redacted] CO2:** 21 MEQ/L (normal 20 to 30)

[redacted] **20[redacted] CREATINE KINASE:** 1575 U/L (normal 0 to 200)

[redacted] **20[redacted] CREATINE KINASE:** 1863 U/L (normal 0 to 200)

20[redacted] CREATININE: (Baseline): 1.8

[redacted] **20[redacted] CREATININE:** 2.63 mg/dL (normal 0 to 1.5)

[redacted] **20[redacted] CREATININE:** 2.27 mg/dL (normal 0 to 1.5)

[redacted] **20[redacted] CREATININE:** 2.37 mg/dL (normal 0 to 1.5)

[redacted] **20[redacted] CREATININE:** 2.23 mg/dL (normal 0 to 1.5)

[redacted] **20[redacted] CT HEAD:** Normal CT of brain; partial right-sided paranasal sinus opacification.

[redacted] **20[redacted] ECG:** Normal sinus rhythm

[redacted] **20[redacted] ELECTROCARDIOGRAM:** NORMAL

[redacted] **20[redacted] EOSINOPHILS %:** 0 %

[redacted] **20[redacted] EOSINOPHILS %:** 0 %

[redacted] **20[redacted] EOSINOPHILS ABS:** 0.0 K/UL (normal 0.1 to 0.3)

[redacted] **20[redacted] EOSINOPHILS ABS:** 0.0 K/UL (normal 0.1 to 0.3)

[redacted] **20[redacted] HEART RATE:** 138 BPM

[redacted] **20**[redacted] **HEART RATE:** 115 BPM

[redacted] **20**[redacted] **HEART RATE:** 92 BPM

[redacted] **20**[redacted] **HEART RATE:** Upper 90s BPM

[redacted] **20**[redacted] **HEART RATE:** 93 BPM

[redacted] **20**[redacted] **HEMATOCRIT:** 38.0 % (normal 41.5 to 50.4)

[redacted] **20**[redacted] **HEMATOCRIT:** 36.6 % (normal 41.5 to 50.4)

[redacted] **20**[redacted] **HEMATOCRIT:** 38.0 % (normal 41.5 to 50.4)

[redacted] **20**[redacted] **HEMOGLOBIN:** 12.7 G/DL (normal 14.0 to 17.4)

[redacted] **20**[redacted] **HEMOGLOBIN:** 12.5 G/DL (normal 14.0 to 17.4)

[redacted] **20**[redacted] **HEMOGLOBIN:** 11.1 G/DL (normal 14.0 to 17.4)

[redacted] **20**[redacted] **LDH:** 518 U/L (normal 0 to 240)

[redacted] **20**[redacted] **LYMPHOCYTES %:** 11 %

[redacted] **20**[redacted] **LYMPHOCYTES %:** 19 %

[redacted] **20**[redacted] **LYMPHOCYTES %:** 16 %

[redacted] **20**[redacted] **LYMPHOCYTES ABS:** 0.6 K/UL (normal 1.0 to 4.8)

[redacted] **20**[redacted] **LYMPHOCYTES ABS:** 0.8 K/UL (normal 1.0 to 4.8)

[redacted] **20**[redacted] **LYMPHOCYTES ABS:** 0.6 K/UL (normal 1.0 to 4.8)

[redacted] **20**[redacted] **MAGNESIUM:** 1.2 mg/dL (normal 1.7 to 2.8)

[redacted] **20**[redacted] **MAGNESIUM:** 1.5 mg/dL (normal 1.7 to 2.8)

[redacted] **20**[redacted] **MONOCYTES %:** 2 %

[redacted] **20**[redacted] **MONOCYTES %:** 7 %

[redacted] **20**[redacted] **MONOCYTES ABS:** 0.1 K/UL (normal 0.3 to 0.5)

[redacted] **20**[redacted] **MONOCYTES ABS:** 0.3 K/UL (normal 0.3 to 0.5)

[redacted] **20**[redacted] **NASOPHARYNGEAL SWAB COVID-19 PCR:** Positive; Novel coronavirus

[redacted] **20**[redacted] **NASOPHARYNGEAL SWAB INFLUENZA A/B:** Negative

[redacted] **20**[redacted] **NASOPHARYNGEAL SWAB RESPIRATORY SYNCYTIAL VIRUS:** Negative

[redacted] 20[redacted] **NEUTROPHILS %:** 84 %

[redacted] 20[redacted] **NEUTROPHILS %:** 78 %

[redacted] 20[redacted] **NEUTROPHILS %:** 76 %

[redacted] 20[redacted] **NEUTROPHILS ABS:** 4.4 K/UL (normal 1.8 to 7.7)

[redacted] 20[redacted] **NEUTROPHILS ABS:** 3.0 K/UL (normal 1.8 to 7.7)

[redacted] 20[redacted] **NEUTROPHILS ABS:** 2.9 K/UL (normal 1.8 to 7.7)

[redacted] 20[redacted] **OXYGEN SATURATION:** 99% at room air

[redacted] 20[redacted] **OXYGEN SATURATION:** 100% at room air

[redacted] 20[redacted] **OXYGEN SATURATION:** 97% at room air

[redacted] 20[redacted] **OXYGEN SATURATION:** 99% at room air

[redacted] 20[redacted] **OXYGEN SATURATION:** 95% on oxygen therapy

[redacted] 20[redacted] **OXYGEN SATURATION:** 99% at room air

[redacted] 20[redacted] **OXYGEN SATURATION:** 100% at room air

[redacted] 20[redacted] **OXYGEN SATURATION:** 93% on oxygen therapy 2 Liters on nasal cannula

[redacted] 20[redacted] **OXYGEN SATURATION:** 97% on oxygen therapy 2 Liters on nasal cannula

[redacted] 20[redacted] **OXYGEN SATURATION:** 92% on oxygen therapy 2 Liters on nasal cannula[redacted] [redacted] 20[redacted]
OXYGEN SATURATION: 100% on oxygen therapy 2 Liters on nasal cannula

[redacted] 20[redacted] **OXYGEN SATURATION:** 98% on oxygen therapy 2 Liters on nasal cannula

[redacted] 20[redacted] **OXYGEN SATURATION:** 99% at room air

[redacted] 20[redacted] **PHOSPHORUS:** 2.0 mg/dL (normal 2.5 to 4.5)

[redacted] 20[redacted] **PLATELET COUNT:** 119 K/UL (normal 150 to 400)

[redacted] 20[redacted] **PLATELET COUNT:** 99 K/UL (normal 150 to 400)

[redacted] 20[redacted] **PLATELET COUNT:** 108 K/UL (normal 150 to 400)

[redacted] 20[redacted] **PORTABLE AP CHEST X RAY:** CLEAR LUNGS

[redacted] 20[redacted] **POTASSIUM:** 3.5 MEQ/L (normal 3.5 to 5.0)

[redacted] 20[redacted] **POTASSIUM:** 3.1 MEQ/L (normal 3.5 to 5.0)

[redacted] 20[redacted] **POTASSIUM:** 3.0 MEQ/L (normal 3.5 to 5.0)

[redacted] 20[redacted] **PROCALCITONIN:** 3.6 NG/ML (normal 0 to 0.1)

[redacted] 20[redacted] **RED BLOOD CELLS:** 4.29 MIL/UL (normal 4.5 to 5.9)

[redacted] 20[redacted] **RED BLOOD CELLS:** 4.18 MIL/UL (normal 4.5 to 5.9)

[redacted] 20[redacted] **RED BLOOD CELLS:** 3.80 MIL/UL (normal 4.5 to 5.9)

[redacted] 20[redacted] **RESPIRATORY RATE:** 18 /min

[redacted] 20[redacted] **RESPIRATORY RATE:** 22 /min

[redacted] 20[redacted] **RESPIRATORY RATE:** 19 /min

[redacted] 20[redacted] **RESPIRATORY RATE:** 18 /min

[redacted] 20[redacted] **RESPIRATORY RATE:** 20 /min

[redacted] 20[redacted] **RESPIRATORY RATE:** 18 /min

[redacted] 20[redacted] **SCREENING CHEST X-RAY:** Normal

[redacted] 20[redacted] **SODIUM:** 136 MEQ/L (normal 135 to 145)

[redacted] 20[redacted] **SODIUM:** 131 MEQ/L (normal 135 to 145)

[redacted] 20[redacted] **SODIUM:** 138 MEQ/L (normal 135 to 145)

[redacted] 20[redacted] **TROPONIN:** 0.01 NG/ML (normal 0 to 0.1)

[redacted] 20[redacted] **WHITE BLOOD CELLS:** 5.3 K/UL (normal 4.8 to 10.8)

[redacted] 20[redacted] **WHITE BLOOD CELLS:** 3.8 K/UL (normal 4.8 to 10.8)

[redacted] 20[redacted] **WHITE BLOOD CELLS:** 3.7 K/UL (normal 4.8 to 10.8)

[redacted] 20[redacted] **WHITE BLOOD CELLS:** 3.8 K/UL (normal 4.8 to 10.8)

[redacted] 20[redacted] **XR CHEST PORTABLE AP:** Bilateral patchy peripheral and left perihiliar infiltrates with air bronchograms are noted, not visualized on the most recent previous examination.

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
坐骨神経痛	X			
背部痛	X			
椎間板突出	X			
瘢痕	X			
椎間板炎	X			X

Treatment Group	Age at Study Start	Sex	Race
UPA 15 MG QD/UPA 15 MG QD	4[redacted]	FEMALE	WHITE

Medical History	Onset Year
ALLERGIC RHINITIS	19[redacted]
ASTHMA	19[redacted]
ABDOMINAL PAIN DURING PERIOD	19[redacted]
ATOPIC DERMATITIS	19[redacted]
FRACTURE OF THE JAW	19[redacted]
ACNE	19[redacted]
IMPETIGO INFECTION	20[redacted]
LUMBAGO	20[redacted]
VAGINITIS	20[redacted]
DEPRESSIVE SYNDROME	20[redacted]
OTITIS	20[redacted]
ABORTION	20[redacted]
ACNE	NOT REPORTED
ALERGGY MITES	NOT REPORTED
ALLERGIC CONJUNCTIVITIS	NOT REPORTED
ALLERGIC RHINITIS	NOT REPORTED
ALLERGY CHROME	NOT REPORTED
ALLGERY TO PERON BALM	NOT REPORTED
ASTHMA	NOT REPORTED
CHLORURE BENZALKONIUM ALLERGY	NOT REPORTED
DEPRESSIVE SYNDROME	NOT REPORTED
FOOD ALLERGY	NOT REPORTED
LABIAL HERPES SIMPLEX INFECTION	NOT REPORTED
NICKEL ALLERGY	NOT REPORTED

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			

CIGARETTES	NEVER
CIGARS	NEVER
E-CIGARETTES	NEVER
PIPES	NEVER

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 115	115
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 116		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
SALBUTAMOL	200 ug	OTHER: IF NEEDED	Y-M: 19[redacted]
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
ALL OTHER NON-THERAPEUTIC PRODUCTS	UK OTHER: UK	OTHER: UK	Y-M: 20[redacted]
METHOTREXATE	UNK OTHER: UNK	OTHER: UNK	Y-M: 20[redacted]
INFLIXIMAB	UK OTHER: UK	EVERY 2 WEEKS	Y-M: 20[redacted]
MYCOPHENOLIC ACID	500 mg	BID	Y-M: 20[redacted]
TACROLIMUS	UK %	QD	Y-M: 20[redacted]
CICLOSPORIN	250 mg	QD	Y-M: 20[redacted]
CICLOSPORIN	150 mg	BID	Y-M: 20[redacted]
BILASTINE	20 mg	QD	Y-M: 20[redacted]
MONTELUKAST	10 mg	QD	Y-M: 20[redacted]
CLOBETASOL	0.05 %	QD	Y-M: 20[redacted]
DIFLUCORTOLONE	0.1 %	QD	Y-M: 20[redacted]
INTRAUTERINE CONTRACEPTIVE DEVICE	DIU UT 380 FILS 1.5CM OTHER: NA	OTHER: NA	Y-M: 20[redacted]
UREA	NA OTHER: UNK	BID	Y-M: 20[redacted] / -41

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
SALBUTAMOL	200 ug	OTHER: IF NEEDED	Y-M: 19[redacted]	NOT REPORTED
MONTELUKAST	10 mg	QD	Y-M: 20[redacted]	Y-M: 20[redacted] / 203
INTRAUTERINE CONTRACEPTIVE DEVICE	DIU UT 380 FILS 1.5CM OTHER: NA	OTHER: NA	Y-M: 20[redacted]	NOT REPORTED
UREA	NA OTHER: UNK	BID	Y-M: 20[redacted] / -41	Y-M: 20[redacted] / 288

DIFLUCORTOLONE	0.1 %	QD	Y-M: 20[redacted] / 141	NOT REPORTED
PARACETAMOL	1 g	PRN	Y-M: 20[redacted] / 195	NOT REPORTED
KETOPROFEN	100 mg	BID	Y-M: 20[redacted] / 195	Y-M: 20[redacted] / 201
MACROGOL	20 g	QD	Y-M: 20[redacted] / 196	Y-M: 20[redacted] / 200
MORPHINE	5 mg	PRN	Y-M: 20[redacted] / 196	Y-M: 20[redacted] / 201
ENOXAPARIN	4000 IU	QD	Y-M: 20[redacted] / 214	Y-M: 20[redacted] / 235
ALPRAZOLAM	0.5 mg	QD	Y-M: 20[redacted] / 215	Y-M: 20[redacted] / 219
METHOCARBAMOL	500 mg	BID	Y-M: 20[redacted] / 219	Y-M: 20[redacted] / 220
ALPRAZOLAM	0.5 mg	BID	Y-M: 20[redacted] / 219	Y-M: 20[redacted] / 251
THIOCOLCHICOSIDE	4 mg	QD	Y-M: 20[redacted] / 220	Y-M: 20[redacted] / 231
LEVOFLOXACIN	500 mg	QD	Y-M: 20[redacted] / 270	Y-M: 20[redacted] / 285
RIFAMPICIN	300 mg	BID	Y-M: 20[redacted] / 270	Y-M: 20[redacted] / 298
AMPHOTERICIN B	100MG/ML OTHER: MG/ML	TID	Y-M: 20[redacted] / 286	Y-M: 20[redacted] / 292
ECONAZOLE	1 %	BID	Y-M: 20[redacted] / 286	Y-M: 20[redacted] / 292
BACTRIM	800/160 mg	BID	Y-M: 20[redacted] / 286	Y-M: 20[redacted] / 298
TOLERIANE	NA OTHER: NA	QD	Y-M: 20[redacted] / 288	NOT REPORTED
FOLIC ACID	0.4 mg	TID	Y-M: 20[redacted] / 288	Y-M: 20[redacted] / 298
DESONIDE	0.1 %	QD	Y-M: 20[redacted] / 288	Y-M: 20[redacted] / 360

Event #1: Serious Adverse Event

Event Description	SCIATICA
Preferred term	坐骨神経痛
AE Onset Date / Rx Day	[redacted]20[redacted] / 185
Age at AE Onset	4[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 201): HERNIATED DISC CURE L5-S1: EXCISION DISC, ROOT FREEDOM AND ABSENCE OF RESIDUAL FRAGMENT
AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Toxicity Grade	3
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY

Investigator Alternative Etiology	DISCAL HERNIA L5S1
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Event #2: Serious Adverse Event

Event Description	LOW BACK PAIN, SCAR FROM THE SURGERY OF INFLAMMATORY DISC HERNIATION.
Preferred term	背部痛
AE Onset Date / Rx Day	[redacted]20[redacted] / 210
Age at AE Onset	4[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	[redacted]20[redacted] (RX DAY 266): WOUND NPTST062-MICROBIAL CULTURE: POSITIVE-STAPHYLOCOCCUS CAPITIS
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 222): LUMBAR RACHIS MRI: RECURRENCE OF POSTEROMEDIAL AND POSTEROLATERAL LEFT L5S1 DISC HERNIATION IN CONFLICT WITH THE EMERGENCE OF THE LEFT S1 ROOT.; [redacted]20[redacted] (RX DAY 266): BIOPSY OF THE OPERATING SITE WITH BACTERIOLOGICAL SAMPLES: STAPHYLOCOCCUS CAPITIS INFECTION
AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Toxicity Grade	3
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	RECENT OPERATION OF A HERNIATED DISC
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Event #3: Serious Adverse Event

Event Description	LOW BACK PAIN, SCAR FROM THE SURGERY OF INFLAMMATORY DISC HERNIATION.
Preferred term	椎間板突出
AE Onset Date / Rx Day	[redacted]20[redacted] / 210
Age at AE Onset	4[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	[redacted]20[redacted] (RX DAY 266): WOUND NPTST062-MICROBIAL CULTURE: POSITIVE-STAPHYLOCOCCUS CAPITIS
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 222): LUMBAR RACHIS MRI: RECURRENCE OF POSTEROMEDIAL AND POSTEROLATERAL LEFT L5S1 DISC HERNIATION IN CONFLICT WITH THE EMERGENCE OF THE LEFT S1 ROOT.; [redacted]20[redacted] (RX DAY 266): BIOPSY OF THE OPERATING SITE WITH BACTERIOLOGICAL SAMPLES: STAPHYLOCOCCUS CAPITIS INFECTION

AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Toxicity Grade	3
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	RECENT OPERATION OF A HERNIATED DISC
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Event #4: Serious Adverse Event

Event Description	LOW BACK PAIN, SCAR FROM THE SURGERY OF INFLAMMATORY DISC HERNIATION.
Preferred term	瘢痕
AE Onset Date / Rx Day	[redacted]20[redacted] / 210
Age at AE Onset	4[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	[redacted]20[redacted] (RX DAY 266): WOUND NPTST062-MICROBIAL CULTURE: POSITIVE-STAPHYLOCOCCUS CAPITIS
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 222): LUMBAR RACHIS MRI: RECURRENCE OF POSTEROMEDIAL AND POSTEROLATERAL LEFT L5S1 DISC HERNIATION IN CONFLICT WITH THE EMERGENCE OF THE LEFT S1 ROOT.; [redacted]20[redacted] (RX DAY 266): BIOPSY OF THE OPERATING SITE WITH BACTERIOLOGICAL SAMPLES: STAPHYLOCOCCUS CAPITIS INFECTION
AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Toxicity Grade	3
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	RECENT OPERATION OF A HERNIATED DISC
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Event #5: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	SPONDYLODISCITIS
Preferred term	椎間板炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 266

Age at AE Onset	4[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	[redacted]20[redacted] (RX DAY 266): WOUND NPTST062-MICROBIAL CULTURE: POSITIVE-STAPHYLOCOCCUS CAPITIS
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 222): LUMBAR RACHIS MRI: RECURRENCE OF POSTEROMEDIAL AND POSTEROLATERAL LEFT L5S1 DISC HERNIATION IN CONFLICT WITH THE EMERGENCE OF THE LEFT S1 ROOT.; [redacted]20[redacted] (RX DAY 266): BIOPSY OF THE OPERATING SITE WITH BACTERIOLOGICAL SAMPLES: STAPHYLOCOCCUS CAPITIS INFECTION
AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者はフランスの 4[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，脊椎椎間板炎，坐骨神経痛及び腰痛，炎症性椎間板ヘルニアの手術とその瘢痕を発現した。被験者は非喫煙者かつ飲酒者（2 杯未満／日）であり，関連する病歴はアトピー性皮膚炎及び腰痛症であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は坐骨神経痛を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は腰痛及び炎症性椎間板ヘルニアの手術とその瘢痕を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は脊椎椎間板炎を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は腰痛のため入院した。症状及び徴候として椎間板ヘルニアがあった。被験者は後方アプローチで第 5 腰椎／仙骨間椎間板（以下，「L5-S1」）のヘルニア治療を受けた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

20[redacted] 年 [redacted] 月 [redacted] 日，退院以降持続していた腰痛，椎間板ヘルニアの瘢痕の炎症，その朝から続く発熱のため，被験者は再入院した。治療のため鎮痛薬の用量を変更し，筋弛緩薬及び抗不安薬を追加した。治験責任医師は，リスク因子として直近の椎間板ヘルニア（L5-S1）治療を挙げた。20[redacted] 年 [redacted] 月 [redacted] 日，核磁気共鳴画像検査で椎間板ヘルニア（L5-S1）の再発及び左第 1 仙骨神経根の炎症が確認された。

20[redacted] 年 [redacted] 月 [redacted] 日，L5-S1 に脊椎椎間板炎が認められた。感染性疾患が認められ，被験者は 6 ヵ月間の治験治療中断を勧められた。このため，脊椎椎間板炎のため治験薬の投与は中断された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

全情報を本報告に統合したため，AER 19P-056-3169091-00 は論理的に削除された。

メトカルバモール，thiocolchicoside，アルプラゾラム，スルファメトキサゾール／トリメトプリム，ケトプロフェン，paracetamol，levofloxacin，リファンピシン，及び morphine sulfate が投与された。

The patient's past medications include:

METHOTREXATE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

INFLIXIMAB for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

MYCOPHENOLATE MOFETIL for ATOPIC DERMATITIS [redacted] 20[redacted] - [redacted] [redacted] 20[redacted])

TACROLIMUS for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

CYCLOSPORIN for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

CLOBETASOL for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DIFLUCORTOLONE VALERATE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

CHLORURE BENZALKONIUM for UNKNOWN INDICATION

Causality for UPADACITINIB (Blinded)

---

1) Spondylodiscitis (10062691) (Intervertebral discitis (10060738)) [v.23.0] [10062691]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: No

2) Sciatica (10039674) (Sciatica (10039674)) [v.23.0] [10039674]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

3) Low back pain (10024891) (Back pain (10003988)) [v.23.0] [10024891]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: No

4) Surgical scar (10057060) (Scar (10039580)) [v.23.0] [10057060]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: No

5) Intervertebral disc herniation (10048856) (Intervertebral disc protrusion (10050296)) [v.23.0] [10048856]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: No

Alternative Etiology for UPADACITINIB (Blinded)

Event of SPONDYLODISCITIS

- Investigator: Not applicable

- AbbVie: Risk factor includes previous surgery for lumbar disc herniation with biopsy of operating site showing Staphylococcus capitis. Published data shows that Staphylococci infection account for up to 39% of

reported spondylodiscitis.

Event of SCIATICA

- Investigator: Discal hernia L5-S1.

- AbbVie: Etiology of the event is not consistent with the study drug's mechanism of action. Pre-existing lumbago is an additional risk factor.

Event of LOW BACK PAIN; SCAR FROM SURGERY OF INFLAMMATORY DISC HERNIATION

- Investigator: Recent operation of a herniated disc.

- AbbVie: Events of low back pain and scar are more likely related to recent lumbar spine surgery and pre-existing lumbago. Event of disc herniation is not consistent with study drug's mechanism of action.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BIOPSY OF THE OPERATING SITE WITH BACTERIOLOGICAL SAMPLES:** Staphylococcus capitis infection

[redacted] **20[redacted] LUMBAR RACHIS MRI:** Recurrence of posteromedial and posterolateral left L5-S1 disc herniation in conflict with the emergence of the left S1 root.

[redacted] **20[redacted] WOUND MICROBIAL CULTURE:** Positive - Staphylococcus capitis

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
胸痛	X			

Treatment Group	Age at Study Start	Sex	Race
UPA 15 MG QD/UPA 15 MG QD	5[redacted]	MALE	WHITE

Medical History	Onset Year
ATOPIC DERMATITIS	19[redacted]
CHRONIC L4 CRURALGIE	20[redacted]
HERNIATED DISC L4-L5	20[redacted]
MYELEMIA	20[redacted]
HEADACHE	NOT REPORTED
INSOMNIA	NOT REPORTED
OBESITY	NOT REPORTED
SMOKER	NOT REPORTED
SORE THROAT	NOT REPORTED

Prior Procedures	Procedure Year
PRIOR PROCEDURES: EPIDURAL INFILTRATION OF HYDROCORTANCYL	20[redacted]
PRIOR PROCEDURES: PERI-RADICULAR INFILTRATION L4 RIGHT WITH CORTIVAZOL	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	10 CIGARETTE	37	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	2 - 4

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 112	112
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 113	[redacted]20[redacted] / 225	113

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 19[redacted]
PIROXICAM	20 mg	PRN	Y-M: 20[redacted]
ALPHA-AMYLASE SWINE PANCREAS	3000 OTHER: U CEIP	PRN	Y: 20[redacted]
IBUPROFEN	400 mg	PRN	Y: 20[redacted]
ZOLPIDEM	10 mg	PRN	Y: 20[redacted]
ALL OTHER NON-THERAPEUTIC PRODUCTS	2.4 OTHER: MJOULES	OTHER: 17 SESSION	Y-M: 20[redacted]
ALL OTHER NON-THERAPEUTIC PRODUCTS	40.5 OTHER: MJOULES	OTHER: 17 SESSION	Y-M: 20[redacted]
BETAMETHASONE	15 mg	QD	Y-M: 20[redacted] / -327
METHOTREXATE	15 mg	QD	Y-M: 20[redacted] / -319
LIPIKAR	NA OTHER: UNK	BID	Y-M: 20[redacted] / -7

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
PIROXICAM	20 mg	PRN	Y-M: 20[redacted]	ONGOING
ALPHA-AMYLASE SWINE PANCREAS	3000 OTHER: U CEIP	PRN	Y: 20[redacted]	ONGOING
IBUPROFEN	400 mg	PRN	Y: 20[redacted]	ONGOING
ZOLPIDEM	10 mg	PRN	Y: 20[redacted]	ONGOING
LIPIKAR	NA OTHER: UNK	BID	Y-M: 20[redacted] / -7	ONGOING
CICAPLAST	ONCE PER DAY OTHER: APPLYING	QD	Y-M: 20[redacted] / 1	ONGOING

Event #1: Serious Adverse Event

Event Description	THORACIC PAIN
Preferred term	胸痛
AE Onset Date / Rx Day	[redacted]20[redacted] / 43
Age at AE Onset	5[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 57): NPTST031-D DIMER: 623 [NOT REPORTED - 500] ng/mL; NPTST057-LIPASES: 47 [13 - 60] IU/L; NPTST090-TROPONIN TC HS: 13 [0 - 14] UNIT NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 57): ANGIOSCANNER: NEGATIVE RESULT, NO SIGN OF RECENT PULMONARY EMBOLISM; ECG: NORMAL RESULT; [redacted]20[redacted] (RX DAY 58): VENOUS DOPPLER ULTRASOUND OF THE LOWER LIMBS: ABSENCE OF DEEP OR SUPERFICIAL VENOUS THROMBOSIS OF THE LOWER LIMBS
AE Stopped Rx Day	59
Duration of AE	17 DAYS
Toxicity Grade	2

Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者はフランスの 5[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，胸郭痛を発現した。被験者は喫煙者（紙巻タバコ 10 本／日，37 年間）かつ飲酒者（2～4 杯／日）であり，関連する病歴はアトピー性皮膚炎及び慢性下肢神経痛（第 4 腰神経），椎間板ヘルニア（第 4／第 5 腰椎）及びコレステロール高値であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は胸郭痛を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，胸郭痛は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，胸痛の強さが 15 日間にわたって変化したため，被験者は入院した。特に治療することなく胸痛は消失した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

The patient's past medications include:

METHOTREXATE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINB (Blinded)

---

1) Thoracic pain (10043471) (Chest pain (10008479)) [v.22.0] [10043471]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINB (Blinded)

Event of THORACIC PAIN

- Investigator: Not applicable

- AbbVie: Non-specific reported event; risk factors for most common reported etiologies in gender and age group are obesity (BMI 30), current smoker, and alcohol use.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ANGIOSCANNER:** NEGATIVE RESULT, NO SIGN OF RECENT PULMONARY EMBOLISM

[redacted] **20[redacted] BMI:** 30 kg/m2

[redacted] **20[redacted] D DIMER:** 623 NG/ML (normal <500)

[redacted] **20[redacted] ECG:** Normal

[redacted] **20[redacted] LIPASE:** 47.0 IU/L (normal 13 to 60)

[redacted] **20[redacted] TROPONIN:** 13 ng/L (normal 0 to 14)

[redacted] **20[redacted] VENOUS DOPPLER ULTRASOUND OF THE LOWER LIMBS:** ABSENCE OF DEEP OR SUPERFICIAL VENOUS THROMBOSIS OF THE LOWER LIMBS

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
肺炎	X			X

Treatment Group	Age at Study Start	Sex	Race
UPA 30 MG QD/UPA 30 MG QD	3[redacted]	FEMALE	WHITE

Medical History	Onset Year
ATOPIC DERMATITIS	19[redacted]
ATOPIC DERMATITIS	19[redacted]
ALLERGIC RHINITIS	20[redacted]
TRUE ABSTINENCE AS CONTRACEPTION	20[redacted]
ALLERGIC RHINITIS	NOT REPORTED

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	6 CIGARETTE	3	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 111	111
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 112		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BETAMETHASONE	4 MG DAILY, DECREASING mg	QD	Y-M: 20[redacted]
TACROLIMUS	DAILY %	BID	Y-M: 20[redacted]
CLOBETASOL	DAILY %	BID	Y-M: 20[redacted] / -124
TRIDERM	2 APPLICATIONS/DAY OTHER: APPLICATIONS	BID	Y-M: 20[redacted] / -38

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
TRIDERM	2 APPLICATIONS/DAY OTHER: APPLICATIONS	BID	Y-M: 20[redacted] / -38	ONGOING
CEFDITOREN	1 PILL TWICE A DAY FOR 7 DAYS mg	BID	Y-M: 20[redacted] / 125	Y-M: 20[redacted] / 131
CLARITHROMYCIN	2 PILLS/DAY mg	BID	Y-M: 20[redacted] / 125	Y-M: 20[redacted] / 131
ACETYLCYSTEINE	1 PILL A DAY FOR 10 DAYS OTHER: PILL	QD	Y-M: 20[redacted] / 125	Y-M: 20[redacted] / 135
FLUNISOLIDE	1 VIAL THRICE A DAY + 1 CC SALINE OTHER: 1 VIAL A DAY	QD	Y-M: 20[redacted] / 125	Y-M: 20[redacted] / 138
PREDNISONE	1 PILL/DAY FOR 4 DAYS, 1/2 PILL FOR 4 D, 1/4 PILL FOR 6 D mg	QD	Y-M: 20[redacted] / 125	Y-M: 20[redacted] / 138

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	PNEUMONIA
Preferred term	肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 121
Age at AE Onset	3[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 123): CHEST X RAY: EXCLUSION OF PNEUMOTHORAX, AREA OF CONSOLIDATION IN THE LEFT UPPER LUNG LOBE COMPATIBLE WITH PNEUMONIA
AE Stopped Rx Day	138
Duration of AE	18 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	LOWER RESPIRATORY TRACT INFECTION
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated:[redacted]
Program Source Code:[redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者はイタリアの 3[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，肺炎を発現した。被験者は喫煙者（紙巻タバコ 6 本／日，3 年間）かつ飲酒者

（2 杯未満／日）であり，関連する病歴はアトピー性皮膚炎であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年[redacted] 月[redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年[redacted] 月[redacted] 日，被験者は肺炎を発現した。20[redacted] 年[redacted] 月[redacted] 日，肺炎は消失した。

20[redacted] 年[redacted] 月[redacted] 日，被験者は発熱及び左胸郭痛のため入院した。20[redacted] 年[redacted] 月[redacted] 日，被験者は退院した。

N-アセチルシステイン，セフジトレンピボキシル，クラリスロマイシン，DELTACORTENE 及び FLUNISOLIDE AEROSOL が投与された。

The patient's past medications include:

BETAMETHASONE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

TACROLIMUS for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

CLOBETASOL PROPIONATE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Pneumonia (10035664) (Pneumonia (10035664)) [v.22.1] [10035664]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of PNEUMONIA

- Investigator: Lower respiratory tract infection

- AbbVie: Not applicable

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] CHEST X-RAY:** Screening: Normal

[redacted] **20[redacted] CXR:** EXCLUSION OF PNEUMOTHORAX, AREA OF CONSOLIDATION IN THE LEFT UPPER LUNG LOBE COMPATIBLE WITH PNEUMONIA

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
アレルギー性鼻炎	X			

Treatment Group	Age at Study Start	Sex	Race
PLACEBO/UPA 15 MG QD	4[redacted]	FEMALE	MULTIPLE

Medical History	Onset Year
ALLERGIC RHINITIS	19[redacted]
ATOPIC DERMATITIS	19[redacted]
ATOPIC DERMATITIS	19[redacted]
GALLSTONES	19[redacted]
TRUE ABSTINENCE AS CONTRACEPTION	20[redacted]
ALLERGIC RHINITIS	NOT REPORTED

Prior Procedures	Procedure Year
PRIOR PROCEDURES: CHOLECYSTECTOMY	19[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 50	50
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 130		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
BETAMETHASONE	4 MG/DIE, DECREASING EACH 2 DAYS mg	QD	Y-M: 20[redacted]
BILASTINE	10 MG/DIE mg	QD	Y-M: 20[redacted]
TACROLIMUS	TWICE A DAY %	BID	Y-M: 20[redacted]
BETAMETHASONE W/FUSIDIC ACID	ONCE A DAY g	BID	Y-M: 20[redacted] / -164

METHYLPREDNISOLONE	TWICE A DAY %	BID	Y-M: 20[redacted] / - 97
DEXERYL	2 APPLICATIONS A DAY OTHER: APPLICATIONS	BID	Y-M: 20[redacted] / - 17

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
DEXERYL	2 APPLICATIONS A DAY OTHER: APPLICATIONS	BID	Y-M: 20[redacted] / - 17	NOT REPORTED

Event #1: Serious Adverse Event

Event Description	WORSENING ALLERGIC RHINITIS
Preferred term	アレルギー性鼻炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 53
Age at AE Onset	4[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 50): Lymphocytes: 1.27 [1 - 4] 10^9/L; Lymphocytes/Leukocytes: 20.5 [20 - 45] %; [redacted]20[redacted] (RX DAY 53): NPTST076-QUANTIFERON TB GOLD TEST: 0.02 [0 - 0.34] IU/ML; [redacted]20[redacted] (RX DAY 82): NPTST076-QUANTIFERON TB GOLD TEST: 0.03 [0 - 0.34] IU/ML
Microbiology	[redacted]20[redacted] (RX DAY 53): SPUTUM NPTST083-SPUTUM CULTURE: NEGATIVE-SPECIMEN CONTAMINED BY SALIVA, STAPHYLOCOCCUS AUREUS, LEUKOCYTES >25 CELLS/FIELD, EPITHELIAL SQUAMOUS CELLS
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 53): CHEST X RAY: NEGATIVE
AE Stopped Rx Day	54
Duration of AE	2 DAYS
Toxicity Grade	1
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	HOSPITALIZATION FOR EVALUATION OF SUSPECT OF TB
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者はイタリアの 4[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，アレルギー性鼻炎増悪を発現した。被験者は非喫煙者かつ非飲酒者であり，

関連する病歴はアレルギー性鼻炎及びアトピー性皮膚炎であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者はアレルギー性鼻炎増悪を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，アレルギー性鼻炎増悪は消失した。

本事象発現前の 20[redacted] 年 [redacted] 月 [redacted] 日，被験者は Quantiferon 検査（以下，「QTF 検査」）の結果が陽性であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は結核疑いの精査を目的に入院した。後鼻漏（非重篤）及び夜間咳嗽を発現していた。同日，QTF 検査及び胸部X線検査を行ったが，いずれも異常なしであった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は状態が改善しており，退院した。

20[redacted] 年 [redacted] 月 [redacted] 日，当該医療機関で再度 QTF 検査が行われ，検査判定は陰性であった。2 回の QTF 検査が陰性であり，胸部X線検査及び感染症専門医の診察で異常なしと判断されたことから，潜伏結核は否定された。

関連するリスク因子として，20 年間の南米居住歴が挙げられた。

The patient's past medications include:

BETAMETHASONE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

BILASTINE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

TACROLIMUS OINTMENT for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

BECLOMETASONE W/FUSIDIC ACID for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

METHYLPREDNISOLONE CREAM for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Allergic rhinitis (10001723) (Rhinitis allergic (10039085)) [v.22.1] [10001723]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of WORSENING ALLERGIC RHINITIS

- Investigator: Hospitalization for evaluation of suspect of TB.

- AbbVie: Reported event more likely related to pre-existing allergic rhinitis.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BLOOD; QUANTIFERON TB GOLD TEST:** Negative: 0.02 IU/ML (Reference range: 0.00-0.34)

[redacted] **20[redacted] BLOOD; QUANTIFERON TB GOLD TEST:** Negative: 0.03 IU/ML (Reference range: 0.00-0.34)

[redacted] **20[redacted] CHEST X-RAY:** Screening: Normal

[redacted] **20[redacted] CHEST X-RAY:** Negative.

[redacted] **20[redacted] LYMPHOCYTES %:** 20.50 % (normal 20.00 to 45.00)

[redacted] **20[redacted] LYMPHOCYTES ABS:** 1.27 X10**3/MM**3 (normal 1.00 to 4.00)

[redacted] **20[redacted] SCREENING QUANTIFERON TB GOLD:** Positive

[redacted] **20[redacted] SPUTUM CULTURE:** Specimen contaminated by saliva, staphylococcus aureus, leukocytes >25 cells/field, epithelial squamous cells.

[redacted] **20[redacted] SPUTUM CULTURE FOR TB:** neg. for TB mycobacterium

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
肺炎	X	X		X

Treatment Group	Age at Study Start	Sex	Race
UPA 30 MG QD/UPA 30 MG QD	1[redacted]	FEMALE	WHITE

Medical History	Onset Year
ATOPIC DERMATITIS	20[redacted]
ASTHMA	20[redacted]
ALLERGIC RHINITIS	20[redacted]
FOOD ALLERGY	20[redacted]
TRUE SEXUAL ABSTINENCE	20[redacted]
ALLERGIC RHINITIS	NOT REPORTED
ASTHMA	NOT REPORTED
FOOD ALLERGY	NOT REPORTED

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 111	111
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 112	[redacted]20[redacted] / 183	72

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
BCG Vaccine	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
ALL OTHER NON-THERAPEUTIC PRODUCTS	0.3 OTHER: J/CM2	QD	Y-M: 20[redacted] / -90
CHLOROPYRAMINE	20 mg	QD	Y-M: 20[redacted] / -90
DIPROGENT	30 g	BID	Y-M: 20[redacted] / -90
LEVOCETIRIZINE	5 mg	QD	Y-M: 20[redacted] / -90
MOMETASONE	100 ug	QD	Y-M: 20[redacted] / -90
METHOTREXATE	15 mg	1 TIME PER WEEK	Y-M: 20[redacted] / -85
BUTYROSPERMUM PARKII;DIMETHICONOL;DIMETICONE;	0.5 g	BID	Y-M: 20[redacted] / -77
ALCLOMETASONE	0,5 g	BID	Y-M: 20[redacted] / -37

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
BUTYROSPERMUM PARKII;DIMETHICONOL;DIMETICONE;	0.5 g	BID	Y-M: 20[redacted] / -77	Y-M: 20[redacted] / 186
UNACID	2500 mg	TID	Y-M: 20[redacted] / 185	Y-M: 20[redacted] / 187
LEVOFLOXACIN	500 mg	QD	Y-M: 20[redacted] / 187	Y-M: 20[redacted] / 196
FLUCONAZOLE	300 mg	QD	Y-M: 20[redacted] / 188	Y-M: 20[redacted] / 192
MEROPENEM	1000 mg	TID	Y-M: 20[redacted] / 188	Y-M: 20[redacted] / 196

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Event of Interest - Serious Infections

Event Description	COMMUNITY-ACQUIRED BILATERAL PNEUMONIA
Preferred term	肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 183
Age at AE Onset	1[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 187): Creatine Kinase: 603 [29 - 200] U/L; NPTST013-BUN: 1.3 [1.7 - 8.3] MMOL/L; NPTST025-CRP: 60.9 [0.1 - 8.2] MG/L; NPTST046-IGE: 46430 [0 - 120] IU/ML; NPTST053-LDH: 514 [125 - 450] U/L; [redacted]20[redacted] (RX DAY 188): NPTST020-CHLAMYDIA PNEUMONIA IGM: 14.3 [0 - 10] IU/ML; NPTST029-CYTOMEGALOVIRUS (GRADE ANALYSIS: POSITIVE [0 - 0] UNIT NOT REPORTED; NPTST030-CYTOMEGALOVIRUS (IGG): 16.2 [0 - 0] UNIT NOT REPORTED; NPTST044-HERPES SIMPLEX VIRUS (I+II) IGM: 191.1 [0 - 20] IU/ML; NPTST067-MYCOPLASMA PNEUMONIA IGG: 32.1 [0 - 20] IU/ML; NPTST068-MYCOPLASMA PNEUMONIA IGM: 150 [0 - 13] IU/ML; [redacted]20[redacted] (RX DAY 189): NPTST047-IGG: 14.59 [8.2 - 10.7] G/L; NPTST048-IGM: 435 [0.6 - 2] G/L; [redacted]20[redacted] (RX DAY 191): Erythrocytes: 3.3 [4.1 - 5.1] 10^12/L; Hematocrit: 0.34 [0.34 - 0.44] FRACTION OF 1; Leukocytes: 14.6 [4.5 - 13] 10^9/L;

	Lymphocytes/Leukocytes: 18 [30 - 46] %; Monocytes: 0.93 [0.19 - 0.72] 10^9/L; NPTST032-ESR ACCELERATION: 51 [2 - 15] MM/H; Neutrophils: 11 [1.82 - 7.47] 10^9/L; Neutrophils/Leukocytes: 77.6 [46 - 65] %; Platelets: 514 [154 - 442] 10^9/L
Microbiology	[redacted]20[redacted] (RX DAY 187): SPUTUM NPTST027-CULTURE FROM THE THROAT TO THE FLORA: POSITIVE-STREPTOCOCCUS VIRIDANS, CANDIDA ALBICANS
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 183): TEMPERATURE: 40C; [redacted]20[redacted] (RX DAY 185): CHEST X-RAY: X-RAY PICTURE CORRESPONDS TO LEFT-SIDED POLYSEGMENTAL PNEUMONIA; [redacted]20[redacted] (RX DAY 188): RESPIRATORY FUNCTION: A SHARP DECREASE IN BRONCHIAL CONDUCTION ACCORDING TO THE MIXED TYPE, MAINLY DUE TO THE INFLAMMATORY COMPONENT, THE TEST WITH A BRONCHODILATOR IS NEGATIVE; [redacted]20[redacted] (RX DAY 189): CT SCAN (COMPUTED TOMOGRAPHY): CT PICTURE OF BILATERAL INTERSTITIAL PNEUMONIA; [redacted]20[redacted] (RX DAY 191): ECG: SINUS ARRHYTHMIA DISAPPEARING WITH HOLDING YOUR BREATH; [redacted]20[redacted] (RX DAY 194): T-SPOT: NEGATIVE
AE Stopped Rx Day	ONGOING
Duration of AE	ONGOING
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者はロシア連邦の 1[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，市中感染性両側性肺炎（グレード 3）を発現した。被験者は非喫煙者かつ非飲酒者であり，関連する病歴はアトピー性皮膚炎，喘息，アレルギー性鼻炎及び食物アレルギーであった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は市中感染性両側性肺炎を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は高体温（最高 40℃），咳嗽及び胸郭痛のため入院した。被験者はマイコプラズマ感染とクラミジア感染を併発していると診断された（重度の市中感染性両側性肺炎，I 度の呼吸不全）。

ampicillin + sulbactam，levofloxacin，meropenem，及びフルコナゾールが投与された。

The patient's past medications include:

BETAMETHASONE W/GENTAMICIN for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

CHLOROPYRAMINE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

LEVOCETIRIZINE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

MOMETASONE for ALLERGIC RHINITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

METHOTREXATE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

ALCLOMETASONE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Community acquired pneumonia (10010120) (Pneumonia (10035664)) [v.22.1] [10010120]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: No

Alternative Etiology for UPADACITINIB (Blinded)

Event of COMMUNITY-ACQUIRED BILATERAL PNEUMONIA

- Investigator: Notapplicable.

- AbbVie: Not applicable.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ABSOLUTE LYMPHOCYTE COUNT:** 2.06 x10^3/uL (normal 0.95 to 5.25)

[redacted] **20[redacted] ABSOLUTE LYMPHOCYTE COUNT:** 2.92 x10^3/uL (normal 0.95 to 5.25)

[redacted] **20[redacted] ABSOLUTE LYMPHOCYTE COUNT:** 3.39 x10^3/uL (normal 0.95 to 5.25)

[redacted] **20[redacted] ABSOLUTE LYMPHOCYTE COUNT:** 2.45 x10^3/uL (normal 0.95 to 5.25)

[redacted] **20[redacted] ANC:** 2.91 x10^3/uL (normal 1.65 to 8.15)

[redacted] **20[redacted] ANC:** 2.51 x10^3/uL (normal 1.65 to 8.15)

[redacted] **20[redacted] ANC:** 3.68 x10^3/uL (normal 1.65 to 8.15)

[redacted] **20[redacted] ANC:** 3.53 x10^3/uL (normal 1.65 to 8.15)

[redacted] **20[redacted] BUN:** 1.3 MMOL/L (normal 1.7 to 8.3)

[redacted] **20[redacted] CHEST X-RAY:** Screening: Normal

[redacted] **20[redacted] CHEST X-RAY:** X-ray picture corresponds to left-sided polysegmental pneumonia

[redacted] **20[redacted] CHLAMYDIA PNEUMONIA IGM:** 14.3 IU/mL (normal 0 to 10)

[redacted] **20[redacted] CREATINE KINASE:** 603 U/L (normal 29 to 200)

[redacted] **20[redacted] CRP:** 60.9 MG/L (normal 0.1 to 8.2)

[redacted] **20[redacted] CT SCAN:** CT picture of bilateral interstitial pneumonia

[redacted] **20[redacted] CYTOMEGALOVIRUS (IGG):** 16.2 AU/ml (normal 0 to 0)

[redacted] **20[redacted] CYTOMEGALOVIRUS GRADE ANALYSIS:** Positive

[redacted] **20[redacted] ECG:** Sinus arrhythmia disappearing with holding your breath

[redacted] **20[redacted] ESR ACCELERATION:** 51 MM/HR (normal 2 to 15)

[redacted] **20[redacted] HEMATOCRIT:** 33.8 % (normal 34 to 44)

[redacted] **20[redacted] HERPES SIMPLEX VIRUS I AND II IGM:** 191.1 IU/mL (normal 0 to 20)

[redacted] **20[redacted] IGE:** 46430 IU/mL (normal 0 to 120)

[redacted] **20[redacted] IGG:** 14.59 G/L (normal 8.2 to 10.7)

[redacted] **20[redacted] IGM:** 435 G/L (normal 0.6 to 2)

[redacted] **20[redacted] LDH:** 514 U/L (normal 125 to 450)

[redacted] **20[redacted] LYMPHOCYTES %:** 18 % (normal 30 to 46)

[redacted] **20[redacted] MONOCYTES ABS:** 0.93 X10**6/MCL (normal 0.19 to 0.72)

[redacted] **20[redacted] MYCOPLASMA PNEUMONIA IGG:** 32.1 IU/mL (normal 0 to 20)

[redacted] **20[redacted] MYCOPLASMA PNEUMONIA IGM:** 150 IU/mL (normal 0 to 13)

[redacted] **20[redacted] NEUTROPHILS %:** 77.6 % (normal 46 to 65)

[redacted] **20[redacted] NEUTROPHILS ABS:** 11.00 X10**6/MCL (normal 1.82 to 7.47)

[redacted] **20[redacted] PLATELET COUNT:** 514 X10**6/MCL (normal 154 to 442)

[redacted] **20[redacted] PULSE:** 40C

[redacted] **20[redacted] RED BLOOD CELLS:** 3.33 X10**6/MCL (normal 4.1 to 5.1)

[redacted] **20[redacted] RESPIRATORY FUNCTION TEST:** A sharp decrease in bronchial conduction according to the mixed type, mainly due to the inflammatory component, the test with a bronchodilator is negative

[redacted] **20[redacted] SPUTUM CULTURE:** Positive: streptococcus viridans, candida albicans

[redacted] **20[redacted] T-SPOT:** Negative

[redacted] **20[redacted] TEMPERATURE:** 40 Degrees C

[redacted] **20[redacted] WBC:** 6.07 x10^3/uL (normal 4.35 to 13.15)

[redacted] **20[redacted] WBC:** 6.13 x10^3/uL (normal 4.35 to 13.15)

[redacted] **20[redacted] WBC:** 8.11 x10^3/uL (normal 4.35 to 13.15)

[redacted] **20[redacted] WBC:** 7.40 x10^3/uL (normal 4.35 to 13.15)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 14.6 X10**6/MCL (normal 4.5 to 13)

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
筋肉痛	X	X		

Treatment Group	Age at Study Start	Sex	Race
UPA 30 MG QD/UPA 30 MG QD	3[redacted]	MALE	WHITE

Medical History	Onset Year
ATOPIC DERMATITIS	19[redacted]
ASTHMA	19[redacted]
ALLERGIC RHINITIS	20[redacted]
ALLERGY ON CAT HAIR	20[redacted]
MAMMARY GLAND SWELLING LEFT SIDE	20[redacted]
ALLERGIC RHINITIS	NOT REPORTED
ASTHMA	NOT REPORTED

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 112	112
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 113	[redacted]20[redacted] / 199	87

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
CLOBETASOL	0.5 OTHER: MG/G	QD	Y-M: 20[redacted]
NIVEA	WHOLE BODY OTHER: APPLICATION	BID	Y-M: 20[redacted] / -248
LEVOCETIRIZINE	5 mg	PRN	Y-M: 20[redacted] / -105
PREDNISONE	50 mg	QD	Y-M: 20[redacted] / -105
PRURI-MED	WHOLE BODY OTHER: APPLICATION	QD	Y-M: 20[redacted] / -105
ALL OTHER NON-THERAPEUTIC PRODUCTS	NA OTHER: MINUTES	OTHER: 3 TIMES PER WEEK	Y-M: 20[redacted] / -104
CLOBETASOL	BLANKET THERAPY OTHER: 0.5 MG/G	OTHER: 2 TIMES PER WEEK	Y-M: 20[redacted] / -104
CLOBETASOL	0,5 OTHER: MG/G	OTHER: 2 - 3 TIMES PER WEEK	Y-M: 20[redacted] / -62
TACROLIMUS	0.1 %	OTHER: 2 TIMES DAILY	Y-M: 20[redacted] / -47
PREDNICARBATE	0.25 %	QD	Y-M: 20[redacted] / -37

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
NIVEA	WHOLE BODY OTHER: APPLICATION	BID	Y-M: 20[redacted]- [redacted] / -248	NOT REPORTED
LEVOCETIRIZINE	5 mg	PRN	Y-M: 20[redacted]- [redacted] / -105	NOT REPORTED
PRURI-MED	WHOLE BODY OTHER: APPLICATION	QD	Y-M: 20[redacted]- [redacted] / -105	NOT REPORTED
MAGNESIUM PHOSPHATE	1 OTHER: TABLET	QID	Y-M: 20[redacted]- [redacted] / 198	NOT REPORTED
ARNICA MONTANA	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]- [redacted] / 198	Y-M: 20[redacted]-[redacted] / 207
IBUPROFEN	400 mg	OTHER: ON DEMAND	Y-M: 20[redacted]- [redacted] / 198	Y-M: 20[redacted]-[redacted] / 207
PRUNUS SPINOSA	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]- [redacted] / 198	Y-M: 20[redacted]-[redacted] / 207
APIS MELLIFICA W/LEVISTICUM OFFICINALE	1 mL	QD	Y-M: 20[redacted]- [redacted] / 198	Y-M: 20[redacted]-[redacted] / 219
HOMEOPATHIC PREPARATION	1 mL	QD	Y-M: 20[redacted]- [redacted] / 198	Y-M: 20[redacted]-[redacted] / 219
PARACETAMOL	500 mg	OTHER: ON DEMAND	Y-M: 20[redacted]- [redacted] / 198	Y-M: 20[redacted]-[redacted] / 223
GENTIANA LUTEA	10 gtt	TID	Y-M: 20[redacted]- [redacted] / 199	NOT REPORTED
HOMEOPATHIC PREPARATION	1 OTHER: TEASPOON	BID	Y-M: 20[redacted]- [redacted] / 199	NOT REPORTED
LEVOCETIRIZINE	5 mg	QD	Y-M: 20[redacted]- [redacted] / 199	NOT REPORTED
ROSMARINUS OFFICINALIS	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]- [redacted] / 199	NOT REPORTED
RAMIPRIL	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]- [redacted] / 199	Y-M: 20[redacted]-[redacted] / 207
HOMEOPATHIC PREPARATION	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]- [redacted] / 199	Y-M: 20[redacted]-[redacted] / 219
SICORTEN PLUS	1 OTHER: APPLICATION	OTHER: ON DEMAND	Y-M: 20[redacted]- [redacted] / 207	Y-M: 20[redacted]-[redacted] / 219
FUCICORT	20 mg	BID	Y-M: 20[redacted]- [redacted] / 220	NOT REPORTED
RETINOL	1 OTHER: 0.5 CM	QD	Y-M: 20[redacted]- [redacted] / 231	NOT REPORTED
OTHER OPHTHALMOLOGICALS	1 gtt	OTHER: EVERY 4 HOURS	Y-M: 20[redacted]- [redacted] / 231	Y-M: 20[redacted]-[redacted] / 252
TOBRADEX	1 AND 3 OTHER: MG/ML	OTHER: EVERY 4 HOURS	Y-M: 20[redacted]- [redacted] / 231	Y-M: 20[redacted]-[redacted] / 252
HERBAL OPHTHALMOLOGICALS, OTHER	1 gtt	OTHER: 3-4 TIMES DAILY	Y-M: 20[redacted]- [redacted] / 252	NOT REPORTED
SALVIA OFFICINALIS	1 OTHER: APPLICATION	OTHER: EVERY SECOND DAY	Y-M: 20[redacted]- [redacted] / 253	NOT REPORTED

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug

Event Description	MUSCULAR PAIN UPPER LEG LEFT - CAUSE UNKNOWN
Preferred term	筋肉痛
AE Onset Date / Rx Day	[redacted]20[redacted] / 198
Age at AE Onset	3[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 198): Alkaline Phosphatase: 24 [0 - 46] U/L; Aspartate Aminotransferase: 19 [0 - 40] U/L; Creatine Kinase: 190 [39 - 308] U/L; Leukocytes: 8.8 [4 - 10] 10^9/L; NPTST025-CRP: 7.8 [0 - 5] MG/L; NPTST053-LDH: 287 [135 - 225] U/L
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 177): MRI UPPER LEG LEFT: NORMAL
AE Stopped Rx Day	259 (60 DAYS AFTER LAST TREATMENT)
Duration of AE	62 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者はスイスの 3[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，左大腿部筋肉痛（原因不明）を発現した。被験者は非喫煙者かつ飲酒者（2 杯未満／日）であり，関連する病歴はアトピー性皮膚炎及び左胸乳腺の腫れであった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加し，20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左大腿部筋肉痛（原因不明）を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，左大腿部筋肉痛（原因不明）は消失した。

20[redacted] 年 [redacted] 月，被験者は左大腿部の疼痛（非重篤）を自覚し始めた。20[redacted] 年 [redacted] 月 [redacted] 日，鎮痛薬及び理学療法による治療でも改善しなかったため被験者は入院し，この際に本事象は重篤に変更された。入院時，被験者は大腿四頭筋外側（主に大腿直筋から外側広筋にかけて）の圧痛を訴えていた。大腿部を外旋させながら屈曲する際も疼痛を訴えた。疼痛により，荷重はかなり制限されていた。血栓症，静脈炎及び浮腫の徴候はなく，核磁気共鳴画像に異常所見はなく，臨床検査値にも問題となる臨床所見はなかった。治療には，薬剤による疼痛管理，治療的オイ

リュトミー，律動的マッサージ，理学療法，スピノサスモモの花のオイルを使用した治療浴，アルニカ湿布及びローズマリーオイル（左大腿部の按摩に使用）が用いられた。転帰は，左大腿部の疼痛が部分的に緩和したと報告された。退院時，左脚は荷重可能に復していた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。リスク因子として，被験者の体重が原因で仕事中に不適切な座位をとっていることが挙げられた。

被験者は本事象を理由に試験を中止した。

アルニカ，WELEDA ARNICA GLOBULI D6，MAGNESIUM PHOSPHORICUM D6，DAFALGAN，ROSMARINUS FOL ET FLOS 20% OIL，塩化マグネシウム，BRYONIA / STANNUM，APIS CUM LEVISTICO D3，イブプロフェン，スピノサスモモの花のオイル及び WELEDA ARNICA COMP/FORMICA UNGUENT が投与された。

The patient's past medications include:

DERMOVATE UNGUENT for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

PREDNISON for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

UVB NB for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DERMOVATE SCALP APPLICATION for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

PROTOPIC 0.1% for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

PREDNITOP for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DEXERYL CREAM for EMOLLIENT THERAPY ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinde

---

1) Myalgia of lower extremities (10051587) (Myalgia (10028411)) [v.22.1] [10051587]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of MUSCULAR PAIN UPPER LEG LEFT-CAUSE UNKNOWN

- Investigator: Not Applicable

- AbbVie: Event is common in the general population, with a wide array of possible causes. Sub-optimal sitting posture during work, because of patient's weight, is an additional risk factor (as per reporter)

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ALKALINE PHOSPHASE:** 24 U/L (normal 0 to 46)

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 19 U/L (normal 0 to 40)

[redacted] **20[redacted] BMI:** 31.0 kg/m2

[redacted] **20[redacted] CREATINE KINASE:** 190 U/L (normal 39 to 308)

[redacted] **20[redacted] CRP:** 7.8 MG/L (normal 0 to 5)

[redacted] **20[redacted] LDH:** 287 U/L (normal 135 to 225)

[redacted] **20[redacted] MRI:** upper left leg - normal

[redacted] **20[redacted] WBC:** 8.8 G/L (normal 4 to 10)

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
全身性剥脱性皮膚炎	X	X		

Treatment Group	Age at Study Start	Sex	Race
PLACEBO	4[redacted]	FEMALE	WHITE

Medical History	Onset Year
ATOPIC DERMATITIS	19[redacted]
EGG ALERGY	19[redacted]
ASTHMA	19[redacted]
HAY FEVER	19[redacted]
NUT ALLERGY	20[redacted]
EARLY MENOPAUSE	20[redacted]
ALOPECIA	20[redacted]
LOCALISED SHINGLES	20[redacted]
ALLERGIC RHINITIS	NOT REPORTED
ASTHMA	NOT REPORTED
FOOD ALLERGY	NOT REPORTED

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 14	14

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
MOMETASONE	1 OTHER: APPLICATION	PRN	Y: 19[redacted]
EPADERM	1 OTHER: APPLICATION	BID	Y: 20[redacted]
PROGARON	1 OTHER: APPLICATION	QD	Y: 20[redacted]
QV	1 OTHER: APPLICATION	PRN	Y: 20[redacted]
ALL OTHER NON-THERAPEUTIC PRODUCTS	UNKNOWN OTHER: UNKNOWN	OTHER: UNKNOWN	Y-M: 20[redacted]
ALL OTHER NON-THERAPEUTIC PRODUCTS	UNKNOWN OTHER: UNKNOWN	OTHER: UNKNOWN	Y-M: 20[redacted]
AZATHIOPRINE	50 mg	BID	Y-M: 20[redacted]
CICLOSPORIN	75 mg	BID	Y-M: 20[redacted]
CICLOSPORIN	100 mg	BID	Y-M: 20[redacted]
DIPROBASE	1 OTHER: APPLICATION	PRN	Y: 20[redacted]
HERPES ZOSTER IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted] / -216
ZUMESTON	10.5/2.5 mg	QD	Y-M: 20[redacted] / -67

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
EPADERM	1 OTHER: APPLICATION	BID	Y: 20[redacted]	ONGOING
PROGARON	1 OTHER: APPLICATION	QD	Y: 20[redacted]	ONGOING
QV	1 OTHER: APPLICATION	PRN	Y: 20[redacted]	ONGOING
DIPROBASE	1 OTHER: APPLICATION	PRN	Y: 20[redacted]	ONGOING
ZUMESTON	10.5/2.5 mg	QD	Y-M: 20[redacted] / -67	ONGOING
CLOBETASOL	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / 14	Y-M: 20[redacted] / 18
PREDNISOLONE	30 mg	QD	Y-M: 20[redacted] / 14	Y-M: 20[redacted] / 36

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug

Event Description	ERYTHRODERMA
Preferred term	全身性剥脱性皮膚炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 14
Age at AE Onset	4[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	NOT REPORTED
AE Stopped Rx Day	18 (4 DAYS AFTER LAST TREATMENT)
Duration of AE	5 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は英国の 4[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，紅皮症を発現した。被験者は非喫煙者かつ飲酒者（2 杯未満／日）であり，関連する病歴はアトピー性皮膚炎，卵アレルギー，喘息，ナッツアレルギー，脱毛症，早発閉経及びアレルギー性鼻炎であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加していた。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は紅皮症を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，紅皮症は消失した。

本事象発現に先行し，被験者は 20[redacted] 年 [redacted] 月 [redacted] 日に湿疹のフレア（非重篤）を発現した。

入院前の直近 3 週間，被験者はステロイド外用薬を中止した事により症状が再燃しており，20[redacted] 年 [redacted] 月 [redacted] 日には症状が管理困難となっていた。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は極度の疼痛，熱感及び皮膚そう痒のため入院した。被験者は診察で疼痛及び不快感を訴え，紅皮症が認められた。被験者は始めのうち頻脈であったが，心拍数は改善した。湿疹面積重症度指数のスコアは 41.1 であった。被験者は糖質コルチコイドの経口薬及び外用薬を投与され，20[redacted] 年 [redacted] 月 [redacted] 日に退院した。本事象を理由に治験薬の投与は中止された。

プレドニゾロン及び clobetasol が投与された。

The patient's past medications include:

ELOCON for ATOPIC DERMATITIS (19[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

UVB for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

AZATHIOPRINE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

CICLOSPORINE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

Causality for ABT-494 (Blinded)

---

1) Erythroderma (10015277) (Dermatitis exfoliative generalised (10012456)) [v.22.0] [10015277]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for ABT-494 (Blinded)

Event of ERYTHRODERMA

- Investigator: Not applicable.

- AbbVie: Event is more likely related to pre-existing atopic dermatitis.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] EASI SCORE:** 23.4 no units

[redacted] **20[redacted] EASI SCORE:** 16 no units

[redacted] **20[redacted] EASI SCORE:** 41.1 no units

[redacted] **20[redacted] HEART RATE:** 114 BPM

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
アトピー性皮膚炎	X			
血液培養陽性	X	X		X
心雑音		X		
尿培養陽性	X	X		X
骨髄炎	X	X		X
敗血症		X		
ブドウ球菌性敗血症	X	X		X

Treatment Group	Age at Study Start	Sex	Race
PLACEBO/UPA 30 MG QD	1[redacted]	MALE	WHITE

Medical History	Onset Year
ATOPIC DERMATITIS	20[redacted]
AUTISTIC SPECTRUM DISORDER (ASPERGERS)	20[redacted]
ALLERGIC RHINITIS	20[redacted]
ASTHMA	20[redacted]
INFECTED ECZEMA	20[redacted]
ALLERGIC RHINITIS	NOT REPORTED
ASTHMA	NOT REPORTED

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 120	120
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 121	[redacted]20[redacted] / 243	123

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
EMOLLIENTS AND PROTECTIVES	DOSE UNKNOWN OTHER: UNITS UNKNOWN	BID	Y: 20[redacted]
QV	DOSE UNKNOWN OTHER: UNITS UNKNOWN	BID	Y: 20[redacted]
BETAMETHASONE	0.02 %	BID	Y: 20[redacted]
BETAMETHASONE	0.05 %	PRN	Y: 20[redacted]
FEXOFENADINE	360 mg	BID	Y: 20[redacted]
AZATHIOPRINE	50 mg	BID	Y-M: 20[redacted]
CICLOSPORIN	200 mg	QD	Y: 20[redacted]
MYCOPHENOLIC ACID	1 g	BID	Y-M: 20[redacted]
SERTRALINE	100 mg	QD	Y: 20[redacted]
TACROLIMUS	4 mg	BID	Y-M: 20[redacted] / -174
CLONIDINE	50 mg	BID	Y-M: 20[redacted] / -115
RANITIDINE	150 mg	QD	Y-M: 20[redacted] / -115

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
EMOLLIENTS AND PROTECTIVES	DOSE UNKNOWN OTHER: UNITS UNKNOWN	BID	Y: 20[redacted]	ONGOING
QV	DOSE UNKNOWN OTHER: UNITS UNKNOWN	BID	Y: 20[redacted]	ONGOING
FEXOFENADINE	360 mg	BID	Y: 20[redacted]	Y-M: 20[redacted] / 251
SERTRALINE	100 mg	QD	Y: 20[redacted]	ONGOING
CLONIDINE	50 mg	BID	Y-M: 20[redacted] / -115	ONGOING
RANITIDINE	150 mg	QD	Y-M: 20[redacted] / -115	Y-M: 20[redacted] / 251
GUANFACINE	1 mg	QD	Y-M: 20[redacted] / 9	ONGOING
TEMAZEPAM	10 mg	QD	Y-M: 20[redacted] / 9	Y-M: 20[redacted] / 134
ALIMEMAZINE	50 mg	PRN	Y-M: 20[redacted] / 14	Y-M: 20[redacted] / 147
COAL TAR	1 %	BID	Y-M: 20[redacted] / 22	ONGOING
BETAMETHASONE	0.02 %	BID	Y-M: 20[redacted] / 30	ONGOING

BETAMETHASONE	0.05 %	BID	Y-M: 20[redacted]-[redacted] / 30	ONGOING
CEFALEXIN	500 mg	BID	Y-M: 20[redacted]-[redacted] / 43	Y-M: 20[redacted]-[redacted] / 64
LORATADINE	20 mg	PRN	Y-M: 20[redacted]-[redacted] / 57	ONGOING
MUPIROCIN	2 %	BID	Y-M: 20[redacted]-[redacted] / 57	Y-M: 20[redacted]-[redacted] / 251
FLUCLOXACILLIN	500 mg	QID	Y-M: 20[redacted]-[redacted] / 69	Y-M: 20[redacted]-[redacted] / 73
BETAMETHASONE	UNKNOWN- GIVEN IN HOSPITAL (SAE 30061002007) OTHER: UNKNOWN-GIVEN IN HOSPITAL (SAE 30061002007)	OTHER: UNKNOWN-GIVEN IN HOSPITAL (SAE 30061002007)	Y-M: 20[redacted]-[redacted] / 69	Y-M: 20[redacted]-[redacted] / 75
FLUCLOXACILLIN	250 mg	QID	Y-M: 20[redacted]-[redacted] / 74	Y-M: 20[redacted]-[redacted] / 78
CEFALEXIN	500 mg	BID	Y-M: 20[redacted]-[redacted] / 216	Y-M: 20[redacted]-[redacted] / 220
CEFAZOLIN			Y-M: 20[redacted]-[redacted] / 242	ONGOING
FLUCLOXACILLIN			Y-M: 20[redacted]-[redacted] / 242	ONGOING
CEFTRIAXONE	2 g	OTHER: STAT	Y-M: 20[redacted]-[redacted] / 244	ONGOING
CLINDAMYCIN	600 mg	OTHER: STAT	Y-M: 20[redacted]-[redacted] / 244	ONGOING
VANCOMYCIN	2 g	OTHER: STAT	Y-M: 20[redacted]-[redacted] / 244	ONGOING
MEROPENEM			Y-M: 20[redacted]-[redacted] / 260	ONGOING
CIPROFLOXACIN	750 mg	BID	Y-M: 20[redacted]-[redacted] / 267	ONGOING
CLINDAMYCIN	450 mg	TID	Y-M: 20[redacted]-[redacted] / 267	ONGOING
GABAPENTIN	300 mg	PRN	Y-M: 20[redacted]-[redacted] / 270	ONGOING

OXYCODONE	5 mg	PRN	Y-M: 20[redacted]- / 270	ONGOING
PARACETAMOL	1 g	QID	Y-M: 20[redacted]- / 270	ONGOING

Event #1: Serious Adverse Event

Event Description	HOSPITALISATION DUE TO EXACERBATION OF ATOPIC DERMATITIS
Preferred term	アトピー性皮膚炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 68
Age at AE Onset	1[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	NOT REPORTED
AE Stopped Rx Day	75
Duration of AE	8 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	EXACCERBATION OF PRE-EXISTING SEVERE ATOPIC DERMATITIS
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Event #2: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Event of Interest - Serious Infections

Event Description	MRSA SEPSIS (WITH POSITIVE BLOOD AND URINE CULTURES)
Preferred term	血液培養陽性
AE Onset Date / Rx Day	[redacted]20[redacted] / 242
Age at AE Onset	1[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 242): Alanine Aminotransferase: 25 [NOT REPORTED - NOT REPORTED] U/L; Albumin: 23 [NOT REPORTED - NOT REPORTED] g/L; Alkaline Phosphatase: 123 [NOT REPORTED - NOT REPORTED] U/L; Aspartate Aminotransferase: 41 [NOT REPORTED - NOT REPORTED] U/L; Bicarbonate: 22 [NOT REPORTED - NOT REPORTED] mmol/L; Bilirubin: 10 [NOT REPORTED - NOT REPORTED] umol/L; Calcium: 2.23 [NOT REPORTED - NOT REPORTED] mmol/L; Chloride: 90 [NOT REPORTED - NOT REPORTED] mmol/L; Creatinine: 51 [NOT REPORTED - NOT REPORTED] umol/L; Glucose: 5.9 [NOT REPORTED - NOT REPORTED] mmol/L; Hemoglobin: 85 [NOT REPORTED - NOT REPORTED] g/L; Leukocytes: 5.9 [NOT REPORTED - NOT REPORTED] 10^9/L; NPTST014-C REACTIVE PROTEIN: 314.9 [NOT REPORTED - NOT REPORTED] mg/L; NPTST035-GAMMA GT: 24 [NOT REPORTED - NOT REPORTED] U/L; NPTST059-MAGNESIUM: 1.00 [NOT REPORTED - NOT REPORTED] mmol/L; NPTST071-PHOSPHATE: 1.10 [NOT REPORTED - NOT REPORTED] mmol/L; Platelets: 160 [NOT REPORTED - NOT REPORTED] 10^9/L; Potassium: 2.8 [3.5 - 4.5] MMOL/L; Protein: 67 [NOT REPORTED - NOT REPORTED] g/L; Sodium: 134 [NOT REPORTED - NOT REPORTED] mmol/L; Urate: 6.6 [NOT REPORTED - NOT REPORTED] mmol/L; [redacted]20[redacted] (RX DAY 270): Leukocytes: 7.58 [NOT REPORTED - NOT REPORTED] 10^9/L; Neutrophils: 5.00 [NOT REPORTED - NOT REPORTED] 10^9/L
Microbiology	[redacted]20[redacted] (RX DAY 242): WOUND NPTST026-CULTURE: POSITIVE-STAPHYLOCOCCUS AUREUS ISOLATED; BLOOD NPTST028-CULTURES: POSITIVE-MRSA; URINE NPTST091-

	URINE CULTURE: POSITIVE-MRSA; [redacted]20[redacted] (RX DAY 245): OTHER MCS NPTST055-LEFT HIP MCS: POSITIVE-MRSA
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 237): HEART RATE: 104 BPM; SPO2: 100%; TEMPERATURE (TYMPANIC): 38.1 CELCIUS; [redacted]20[redacted] (RX DAY 243): CHEST XRAY: NORMAL; DRAINAGE OF RIGHT HIP: FRANK PUS FROM JOINT +++. VOLUME UNKNOWN; INSERTION OF PERIPHERALLY INSERTED CENTRAL CATHETER LINE: PROCEDURE WELL TOLERATED.; TEMPERATURE: 39.2 CELSIUS; [redacted]20[redacted] (RX DAY 245): LEFT HIP ASPIRATE AND BILATERAL HIP WASHOUT: LEFT HIP MCS: MRSA; MRI RIGHT HIP: RIGHT HIP JOINT EFFUSION. OSTOMYOLITIC CHANGES IN RIGHT ILIUM AND ACETABULUM, COLLECTION DEEP TO GLUTEUS MINIMUS AND OBTURATOR INTERNUS; [redacted]20[redacted] (RX DAY 246): TRANSTHORACIC ECHOCARDIOGRAM: GRADE 1-2 VIBRATORY END-SYSTOLIC MURMUR AT LOWER LEFT STERNAL EDGE WITH NIL RADIATION. NO EVIDENCE OF INFECTIVE ENDOCARDITIS; [redacted]20[redacted] (RX DAY 257): BONE SCAN: INVOLVEMENT OF RIGHT ELBOW, DISTAL RIGHT RADIUS, RIGHT TARSAL REGION, PREVIOUS AREAS STILL INVOLVED (RIGHT HIP, RIGHT SIJ, DISTAL RIGHT FEMUR, DISTAL LEFT TIBIA); [redacted]20[redacted] (RX DAY 261): WASHOUT RIGHT HIP: MCS: SCANTY GROWTH ESBL; [redacted]20[redacted] (RX DAY 262): TRANSTHORACIC ECHOCARDIOGRAM: NO EVIDENCE OF INFECTIVE ENDOCARDITIS
AE Stopped Rx Day	ONGOING
Duration of AE	ONGOING
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Event #3: AE Leading to Discontinuation of Study Drug

Event Description	SYSTOLIC FLOW MURMUR (RELATED TO SEPSIS)
Preferred term	心雑音
AE Onset Date / Rx Day	[redacted]20[redacted] / 242
Age at AE Onset	1[redacted]
Laboratory Testing	NOT APPLICABLE
Microbiology	NOT APPLICABLE
SAE Supplemental Procedure	NOT APPLICABLE
AE Stopped Rx Day	246 (3 DAYS AFTER LAST TREATMENT)
Duration of AE	5 DAYS
Toxicity Grade	1
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT APPLICABLE
Discontinued Study Drug Due to the Event	YES
SAE Criteria	NONE

Event #4: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Event of Interest - Serious Infections

Event Description	MRSA SEPSIS (WITH POSITIVE BLOOD AND URINE CULTURES)
Preferred term	尿培養陽性
AE Onset Date / Rx Day	[redacted]20[redacted] / 242
Age at AE Onset	1[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 242): Alanine Aminotransferase: 25 [NOT REPORTED - NOT REPORTED] U/L; Albumin: 23 [NOT REPORTED - NOT REPORTED] g/L; Alkaline Phosphatase: 123 [NOT REPORTED - NOT REPORTED] U/L; Aspartate Aminotransferase: 41 [NOT REPORTED - NOT REPORTED] U/L; Bicarbonate: 22 [NOT REPORTED - NOT REPORTED] mmol/L; Bilirubin: 10 [NOT REPORTED - NOT REPORTED] umol/L; Calcium: 2.23 [NOT REPORTED - NOT REPORTED] mmol/L; Chloride: 90 [NOT REPORTED - NOT REPORTED] mmol/L; Creatinine: 51 [NOT REPORTED - NOT REPORTED] umol/L; Glucose: 5.9 [NOT REPORTED - NOT REPORTED] mmol/L; Hemoglobin: 85 [NOT REPORTED - NOT REPORTED] g/L; Leukocytes: 5.9 [NOT REPORTED - NOT REPORTED] 10^9/L; NPTST014-C REACTIVE PROTEIN: 314.9 [NOT REPORTED - NOT REPORTED] mg/L; NPTST035-GAMMA GT: 24 [NOT REPORTED - NOT REPORTED] U/L; NPTST059-MAGNESIUM: 1.00 [NOT REPORTED - NOT REPORTED] mmol/L; NPTST071-PHOSPHATE: 1.10 [NOT REPORTED - NOT REPORTED] mmol/L; Platelets: 160 [NOT REPORTED - NOT REPORTED] 10^9/L; Potassium: 2.8 [3.5 - 4.5] MMOL/L; Protein: 67 [NOT REPORTED - NOT REPORTED] g/L; Sodium: 134 [NOT REPORTED - NOT REPORTED] mmol/L; Urate: 6.6 [NOT REPORTED - NOT REPORTED] mmol/L; [redacted]20[redacted] (RX DAY 270): Leukocytes: 7.58 [NOT REPORTED - NOT REPORTED] 10^9/L; Neutrophils: 5.00 [NOT REPORTED - NOT REPORTED] 10^9/L
Microbiology	[redacted]20[redacted] (RX DAY 242): WOUND NPTST026-CULTURE: POSITIVE-STAPHYLOCOCCUS AUREUS ISOLATED; BLOOD NPTST028-CULTURES: POSITIVE-MRSA; URINE NPTST091-URINE CULTURE: POSITIVE-MRSA; [redacted]20[redacted] (RX DAY 245): OTHER MCS NPTST055-LEFT HIP MCS: POSITIVE-MRSA
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 237): HEART RATE: 104 BPM; SPO2: 100%; TEMPERATURE (TYMPANIC): 38.1 CELCIUS; [redacted]20[redacted] (RX DAY 243): CHEST XRAY: NORMAL; DRAINAGE OF RIGHT HIP: FRANK PUS FROM JOINT +++. VOLUME UNKNOWN; INSERTION OF PERIPHERALLY INSERTED CENTRAL CATHETER LINE: PROCEDURE WELL TOLERATED.; TEMPERATURE: 39.2 CELSIUS; [redacted]20[redacted] (RX DAY 245): LEFT HIP ASPIRATE AND BILATERAL HIP WASHOUT: LEFT HIP MCS: MRSA; MRI RIGHT HIP: RIGHT HIP JOINT EFFUSION. OSTOMYOLITIC CHANGES IN RIGHT ILIUM AND ACETABULUM, COLLECTION DEEP TO GLUTEUS MINIMUS AND OBTURATOR INTERNUS; [redacted]20[redacted] (RX DAY 246): TRANSTHORACIC ECHOCARDIOGRAM: GRADE 1-2 VIBRATORY END-SYSTOLIC MURMUR AT LOWER LEFT STERNAL EDGE WITH NIL RADIATION. NO EVIDENCE OF INFECTIVE ENDOCARDITIS; [redacted]20[redacted] (RX DAY 257): BONE SCAN: INVOLVEMENT OF RIGHT ELBOW, DISTAL RIGHT RADIUS, RIGHT TARSAL REGION, PREVIOUS AREAS STILL INVOLVED (RIGHT HIP, RIGHT SIJ, DISTAL RIGHT FEMUR, DISTAL LEFT TIBIA); [redacted]20[redacted] (RX DAY 261): WASHOUT RIGHT HIP: MCS: SCANTY GROWTH ESBL; [redacted]20[redacted] (RX DAY 262): TRANSTHORACIC ECHOCARDIOGRAM: NO EVIDENCE OF INFECTIVE ENDOCARDITIS
AE Stopped Rx Day	ONGOING
Duration of AE	ONGOING
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED

Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Event #5: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Event of Interest - Serious Infections

Event Description	MULTIFOCAL OSTEOMYELITIS
Preferred term	骨髄炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 242
Age at AE Onset	1[redacted]
Laboratory Testing	[redacted]20[redacted](RX DAY 242): Alanine Aminotransferase: 25 [NOT REPORTED - NOT REPORTED] U/L; Albumin: 23 [NOT REPORTED - NOT REPORTED] g/L; Alkaline Phosphatase: 123 [NOT REPORTED - NOT REPORTED] U/L; Aspartate Aminotransferase: 41 [NOT REPORTED - NOT REPORTED] U/L; Bicarbonate: 22 [NOT REPORTED - NOT REPORTED] mmol/L; Bilirubin: 10 [NOT REPORTED - NOT REPORTED] umol/L; Calcium: 2.23 [NOT REPORTED - NOT REPORTED] mmol/L; Chloride: 90 [NOT REPORTED - NOT REPORTED] mmol/L; Creatinine: 51 [NOT REPORTED - NOT REPORTED] umol/L; Glucose: 5.9 [NOT REPORTED - NOT REPORTED] mmol/L; Hemoglobin: 85 [NOT REPORTED - NOT REPORTED] g/L; Leukocytes: 5.9 [NOT REPORTED - NOT REPORTED] 10^9/L; NPTST014-C REACTIVE PROTEIN: 314.9 [NOT REPORTED - NOT REPORTED] mg/L; NPTST035-GAMMA GT: 24 [NOT REPORTED - NOT REPORTED] U/L; NPTST059-MAGNESIUM: 1.00 [NOT REPORTED - NOT REPORTED] mmol/L; NPTST071-PHOSPHATE: 1.10 [NOT REPORTED - NOT REPORTED] mmol/L; Platelets: 160 [NOT REPORTED - NOT REPORTED] 10^9/L; Potassium: 2.8 [3.5 - 4.5] MMOL/L; Protein: 67 [NOT REPORTED - NOT REPORTED] g/L; Sodium: 134 [NOT REPORTED - NOT REPORTED] mmol/L; Urate: 6.6 [NOT REPORTED - NOT REPORTED] mmol/L; [redacted]20[redacted] (RX DAY 270): Leukocytes: 7.58 [NOT REPORTED - NOT REPORTED] 10^9/L; Neutrophils: 5.00 [NOT REPORTED - NOT REPORTED] 10^9/L
Microbiology	[redacted]20[redacted] (RX DAY 242): WOUND NPTST026-CULTURE: POSITIVE-STAPHYLOCOCCUS AUREUS ISOLATED; BLOOD NPTST028-CULTURES: POSITIVE-MRSA; URINE NPTST091-URINE CULTURE: POSITIVE-MRSA; [redacted]20[redacted] (RX DAY 245): OTHER MCS NPTST055-LEFT HIP MCS: POSITIVE-MRSA
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 237): HEART RATE: 104 BPM; SPO2: 100%; TEMPERATURE (TYMPANIC): 38.1 CELCIUS; [redacted]20[redacted] (RX DAY 243): CHEST XRAY: NORMAL; DRAINAGE OF RIGHT HIP: FRANK PUS FROM JOINT +++. VOLUME UNKNOWN; INSERTION OF PERIPHERALLY INSERTED CENTRAL CATHETER LINE: PROCEDURE WELL TOLERATED.; TEMPERATURE: 39.2 CELSIUS; [redacted]20[redacted] (RX DAY 245): LEFT HIP ASPIRATE AND BILATERAL HIP WASHOUT: LEFT HIP MCS: MRSA; MRI RIGHT HIP: RIGHT HIP JOINT EFFUSION. OSTOMYOLITIC CHANGES IN RIGHT ILIUM AND ACETABULUM, COLLECTION DEEP TO GLUTEUS MINIMUS AND OBTURATOR INTERNUS; [redacted]20[redacted] (RX DAY 246): TRANSTHORACIC ECHOCARDIOGRAM: GRADE 1-2 VIBRATORY END-SYSTOLIC MURMUR AT LOWER LEFT STERNAL EDGE WITH NIL RADIATION. NO EVIDENCE OF INFECTIVE ENDOCARDITIS; [redacted]20[redacted] (RX DAY 257): BONE SCAN: INVOLVEMENT OF RIGHT ELBOW, DISTAL RIGHT RADIUS, RIGHT TARSAL REGION, PREVIOUS AREAS STILL INVOLVED (RIGHT HIP, RIGHT SIJ, DISTAL RIGHT FEMUR, DISTAL LEFT TIBIA); [redacted]20[redacted] (RX DAY 261): WASHOUT RIGHT HIP: MCS: SCANTY GROWTH ESBL; [redacted]20[redacted] (RX DAY 262): TRANSTHORACIC ECHOCARDIOGRAM: NO EVIDENCE OF INFECTIVE ENDOCARDITIS
AE Stopped Rx Day	ONGOING
Duration of AE	ONGOING
Toxicity Grade	3

Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	IMPACT INJURY TO RIGHT HIP FOLLOWING A FALL
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Event #6: AE Leading to Discontinuation of Study Drug

Event Description	SYSTOLIC FLOW MURMUR (RELATED TO SEPSIS)
Preferred term	敗血症
AE Onset Date / Rx Day	[redacted]20[redacted] / 242
Age at AE Onset	1[redacted]
Laboratory Testing	NOT APPLICABLE
Microbiology	NOT APPLICABLE
SAE Supplemental Procedure	NOT APPLICABLE
AE Stopped Rx Day	246 (3 DAYS AFTER LAST TREATMENT)
Duration of AE	5 DAYS
Toxicity Grade	1
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT APPLICABLE
Discontinued Study Drug Due to the Event	YES
SAE Criteria	NONE

Event #7: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Event of Interest - Serious Infections

Event Description	MRSA SEPSIS (WITH POSITIVE BLOOD AND URINE CULTURES)
Preferred term	ブドウ球菌性敗血症
AE Onset Date / Rx Day	[redacted]20[redacted] / 242
Age at AE Onset	1[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 242): Alanine Aminotransferase: 25 [NOT REPORTED - NOT REPORTED] U/L; Albumin: 23 [NOT REPORTED - NOT REPORTED] g/L; Alkaline Phosphatase: 123 [NOT REPORTED - NOT REPORTED] U/L; Aspartate Aminotransferase: 41 [NOT REPORTED - NOT REPORTED] U/L; Bicarbonate: 22 [NOT REPORTED - NOT REPORTED] mmol/L; Bilirubin: 10 [NOT REPORTED - NOT REPORTED] umol/L; Calcium: 2.23 [NOT REPORTED - NOT REPORTED] mmol/L; Chloride: 90 [NOT REPORTED - NOT REPORTED] mmol/L; Creatinine: 51 [NOT REPORTED - NOT REPORTED] umol/L; Glucose: 5.9 [NOT REPORTED - NOT REPORTED] mmol/L; Hemoglobin: 85 [NOT REPORTED - NOT REPORTED] g/L; Leukocytes: 5.9 [NOT REPORTED - NOT REPORTED] 10^9/L; NPTST014-C REACTIVE PROTEIN: 314.9 [NOT REPORTED - NOT REPORTED] mg/L; NPTST035-GAMMA GT: 24 [NOT REPORTED - NOT REPORTED] U/L; NPTST059-MAGNESIUM: 1.00 [NOT REPORTED - NOT REPORTED] mmol/L; NPTST071-PHOSPHATE: 1.10 [NOT REPORTED - NOT REPORTED] mmol/L; Platelets: 160 [NOT REPORTED - NOT REPORTED] 10^9/L; Potassium: 2.8 [3.5 - 4.5] MMOL/L; Protein: 67 [NOT REPORTED - NOT REPORTED] g/L; Sodium: 134 [NOT REPORTED - NOT REPORTED] mmol/L; Urate: 6.6 [NOT REPORTED - NOT REPORTED] mmol/L; [redacted]20[redacted] (RX DAY 270): Leukocytes:

	7.58 [NOT REPORTED - NOT REPORTED] 10^9/L; Neutrophils: 5.00 [NOT REPORTED - NOT REPORTED] 10^9/L
Microbiology	[redacted]20[redacted] (RX DAY 242): WOUND NPTST026-CULTURE: POSITIVE-STAPHYLOCOCCUS AUREUS ISOLATED; BLOOD NPTST028-CULTURES: POSITIVE-MRSA; URINE NPTST091-URINE CULTURE: POSITIVE-MRSA; [redacted]20[redacted] (RX DAY 245): OTHER MCS NPTST055-LEFT HIP MCS: POSITIVE-MRSA
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 237): HEART RATE: 104 BPM; SPO2: 100%; TEMPERATURE (TYMPANIC): 38.1 CELCIUS; [redacted]20[redacted] (RX DAY 243): CHEST XRAY: NORMAL; DRAINAGE OF RIGHT HIP: FRANK PUS FROM JOINT +++. VOLUME UNKNOWN; INSERTION OF PERIPHERALLY INSERTED CENTRAL CATHETER LINE: PROCEDURE WELL TOLERATED.; TEMPERATURE: 39.2 CELSIUS; [redacted]20[redacted] (RX DAY 245): LEFT HIP ASPIRATE AND BILATERAL HIP WASHOUT: LEFT HIP MCS: MRSA; MRI RIGHT HIP: RIGHT HIP JOINT EFFUSION. OSTOMYOLITIC CHANGES IN RIGHT ILIUM AND ACETABULUM, COLLECTION DEEP TO GLUTEUS MINIMUS AND OBTURATOR INTERNUS; [redacted]20[redacted] (RX DAY 246): TRANSTHORACIC ECHOCARDIOGRAM: GRADE 1-2 VIBRATORY END-SYSTOLIC MURMUR AT LOWER LEFT STERNAL EDGE WITH NIL RADIATION. NO EVIDENCE OF INFECTIVE ENDOCARDITIS; [redacted]20[redacted] (RX DAY 257): BONE SCAN: INVOLVEMENT OF RIGHT ELBOW, DISTAL RIGHT RADIUS, RIGHT TARSAL REGION, PREVIOUS AREAS STILL INVOLVED (RIGHT HIP, RIGHT SIJ, DISTAL RIGHT FEMUR, DISTAL LEFT TIBIA); [redacted]20[redacted] (RX DAY 261): WASHOUT RIGHT HIP: MCS: SCANTY GROWTH ESBL; [redacted]20[redacted] (RX DAY 262): TRANSTHORACIC ECHOCARDIOGRAM: NO EVIDENCE OF INFECTIVE ENDOCARDITIS
AE Stopped Rx Day	ONGOING
Duration of AE	ONGOING
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Generated [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者はオーストラリアの1[redacted]歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，入院に至るアトピー性皮膚炎増悪を発現した。被験者は非喫煙者かつ非飲酒者であり，関連する病歴はアトピー性皮膚炎，自閉症スペクトラム症（アスペルガー障害），アレルギー性鼻炎及び喘息であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院に至るアトピー性皮膚炎増悪を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，入院に至るアトピー性皮膚炎増悪は消失した。

入院前の関連情報として，被験者は本試験に組み入れられる際，治験実施計画書に従い前治療薬をウォッシュアウトした。被験者の湿疹（アトピー性皮膚炎増悪［非重篤］）はすぐに悪化し始め，11 週間悪化が続き，入院を要するまでに感染性湿疹（非重篤）を 3 回発現した。20[redacted] 年 [redacted] 月，副腎皮質ホルモンの外用薬が投与再開された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者はほぼ全身に及ぶ湿疹のフレア（アトピー性皮膚炎）を理由に入院した。滲出性病変であり，登校などの活動が障害されていた。その他の症状として，そう痒の増強，疼痛及び頭部ふらふら感があった。不快感及び感染リスクがあったため，ウェットドレッシング療法を毎日行えるよう，治験責任医師は入院を勧めた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

flucloxacillin，スルファメトキサゾール・トリメトプリム，及び DIPROSONE CREAM が投与された。

The patient's past medications include:

AZATHIOPRINE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

CYCLOSPORIN for ATOPIC DERMATITIS (20[redacted] - [redacted])

MYCOPHENOLATE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

TACROLIMUS for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

CEPHALEXIN for INFECTED ECZEMA ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Dermatitis atopic aggravated (10012439) (Dermatitis atopic (10012438)) [v.22.1] [10012439]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of HOSPITALIZATION DUE TO EXACERBATION OF ATOPIC DERMATITIS

- Investigator: EXACCERBATION OF PRE-EXISTING SEVERE ATOPIC DERMATITIS

- AbbVie: Event is more likely related to pre-existing atopic dermatitis.

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者はオーストラリアの 1[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，メチシリン耐性黄色ブドウ球菌性敗血症（以下「MRSA 敗血症」）（血液培養及び尿培養で陽性）及び多発性骨髄炎を発現した。被験者は非喫煙者かつ非飲酒者であり，関連する病歴はアトピー性皮膚炎，自閉症スペクトラム症（アスペルガー障害），アレルギー性鼻炎及び喘息であった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は MRSA 敗血症（血液培養及び尿培養で陽性）及び多発性骨髄炎を発現した。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加し，20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は階段から転落して右股関節部を激しく打ち付けた。被験者は数日間，股関節部に疼痛を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は擦過傷を伴う右股関節部の疼痛及び腫脹が増強していることを自覚し，化膿した右股関節のドレナージを受けるため入院となった。関節から膿を除去した（量は不明）。その後，主診断名は MRSA 敗血症及び化膿性関節炎とつけられた。右足の遠位趾節間関節及び近位趾節間関節にも腫脹が認められた。血液培養検査の結果はメチシリン耐性黄色ブドウ球菌（以下「MRSA」）陽性であり，尿検査所見はブドウ球菌陽性，血尿，蛋白尿，ケトン体陽性であった。心雑音が新規に確認され，被験者は厳密な体液バランス管理下におかれた。20[redacted] 年 [redacted] 月 [redacted] 日，末梢留置型中心静脈注射用カテーテルが挿入され，処置の忍容性は良好であった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左股関節の穿刺及び両股関節部の洗浄を受けた。左股関節は MRSA 陽性であった。20[redacted] 年 [redacted] 月 [redacted] 日，右股関節に基質拡張型 β-ラクタマーゼ産生菌のわずかな増殖が確認され，右股関節部は再度洗浄された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

被験者は本試験を中止した。

vancomycin，ceftriaxone，clindamycin，シプロフロキサシン，meropenem，oxycodone，ガバペンチン，paracetamol，CEPHAZOLIN 及び flucloxacillin が投与された。

The patient's past medications include:

AZATHIOPRINE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

CYCLOSPORIN for ATOPIC DERMATITIS (20[redacted] - [redacted] 20[redacted])

MYCOPHENOLATE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

TACROLIMUS for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

TEMAZEPAM for ITCH DUE TO ATOPIC DERMATITIS and ITCH DUE TO ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

VALLERGAN for ITCHING DUE TO ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Methicillin-resistant Staphylococcus aureus sepsis (10058867) (Staphylococcal sepsis (10056430)) [v.22.1] [10058867]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: No

2) Urine culture positive (10046624) (Culture urine positive (10011640)) [v.22.1] [10046624]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: No

3) Blood culture positive (10005488) (Blood culture positive (10005488)) [v.22.1] [10005488]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: No

4) Osteomyelitis (10031252) (Osteomyelitis (10031252)) [v.22.1] [10031252]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: No

Alternative Etiology for UPADACITINIB (Blinded)

Event of MRSA SEPSIS (WITH POSITIVE BLOOD AND URINE CULTURES)

- Investigator: Not Applicable

- AbbVie: Not Applicable

Event of MULTIFOCAL OSTEOMYELITIS

- Investigator: Impact injury to right hip following a fall.

- AbbVie: Not Applicable

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ALANINE AMINO TRANSFERASE:** 25 U/L

[redacted] **20[redacted] ALBUMIN:** 23 G/L

[redacted] **20[redacted] ALKALINE PHOSPHATASE:** 123 U/L

[redacted] **20[redacted] ASPARTATE AMINO TRANSFERASE:** 41 U/L

[redacted] **20[redacted] BICARBONATE:** 22 MMOL/L

[redacted] **20[redacted] BILIRUBIN:** 10 MCMOL/L

[redacted] **20[redacted] BLOOD CULTURES:** Positive for MRSA.

[redacted] **20[redacted] BONE SCAN:** INVOLVEMENT OF RIGHT ELBOW, DISTAL RIGHT RADIUS, RIGHT TARSAL REGION, PREVIOUS AREAS STILL INVOLVED (RIGHT HIP, RIGHT SIJ, DISTAL RIGHT FEMUR, DISTAL LEFT TIBIA)

[redacted] **20[redacted] CALCIUM:** 2.23 MMOL/L

[redacted] **20[redacted] CHEST X-RAY:** Normal

[redacted] **20[redacted] CHLORIDE:** 90 MMOL/L

[redacted] **20[redacted] CREATININE:** 51 umol/L

[redacted] **20[redacted] CRP:** 314.9 MG/L

[redacted] **20[redacted] GAMMA GT:** 24 U/L

[redacted] **20[redacted] GLUCOSE:** 5.9 MMOL/L

[redacted] **20[redacted] HEMOGLOBIN:** 85 G/L

[redacted] **20[redacted] MAGNESIUM:** 1.00 MMOL/L

[redacted] **20[redacted] MRI RIGHT HIP:** RIGHT HIP JOINT EFFUSION. OSTOMYOLITIC CHANGES IN RIGHT ILIUM AND ACETABULUM, COLLECTION DEEP TO GLUTEUS MINIMUS AND OBTURATOR INTERNUS

[redacted] **20[redacted] PHOSPHATE:** 1.10 MMOL/L

[redacted] **20[redacted] PLATELET COUNT:** 160 X10**9/L

[redacted] **20[redacted] POTASSIUM:** 2.8 MMOL/L

[redacted] **20[redacted] PROTEIN:** 67 G/L

[redacted] **20[redacted] SODIUM:** 134 MMOL/L

[redacted] **20[redacted] TRANSTHORACIC ECHOCARDIOGRAM:** GRADE 1-2 VIBRATORY END-SYSTOLIC MURMUR AT LOWER LEFT STERNAL EDGE WITH NIL RADIATION. NO EVIDENCE OF INFECTIVE ENDOCARDITIS

[redacted] **20[redacted] TRANSTHORACIC ECHOCARDIOGRAM:** NO EVIDENCE OF INFECTIVE ENDOCARDITIS

[redacted] **20[redacted] URIC ACID:** 6.6 MMOL/L

[redacted] **20[redacted] URINE CULTURE:** Positive for MRSA

[redacted] **20[redacted] URINE TEST:** Hematuria, proteinuria and ketones.

[redacted] **20[redacted] WHITE BLOOD CELLS:** 5.9 X10**9/L

[redacted] **20[redacted] WOUND CULTURE:** Positive: staphylococcus aureus isolated

Subject [redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
咽頭膿瘍	X	X		X

Treatment Group	Age at Study Start	Sex	Race
UPA 30 MG QD	3[redacted]	FEMALE	ASIAN

Medical History	Onset Year
RETINITIS PIGMENTOSA	19[redacted]
ALLERGIC RHINITIS	19[redacted]
ATOPIC DERMATITIS	19[redacted]
ASTHMA	19[redacted]
GESTATIONAL HYPOTHYROIDISM	20[redacted]
RECURRENT TORTICOLLIS	20[redacted]
REPETITIVE TONSILLITIS	20[redacted]
NEURALGIA LEFT ARM SECONDARY TO VERTEBRAL COLLAPSE	20[redacted]
VERTEBRAL COLLAPSE	20[redacted]
DEPRESSION	20[redacted]
ACNE	20[redacted]
ATOPIC DERMATITIS	20[redacted]
LATENTE TUBERCULOSIS	20[redacted]
LOW BACK PAIN	20[redacted]
LUMBAR SPRAIN	20[redacted]
ALLERGIC RHINITIS	NOT REPORTED
ASTHMA	NOT REPORTED
LATENT TUBERCULOSIS	NOT REPORTED

Prior Procedures	Procedure Year
PRIOR PROCEDURES: RETINAL IMPLANT	20[redacted]
PRIOR PROCEDURES: TONSILLECTOMY	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	0.14 CIGARETTE	0.2	20[redacted]
CIGARS	FORMER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 30	30

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y: 20[redacted]
SERETIDE	1 OTHER: INHALATION	BID	Y: 20[redacted]
LEVONORGESTREL	1 OTHER: DEVICE	OTHER: CONTINUOUS	Y-M: 20[redacted]-[redacted]
CORTICOSTEROIDS	1 OTHER: APPLICATION	PRN	Y: 20[redacted]
HYDROCORTISONE	1 OTHER: APPLICATION	PRN	Y: 20[redacted]
VENLAFAXINE	150 mg	QD	Y-M: 20[redacted]-[redacted]
CYCLOBENZAPRINE	10 mg	PRN	Y: 20[redacted]
CETIRIZINE	10 mg	QD	Y-M: 20[redacted]-[redacted]
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	QD	Y: 20[redacted]
MONTELUKAST	10 mg	QD	Y-M: 20[redacted]-[redacted]
SHAMPOOS	1 OTHER: APPLICATION	OTHER: ONCE	Y-M: 20[redacted]-[redacted] / -222
HYDROXYZINE	25 mg	QD	Y-M: 20[redacted]-[redacted] / -102
ESOMEPRAZOLE W/NAPROXEN	1 OTHER: TABLET	QD	Y-M: 20[redacted]-[redacted] / -71
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]-[redacted] / -34
ISONIAZID	300 mg	QD	Y-M: 20[redacted]-[redacted] / -26
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	OTHER: ONCE	Y-M: 20[redacted]-[redacted] / -1

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
SERETIDE	1 OTHER: INHALATION	BID	Y: 20[redacted]	ONGOING
LEVONORGESTREL	1 OTHER: DEVICE	OTHER: CONTINUOUS	Y-M: 20[redacted]-[redacted]	ONGOING
VENLAFAXINE	150 mg	QD	Y-M: 20[redacted]-[redacted]	ONGOING
CYCLOBENZAPRINE	10 mg	PRN	Y: 20[redacted]	ONGOING
CETIRIZINE	10 mg	QD	Y-M: 20[redacted]-[redacted]	ONGOING
MONTELUKAST	10 mg	QD	Y-M: 20[redacted]-[redacted]	Y-M: 20[redacted]-[redacted] / 31
HYDROXYZINE	25 mg	QD	Y-M: 20[redacted]-[redacted] / -102	ONGOING
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]-[redacted] / -34	ONGOING
ISONIAZID	300 mg	QD	Y-M: 20[redacted]-[redacted] / -26	ONGOING

EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	OTHER: ONCE	Y-M: 20[redacted] / -1	Y-M: 20[redacted] / -1
PARACETAMOL	2 OTHER: TABLET	TID	Y-M: 20[redacted] / 12	Y-M: 20[redacted] / 12
CLINDAMYCIN	450 mg	QID	Y-M: 20[redacted] / 29	Y-M: 20[redacted] / 30
DEXAMETHASONE	10 mg	OTHER: ONCE	Y-M: 20[redacted] / 30	Y-M: 20[redacted] / 30
DEXAMETHASONE	4 mg	TID	Y-M: 20[redacted] / 30	Y-M: 20[redacted] / 31
PIP/TAZO	UNK OTHER: UNK	OTHER: UNK	Y-M: 20[redacted] / 30	Y-M: 20[redacted] / 37
SERETIDE	1 OTHER: INHALATION	BID	Y-M: 20[redacted] / 32	ONGOING
PROPOFOL	20 OTHER: CC	OTHER: PER HOUR	Y-M: 20[redacted] / 33	Y-M: 20[redacted] / 35
FENTANYL	150 ug	OTHER: HOUR	Y-M: 20[redacted] / 33	Y-M: 20[redacted] / 36
DEXAMETHASONE	4 mg	TID	Y-M: 20[redacted] / 33	Y-M: 20[redacted] / 39
DALTEPARIN	5000 OTHER: UNIT	QD	Y-M: 20[redacted] / 34	Y-M: 20[redacted] / 46
PROPOFOL	22 OTHER: CC	OTHER: PER HOUR	Y-M: 20[redacted] / 35	Y-M: 20[redacted] / 36
FENTANYL	50 ug	OTHER: HOUR	Y-M: 20[redacted] / 36	Y-M: 20[redacted] / 37
PROPOFOL	30 OTHER: CC	OTHER: HOUR	Y-M: 20[redacted] / 36	Y-M: 20[redacted] / 37
BENZYLPENICILLIN	4 OTHER: M UNIT	OTHER: EVERY 4 HOURS	Y-M: 20[redacted] / 37	Y-M: 20[redacted] / 51
CLINDAMYCIN	900 mg	TID	Y-M: 20[redacted] / 37	Y-M: 20[redacted] / 51
MONTELUKAST	10 mg	QD	Y-M: 20[redacted] / 38	ONGOING
NAPROXEN	500 mg	BID	Y-M: 20[redacted] / 38	ONGOING
PANTOPRAZOLE	40 mg	QD	Y-M: 20[redacted] / 39	ONGOING
CLINDAMYCIN	UNK OTHER: UNK	OTHER: UNK	Y-M: 20[redacted] / 51	ONGOING

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Event of Interest - Serious Infections

Event Description	RETROPHARYNGEAL ABSCESS
Preferred term	咽頭膿瘍
AE Onset Date / Rx Day	[redacted]20[redacted] / 27
Age at AE Onset	3[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	[redacted]20[redacted] (RX DAY 29): OTHER THROAT CULTURE NPTST085-THROAT CULTURE: POSITIVE-STREPTOCOCCUS GROUP A

SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 30): CT-SCAN: 6 CM X 1.3 CM ABSCESS; [redacted]20[redacted] (RX DAY 31): ABSCESS DRAINED: DRAINED FAILED; [redacted]20[redacted] (RX DAY 33): ABSCESS DRAINED UNDER GENERAL ANESTHESIA: DRAINED FAILED; CT-SCAN: 30 MM X 22 MM X 14 MM ABSCESS WITH CONTACT WITH THE LEFT CAROTID ARTERY WHOSE CALIBER IS DECREASED; TRACHEAL INTUBATION: [redacted] 20[redacted] TO [redacted] 20[redacted]; [redacted]20[redacted] (RX DAY 35): CT-SCAN: 26MM X 13MM X 9MM ABSCESS; [redacted]20[redacted] (RX DAY 37): CT-SCAN: RESULT PENDING; [redacted]20[redacted] (RX DAY 41): CT-SCAN: 21MM X 14MM X 9MM ABSCESS; [redacted]20[redacted] (RX DAY 45): CT-SCAN: 17MM X 12MM X 4MM ABSCESS
AE Stopped Rx Day	64 (34 DAYS AFTER LAST TREATMENT)
Duration of AE	38 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者はカナダの 3[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，咽後膿瘍を発現した。被験者は元喫煙者（紙巻タバコ 0.14 本／日，0.2 年間），元葉巻喫煙者かつ飲酒者（2 杯未満／日）であり，関連する病歴はアレルギー性鼻炎，喘息，再発性扁桃炎，うつ病及びアトピー性皮膚炎であった。扁桃摘出による治療歴があった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は咽後膿瘍を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，咽後膿瘍は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者には微熱及び左顎の疼痛があった。被験者は抗生物質を投与され，耳鼻咽喉科に紹介された。耳鼻咽喉科を受診後，2[redacted]9 年 [redacted] 月 [redacted] 日，被験者は咽後膿瘍を理由に入院した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は抗生物質に反応せず，膿瘍ドレナージを受けたが改善が得られなかった。皮下組織の浮腫が始まり，被験者は集中治療室に入室した。同時期の 20[redacted] 年 [redacted] 月 [redacted] 日～20[redacted] 年 [redacted] 月 [redacted] 日，被験者は気管挿管を受けた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は抗生物質の処方を受け，退院した。

治験責任医師は，リスク因子として A 群レンサ球菌に繰り返し感染していたことを挙げた。

PENICILLIN G，clindamycin，DECADRON，TAZOCIN 及び ADVAIR が投与された。

Causality for UPADACITINIB (Blinded)

---

1) Retropharyngeal abscess (10038984) (Pharyngeal abscess (10067781)) [v.22.0] [10038984]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of RETROPHARYNGEAL ABSCESS

- Investigator: Not applicable

- AbbVie: Risk factor includes past history of tonsillectomy which has a hazard ratio of 1.87 in adolescents and adults. Pre-existing history of repetitive tonsillitis is an additional risk factor.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] CT SCAN:** 6cm x 1.3 cm abscess

[redacted] **20[redacted] CT SCAN:** 30mm x 22 mm x 14 abscess with contact with the left carotid artery where caliber is decreased

[redacted] **20[redacted] CT SCAN:** 26MM X 13MM X 9MM ABSCESS

[redacted] **20[redacted] CT SCAN:** 21MM X 14MM X 9MM ABSCESS

[redacted] **20[redacted] CT SCAN:** 17MM X 12MM X 4MM ABSCESS

[redacted] **20[redacted] THROAT CULTURE:** Positive, Group A streptococcus

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
腎盂腎炎	X			X

Treatment Group	Age at Study Start	Sex	Race
PLACEBO/UPA 30 MG QD	1[redacted]	FEMALE	ASIAN

Medical History	Onset Year
ATOPIC DERMATITIS	20[redacted]
DISLOCATED RIGHT ARM	20[redacted]
MILD SITUATIONAL DEPRESSION	20[redacted]
ACNE VULGARIS	20[redacted]
SEASONAL ALLERGIES	20[redacted]
TENSION HEADACHE	20[redacted]
UPPER RESPIRATORY TRACT INFECTION	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 112	112
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 113		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
HERPES ZOSTER IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y: 20[redacted]
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y: 20[redacted]
PETROLATUM	1 OTHER: APPLICATION	BID	Y: 20[redacted]
BETAMETHASONE	1 OTHER: APPLICATION	BID	Y: 20[redacted]
TACROLIMUS	1 OTHER: APPLICATION	PRN	Y: 20[redacted]
HYDROCORTISONE	1 OTHER: APPLICATION	QD	Y-M: 20[redacted]
PARACETAMOL	1000 mg	PRN	Y: 20[redacted]
PARACETAMOL	1 OTHER: TABLET	PRN	Y-M: 20[redacted] / -17

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
PARACETAMOL	1000 mg	PRN	Y: 20[redacted]	NOT REPORTED
CETAPHIL	1 OTHER: APPLICATION	PRN	Y-M: 20[redacted] / 70	NOT REPORTED
PARACETAMOL	500 mg	PRN	Y-M: 20[redacted] / 164	Y-M: 20[redacted] / 166
CEFTRIAXONE	2 g	QD	Y-M: 20[redacted] / 177	Y-M: 20[redacted] / 177
CEFTRIAXONE	2 g	OTHER: Q8H	Y-M: 20[redacted] / 178	Y-M: 20[redacted] / 180
PARACETAMOL	1000 mg	PRN	Y-M: 20[redacted] / 179	Y-M: 20[redacted] / 180
CEFTRIAXONE	2 g	QD	Y-M: 20[redacted] / 181	Y-M: 20[redacted] / 191

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	PYELONEPHRITIS
Preferred term	腎盂腎炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 176
Age at AE Onset	1[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 177): Leukocytes: 9.2 [3.9 - 10.2] 10^9/L; Lymphocytes: 0.5 [1 - 3.6] 10^9/L; Neutrophils: 8.4 [1.8 - 6.8] 10^9/L; [redacted]20[redacted] (RX DAY 178): Blood: GRAM (-) E COLI [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 181): ABDOMINAL ULTRASOUND: NORMAL
AE Stopped Rx Day	181
Duration of AE	6 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY

Investigator Alternative Etiology NOT REPORTED
Discontinued Study Drug Due to the Event NO
SAE Criteria REQUIRES OR PROLONGS HOSPITALIZATION

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者はカナダの 1[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，腎盂腎炎を発現した。被験者は非喫煙者かつ非飲酒者であり，関連する病歴はアトピー性皮膚炎であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は腎盂腎炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，腎盂腎炎は消失した。

本事象発現に先行して，被験者は 20[redacted] 年 [redacted] 月に尿路感染（非重篤）を発現し，20[redacted] 年 [redacted] 月に発熱（非重篤）を自覚した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は側腹部痛及び発熱を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は症状悪化を理由に救急治療室を受診した。被験者は抗生物質の単回投与及び血液検査を受けた後，帰宅した。20[redacted] 年 [redacted] 月 [redacted] 日，臨床検査の結果から腎盂腎炎と診断された。同日，被験者は入院し，抗生物質が静脈内投与された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

TYLENOL ES 及び ceftriaxone が投与された。

Causality for UPADACITINIB (Blinded)

---

1) Pyelonephritis (10037596) (Pyelonephritis (10037596)) [v.22.1] [10037596]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of PYELONEPHRITIS

- Investigator: Not applicable

- AbbVie: Not applicable

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ABDOMINAL ULTRASOUND:** Normal

[redacted] **20[redacted] ABSOLUTE LYMPHOCYTES:** 0.5 X10**9/L (normal 1.0 to 3.6)

[redacted] **20[redacted] ABSOLUTE NEUTROPHILS:** 8.4 X10**9/L (normal 1.8 to 6.8)

[redacted] **20[redacted] BLOOD TEST:** Gram (-) E. Coli

[redacted] **20[redacted] LABORATORY TESTS:** Pyelonephritis

[redacted] **20[redacted] WBC:** 9.5 X10**9/L (normal 3.9 to 10.2)

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
肺炎	X			X
脂肪肝				X

Treatment Group	Age at Study Start	Sex	Race
UPA 30 MG QD/UPA 30 MG QD	3[redacted]	MALE	ASIAN

Medical History	Onset Year
ASTHMA	19[redacted]
ATOPIC DERMATITIS	20[redacted]
ATOPIC DERMATITIS	20[redacted]
HEPATIC HEMANGIOMA	20[redacted]
LATENT TB	20[redacted]
ASTHMA	NOT REPORTED
LATENT TUBERCULOSIS	NOT REPORTED

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 114	114
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 115		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
CAMPHOR	APPROPRIATE OTHER: NA	TID	Y-M: 20[redacted]-[redacted] / -59

CEFTRIAXONE	3 g	QD	Y-M: 20[redacted] / -59
DEXAMETHASONE	APPROPRIATE OTHER: NA	BID	Y-M: 20[redacted] / -59
EBASTINE	10 mg	QD	Y-M: 20[redacted] / -59
GLYCYRRHIZA GLABRA	80 mg	QD	Y-M: 20[redacted] / -59
LORATADINE	10 mg	QD	Y-M: 20[redacted] / -59
OLOPATADINE	5 mg	OTHER: QN	Y-M: 20[redacted] / -59
PINUS SYLVESTRIS	APPROPRIATE OTHER: NA	OTHER: INTERMITTENT	Y-M: 20[redacted] / -59
TACROLIMUS	APPROPRIATE OTHER: NA	OTHER: QN	Y-M: 20[redacted] / -59
TOPSYNE NEOMYCINE	APPROPRIATE OTHER: NA	QD	Y-M: 20[redacted] / -59
EMOLLIENTS AND PROTECTIVES	APPROPRIATE OTHER: NA	BID	Y-M: 20[redacted] / -27
ISONIAZID	0.2 g	QD	Y-M: 20[redacted] / -15

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
EMOLLIENTS AND PROTECTIVES	APPROPRIATE OTHER: NA	BID	Y-M: 20[redacted] / -27	NOT REPORTED
ISONIAZID	0.2 g	QD	Y-M: 20[redacted] / -15	Y-M: 20[redacted] / 171
AMOXICILLIN	0.5 g	TID	Y-M: 20[redacted] / 157	Y-M: 20[redacted] / 167
FAGOPYRUM ESCULENTUM	1.65 g	TID	Y-M: 20[redacted] / 157	Y-M: 20[redacted] / 167
UNSPECIFIED HERBAL AND TRADITIONAL MEDICINE	1.4 g	TID	Y-M: 20[redacted] / 157	Y-M: 20[redacted] / 167

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	PNEUMONIA
Preferred term	肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 157
Age at AE Onset	3[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 158): Leukocytes: 8.1 [3.5 - 9.5] 10^9/L; Neutrophils/Leukocytes: 76.37 [40 - 75] %
Microbiology	[redacted]20[redacted] (RX DAY 158): OTHER THROAT SWAB NPTST069-NOVEL CORONAVIRUS NUCLEIC ACID TESTING: NEGATIVE
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 158): CHEST CT: 1.RIGHT LOWER PULMONARY NODULES, REGULAR REEXAMINATION IS RECOMMENDED 2.RIGHT MIDDLE LOBE BRONCHIECTASIS WITH INFECTION 3.RIGHT HORIZONTAL CRACK HYPERTROPHY ADHESION 4.FATTY LIVER DISEASE; [redacted]20[redacted] (RX DAY 159): BODY TEMPERATURE: THE MAXIMUM BODY TEMPERATURE WAS 38.2? BEFORE HOSPITALIZATION; [redacted]20[redacted] (RX DAY 161): COLOR ULTRASONOGRAPHY OF LIVER, GALLBLADDER, SPLEEN AND PANCREAS: FATTY LIVER, LIVER SLIGHTLY HYPERECHOIC LIGHT GROUP; ELECTROCARDIOGRAM: 1.SINUS RHYTHM 2.T WAVE CHANGES
AE Stopped Rx Day	167

Duration of AE	11 DAYS
Toxicity Grade	2
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	ASTHMA
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION

Event #2: Event of Interest - Hepatic Disorder

Event Description	FATTY LIVER
Preferred term	脂肪肝
AE Onset Date / Rx Day	[redacted]20[redacted] / 161
Age at AE Onset	3[redacted]
Laboratory Testing	NOT APPLICABLE
Microbiology	NOT APPLICABLE
SAE Supplemental Procedure	NOT APPLICABLE
AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Toxicity Grade	1
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT APPLICABLE
Discontinued Study Drug Due to the Event	NO
SAE Criteria	NONE

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は中国の 3[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，肺炎を発現した。被験者は非喫煙者で禁酒しており，関連する病歴は喘息，アトピー性皮膚炎及び潜在結核であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は肺炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，肺炎は消失した。

入院前，被験者は咳嗽及び鼻閉に対し，経口薬にて対症療法を受けていた。20[redacted] 年 [redacted] 月 [redacted] 日，胸部コンピュータ断層撮影が行われ，右肺下葉の小結節及び右肺中葉の気管支拡張症が認めら

れた。20[redacted] 年 [redacted] 月 [redacted] 日，38.2°C の発熱があった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。

ソバカズラ，amoxicillin 及び LIANHUA-QINGWEN が投与された。

The patient's past medications include:

CEFTRIAXONE SODIUM for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

COMPOUND CAMPHOR CREAM for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

COMPOUND GLYCYRRHIZIN INJECTION for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

COMPOUND PINE DISTILLATE OINTMENT for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

DEXAMETHASONE ACETATE CREAM for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted]g 20[redacted])

EBASTINE TABLETS for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

LORATADINE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

NEOMYCIN SULFATE AND FLUOCINONIDE CREAM for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

OLOPATADINE HYDROCHLORIDE TABLETS for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

TACROLIMUS for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Pneumonia (10035664) (Pneumonia (10035664)) [v.22.1] [10035664]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): Reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of PNEUMONIA

- Investigator: Unknown

- AbbVie: Non-Applicable

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BODY TEMPERATURE:** 38.2 Degrees C

[redacted] **20[redacted] CHEST CT:** 1.RIGHT LOWER PULMONARY NODULES, REGULAR REEXAMINATION IS RECOMMENDED 2.RIGHT MIDDLE LOBE BRONCHIECTASIS WITH INFECTION 3.RIGHT HORIZONTAL CRACK HYPERTROPHY ADHESION 4.FATTY LIVER DISEASE

[redacted] **20[redacted] ECHO:** 1.SINUS RHYTHM 2.T WAVE CHANGES

[redacted] **20[redacted] NEUTROPHILS:** 76.37 % (normal 40.00 to 75.00)

[redacted] **20[redacted] ULTRASONOGRAPHY:** LIVER, GALLBLADDER, SPLEEN AND PANCREAS: FATTY LIVER, LIVER SLIGHTLY HYPERECHOIC LIGHT GROUP

[redacted] **20[redacted] WBC:** 8.09 X10**9/L (normal 3.50 to 9.50)

M16-045 試験（投与 52 週時）

治験の標題： 中等症から重症の青少年及び成人アトピー性皮膚炎患者を対象としたウパダシチニブの第 III 相，ランダム化，プラセボ対照，二重盲検試験	
治験実施施設： 24 ヵ国（アルゼンチン，オーストラリア，ボスニア・ヘルツェゴビナ，ブルガリア，カナダ，中国，コロンビア，クロアチア，デンマーク，エストニア，フィンランド，フランス，ドイツ，イタリア，日本，マレーシア，ニュージーランド，ルーマニア，ロシア連邦，スイス，トルコ，ウクライナ，英国及び米国［プエルトリコ］）の 151 施設	
治験調整医師： [redacted], MD, PhD	
公表文献（参考資料）： なし	
試験期間（年数）： 最初の被験者の初回来院日：2018 年 8 月 13 日 最後の被験者の最終来院日：20[redacted] 年 [redacted] 月 [redacted] 日（投与 52 週時）	開発のフェーズ：III
目的： 全身療法の対象となる中等症から重症の青少年及び成人アトピー性皮膚炎患者の治療におけるウパダシチニブの有効性及び安全性を評価する。 16 週間の二重盲検投与期では，ウパダシチニブ 30 mg 及び 15 mg を 1 日 1 回（以下「QD」）投与時の安全性及び有効性をプラセボ投与時と比較した。盲検継続投与期では，二重盲検投与期を完了した中等症から重症の青少年及び成人アトピー性皮膚炎患者を対象として，ウパダシチニブ 30 mg 及び 15 mg QD 投与時の長期的な安全性，忍容性及び有効性を評価中である。 投与 16 週時までのデータは，M16-045 試験の 16 週時総括報告書に示している。	
被験者数（計画時と解析時）： 計画時：810 名，解析時：810 名	
診断と主要な組入れ基準： 選択基準は以下のとおりであった。 1）スクリーニング来院時に 12 歳以上 75 歳以下の男性及び女性，2）Hanifin & Rajka の診断基準に基づく慢性アトピー性皮膚炎である，3）外用薬が効果不十分であったことを示す記録がある，又はアトピー性皮膚炎に対する全身療法の記録がある，4）以下の疾患活動性基準をすべて満たす：スクリーニング及びベースライン来院時に湿疹面積重症度指数（以下「EASI」）スコア 16 以上，スクリーニング及びベースライン来院時にバリデートされた治験責任医師による包括的評価-アトピー性皮膚炎（以下「vIGA-AD」）スコア 3 以上，スクリーニング及びベースライン来院時にアトピー性皮膚炎病変の体表面積 10%以上，及び毎日の最悪のかゆみの数値評価尺度（以下「NRS」）のベースライン来院時の週平均値 4 以上	
治験方法： 本試験（継続中）は全身療法の対象である中等症から重症の青少年（12～17 歳）及び成人（18～75 歳）アトピー性皮膚炎患者を対象として，ウパダシチニブ単独投与の有効性及び安全性を評価する，第 III 相，ランダム化，二重盲検，プラセボ対照，多施設共同試験であった。 本試験は，主試験（青少年及び成人を対象）及び青少年サブスタディ（青少年を対象）で構成された。主試験及び青少年サブスタディのいずれも，35 日間のスクリーニング期間，16 週間の二重盲検投与期（主解析）及び最長で投与 260 週時までの盲検継続投与期から構成され，治験薬の最終投与から約 30 日後に追跡調査来院を行う。	

主試験の適格性基準を満たした被験者を，1：1：1 の割合でウパダシチニブ 30 mg，ウパダシチニブ 15 mg 又はプラセボの経口投与（QD）にランダム化した。主試験への目標例数の登録が完了後，引き続き追加試験（青少年サブスタディ）への青少年被験者の登録を行い，青少年被験者の登録数が試験全体（主試験 + 青少年サブスタディ）で計 180 名になるまで継続することとした。本中間報告書のデータカットオフ日は，すべての被験者の投与 52 週時来院完了が予定されていた 20[redacted] 年 [redacted] 月 [redacted] 日とした。したがって，本報告書では投与 52 週時までに得られたデータを示している。青少年サブスタディは，被験者登録を継続中である。 主試験では，ベースライン疾患重症度（中等症［vIGA-AD スコア 3］ / 重症［vIGA-AD スコア 4］），地理的地域（米国・プエルトリコ・カナダ / 日本 / 中国 / その他）及び年齢（青少年［12～17 歳］ / 成人［18～75 歳］）による層別ランダム化を行った。二重盲検投与期終了時（投与 16 週時）に，プラセボ群の被験者を 1：1 の割合で盲検継続投与期におけるウパダシチニブ 15 mg 又は 30 mg の経口投与（QD）に再度割り付けた。また，投与 16 週時までの EASI 50 レスポンダー（はい / いいえ），地理的地域（米国・プエルトリコ・カナダ / 中国 / 日本 / その他）及び年齢（青少年［12～17 歳］ / 成人［18～75 歳］）による層別ランダム化を行った。最初にウパダシチニブ群にランダム化された被験者には，盲検継続投与期も継続して同じ用量のウパダシチニブを投与することとした。投与 4 週時来院以降，医学的に必要と判断された特定のパラメータに合致した場合，治験責任（担当）医師の判断でアトピー性皮膚炎に対するレスキュー治療を行うことが可能であった。投与 16 週時来院以降，治験責任（担当）医師の判断でアトピー性皮膚炎に対する外用併用薬の使用を可能とし，当該薬の使用はレスキュー治療とみなさなかった。
被験薬，用量 / 含量 / 濃度，投与法，ロット番号： ウパダシチニブ 15 mg フイルムコート錠（経口），バルクロット番号：[redacted] ウパダシチニブ 30 mg フイルムコート錠（経口），バルクロット番号：[redacted]
治療期間：二重盲検投与期：16 週間，盲検継続投与期：最長で投与 260 週時まで 本報告書では 20[redacted] 年 [redacted] 月 [redacted] 日（投与 52 週時）までに得られたデータを示している。
対照薬，用量 / 含量 / 濃度，投与法，ロット番号： ウパダシチニブに対応するプラセボ錠剤（経口），バルクロット番号：[redacted]

評価基準：

有効性：

共主要評価項目は，投与 16 週時に EASI スコアのベースラインからの 75%以上の低下（以下「EASI 75」）を達成した被験者の割合，及び投与 16 週時の vIGA-AD スコアが 0（消失）又は 1（ほぼ消失）であり，かつベースラインと比較して 2 グレード以上改善（低下）した被験者の割合であった。

米国当局 / 米国食品医薬品局（以下「FDA」）及び欧州当局 / 欧州医薬品庁（以下「EMA」）の規制に対応する重要な副次評価項目では，特に記載のない限り，多重性の調整を行い，これらの副次評価項目を用いてプラセボに対するウパダシチニブの優越性の解析を実施した。

重要な副次評価項目（米国 FDA）	重要な副次評価項目（EMA）
投与 16 週時に最悪のかゆみの NRS がベースラインから 4 以上改善（低下）した被験者の割合	投与 16 週時に最悪のかゆみの NRS がベースラインから 4 以上改善（低下）した被験者の割合
投与 16 週時に EASI スコアのベースラインからの 90%以上の低下（以下「EASI 90」）を達成した被験者の割合	投与 16 週時に EASI 90 を達成した被験者の割合
投与 4 週時に最悪のかゆみの NRS がベースラインから 4 以上改善（低下）した被験者の割合	投与 16 週時の最悪のかゆみの NRS のベースラインからの変化率
投与 2 週時に EASI 75 を達成した被験者の割合	投与 16 週時の EASI スコアのベースラインからの変化率
投与 1 週時に最悪のかゆみの NRS がベースラインから 4 以上改善（低下）した被験者の割合	投与 2 週時に EASI 75 を達成した被験者の割合
投与 2 日目に最悪のかゆみの NRS がベースラインから 4 以上改善（低下）した被験者の割合（30 mg のみ）	投与 1 週時に最悪のかゆみの NRS がベースラインから 4 以上改善（低下）した被験者の割合
投与 3 日目に最悪のかゆみの NRS がベースラインから 4 以上改善（低下）した被験者の割合（15 mg のみ）	投与 16 週時に患者評価による湿疹重症度スコア（以下「POEM」）がベースラインから 4 以上改善（低下）した被験者の割合
二重盲検投与期に再燃が認められた被験者の割合	投与 16 週時に皮膚科関連 QOL 評価指標（以下「DLQI」）スコアがベースラインから 4 以上改善（低下）した被験者の割合
投与 16 週時にアトピー性皮膚炎の影響の評価尺度（以下「ADerm-IS」）睡眠ドメインスコアがベースラインから 12 以上改善（低下）した被験者の割合	投与 2 日目に最悪のかゆみの NRS がベースラインから 4 以上改善（低下）した被験者の割合（30 mg のみ）
投与 16 週時にアトピー性皮膚炎症状の尺度（以下「ADerm-SS」）の皮膚の痛みスコアがベースラインから 4 以上改善（低下）した被験者の割合	投与 3 日目に最悪のかゆみの NRS がベースラインから 4 以上改善（低下）した被験者の割合（15 mg のみ）
投与 16 週時に ADerm-SS の 7 項目合計症状スコア（以下「TSS-7」）がベースラインから 28 以上改善（低下）した被験者の割合	二重盲検投与期に再燃が認められた被験者の割合
投与 16 週時に ADerm-IS の精神状態ドメインスコアがベースラインから 11 以上改善（低下）した被験者の割合	投与 16 週時のアトピー性皮膚炎の重症度分類スコア（以下「SCORAD」）のベースラインからの変化率

投与 16 週時に ADerm-IS の日常活動ドメインスコアがベースラインから 14 以上改善（低下）した被験者の割合	投与 16 週時に一般外来患者用不安抑うつテスト-不安（以下「HADS-A」）8 未満及び一般外来患者用不安抑うつテスト-抑うつ（以下「HADS-D」）8 未満を達成した被験者の割合
投与 16 週時に EASI スコアのベースラインからの 100%の低下（以下「EASI 100」）を達成した被験者の割合	投与 16 週時に ADerm-IS 睡眠ドメインスコアがベースラインから 12 以上改善（低下）した被験者の割合
	投与 16 週時に ADerm-SS の皮膚の痛みスコアがベースラインから 4 以上改善（低下）した被験者の割合
	投与 16 週時に ADerm-SS の TSS-7 がベースラインから 28 以上改善（低下）した被験者の割合
	投与 16 週時に ADerm-IS の精神状態ドメインスコアがベースラインから 11 以上改善（低下）した被験者の割合
	投与 16 週時に ADerm-IS の日常活動ドメインスコアがベースラインから 14 以上改善（低下）した被験者の割合
	投与 16 週時に EASI 100 を達成した被験者の割合
	投与 16 週時に DLQI スコア 0 又は 1 を達成した被験者の割合

この他に，追加の評価項目として，投与 16 週時及びその他の事前に規定した時点での健康関連の生活の質（以下「QOL」）を設定した（ただし，これに限定されない）。

薬物動態：
二重盲検投与期でのみ解析を実施した薬物動態のデータは，M16-045 試験の 16 週時総括報告書に示している。

安全性：
試験期間を通して，有害事象，バイタルサインの変動，身体検査，心電図，臨床検査（血液学的検査，血液生化学検査，尿検査）及び製品苦情のデータを評価した。

統計手法：

有効性：

主試験の ITT 集団（以下「ITT_M 集団」）は，主試験のすべてのランダム化された被験者から構成され，すべての有効性解析に用いた。ITT_M 集団の被験者の解析は，被験者が実際に投与された治験薬に関わらず，主試験でランダム化された投与群に基づいて実施した。二重盲検投与期にプラセボ群にランダム化され，盲検継続投与期に移行しなかった被験者は，盲検継続投与期の解析に含めなかった。投与 52 週時までの盲検継続投与期では，有効性の主要評価項目及び副次的評価項目は記述的に要約（カテゴリー変数）又は混合効果・反復測定モデル（以下「MMRM」）を用いて解析（連続変数）した。EASI 75 を達成した被験者の割合，vIGA-AD スコアが 0 又は 1 であり，かつベースラインと比較して 2 グレード以上改善した被験者の割合，及び最悪のかゆみの NRS がベースラインから 4 以上改善した被験者の割合は，多重補完（以下「MI」）法を用いて要約した。長期有効性は，MI 法，MMRM 法又は OC 法を用いて要約した。

安全性：

主試験の二重盲検投与期（16 週間）の安全性解析対象集団は，主試験の二重盲検投与期に治験薬投与を 1 回以上受けたすべてのランダム化された被験者から構成された。主試験の全ウパダシチニブ投与集団は，主試験でウパダシチニブ投与を 1 回以上受けたすべての被験者から構成された。主試験の盲検継続投与期の安全性解析対象集団は，主試験の盲検継続投与期に治験薬投与を 1 回以上受けたすべてのランダム化された被験者から構成された（主試験の盲検継続投与期の安全性解析対象集団は，臨床検査の解析にのみ用いた）。

安全性は，有害事象，身体検査，臨床検査及びバイタルサインにより評価した。有害事象が発現した被験者の数及び割合並びに曝露期間で調整した有害事象の発現率を，ICH 国際医薬用語集（以下「MedDRA」）の器官別大分類及び基本語を用いて投与群ごとに示した。また，重篤な有害事象の要約，並びに重症度別及び治験責任（担当）医師が評価した治験薬との因果関係別の有害事象の要約も示した。重篤な有害事象及び治験薬の投与中止に至った有害事象を一覧表に示した。各来院時のバイタルサイン，身体検査及び臨床検査の変化を要約した。規定の時点での臨床検査値のベースラインからの変動を表に示した。

要約 / 結論：

有効性の結果：

ウパダシチニブ 30 mg 及び 15 mg QD 投与時の有効性は，中等症から重症の青少年（12 歳以上 17 歳以下）及び成人（18 歳以上 75 歳以下）アトピー性皮膚炎患者に対し，盲検継続投与期の投与 52 週時まで，ウパダシチニブ継続投与群では，おおむね維持され，プラセボ投与からウパダシチニブ投与に切り替えた被験者群では，改善が続いた。また，投与 16 週時に EASI 75 を達成し，vIGA-AD スコアが 0 又は 1 であり，かつベースラインと比較して 2 グレード以上改善した被験者では，いずれの投与群でも投与 52 週時までに治験実施計画書で事前に規定した治療効果の喪失に該当する被験者はごくわずかであった（ウパダシチニブ 15 mg 群 4 名，ウパダシチニブ 30 mg 群 6 名）。治療効果は，ウパダシチニブ 15 mg 群と比較して，ウパダシチニブ 30 mg 群で数値的に高い結果が継続して得られた。

プラセボ投与からウパダシチニブ投与に切り替えた被験者のうち，EASI 75 を達成した被験者の割合，及び vIGA-AD スコアが 0 又は 1 であり，かつベースラインと比較して 2 グレード以上改善した被験者の割合は，ウパダシチニブ継続投与群での結果と類似しており，投与 52 週時まで両被験者群間で類似した結果が維持された。

皮膚症状の改善及び疾患活動性，かゆみの軽減，皮膚の痛み及び全般的症状，睡眠，アトピー性皮膚炎の影響，健康関連の QOL，並びにアトピー性皮膚炎の患者評価のいずれの評価項目の結果も，ウパダシチニブを投与された青少年被験者及び成人被験者の両集団で，投与 52 週時まで長期的に改善効果が維持されたことを示している。

安全性の結果：

ウパダシチニブはアトピー性皮膚炎患者に対し，おおむね安全で，忍容性も良好であった。ウパダシチニブの他の適応症（関節リウマチ及び乾癬性関節炎）の試験と比較して，新たな重大な安全性の懸念は認められなかったが，ウパダシチニブの投与を受けた被験者でのざ瘡の発現率は，関節リウマチを適応症とした試験と比較して，アトピー性皮膚炎を対象とした本試験で顕著に高かった。

データカットオフ日（20[redacted] 年 [redacted] 月 [redacted] 日）までにウパダシチニブの投与を受けたすべての被験者では，重篤な感染症の発現率は，ウパダシチニブ 15 mg 群と比較してウパダシチニブ 30 mg 群で高かった。日和見感染の多くは，ヘルペス性状湿疹（カポジ水痘様発疹と同義）であった。ヘルペス性状湿疹は，アトピー性皮膚炎患者集団で多く認められるウイルス性の合併症である。帯状疱疹はヤヌスキナーゼ（以下「JAK」）阻害薬では予期される有害事象であり，ウパダシチニブ群でリスクの上昇が認められ，その発現率はウパダシチニブ 15 mg 群と比較してウパダシチニブ 30 mg 群で高かった。ほとんどの帯状疱疹が単一の皮節のみに認められた。

ウパダシチニブ 15 mg 群で，判定された消化管穿孔及び活動性結核が各 1 件報告された。悪性腫瘍の発現率は，両ウパダシチニブ群で低かった。ウパダシチニブ 15 mg 群のコントロール不能の高血圧の既往歴を有する被験者で，判定された主要心血管事象（非致死性脳卒中）が 1 件報告された。ウパダシチニブ 15 mg 群の複数のリスク因子（深部静脈血栓症及び肺塞栓症の既往歴，プロトロビン遺伝子突然変異，肥満並びに喫煙）を有する被験者で，判定された静脈血栓塞栓症（深部静脈血栓症）が 1 件報告された。また，ウパダシチニブ 30 mg 群で，腎機

能障害が 2 件（急性腎障害及び腎不全）認められ，いずれの事象も新型コロナウイルス感染症（以下「COVID-19」）と関連があった。

クレアチンホスホキナーゼ増加，肝障害（大部分が無症候性の肝酵素増加），貧血及び好中球減少症の発現率は，ウパダシチニブ 15 mg 群と比較してウパダシチニブ 30 mg 群で高かった。JAK 阻害薬では，これらの臨床検査異常に対するウパダシチニブの用量依存性は予期されている。

成人被験者及び青少年被験者の両集団でわずかな体重増加が認められた。体重及び身長の増加は成長期の青少年では予期されている。

成人と比較して青少年の組入れ例数が少なかったが，好中球減少症及びざ瘡の発現率にわずかな上昇が認められたことを除き，青少年での安全性の結果は本試験に組み入れられた全被験者での結果と一貫していた。

結論：

中等症から重症のアトピー性皮膚炎患者を対象にウパダシチニブ 15 mg 及び 30 mg の安全性及び有効性を長期間評価した結果，投与 52 週時までの様々な皮膚症状の改善，かゆみ及び反応の基準値に関する評価項目で有効性の持続が示された。全体として，長期曝露後もウパダシチニブ 15 mg 及び 30 mg の安全性プロファイルに変化はなかった。

青少年被験者集団での有効性及び安全性は全体集団での結果と一貫した。本試験の結果は，中等症から重症の青少年及び成人アトピー性皮膚炎患者に対し，ウパダシチニブは有効で忍容性が良好な治療の選択肢であることを支持している。

表 1. ウパダシチニブ投与期間中に有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
Any adverse event	304 (75.8)	344 (84.3)	648 (80.1)
血液およびリンパ系障害	15 (3.7)	30 (7.4)	45 (5.6)
貧血	0	10 (2.5)	10 (1.2)
欠乏性貧血	1 (0.2)	1 (0.2)	2 (0.2)
鉄欠乏性貧血	0	1 (0.2)	1 (0.1)
白血球増加症	1 (0.2)	1 (0.2)	2 (0.2)
白血球減少症	0	2 (0.5)	2 (0.2)
リンパ節症	4 (1.0)	4 (1.0)	8 (1.0)
リンパ球減少症	1 (0.2)	2 (0.5)	3 (0.4)
好中球減少症	8 (2.0)	14 (3.4)	22 (2.7)
好中球増加症	2 (0.5)	0	2 (0.2)
汎血球減少症	0	1 (0.2)	1 (0.1)
脾腫	0	1 (0.2)	1 (0.1)
血小板減少症	0	1 (0.2)	1 (0.1)
心臓障害	1 (0.2)	5 (1.2)	6 (0.7)
心房細動	0	1 (0.2)	1 (0.1)
徐脈	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
心臓障害 (Cont.)			
心血管障害	1 (0.2)	0	1 (0.1)
冠動脈疾患	0	1 (0.2)	1 (0.1)
心筋梗塞	0	1 (0.2)	1 (0.1)
動悸	0	1 (0.2)	1 (0.1)
先天性、家族性および遺伝性障害	2 (0.5)	1 (0.2)	3 (0.4)
第 II 因子変異	1 (0.2)	0	1 (0.1)
ネザートン症候群	1 (0.2)	0	1 (0.1)
包茎	0	1 (0.2)	1 (0.1)
耳および迷路障害	2 (0.5)	9 (2.2)	11 (1.4)
耳垢栓塞	0	3 (0.7)	3 (0.4)
耳痛	0	1 (0.2)	1 (0.1)
突発性難聴	0	1 (0.2)	1 (0.1)
鼓膜障害	0	1 (0.2)	1 (0.1)
回転性めまい	2 (0.5)	3 (0.7)	5 (0.6)
内分泌障害	2 (0.5)	2 (0.5)	4 (0.5)
バセドウ病	0	1 (0.2)	1 (0.1)
甲状腺機能低下症	2 (0.5)	0	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
内分泌障害 (Cont.)			
甲状腺腫瘤	0	1 (0.2)	1 (0.1)
眼障害	11 (2.7)	22 (5.4)	33 (4.1)
眼瞼炎	0	2 (0.5)	2 (0.2)
白内障	1 (0.2)	0	1 (0.1)
霰粒腫	1 (0.2)	0	1 (0.1)
結膜出血	0	1 (0.2)	1 (0.1)
アレルギー性結膜炎	1 (0.2)	5 (1.2)	6 (0.7)
ドライアイ	1 (0.2)	3 (0.7)	4 (0.5)
眼瞼湿疹	0	1 (0.2)	1 (0.1)
眼瞼紅斑	0	1 (0.2)	1 (0.1)
眼そう痒症	0	1 (0.2)	1 (0.1)
眼部腫脹	1 (0.2)	1 (0.2)	2 (0.2)
眼瞼浮腫	0	1 (0.2)	1 (0.1)
緑内障	1 (0.2)	0	1 (0.1)
流涙増加	2 (0.5)	1 (0.2)	3 (0.4)
黄斑変性	1 (0.2)	0	1 (0.1)
黄斑円孔	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
眼障害 (Cont.)			
眼窩周囲腫脹	1 (0.2)	2 (0.5)	3 (0.4)
翼状片	1 (0.2)	0	1 (0.1)
網膜剥離	1 (0.2)	0	1 (0.1)
眼瞼腫脹	0	1 (0.2)	1 (0.1)
潰瘍性角膜炎	1 (0.2)	0	1 (0.1)
霧視	1 (0.2)	3 (0.7)	4 (0.5)
視力障害	1 (0.2)	0	1 (0.1)
胃腸障害	59 (14.7)	73 (17.9)	132 (16.3)
腹部不快感	1 (0.2)	1 (0.2)	2 (0.2)
腹部膨満	1 (0.2)	1 (0.2)	2 (0.2)
腹痛	1 (0.2)	8 (2.0)	9 (1.1)
上腹部痛	4 (1.0)	5 (1.2)	9 (1.1)
口角口唇炎	0	1 (0.2)	1 (0.1)
呼気臭	0	1 (0.2)	1 (0.1)
慢性胃炎	1 (0.2)	0	1 (0.1)
大腸炎	0	1 (0.2)	1 (0.1)
便秘	4 (1.0)	3 (0.7)	7 (0.9)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
胃腸障害 (Cont.)			
齲歯	6 (1.5)	3 (0.7)	9 (1.1)
下痢	13 (3.2)	15 (3.7)	28 (3.5)
腸憩室	1 (0.2)	0	1 (0.1)
口内乾燥	0	3 (0.7)	3 (0.4)
細菌叢異常	0	1 (0.2)	1 (0.1)
消化不良	3 (0.7)	2 (0.5)	5 (0.6)
軟便	0	2 (0.5)	2 (0.2)
鼓腸	3 (0.7)	2 (0.5)	5 (0.6)
食中毒	1 (0.2)	3 (0.7)	4 (0.5)
胃潰瘍	1 (0.2)	1 (0.2)	2 (0.2)
胃炎	4 (1.0)	0	4 (0.5)
びらん性胃炎	0	1 (0.2)	1 (0.1)
胃腸障害	1 (0.2)	0	1 (0.1)
消化器痛	1 (0.2)	0	1 (0.1)
胃食道逆流性疾患	2 (0.5)	7 (1.7)	9 (1.1)
歯肉痛	1 (0.2)	1 (0.2)	2 (0.2)
痔核	2 (0.5)	3 (0.7)	5 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
胃腸障害 (Cont.)			
裂孔ヘルニア	2 (0.5)	0	2 (0.2)
歯の知覚過敏	0	1 (0.2)	1 (0.1)
腸管穿孔	1 (0.2)	0	1 (0.1)
過敏性腸症候群	0	1 (0.2)	1 (0.1)
口唇腫脹	0	1 (0.2)	1 (0.1)
口腔内潰瘍形成	0	2 (0.5)	2 (0.2)
悪心	13 (3.2)	14 (3.4)	27 (3.3)
食道狭窄	1 (0.2)	0	1 (0.1)
食道炎	1 (0.2)	0	1 (0.1)
大網梗塞	0	1 (0.2)	1 (0.1)
口腔障害	0	1 (0.2)	1 (0.1)
膵炎	0	1 (0.2)	1 (0.1)
ひだ舌	0	1 (0.2)	1 (0.1)
埋伏歯	3 (0.7)	0	3 (0.4)
歯痛	2 (0.5)	2 (0.5)	4 (0.5)
臍ヘルニア	0	1 (0.2)	1 (0.1)
嘔吐	6 (1.5)	10 (2.5)	16 (2.0)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
一般・全身障害および投与部位の状態	40 (10.0)	37 (9.1)	77 (9.5)
無力症	2 (0.5)	1 (0.2)	3 (0.4)
胸部不快感	2 (0.5)	2 (0.5)	4 (0.5)
胸痛	3 (0.7)	0	3 (0.4)
悪寒	0	2 (0.5)	2 (0.2)
嚢胞	1 (0.2)	0	1 (0.1)
不快感	0	1 (0.2)	1 (0.1)
薬効欠如	1 (0.2)	0	1 (0.1)
薬物不耐性	0	1 (0.2)	1 (0.1)
顔面浮腫	1 (0.2)	1 (0.2)	2 (0.2)
疲労	4 (1.0)	4 (1.0)	8 (1.0)
びくびく感	0	1 (0.2)	1 (0.1)
重力性浮腫	0	1 (0.2)	1 (0.1)
インフルエンザ様疾患	7 (1.7)	11 (2.7)	18 (2.2)
倦怠感	0	1 (0.2)	1 (0.1)
腫瘤	1 (0.2)	0	1 (0.1)
小結節	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
一般・全身障害および投与部位の状態 (Cont.)			
非心臓性胸痛	0	3 (0.7)	3 (0.4)
末梢性浮腫	2 (0.5)	1 (0.2)	3 (0.4)
疼痛	1 (0.2)	3 (0.7)	4 (0.5)
発熱	17 (4.2)	8 (2.0)	25 (3.1)
腫脹	1 (0.2)	0	1 (0.1)
顔面腫脹	1 (0.2)	0	1 (0.1)
血管穿刺部位内出血	0	1 (0.2)	1 (0.1)
乾燥症	0	1 (0.2)	1 (0.1)
肝胆道系障害	6 (1.5)	15 (3.7)	21 (2.6)
胆道仙痛	0	1 (0.2)	1 (0.1)
胆嚢炎	0	1 (0.2)	1 (0.1)
胆石症	2 (0.5)	1 (0.2)	3 (0.4)
胆嚢ポリープ	0	1 (0.2)	1 (0.1)
肝機能異常	1 (0.2)	3 (0.7)	4 (0.5)
脂肪肝	4 (1.0)	7 (1.7)	11 (1.4)
肝炎	0	1 (0.2)	1 (0.1)
肝腫大	0	2 (0.5)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
肝胆道系障害 (Cont.)			
高ビリルビン血症	1 (0.2)	0	1 (0.1)
免疫系障害	9 (2.2)	11 (2.7)	20 (2.5)
節足動物咬傷アレルギー	1 (0.2)	0	1 (0.1)
節足動物刺傷アレルギー	1 (0.2)	0	1 (0.1)
化学物質アレルギー	1 (0.2)	0	1 (0.1)
ワクチンアレルギー	1 (0.2)	0	1 (0.1)
アナフィラキシー反応	0	2 (0.5)	2 (0.2)
薬物過敏症	0	1 (0.2)	1 (0.1)
食物アレルギー	2 (0.5)	3 (0.7)	5 (0.6)
過敏症	2 (0.5)	1 (0.2)	3 (0.4)
乳アレルギー	0	1 (0.2)	1 (0.1)
複合アレルギー	1 (0.2)	0	1 (0.1)
季節性アレルギー	1 (0.2)	2 (0.5)	3 (0.4)
1 型過敏症	0	1 (0.2)	1 (0.1)
感染症および寄生虫症	227 (56.6)	246 (60.3)	473 (58.5)
四肢膿瘍	0	2 (0.5)	2 (0.2)
ダニ皮膚炎	1 (0.2)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
膿疱性ざ瘡	1 (0.2)	0	1 (0.1)
急性副鼻腔炎	1 (0.2)	0	1 (0.1)
虫垂炎	2 (0.5)	0	2 (0.2)
異型肺炎	0	1 (0.2)	1 (0.1)
細菌感染	1 (0.2)	0	1 (0.1)
細菌性前立腺炎	1 (0.2)	0	1 (0.1)
細菌性膣症	0	2 (0.5)	2 (0.2)
細菌尿	0	1 (0.2)	1 (0.1)
体部白癬	4 (1.0)	2 (0.5)	6 (0.7)
乳房膿瘍	1 (0.2)	0	1 (0.1)
気管支炎	9 (2.2)	11 (2.7)	20 (2.5)
ウイルス性気管支炎	1 (0.2)	0	1 (0.1)
カンジダ感染	1 (0.2)	1 (0.2)	2 (0.2)
ネコ引っかき病	0	1 (0.2)	1 (0.1)
蜂巣炎	4 (1.0)	2 (0.5)	6 (0.7)
結膜炎	5 (1.2)	7 (1.7)	12 (1.5)
細菌性結膜炎	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
コロナウイルス感染	14 (3.5)	13 (3.2)	27 (3.3)
感染性クループ	1 (0.2)	0	1 (0.1)
膀胱炎	2 (0.5)	4 (1.0)	6 (0.7)
感染性皮膚炎	1 (0.2)	1 (0.2)	2 (0.2)
皮膚糸状菌症	1 (0.2)	3 (0.7)	4 (0.5)
爪の皮膚糸状菌症	1 (0.2)	0	1 (0.1)
憩室炎	0	2 (0.5)	2 (0.2)
耳感染	2 (0.5)	8 (2.0)	10 (1.2)
膿瘡	2 (0.5)	0	2 (0.2)
ヘルペス性状湿疹	3 (0.7)	5 (1.2)	8 (1.0)
感染性湿疹	1 (0.2)	3 (0.7)	4 (0.5)
蟯虫症	0	1 (0.2)	1 (0.1)
エプスタイン・バーウイルス感染	0	1 (0.2)	1 (0.1)
丹毒	0	1 (0.2)	1 (0.1)
大腸菌性尿路感染	1 (0.2)	1 (0.2)	2 (0.2)
外耳蜂巣炎	1 (0.2)	0	1 (0.1)
眼感染	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
毛包炎	11 (2.7)	19 (4.7)	30 (3.7)
真菌感染	1 (0.2)	0	1 (0.1)
皮膚真菌感染	1 (0.2)	0	1 (0.1)
せつ	6 (1.5)	3 (0.7)	9 (1.1)
胃腸炎	5 (1.2)	14 (3.4)	19 (2.3)
ウイルス性胃腸炎	2 (0.5)	3 (0.7)	5 (0.6)
ウイルス性消化管感染	0	1 (0.2)	1 (0.1)
陰部ヘルペス	1 (0.2)	1 (0.2)	2 (0.2)
陰部単純ヘルペス	0	2 (0.5)	2 (0.2)
真菌性性器感染	1 (0.2)	1 (0.2)	2 (0.2)
歯肉炎	2 (0.5)	0	2 (0.2)
手足口病	1 (0.2)	0	1 (0.1)
蠕虫感染	0	1 (0.2)	1 (0.1)
B 型肝炎	0	1 (0.2)	1 (0.1)
ヘルパンギーナ	0	1 (0.2)	1 (0.1)
ヘルペス性皮膚炎	0	2 (0.5)	2 (0.2)
ヘルペス眼感染	0	5 (1.2)	5 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
単純ヘルペス	12 (3.0)	20 (4.9)	32 (4.0)
ヘルペスウイルス感染	2 (0.5)	1 (0.2)	3 (0.4)
帯状疱疹	16 (4.0)	24 (5.9)	40 (4.9)
皮膚播種性帯状疱疹	0	2 (0.5)	2 (0.2)
麦粒腫	4 (1.0)	12 (2.9)	16 (2.0)
膿痂疹	13 (3.2)	7 (1.7)	20 (2.5)
感染性皮膚嚢腫	0	1 (0.2)	1 (0.1)
インフルエンザ	4 (1.0)	10 (2.5)	14 (1.7)
椎間板炎	1 (0.2)	0	1 (0.1)
カポジ水痘様発疹	2 (0.5)	5 (1.2)	7 (0.9)
喉頭炎	2 (0.5)	3 (0.7)	5 (0.6)
ウイルス性喉頭炎	1 (0.2)	0	1 (0.1)
潜伏結核	4 (1.0)	5 (1.2)	9 (1.1)
限局性感染	2 (0.5)	0	2 (0.2)
下気道感染	1 (0.2)	0	1 (0.1)
細菌性リンパ節炎	0	1 (0.2)	1 (0.1)
伝染性軟属腫	6 (1.5)	5 (1.2)	11 (1.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
マイコプラズマ感染	0	1 (0.2)	1 (0.1)
上咽頭炎	50 (12.5)	49 (12.0)	99 (12.2)
乳頭感染	1 (0.2)	0	1 (0.1)
食道カンジダ症	0	1 (0.2)	1 (0.1)
爪真菌症	2 (0.5)	3 (0.7)	5 (0.6)
眼部単純ヘルペス	2 (0.5)	4 (1.0)	6 (0.7)
眼帯状疱疹	1 (0.2)	1 (0.2)	2 (0.2)
口腔カンジダ症	2 (0.5)	4 (1.0)	6 (0.7)
口腔ヘルペス	13 (3.2)	25 (6.1)	38 (4.7)
骨髄炎	0	1 (0.2)	1 (0.1)
外耳炎	3 (0.7)	2 (0.5)	5 (0.6)
中耳炎	3 (0.7)	5 (1.2)	8 (1.0)
急性中耳炎	1 (0.2)	1 (0.2)	2 (0.2)
爪囲炎	2 (0.5)	7 (1.7)	9 (1.1)
ヘリコバクター性消化性潰瘍	0	1 (0.2)	1 (0.1)
インプラント周囲炎	0	1 (0.2)	1 (0.1)
歯周炎	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
咽頭膿瘍	0	1 (0.2)	1 (0.1)
咽頭炎	6 (1.5)	5 (1.2)	11 (1.4)
レンサ球菌性咽頭炎	1 (0.2)	0	1 (0.1)
咽頭扁桃炎	1 (0.2)	1 (0.2)	2 (0.2)
肺炎	4 (1.0)	3 (0.7)	7 (0.9)
細菌性肺炎	0	1 (0.2)	1 (0.1)
ブドウ球菌性肺炎	0	1 (0.2)	1 (0.1)
術後創感染	1 (0.2)	1 (0.2)	2 (0.2)
肺結核	1 (0.2)	0	1 (0.1)
膿疱	0	1 (0.2)	1 (0.1)
腎盂腎炎	0	2 (0.5)	2 (0.2)
膿皮症	1 (0.2)	0	1 (0.1)
膿疱性皮疹	1 (0.2)	1 (0.2)	2 (0.2)
RS ウイルス感染	0	1 (0.2)	1 (0.1)
気道感染	3 (0.7)	2 (0.5)	5 (0.6)
ウイルス性気道感染	1 (0.2)	2 (0.5)	3 (0.4)
鼻炎	5 (1.2)	6 (1.5)	11 (1.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
ライノウイルス感染	0	1 (0.2)	1 (0.1)
根管感染	0	1 (0.2)	1 (0.1)
敗血症	0	2 (0.5)	2 (0.2)
副鼻腔炎	9 (2.2)	8 (2.0)	17 (2.1)
皮膚細菌感染	2 (0.5)	3 (0.7)	5 (0.6)
皮膚カンジダ	1 (0.2)	1 (0.2)	2 (0.2)
植皮感染	0	1 (0.2)	1 (0.1)
皮膚感染	5 (1.2)	7 (1.7)	12 (1.5)
ブドウ球菌性膿痂疹	0	1 (0.2)	1 (0.1)
ブドウ球菌感染	1 (0.2)	5 (1.2)	6 (0.7)
ブドウ球菌性敗血症	1 (0.2)	1 (0.2)	2 (0.2)
ブドウ球菌皮膚感染	1 (0.2)	1 (0.2)	2 (0.2)
皮下組織膿瘍	0	1 (0.2)	1 (0.1)
股部白癬	0	4 (1.0)	4 (0.5)
足部白癬	4 (1.0)	6 (1.5)	10 (1.2)
癜風	3 (0.7)	1 (0.2)	4 (0.5)
扁桃炎	2 (0.5)	5 (1.2)	7 (0.9)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
細菌性扁桃炎	0	1 (0.2)	1 (0.1)
歯膿瘍	4 (1.0)	2 (0.5)	6 (0.7)
歯感染	3 (0.7)	3 (0.7)	6 (0.7)
気管炎	0	2 (0.5)	2 (0.2)
上気道感染	53 (13.2)	55 (13.5)	108 (13.3)
細菌性上気道感染	0	1 (0.2)	1 (0.1)
クラミジア性尿道炎	1 (0.2)	0	1 (0.1)
尿路感染	15 (3.7)	21 (5.1)	36 (4.4)
細菌性尿路感染	1 (0.2)	0	1 (0.1)
水痘	0	1 (0.2)	1 (0.1)
ウイルス性下痢	0	1 (0.2)	1 (0.1)
ウイルス感染	3 (0.7)	1 (0.2)	4 (0.5)
ウイルス性咽頭炎	1 (0.2)	0	1 (0.1)
ウイルス性発疹	1 (0.2)	0	1 (0.1)
ウイルス性上気道感染	10 (2.5)	15 (3.7)	25 (3.1)
外陰部腟カンジダ症	3 (0.7)	2 (0.5)	5 (0.6)
外陰腟真菌感染	2 (0.5)	0	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
外陰膣炎	1 (0.2)	0	1 (0.1)
創傷感染	0	1 (0.2)	1 (0.1)
ブドウ球菌性創感染	0	1 (0.2)	1 (0.1)
傷害、中毒および処置合併症	42 (10.5)	48 (11.8)	90 (11.1)
腹壁損傷	1 (0.2)	0	1 (0.1)
偶発的過量投与	0	1 (0.2)	1 (0.1)
アルコール中毒	0	1 (0.2)	1 (0.1)
動物咬傷	1 (0.2)	0	1 (0.1)
節足動物咬傷	4 (1.0)	3 (0.7)	7 (0.9)
節足動物刺傷	0	1 (0.2)	1 (0.1)
背部損傷	1 (0.2)	0	1 (0.1)
第１度熱傷	1 (0.2)	1 (0.2)	2 (0.2)
第２度熱傷	1 (0.2)	0	1 (0.1)
第３度熱傷	0	1 (0.2)	1 (0.1)
軟骨損傷	1 (0.2)	0	1 (0.1)
脳振盪	2 (0.5)	1 (0.2)	3 (0.4)
挫傷	3 (0.7)	1 (0.2)	4 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
傷害、中毒および処置合併症 (Cont.)			
転倒	4 (1.0)	5 (1.2)	9 (1.1)
大腿骨骨折	0	1 (0.2)	1 (0.1)
腓骨骨折	0	1 (0.2)	1 (0.1)
足骨折	2 (0.5)	3 (0.7)	5 (0.6)
前腕骨折	0	1 (0.2)	1 (0.1)
体内異物	0	1 (0.2)	1 (0.1)
手骨折	0	1 (0.2)	1 (0.1)
頭部損傷	1 (0.2)	1 (0.2)	2 (0.2)
熱疲労	1 (0.2)	0	1 (0.1)
損傷	1 (0.2)	0	1 (0.1)
関節脱臼	1 (0.2)	1 (0.2)	2 (0.2)
関節損傷	3 (0.7)	1 (0.2)	4 (0.5)
靱帯断裂	1 (0.2)	1 (0.2)	2 (0.2)
靱帯捻挫	3 (0.7)	4 (1.0)	7 (0.9)
四肢損傷	3 (0.7)	4 (1.0)	7 (0.9)
口唇損傷	0	1 (0.2)	1 (0.1)
半月板損傷	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
傷害、中毒および処置合併症 (Cont.)			
筋断裂	0	1 (0.2)	1 (0.1)
肉離れ	3 (0.7)	4 (1.0)	7 (0.9)
筋骨格系損傷	0	1 (0.2)	1 (0.1)
膝蓋骨骨折	1 (0.2)	0	1 (0.1)
処置による疼痛	0	2 (0.5)	2 (0.2)
橈骨骨折	0	1 (0.2)	1 (0.1)
肋骨骨折	0	1 (0.2)	1 (0.1)
交通事故	2 (0.5)	1 (0.2)	3 (0.4)
瘢痕	1 (0.2)	0	1 (0.1)
皮膚擦過傷	2 (0.5)	2 (0.5)	4 (0.5)
皮膚裂傷	1 (0.2)	3 (0.7)	4 (0.5)
スポーツ損傷	0	1 (0.2)	1 (0.1)
ストレス骨折	0	1 (0.2)	1 (0.1)
サンバーン	1 (0.2)	1 (0.2)	2 (0.2)
腱損傷	0	1 (0.2)	1 (0.1)
腱断裂	2 (0.5)	2 (0.5)	4 (0.5)
熱傷	1 (0.2)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
傷害、中毒および処置合併症 (Cont.)			
脛骨骨折	0	1 (0.2)	1 (0.1)
歯牙破折	0	1 (0.2)	1 (0.1)
尺骨骨折	1 (0.2)	0	1 (0.1)
上肢骨折	1 (0.2)	0	1 (0.1)
ワクチン接種合併症	0	1 (0.2)	1 (0.1)
臨床検査	59 (14.7)	86 (21.1)	145 (17.9)
アラニンアミノトランスフェラーゼ増加	9 (2.2)	13 (3.2)	22 (2.7)
アスパラギン酸アミノトランスフェラーゼ増加	6 (1.5)	10 (2.5)	16 (2.0)
B リンパ球数増加	1 (0.2)	1 (0.2)	2 (0.2)
血中アルカリホスファターゼ増加	1 (0.2)	0	1 (0.1)
血中ビリルビン増加	1 (0.2)	2 (0.5)	3 (0.4)
血中コレステロール増加	2 (0.5)	7 (1.7)	9 (1.1)
血中クレアチンホスホキナーゼ増加	22 (5.5)	44 (10.8)	66 (8.2)
血中クレアチニン増加	3 (0.7)	0	3 (0.4)
血中ブドウ糖増加	1 (0.2)	2 (0.5)	3 (0.4)
血中免疫グロブリン E 増加	6 (1.5)	2 (0.5)	8 (1.0)
血中乳酸脱水素酵素増加	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
臨床検査 (Cont.)			
血中カリウム増加	1 (0.2)	0	1 (0.1)
血圧上昇	1 (0.2)	0	1 (0.1)
血中トリグリセリド増加	3 (0.7)	0	3 (0.4)
血中尿酸増加	0	3 (0.7)	3 (0.4)
尿中血陽性	3 (0.7)	1 (0.2)	4 (0.5)
CD4 リンパ球減少	1 (0.2)	0	1 (0.1)
CD8 リンパ球百分率減少	1 (0.2)	0	1 (0.1)
CD8 リンパ球減少	0	1 (0.2)	1 (0.1)
心雑音	0	2 (0.5)	2 (0.2)
ケモカイン増加	1 (0.2)	0	1 (0.1)
胸部コンピュータ断層撮影異常	0	1 (0.2)	1 (0.1)
尿中結晶陽性	1 (0.2)	1 (0.2)	2 (0.2)
心電図 QT 間隔異常	1 (0.2)	0	1 (0.1)
好酸球百分率増加	1 (0.2)	0	1 (0.1)
尿中ブドウ糖陽性	0	1 (0.2)	1 (0.1)
ヘモグロビン減少	1 (0.2)	4 (1.0)	5 (0.6)
心拍数増加	0	2 (0.5)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
臨床検査 (Cont.)			
肝酵素上昇	1 (0.2)	1 (0.2)	2 (0.2)
高比重リポ蛋白増加	0	1 (0.2)	1 (0.1)
免疫グロブリン増加	1 (0.2)	0	1 (0.1)
肝機能検査値上昇	1 (0.2)	0	1 (0.1)
低比重リポ蛋白増加	0	2 (0.5)	2 (0.2)
リンパ節触知	1 (0.2)	0	1 (0.1)
リンパ球数減少	0	3 (0.7)	3 (0.4)
ナチュラルキラー細胞数減少	1 (0.2)	1 (0.2)	2 (0.2)
好中球数減少	2 (0.5)	3 (0.7)	5 (0.6)
血小板数増加	1 (0.2)	1 (0.2)	2 (0.2)
尿妊娠反応陽性	1 (0.2)	0	1 (0.1)
尿蛋白	1 (0.2)	0	1 (0.1)
尿中蛋白陽性	2 (0.5)	2 (0.5)	4 (0.5)
赤血球数減少	0	1 (0.2)	1 (0.1)
T リンパ球数減少	1 (0.2)	0	1 (0.1)
トランスアミナーゼ上昇	2 (0.5)	5 (1.2)	7 (0.9)
腫瘍マーカー上昇	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
臨床検査 (Cont.)			
尿円柱	1 (0.2)	0	1 (0.1)
尿中ケトン体陽性	1 (0.2)	0	1 (0.1)
尿中白血球エステラーゼ陽性	0	1 (0.2)	1 (0.1)
尿中シュウ酸塩	1 (0.2)	0	1 (0.1)
体重減少	0	3 (0.7)	3 (0.4)
体重増加	9 (2.2)	16 (3.9)	25 (3.1)
白血球数減少	1 (0.2)	4 (1.0)	5 (0.6)
代謝および栄養障害	23 (5.7)	27 (6.6)	50 (6.2)
食欲減退	1 (0.2)	3 (0.7)	4 (0.5)
糖尿病	1 (0.2)	0	1 (0.1)
脂質異常症	1 (0.2)	2 (0.5)	3 (0.4)
耐糖能障害	0	1 (0.2)	1 (0.1)
痛風	1 (0.2)	1 (0.2)	2 (0.2)
高コレステロール血症	2 (0.5)	5 (1.2)	7 (0.9)
高脂血症	4 (1.0)	1 (0.2)	5 (0.6)
高トリグリセリド血症	3 (0.7)	4 (1.0)	7 (0.9)
高尿酸血症	5 (1.2)	3 (0.7)	8 (1.0)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
代謝および栄養障害 (Cont.)			
低血糖	0	1 (0.2)	1 (0.1)
低カリウム血症	0	3 (0.7)	3 (0.4)
低リン酸血症	1 (0.2)	1 (0.2)	2 (0.2)
食欲亢進	2 (0.5)	2 (0.5)	4 (0.5)
2 型糖尿病	0	1 (0.2)	1 (0.1)
ビタミン B12 欠乏	0	1 (0.2)	1 (0.1)
ビタミン D 欠乏	3 (0.7)	2 (0.5)	5 (0.6)
筋骨格系および結合組織障害	40 (10.0)	45 (11.0)	85 (10.5)
関節痛	7 (1.7)	10 (2.5)	17 (2.1)
関節炎	2 (0.5)	0	2 (0.2)
腋窩腫瘤	0	1 (0.2)	1 (0.1)
背部痛	8 (2.0)	16 (3.9)	24 (3.0)
骨嚢腫	1 (0.2)	0	1 (0.1)
滑液包炎	2 (0.5)	0	2 (0.2)
側腹部痛	1 (0.2)	0	1 (0.1)
足変形	1 (0.2)	0	1 (0.1)
椎間板変性症	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
筋骨格系および結合組織障害 (Cont.)			
椎間板突出	1 (0.2)	1 (0.2)	2 (0.2)
筋力低下	1 (0.2)	0	1 (0.1)
筋骨格系胸痛	0	2 (0.5)	2 (0.2)
筋骨格痛	4 (1.0)	2 (0.5)	6 (0.7)
筋肉痛	6 (1.5)	8 (2.0)	14 (1.7)
筋膜疼痛症候群	1 (0.2)	0	1 (0.1)
頚部痛	2 (0.5)	0	2 (0.2)
変形性関節症	1 (0.2)	2 (0.5)	3 (0.4)
骨端症	0	1 (0.2)	1 (0.1)
四肢痛	1 (0.2)	7 (1.7)	8 (1.0)
顎痛	1 (0.2)	1 (0.2)	2 (0.2)
骨膜炎	0	1 (0.2)	1 (0.1)
肩回旋筋腱板症候群	0	2 (0.5)	2 (0.2)
側弯症	1 (0.2)	0	1 (0.1)
変形性脊椎症	1 (0.2)	0	1 (0.1)
脊椎炎	0	1 (0.2)	1 (0.1)
滑液嚢腫	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
筋骨格系および結合組織障害 (Cont.)			
腱炎	3 (0.7)	3 (0.7)	6 (0.7)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む)	13 (3.2)	18 (4.4)	31 (3.8)
肛門性器疣贅	2 (0.5)	0	2 (0.2)
基底細胞癌	0	1 (0.2)	1 (0.1)
骨新生物	1 (0.2)	0	1 (0.1)
ボーエン病	1 (0.2)	0	1 (0.1)
乳癌	1 (0.2)	0	1 (0.1)
真珠腫	0	1 (0.2)	1 (0.1)
結腸癌	1 (0.2)	0	1 (0.1)
胃癌	0	1 (0.2)	1 (0.1)
血管腫	1 (0.2)	0	1 (0.1)
浸潤性乳管癌	0	1 (0.2)	1 (0.1)
脂肪腫	1 (0.2)	1 (0.2)	2 (0.2)
メラノサイト性母斑	0	1 (0.2)	1 (0.1)
非分泌型下垂体腺腫	0	1 (0.2)	1 (0.1)
脂漏性角化症	0	1 (0.2)	1 (0.1)
皮膚乳頭腫	6 (1.5)	9 (2.2)	15 (1.9)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） (Cont.)			
皮膚有棘細胞癌	0	2 (0.5)	2 (0.2)
神経系障害	44 (11.0)	38 (9.3)	82 (10.1)
健忘	0	1 (0.2)	1 (0.1)
手根管症候群	2 (0.5)	0	2 (0.2)
注意力障害	1 (0.2)	0	1 (0.1)
浮動性めまい	5 (1.2)	7 (1.7)	12 (1.5)
夢幻状態	1 (0.2)	0	1 (0.1)
味覚不全	0	1 (0.2)	1 (0.1)
錐体外路障害	1 (0.2)	0	1 (0.1)
頭痛	23 (5.7)	24 (5.9)	47 (5.8)
過眠症	1 (0.2)	0	1 (0.1)
虚血性脳卒中	1 (0.2)	0	1 (0.1)
片頭痛	2 (0.5)	2 (0.5)	4 (0.5)
前兆を伴う片頭痛	0	1 (0.2)	1 (0.1)
神経痛	0	2 (0.5)	2 (0.2)
錯感覚	2 (0.5)	0	2 (0.2)
失神寸前の状態	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
神経系障害 (Cont.)			
神経根障害	0	1 (0.2)	1 (0.1)
坐骨神経痛	2 (0.5)	2 (0.5)	4 (0.5)
感覚消失	1 (0.2)	0	1 (0.1)
傾眠	2 (0.5)	0	2 (0.2)
失神	0	2 (0.5)	2 (0.2)
緊張性頭痛	3 (0.7)	2 (0.5)	5 (0.6)
製品の問題	1 (0.2)	0	1 (0.1)
医療機器破損	1 (0.2)	0	1 (0.1)
精神障害	20 (5.0)	18 (4.4)	38 (4.7)
適応障害	0	1 (0.2)	1 (0.1)
不安	6 (1.5)	8 (2.0)	14 (1.7)
不安障害	0	1 (0.2)	1 (0.1)
無感情	1 (0.2)	0	1 (0.1)
注意欠陥多動性障害	1 (0.2)	1 (0.2)	2 (0.2)
抑うつ気分	0	1 (0.2)	1 (0.1)
うつ病	3 (0.7)	3 (0.7)	6 (0.7)
自傷性皮膚症	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
精神障害 (Cont.)			
失見当識	0	1 (0.2)	1 (0.1)
不眠症	2 (0.5)	4 (1.0)	6 (0.7)
故意の自傷行為	1 (0.2)	0	1 (0.1)
リビドー減退	1 (0.2)	0	1 (0.1)
大うつ病	1 (0.2)	1 (0.2)	2 (0.2)
躁病	1 (0.2)	0	1 (0.1)
混合性不安抑うつ障害	1 (0.2)	0	1 (0.1)
パニック発作	0	1 (0.2)	1 (0.1)
睡眠障害	3 (0.7)	0	3 (0.4)
ストレス	1 (0.2)	0	1 (0.1)
自殺念慮	1 (0.2)	0	1 (0.1)
腎および尿路障害	10 (2.5)	16 (3.9)	26 (3.2)
急性腎障害	0	1 (0.2)	1 (0.1)
アルブミン尿	1 (0.2)	2 (0.5)	3 (0.4)
排尿困難	1 (0.2)	4 (1.0)	5 (0.6)
血尿	2 (0.5)	1 (0.2)	3 (0.4)
高シュウ酸尿症	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
腎および尿路障害 (Cont.)			
緊張性膀胱	0	1 (0.2)	1 (0.1)
ケトン尿	1 (0.2)	0	1 (0.1)
白血球尿	1 (0.2)	0	1 (0.1)
尿意切迫	1 (0.2)	0	1 (0.1)
腎結石症	1 (0.2)	2 (0.5)	3 (0.4)
頻尿	0	1 (0.2)	1 (0.1)
蛋白尿	3 (0.7)	3 (0.7)	6 (0.7)
腎不全	0	1 (0.2)	1 (0.1)
尿路障害	1 (0.2)	0	1 (0.1)
生殖系および乳房障害	11 (2.7)	10 (2.5)	21 (2.6)
無月経	1 (0.2)	3 (0.7)	4 (0.5)
亀頭包皮炎	1 (0.2)	0	1 (0.1)
良性前立腺肥大症	1 (0.2)	1 (0.2)	2 (0.2)
乳房腫大	0	1 (0.2)	1 (0.1)
乳房圧痛	0	1 (0.2)	1 (0.1)
月経困難症	3 (0.7)	0	3 (0.4)
乳管拡張症	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
生殖系および乳房障害 (Cont.)			
閉経期症状	0	1 (0.2)	1 (0.1)
月経過多	2 (0.5)	1 (0.2)	3 (0.4)
不規則月経	1 (0.2)	0	1 (0.1)
会陰痩	0	1 (0.2)	1 (0.1)
多嚢胞性卵巣	1 (0.2)	1 (0.2)	2 (0.2)
精巣痛	0	1 (0.2)	1 (0.1)
腟分泌物	1 (0.2)	0	1 (0.1)
外陰腟乾燥	0	1 (0.2)	1 (0.1)
呼吸器、胸郭および縦隔障害	41 (10.2)	45 (11.0)	86 (10.6)
喘息	8 (2.0)	6 (1.5)	14 (1.7)
気管支反応性亢進	1 (0.2)	0	1 (0.1)
慢性閉塞性肺疾患	0	1 (0.2)	1 (0.1)
咳嗽	20 (5.0)	11 (2.7)	31 (3.8)
嚢胞性肺疾患	1 (0.2)	0	1 (0.1)
発声障害	1 (0.2)	0	1 (0.1)
呼吸困難	2 (0.5)	3 (0.7)	5 (0.6)
労作性呼吸困難	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
呼吸器、胸郭および縦隔障害 (Cont.)			
鼻出血	3 (0.7)	6 (1.5)	9 (1.1)
鼻閉	1 (0.2)	3 (0.7)	4 (0.5)
鼻乾燥	0	1 (0.2)	1 (0.1)
口腔咽頭痛	9 (2.2)	12 (2.9)	21 (2.6)
気胸	0	1 (0.2)	1 (0.1)
湿性咳嗽	2 (0.5)	1 (0.2)	3 (0.4)
肺腫瘤	0	1 (0.2)	1 (0.1)
アレルギー性鼻炎	2 (0.5)	2 (0.5)	4 (0.5)
鼻漏	2 (0.5)	1 (0.2)	3 (0.4)
副鼻腔うっ血	1 (0.2)	2 (0.5)	3 (0.4)
咽喉刺激感	1 (0.2)	1 (0.2)	2 (0.2)
扁桃結石	0	1 (0.2)	1 (0.1)
上気道の炎症	0	1 (0.2)	1 (0.1)
声帯肥厚	0	1 (0.2)	1 (0.1)
皮膚および皮下組織障害	122 (30.4)	169 (41.4)	291 (36.0)
ざ瘡	41 (10.2)	99 (24.3)	140 (17.3)
光線角化症	3 (0.7)	1 (0.2)	4 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
皮膚および皮下組織障害 (Cont.)			
脱毛症	1 (0.2)	2 (0.5)	3 (0.4)
円形脱毛症	0	1 (0.2)	1 (0.1)
血管浮腫	1 (0.2)	2 (0.5)	3 (0.4)
水疱	1 (0.2)	0	1 (0.1)
冷汗	1 (0.2)	0	1 (0.1)
頭部粃糠疹	0	1 (0.2)	1 (0.1)
皮膚嚢腫	0	2 (0.5)	2 (0.2)
皮膚炎	3 (0.7)	4 (1.0)	7 (0.9)
ざ瘡様皮膚炎	3 (0.7)	15 (3.7)	18 (2.2)
アレルギー性皮膚炎	0	2 (0.5)	2 (0.2)
アトピー性皮膚炎	41 (10.2)	25 (6.1)	66 (8.2)
接触皮膚炎	3 (0.7)	13 (3.2)	16 (2.0)
びまん性脱毛症	0	1 (0.2)	1 (0.1)
薬疹	1 (0.2)	0	1 (0.1)
異汗性湿疹	0	1 (0.2)	1 (0.1)
斑状出血	1 (0.2)	0	1 (0.1)
湿疹	7 (1.7)	4 (1.0)	11 (1.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
皮膚および皮下組織障害 (Cont.)			
紅斑	2 (0.5)	2 (0.5)	4 (0.5)
温熱性紅斑	1 (0.2)	0	1 (0.1)
毛包性ムチン沈着症	0	1 (0.2)	1 (0.1)
毛髪成長異常	0	1 (0.2)	1 (0.1)
逆むけ	0	1 (0.2)	1 (0.1)
汗腺炎	1 (0.2)	1 (0.2)	2 (0.2)
多汗症	0	3 (0.7)	3 (0.4)
嵌入爪	1 (0.2)	0	1 (0.1)
内方発育毛	1 (0.2)	0	1 (0.1)
間擦疹	0	1 (0.2)	1 (0.1)
機械性蕁麻疹	0	1 (0.2)	1 (0.1)
汗疹	1 (0.2)	1 (0.2)	2 (0.2)
神経皮膚炎	1 (0.2)	0	1 (0.1)
寝汗	1 (0.2)	1 (0.2)	2 (0.2)
爪破損	0	1 (0.2)	1 (0.1)
皮膚疼痛	1 (0.2)	0	1 (0.1)
類乾癬	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
皮膚および皮下組織障害 (Cont.)			
口囲皮膚炎	3 (0.7)	1 (0.2)	4 (0.5)
光線過敏性反応	1 (0.2)	2 (0.5)	3 (0.4)
炎症後色素沈着変化	1 (0.2)	0	1 (0.1)
そう痒症	5 (1.2)	1 (0.2)	6 (0.7)
紫斑	0	1 (0.2)	1 (0.1)
発疹	2 (0.5)	3 (0.7)	5 (0.6)
斑状丘疹状皮疹	1 (0.2)	1 (0.2)	2 (0.2)
丘疹性皮疹	1 (0.2)	0	1 (0.1)
酒さ	1 (0.2)	4 (1.0)	5 (0.6)
脂漏	1 (0.2)	0	1 (0.1)
脂漏性皮膚炎	2 (0.5)	3 (0.7)	5 (0.6)
皮膚障害	0	1 (0.2)	1 (0.1)
皮膚剥脱	1 (0.2)	0	1 (0.1)
皮膚亀裂	1 (0.2)	0	1 (0.1)
皮膚病変	1 (0.2)	0	1 (0.1)
皮膚腫脹	2 (0.5)	0	2 (0.2)
日光黒子	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
皮膚および皮下組織障害 (Cont.)			
毛細血管拡張症	1 (0.2)	0	1 (0.1)
中毒性表皮壊死融解症	1 (0.2)	0	1 (0.1)
蕁麻疹	12 (3.0)	9 (2.2)	21 (2.6)
コリン性蕁麻疹	1 (0.2)	0	1 (0.1)
尋常性白斑	0	1 (0.2)	1 (0.1)
黄色板腫	1 (0.2)	0	1 (0.1)
乾皮症	1 (0.2)	0	1 (0.1)
外科および内科処置	2 (0.5)	1 (0.2)	3 (0.4)
人工流産	1 (0.2)	1 (0.2)	2 (0.2)
収れん薬療法	1 (0.2)	0	1 (0.1)
血管障害	13 (3.2)	10 (2.5)	23 (2.8)
血性分泌物	1 (0.2)	0	1 (0.1)
深部静脈血栓症	1 (0.2)	0	1 (0.1)
潮紅	1 (0.2)	0	1 (0.1)
血腫	3 (0.7)	1 (0.2)	4 (0.5)
ほてり	0	1 (0.2)	1 (0.1)
高血圧	8 (2.0)	6 (1.5)	14 (1.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
血管障害 (Cont.)			
低血圧	0	1 (0.2)	1 (0.1)
血栓性静脈炎	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W52 Table 14.3__1.5.1.1

表 2. ウパダシチニブ投与期間中に有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団，青少年）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
Any adverse event	41 (68.3)	50 (83.3)	91 (75.8)
血液およびリンパ系障害	3 (5.0)	4 (6.7)	7 (5.8)
白血球減少症	0	1 (1.7)	1 (0.8)
リンパ節症	1 (1.7)	0	1 (0.8)
好中球減少症	1 (1.7)	3 (5.0)	4 (3.3)
好中球増加症	1 (1.7)	0	1 (0.8)
血小板減少症	0	1 (1.7)	1 (0.8)
眼障害	0	3 (5.0)	3 (2.5)
眼瞼浮腫	0	1 (1.7)	1 (0.8)
流涙増加	0	1 (1.7)	1 (0.8)
霧視	0	1 (1.7)	1 (0.8)
胃腸障害	5 (8.3)	8 (13.3)	13 (10.8)
腹痛	0	1 (1.7)	1 (0.8)
上腹部痛	1 (1.7)	2 (3.3)	3 (2.5)
齲歯	1 (1.7)	1 (1.7)	2 (1.7)
下痢	1 (1.7)	5 (8.3)	6 (5.0)
食中毒	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
胃腸障害 (Cont.)			
胃腸障害	1 (1.7)	0	1 (0.8)
胃食道逆流性疾患	0	1 (1.7)	1 (0.8)
口唇腫脹	0	1 (1.7)	1 (0.8)
悪心	1 (1.7)	1 (1.7)	2 (1.7)
嘔吐	1 (1.7)	3 (5.0)	4 (3.3)
一般・全身障害および投与部位の状態	8 (13.3)	4 (6.7)	12 (10.0)
無力症	1 (1.7)	0	1 (0.8)
インフルエンザ様疾患	1 (1.7)	2 (3.3)	3 (2.5)
疼痛	1 (1.7)	0	1 (0.8)
発熱	5 (8.3)	2 (3.3)	7 (5.8)
免疫系障害	1 (1.7)	3 (5.0)	4 (3.3)
アナフィラキシー反応	0	1 (1.7)	1 (0.8)
薬物過敏症	0	1 (1.7)	1 (0.8)
食物アレルギー	0	1 (1.7)	1 (0.8)
過敏症	1 (1.7)	0	1 (0.8)
感染症および寄生虫症	26 (43.3)	40 (66.7)	66 (55.0)
四肢膿瘍	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
感染症および寄生虫症 (Cont.)			
体部白癬	0	1 (1.7)	1 (0.8)
気管支炎	1 (1.7)	1 (1.7)	2 (1.7)
ネコ引っかき病	0	1 (1.7)	1 (0.8)
結膜炎	0	3 (5.0)	3 (2.5)
細菌性結膜炎	1 (1.7)	0	1 (0.8)
コロナウイルス感染	0	1 (1.7)	1 (0.8)
感染性クループ	1 (1.7)	0	1 (0.8)
膀胱炎	0	1 (1.7)	1 (0.8)
皮膚糸状菌症	0	1 (1.7)	1 (0.8)
耳感染	0	3 (5.0)	3 (2.5)
エプスタイン・バーウイルス感染	0	1 (1.7)	1 (0.8)
毛包炎	0	2 (3.3)	2 (1.7)
せつ	1 (1.7)	0	1 (0.8)
胃腸炎	1 (1.7)	2 (3.3)	3 (2.5)
ウイルス性胃腸炎	0	1 (1.7)	1 (0.8)
手足口病	1 (1.7)	0	1 (0.8)
単純ヘルペス	1 (1.7)	3 (5.0)	4 (3.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
感染症および寄生虫症 (Cont.)			
帯状疱疹	1 (1.7)	2 (3.3)	3 (2.5)
麦粒腫	0	2 (3.3)	2 (1.7)
膿痂疹	4 (6.7)	3 (5.0)	7 (5.8)
インフルエンザ	0	3 (5.0)	3 (2.5)
潜伏結核	0	1 (1.7)	1 (0.8)
伝染性軟属腫	1 (1.7)	0	1 (0.8)
上咽頭炎	6 (10.0)	5 (8.3)	11 (9.2)
乳頭感染	1 (1.7)	0	1 (0.8)
眼部単純ヘルペス	0	1 (1.7)	1 (0.8)
眼帯状疱疹	0	1 (1.7)	1 (0.8)
口腔ヘルペス	0	2 (3.3)	2 (1.7)
骨髄炎	0	1 (1.7)	1 (0.8)
爪囲炎	0	1 (1.7)	1 (0.8)
咽頭炎	0	2 (3.3)	2 (1.7)
咽頭扁桃炎	1 (1.7)	0	1 (0.8)
肺炎	0	1 (1.7)	1 (0.8)
腎盂腎炎	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
感染症および寄生虫症 (Cont.)			
気道感染	2 (3.3)	1 (1.7)	3 (2.5)
鼻炎	1 (1.7)	2 (3.3)	3 (2.5)
敗血症	0	1 (1.7)	1 (0.8)
副鼻腔炎	1 (1.7)	1 (1.7)	2 (1.7)
皮膚細菌感染	1 (1.7)	1 (1.7)	2 (1.7)
皮膚感染	1 (1.7)	1 (1.7)	2 (1.7)
ブドウ球菌感染	1 (1.7)	0	1 (0.8)
ブドウ球菌性敗血症	0	1 (1.7)	1 (0.8)
皮下組織膿瘍	0	1 (1.7)	1 (0.8)
足部白癬	0	1 (1.7)	1 (0.8)
上気道感染	10 (16.7)	12 (20.0)	22 (18.3)
尿路感染	1 (1.7)	3 (5.0)	4 (3.3)
ウイルス性下痢	0	1 (1.7)	1 (0.8)
ウイルス性上気道感染	1 (1.7)	2 (3.3)	3 (2.5)
傷害、中毒および処置合併症	4 (6.7)	3 (5.0)	7 (5.8)
脳振盪	1 (1.7)	0	1 (0.8)
転倒	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
傷害、中毒および処置合併症 (Cont.)			
頭部損傷	1 (1.7)	0	1 (0.8)
熱疲労	1 (1.7)	0	1 (0.8)
関節損傷	0	1 (1.7)	1 (0.8)
靭帯断裂	0	1 (1.7)	1 (0.8)
四肢損傷	0	1 (1.7)	1 (0.8)
半月板損傷	0	1 (1.7)	1 (0.8)
肉離れ	0	1 (1.7)	1 (0.8)
交通事故	0	1 (1.7)	1 (0.8)
皮膚擦過傷	1 (1.7)	0	1 (0.8)
臨床検査	9 (15.0)	15 (25.0)	24 (20.0)
アラニンアミノトランスフェラーゼ増加	1 (1.7)	0	1 (0.8)
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.7)	0	1 (0.8)
血中アルカリホスファターゼ増加	1 (1.7)	0	1 (0.8)
血中ビリルビン増加	1 (1.7)	0	1 (0.8)
血中コレステロール増加	0	2 (3.3)	2 (1.7)
血中クレアチンホスホキナーゼ増加	5 (8.3)	9 (15.0)	14 (11.7)
血中ブドウ糖増加	1 (1.7)	0	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
臨床検査 (Cont.)			
心雑音	0	1 (1.7)	1 (0.8)
ヘモグロビン減少	1 (1.7)	0	1 (0.8)
心拍数増加	0	2 (3.3)	2 (1.7)
肝酵素上昇	1 (1.7)	0	1 (0.8)
トランスアミナーゼ上昇	1 (1.7)	0	1 (0.8)
尿中シュウ酸塩	1 (1.7)	0	1 (0.8)
体重増加	1 (1.7)	4 (6.7)	5 (4.2)
代謝および栄養障害	2 (3.3)	1 (1.7)	3 (2.5)
低リン酸血症	0	1 (1.7)	1 (0.8)
食欲亢進	1 (1.7)	0	1 (0.8)
ビタミン D 欠乏	1 (1.7)	0	1 (0.8)
筋骨格系および結合組織障害	4 (6.7)	3 (5.0)	7 (5.8)
関節痛	1 (1.7)	1 (1.7)	2 (1.7)
筋肉痛	1 (1.7)	0	1 (0.8)
骨端症	0	1 (1.7)	1 (0.8)
四肢痛	0	1 (1.7)	1 (0.8)
顎痛	1 (1.7)	0	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
筋骨格系および結合組織障害 (Cont.)			
側弯症	1 (1.7)	0	1 (0.8)
滑液嚢腫	1 (1.7)	0	1 (0.8)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.7)	1 (1.7)	2 (1.7)
皮膚乳頭腫	1 (1.7)	1 (1.7)	2 (1.7)
神経系障害	7 (11.7)	5 (8.3)	12 (10.0)
錐体外路障害	1 (1.7)	0	1 (0.8)
頭痛	5 (8.3)	4 (6.7)	9 (7.5)
失神	0	1 (1.7)	1 (0.8)
緊張性頭痛	1 (1.7)	0	1 (0.8)
精神障害	6 (10.0)	2 (3.3)	8 (6.7)
適応障害	0	1 (1.7)	1 (0.8)
不安	2 (3.3)	0	2 (1.7)
不安障害	0	1 (1.7)	1 (0.8)
うつ病	2 (3.3)	0	2 (1.7)
故意の自傷行為	1 (1.7)	0	1 (0.8)
大うつ病	1 (1.7)	0	1 (0.8)
パニック発作	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
精神障害 (Cont.)			
睡眠障害	1 (1.7)	0	1 (0.8)
自殺念慮	1 (1.7)	0	1 (0.8)
腎および尿路障害	2 (3.3)	2 (3.3)	4 (3.3)
排尿困難	0	1 (1.7)	1 (0.8)
ケトン尿	1 (1.7)	0	1 (0.8)
白血球尿	1 (1.7)	0	1 (0.8)
蛋白尿	2 (3.3)	1 (1.7)	3 (2.5)
生殖系および乳房障害	2 (3.3)	1 (1.7)	3 (2.5)
無月経	0	1 (1.7)	1 (0.8)
月経困難症	1 (1.7)	0	1 (0.8)
月経過多	1 (1.7)	0	1 (0.8)
呼吸器、胸郭および縦隔障害	9 (15.0)	8 (13.3)	17 (14.2)
咳嗽	8 (13.3)	1 (1.7)	9 (7.5)
呼吸困難	0	1 (1.7)	1 (0.8)
鼻出血	1 (1.7)	2 (3.3)	3 (2.5)
口腔咽頭痛	2 (3.3)	2 (3.3)	4 (3.3)
湿性咳嗽	1 (1.7)	0	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
呼吸器、胸郭および縦隔障害 (Cont.)			
鼻漏	1 (1.7)	0	1 (0.8)
副鼻腔うっ血	1 (1.7)	1 (1.7)	2 (1.7)
扁桃結石	0	1 (1.7)	1 (0.8)
皮膚および皮下組織障害	18 (30.0)	31 (51.7)	49 (40.8)
ざ瘡	6 (10.0)	21 (35.0)	27 (22.5)
円形脱毛症	0	1 (1.7)	1 (0.8)
血管浮腫	0	1 (1.7)	1 (0.8)
皮膚炎	0	1 (1.7)	1 (0.8)
ざ瘡様皮膚炎	0	1 (1.7)	1 (0.8)
アレルギー性皮膚炎	0	1 (1.7)	1 (0.8)
アトピー性皮膚炎	6 (10.0)	2 (3.3)	8 (6.7)
接触皮膚炎	0	3 (5.0)	3 (2.5)
湿疹	3 (5.0)	0	3 (2.5)
紅斑	0	1 (1.7)	1 (0.8)
汗腺炎	0	1 (1.7)	1 (0.8)
多汗症	0	1 (1.7)	1 (0.8)
汗疹	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) n (%)	UPA 30 mg QD (N=60) n (%)	Total (N=120) n (%)
皮膚および皮下組織障害 (Cont.)			
口囲皮膚炎	1 (1.7)	0	1 (0.8)
炎症後色素沈着変化	1 (1.7)	0	1 (0.8)
そう痒症	0	1 (1.7)	1 (0.8)
発疹	0	2 (3.3)	2 (1.7)
斑状丘疹状皮疹	0	1 (1.7)	1 (0.8)
脂漏性皮膚炎	0	1 (1.7)	1 (0.8)
皮膚剥脱	1 (1.7)	0	1 (0.8)
蕁麻疹	5 (8.3)	1 (1.7)	6 (5.0)
尋常性白斑	0	1 (1.7)	1 (0.8)
乾皮症	1 (1.7)	0	1 (0.8)
外科および内科処置	1 (1.7)	0	1 (0.8)
収れん薬療法	1 (1.7)	0	1 (0.8)
血管障害	0	1 (1.7)	1 (0.8)
血腫	0	1 (1.7)	1 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W52 Table 14.3__1.5.1.2

表 3. ウパダシチニブ投与期間中に有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団，成人）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
Any adverse event	263 (77.1)	294 (84.5)	557 (80.8)
血液およびリンパ系障害	12 (3.5)	26 (7.5)	38 (5.5)
貧血	0	10 (2.9)	10 (1.5)
欠乏性貧血	1 (0.3)	1 (0.3)	2 (0.3)
鉄欠乏性貧血	0	1 (0.3)	1 (0.1)
白血球増加症	1 (0.3)	1 (0.3)	2 (0.3)
白血球減少症	0	1 (0.3)	1 (0.1)
リンパ節症	3 (0.9)	4 (1.1)	7 (1.0)
リンパ球減少症	1 (0.3)	2 (0.6)	3 (0.4)
好中球減少症	7 (2.1)	11 (3.2)	18 (2.6)
好中球増加症	1 (0.3)	0	1 (0.1)
汎血球減少症	0	1 (0.3)	1 (0.1)
脾腫	0	1 (0.3)	1 (0.1)
心臓障害	1 (0.3)	5 (1.4)	6 (0.9)
心房細動	0	1 (0.3)	1 (0.1)
徐脈	0	1 (0.3)	1 (0.1)
心血管障害	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
心臓障害 (Cont.)			
冠動脈疾患	0	1 (0.3)	1 (0.1)
心筋梗塞	0	1 (0.3)	1 (0.1)
動悸	0	1 (0.3)	1 (0.1)
先天性、家族性および遺伝性障害	2 (0.6)	1 (0.3)	3 (0.4)
第 II 因子変異	1 (0.3)	0	1 (0.1)
ネザートン症候群	1 (0.3)	0	1 (0.1)
包茎	0	1 (0.3)	1 (0.1)
耳および迷路障害	2 (0.6)	9 (2.6)	11 (1.6)
耳垢栓塞	0	3 (0.9)	3 (0.4)
耳痛	0	1 (0.3)	1 (0.1)
突発性難聴	0	1 (0.3)	1 (0.1)
鼓膜障害	0	1 (0.3)	1 (0.1)
回転性めまい	2 (0.6)	3 (0.9)	5 (0.7)
内分泌障害	2 (0.6)	2 (0.6)	4 (0.6)
バセドウ病	0	1 (0.3)	1 (0.1)
甲状腺機能低下症	2 (0.6)	0	2 (0.3)
甲状腺腫瘤	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
眼障害	11 (3.2)	19 (5.5)	30 (4.4)
眼瞼炎	0	2 (0.6)	2 (0.3)
白内障	1 (0.3)	0	1 (0.1)
霰粒腫	1 (0.3)	0	1 (0.1)
結膜出血	0	1 (0.3)	1 (0.1)
アレルギー性結膜炎	1 (0.3)	5 (1.4)	6 (0.9)
ドライアイ	1 (0.3)	3 (0.9)	4 (0.6)
眼瞼湿疹	0	1 (0.3)	1 (0.1)
眼瞼紅斑	0	1 (0.3)	1 (0.1)
眼そう痒症	0	1 (0.3)	1 (0.1)
眼部腫脹	1 (0.3)	1 (0.3)	2 (0.3)
緑内障	1 (0.3)	0	1 (0.1)
流涙増加	2 (0.6)	0	2 (0.3)
黄斑変性	1 (0.3)	0	1 (0.1)
黄斑円孔	0	1 (0.3)	1 (0.1)
眼窩周囲腫脹	1 (0.3)	2 (0.6)	3 (0.4)
翼状片	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
眼障害 (Cont.)			
網膜剥離	1 (0.3)	0	1 (0.1)
眼瞼腫脹	0	1 (0.3)	1 (0.1)
潰瘍性角膜炎	1 (0.3)	0	1 (0.1)
霧視	1 (0.3)	2 (0.6)	3 (0.4)
視力障害	1 (0.3)	0	1 (0.1)
胃腸障害	54 (15.8)	65 (18.7)	119 (17.3)
腹部不快感	1 (0.3)	1 (0.3)	2 (0.3)
腹部膨満	1 (0.3)	1 (0.3)	2 (0.3)
腹痛	1 (0.3)	7 (2.0)	8 (1.2)
上腹部痛	3 (0.9)	3 (0.9)	6 (0.9)
口角口唇炎	0	1 (0.3)	1 (0.1)
呼気臭	0	1 (0.3)	1 (0.1)
慢性胃炎	1 (0.3)	0	1 (0.1)
大腸炎	0	1 (0.3)	1 (0.1)
便秘	4 (1.2)	3 (0.9)	7 (1.0)
齲歯	5 (1.5)	2 (0.6)	7 (1.0)
下痢	12 (3.5)	10 (2.9)	22 (3.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
胃腸障害 (Cont.)			
腸憩室	1 (0.3)	0	1 (0.1)
口内乾燥	0	3 (0.9)	3 (0.4)
細菌叢異常	0	1 (0.3)	1 (0.1)
消化不良	3 (0.9)	2 (0.6)	5 (0.7)
軟便	0	2 (0.6)	2 (0.3)
鼓腸	3 (0.9)	2 (0.6)	5 (0.7)
食中毒	1 (0.3)	2 (0.6)	3 (0.4)
胃潰瘍	1 (0.3)	1 (0.3)	2 (0.3)
胃炎	4 (1.2)	0	4 (0.6)
びらん性胃炎	0	1 (0.3)	1 (0.1)
消化器痛	1 (0.3)	0	1 (0.1)
胃食道逆流性疾患	2 (0.6)	6 (1.7)	8 (1.2)
歯肉痛	1 (0.3)	1 (0.3)	2 (0.3)
痔核	2 (0.6)	3 (0.9)	5 (0.7)
裂孔ヘルニア	2 (0.6)	0	2 (0.3)
歯の知覚過敏	0	1 (0.3)	1 (0.1)
腸管穿孔	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
胃腸障害 (Cont.)			
過敏性腸症候群	0	1 (0.3)	1 (0.1)
口腔内潰瘍形成	0	2 (0.6)	2 (0.3)
悪心	12 (3.5)	13 (3.7)	25 (3.6)
食道狭窄	1 (0.3)	0	1 (0.1)
食道炎	1 (0.3)	0	1 (0.1)
大網梗塞	0	1 (0.3)	1 (0.1)
口腔障害	0	1 (0.3)	1 (0.1)
膵炎	0	1 (0.3)	1 (0.1)
ひだ舌	0	1 (0.3)	1 (0.1)
埋伏歯	3 (0.9)	0	3 (0.4)
歯痛	2 (0.6)	2 (0.6)	4 (0.6)
臍ヘルニア	0	1 (0.3)	1 (0.1)
嘔吐	5 (1.5)	7 (2.0)	12 (1.7)
一般・全身障害および投与部位の状態	32 (9.4)	33 (9.5)	65 (9.4)
無力症	1 (0.3)	1 (0.3)	2 (0.3)
胸部不快感	2 (0.6)	2 (0.6)	4 (0.6)
胸痛	3 (0.9)	0	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
一般・全身障害および投与部位の状態 (Cont.)			
悪寒	0	2 (0.6)	2 (0.3)
嚢胞	1 (0.3)	0	1 (0.1)
不快感	0	1 (0.3)	1 (0.1)
薬効欠如	1 (0.3)	0	1 (0.1)
薬物不耐性	0	1 (0.3)	1 (0.1)
顔面浮腫	1 (0.3)	1 (0.3)	2 (0.3)
疲労	4 (1.2)	4 (1.1)	8 (1.2)
びくびく感	0	1 (0.3)	1 (0.1)
重力性浮腫	0	1 (0.3)	1 (0.1)
インフルエンザ様疾患	6 (1.8)	9 (2.6)	15 (2.2)
倦怠感	0	1 (0.3)	1 (0.1)
腫瘤	1 (0.3)	0	1 (0.1)
小結節	0	1 (0.3)	1 (0.1)
非心臓性胸痛	0	3 (0.9)	3 (0.4)
末梢性浮腫	2 (0.6)	1 (0.3)	3 (0.4)
疼痛	0	3 (0.9)	3 (0.4)
発熱	12 (3.5)	6 (1.7)	18 (2.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
一般・全身障害および投与部位の状態 (Cont.)			
腫脹	1 (0.3)	0	1 (0.1)
顔面腫脹	1 (0.3)	0	1 (0.1)
血管穿刺部位内出血	0	1 (0.3)	1 (0.1)
乾燥症	0	1 (0.3)	1 (0.1)
肝胆道系障害	6 (1.8)	15 (4.3)	21 (3.0)
胆道仙痛	0	1 (0.3)	1 (0.1)
胆嚢炎	0	1 (0.3)	1 (0.1)
胆石症	2 (0.6)	1 (0.3)	3 (0.4)
胆嚢ポリープ	0	1 (0.3)	1 (0.1)
肝機能異常	1 (0.3)	3 (0.9)	4 (0.6)
脂肪肝	4 (1.2)	7 (2.0)	11 (1.6)
肝炎	0	1 (0.3)	1 (0.1)
肝腫大	0	2 (0.6)	2 (0.3)
高ビリルビン血症	1 (0.3)	0	1 (0.1)
免疫系障害	8 (2.3)	8 (2.3)	16 (2.3)
節足動物咬傷アレルギー	1 (0.3)	0	1 (0.1)
節足動物刺傷アレルギー	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
免疫系障害 (Cont.)			
化学物質アレルギー	1 (0.3)	0	1 (0.1)
ワクチンアレルギー	1 (0.3)	0	1 (0.1)
アナフィラキシー反応	0	1 (0.3)	1 (0.1)
食物アレルギー	2 (0.6)	2 (0.6)	4 (0.6)
過敏症	1 (0.3)	1 (0.3)	2 (0.3)
乳アレルギー	0	1 (0.3)	1 (0.1)
複合アレルギー	1 (0.3)	0	1 (0.1)
季節性アレルギー	1 (0.3)	2 (0.6)	3 (0.4)
1 型過敏症	0	1 (0.3)	1 (0.1)
感染症および寄生虫症	201 (58.9)	206 (59.2)	407 (59.1)
四肢膿瘍	0	1 (0.3)	1 (0.1)
ダニ皮膚炎	1 (0.3)	1 (0.3)	2 (0.3)
膿疱性ざ瘡	1 (0.3)	0	1 (0.1)
急性副鼻腔炎	1 (0.3)	0	1 (0.1)
虫垂炎	2 (0.6)	0	2 (0.3)
異型肺炎	0	1 (0.3)	1 (0.1)
細菌感染	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
感染症および寄生虫症 (Cont.)			
細菌性前立腺炎	1 (0.3)	0	1 (0.1)
細菌性膣症	0	2 (0.6)	2 (0.3)
細菌尿	0	1 (0.3)	1 (0.1)
体部白癬	4 (1.2)	1 (0.3)	5 (0.7)
乳房膿瘍	1 (0.3)	0	1 (0.1)
気管支炎	8 (2.3)	10 (2.9)	18 (2.6)
ウイルス性気管支炎	1 (0.3)	0	1 (0.1)
カンジダ感染	1 (0.3)	1 (0.3)	2 (0.3)
蜂巣炎	4 (1.2)	2 (0.6)	6 (0.9)
結膜炎	5 (1.5)	4 (1.1)	9 (1.3)
コロナウイルス感染	14 (4.1)	12 (3.4)	26 (3.8)
膀胱炎	2 (0.6)	3 (0.9)	5 (0.7)
感染性皮膚炎	1 (0.3)	1 (0.3)	2 (0.3)
皮膚糸状菌症	1 (0.3)	2 (0.6)	3 (0.4)
爪の皮膚糸状菌症	1 (0.3)	0	1 (0.1)
憩室炎	0	2 (0.6)	2 (0.3)
耳感染	2 (0.6)	5 (1.4)	7 (1.0)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
感染症および寄生虫症 (Cont.)			
膿瘡	2 (0.6)	0	2 (0.3)
ヘルペス性状湿疹	3 (0.9)	5 (1.4)	8 (1.2)
感染性湿疹	1 (0.3)	3 (0.9)	4 (0.6)
蟯虫症	0	1 (0.3)	1 (0.1)
丹毒	0	1 (0.3)	1 (0.1)
大腸菌性尿路感染	1 (0.3)	1 (0.3)	2 (0.3)
外耳蜂巣炎	1 (0.3)	0	1 (0.1)
眼感染	1 (0.3)	0	1 (0.1)
毛包炎	11 (3.2)	17 (4.9)	28 (4.1)
真菌感染	1 (0.3)	0	1 (0.1)
皮膚真菌感染	1 (0.3)	0	1 (0.1)
せつ	5 (1.5)	3 (0.9)	8 (1.2)
胃腸炎	4 (1.2)	12 (3.4)	16 (2.3)
ウイルス性胃腸炎	2 (0.6)	2 (0.6)	4 (0.6)
ウイルス性消化管感染	0	1 (0.3)	1 (0.1)
陰部ヘルペス	1 (0.3)	1 (0.3)	2 (0.3)
陰部単純ヘルペス	0	2 (0.6)	2 (0.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
感染症および寄生虫症 (Cont.)			
真菌性性器感染	1 (0.3)	1 (0.3)	2 (0.3)
歯肉炎	2 (0.6)	0	2 (0.3)
蠕虫感染	0	1 (0.3)	1 (0.1)
B 型肝炎	0	1 (0.3)	1 (0.1)
ヘルパンギーナ	0	1 (0.3)	1 (0.1)
ヘルペス性皮膚炎	0	2 (0.6)	2 (0.3)
ヘルペス眼感染	0	5 (1.4)	5 (0.7)
単純ヘルペス	11 (3.2)	17 (4.9)	28 (4.1)
ヘルペスウイルス感染	2 (0.6)	1 (0.3)	3 (0.4)
帯状疱疹	15 (4.4)	22 (6.3)	37 (5.4)
皮膚播種性帯状疱疹	0	2 (0.6)	2 (0.3)
麦粒腫	4 (1.2)	10 (2.9)	14 (2.0)
膿痂疹	9 (2.6)	4 (1.1)	13 (1.9)
感染性皮膚嚢腫	0	1 (0.3)	1 (0.1)
インフルエンザ	4 (1.2)	7 (2.0)	11 (1.6)
椎間板炎	1 (0.3)	0	1 (0.1)
カポジ水痘様発疹	2 (0.6)	5 (1.4)	7 (1.0)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
感染症および寄生虫症 (Cont.)			
喉頭炎	2 (0.6)	3 (0.9)	5 (0.7)
ウイルス性喉頭炎	1 (0.3)	0	1 (0.1)
潜伏結核	4 (1.2)	4 (1.1)	8 (1.2)
限局性感染	2 (0.6)	0	2 (0.3)
下気道感染	1 (0.3)	0	1 (0.1)
細菌性リンパ節炎	0	1 (0.3)	1 (0.1)
伝染性軟属腫	5 (1.5)	5 (1.4)	10 (1.5)
マイコプラズマ感染	0	1 (0.3)	1 (0.1)
上咽頭炎	44 (12.9)	44 (12.6)	88 (12.8)
食道カンジダ症	0	1 (0.3)	1 (0.1)
爪真菌症	2 (0.6)	3 (0.9)	5 (0.7)
眼部単純ヘルペス	2 (0.6)	3 (0.9)	5 (0.7)
眼帯状疱疹	1 (0.3)	0	1 (0.1)
口腔カンジダ症	2 (0.6)	4 (1.1)	6 (0.9)
口腔ヘルペス	13 (3.8)	23 (6.6)	36 (5.2)
外耳炎	3 (0.9)	2 (0.6)	5 (0.7)
中耳炎	3 (0.9)	5 (1.4)	8 (1.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
感染症および寄生虫症 (Cont.)			
急性中耳炎	1 (0.3)	1 (0.3)	2 (0.3)
爪囲炎	2 (0.6)	6 (1.7)	8 (1.2)
ヘリコバクター性消化性潰瘍	0	1 (0.3)	1 (0.1)
インプラント周囲炎	0	1 (0.3)	1 (0.1)
歯周炎	1 (0.3)	0	1 (0.1)
咽頭膿瘍	0	1 (0.3)	1 (0.1)
咽頭炎	6 (1.8)	3 (0.9)	9 (1.3)
レンサ球菌性咽頭炎	1 (0.3)	0	1 (0.1)
咽頭扁桃炎	0	1 (0.3)	1 (0.1)
肺炎	4 (1.2)	2 (0.6)	6 (0.9)
細菌性肺炎	0	1 (0.3)	1 (0.1)
ブドウ球菌性肺炎	0	1 (0.3)	1 (0.1)
術後創感染	1 (0.3)	1 (0.3)	2 (0.3)
肺結核	1 (0.3)	0	1 (0.1)
膿疱	0	1 (0.3)	1 (0.1)
腎盂腎炎	0	1 (0.3)	1 (0.1)
膿皮症	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
感染症および寄生虫症 (Cont.)			
膿疱性皮疹	1 (0.3)	1 (0.3)	2 (0.3)
RS ウイルス感染	0	1 (0.3)	1 (0.1)
気道感染	1 (0.3)	1 (0.3)	2 (0.3)
ウイルス性気道感染	1 (0.3)	2 (0.6)	3 (0.4)
鼻炎	4 (1.2)	4 (1.1)	8 (1.2)
ライノウイルス感染	0	1 (0.3)	1 (0.1)
根管感染	0	1 (0.3)	1 (0.1)
敗血症	0	1 (0.3)	1 (0.1)
副鼻腔炎	8 (2.3)	7 (2.0)	15 (2.2)
皮膚細菌感染	1 (0.3)	2 (0.6)	3 (0.4)
皮膚カンジダ	1 (0.3)	1 (0.3)	2 (0.3)
植皮感染	0	1 (0.3)	1 (0.1)
皮膚感染	4 (1.2)	6 (1.7)	10 (1.5)
ブドウ球菌性膿痂疹	0	1 (0.3)	1 (0.1)
ブドウ球菌感染	0	5 (1.4)	5 (0.7)
ブドウ球菌性敗血症	1 (0.3)	0	1 (0.1)
ブドウ球菌皮膚感染	1 (0.3)	1 (0.3)	2 (0.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
感染症および寄生虫症 (Cont.)			
股部白癬	0	4 (1.1)	4 (0.6)
足部白癬	4 (1.2)	5 (1.4)	9 (1.3)
癜風	3 (0.9)	1 (0.3)	4 (0.6)
扁桃炎	2 (0.6)	5 (1.4)	7 (1.0)
細菌性扁桃炎	0	1 (0.3)	1 (0.1)
歯膿瘍	4 (1.2)	2 (0.6)	6 (0.9)
歯感染	3 (0.9)	3 (0.9)	6 (0.9)
気管炎	0	2 (0.6)	2 (0.3)
上気道感染	43 (12.6)	43 (12.4)	86 (12.5)
細菌性上気道感染	0	1 (0.3)	1 (0.1)
クラミジア性尿道炎	1 (0.3)	0	1 (0.1)
尿路感染	14 (4.1)	18 (5.2)	32 (4.6)
細菌性尿路感染	1 (0.3)	0	1 (0.1)
水痘	0	1 (0.3)	1 (0.1)
ウイルス感染	3 (0.9)	1 (0.3)	4 (0.6)
ウイルス性咽頭炎	1 (0.3)	0	1 (0.1)
ウイルス性発疹	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
感染症および寄生虫症 (Cont.)			
ウイルス性上気道感染	9 (2.6)	13 (3.7)	22 (3.2)
外陰部腟カンジダ症	3 (0.9)	2 (0.6)	5 (0.7)
外陰腟真菌感染	2 (0.6)	0	2 (0.3)
外陰腟炎	1 (0.3)	0	1 (0.1)
創傷感染	0	1 (0.3)	1 (0.1)
ブドウ球菌性創感染	0	1 (0.3)	1 (0.1)
傷害、中毒および処置合併症	38 (11.1)	45 (12.9)	83 (12.0)
腹壁損傷	1 (0.3)	0	1 (0.1)
偶発的過量投与	0	1 (0.3)	1 (0.1)
アルコール中毒	0	1 (0.3)	1 (0.1)
動物咬傷	1 (0.3)	0	1 (0.1)
節足動物咬傷	4 (1.2)	3 (0.9)	7 (1.0)
節足動物刺傷	0	1 (0.3)	1 (0.1)
背部損傷	1 (0.3)	0	1 (0.1)
第１度熱傷	1 (0.3)	1 (0.3)	2 (0.3)
第２度熱傷	1 (0.3)	0	1 (0.1)
第３度熱傷	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
傷害、中毒および処置合併症 (Cont.)			
軟骨損傷	1 (0.3)	0	1 (0.1)
脳振盪	1 (0.3)	1 (0.3)	2 (0.3)
挫傷	3 (0.9)	1 (0.3)	4 (0.6)
転倒	4 (1.2)	4 (1.1)	8 (1.2)
大腿骨骨折	0	1 (0.3)	1 (0.1)
腓骨骨折	0	1 (0.3)	1 (0.1)
足骨折	2 (0.6)	3 (0.9)	5 (0.7)
前腕骨折	0	1 (0.3)	1 (0.1)
体内異物	0	1 (0.3)	1 (0.1)
手骨折	0	1 (0.3)	1 (0.1)
頭部損傷	0	1 (0.3)	1 (0.1)
損傷	1 (0.3)	0	1 (0.1)
関節脱臼	1 (0.3)	1 (0.3)	2 (0.3)
関節損傷	3 (0.9)	0	3 (0.4)
靱帯断裂	1 (0.3)	0	1 (0.1)
靱帯捻挫	3 (0.9)	4 (1.1)	7 (1.0)
四肢損傷	3 (0.9)	3 (0.9)	6 (0.9)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
傷害、中毒および処置合併症 (Cont.)			
口唇損傷	0	1 (0.3)	1 (0.1)
筋断裂	0	1 (0.3)	1 (0.1)
肉離れ	3 (0.9)	3 (0.9)	6 (0.9)
筋骨格系損傷	0	1 (0.3)	1 (0.1)
膝蓋骨骨折	1 (0.3)	0	1 (0.1)
処置による疼痛	0	2 (0.6)	2 (0.3)
橈骨骨折	0	1 (0.3)	1 (0.1)
肋骨骨折	0	1 (0.3)	1 (0.1)
交通事故	2 (0.6)	0	2 (0.3)
瘢痕	1 (0.3)	0	1 (0.1)
皮膚擦過傷	1 (0.3)	2 (0.6)	3 (0.4)
皮膚裂傷	1 (0.3)	3 (0.9)	4 (0.6)
スポーツ損傷	0	1 (0.3)	1 (0.1)
ストレス骨折	0	1 (0.3)	1 (0.1)
サンバーン	1 (0.3)	1 (0.3)	2 (0.3)
腱損傷	0	1 (0.3)	1 (0.1)
腱断裂	2 (0.6)	2 (0.6)	4 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
傷害、中毒および処置合併症 (Cont.)			
熱傷	1 (0.3)	1 (0.3)	2 (0.3)
脛骨骨折	0	1 (0.3)	1 (0.1)
歯牙破折	0	1 (0.3)	1 (0.1)
尺骨骨折	1 (0.3)	0	1 (0.1)
上肢骨折	1 (0.3)	0	1 (0.1)
ワクチン接種合併症	0	1 (0.3)	1 (0.1)
臨床検査	50 (14.7)	71 (20.4)	121 (17.6)
アラニンアミノトランスフェラーゼ増加	8 (2.3)	13 (3.7)	21 (3.0)
アスパラギン酸アミノトランスフェラーゼ増加	5 (1.5)	10 (2.9)	15 (2.2)
B リンパ球数増加	1 (0.3)	1 (0.3)	2 (0.3)
血中ビリルビン増加	0	2 (0.6)	2 (0.3)
血中コレステロール増加	2 (0.6)	5 (1.4)	7 (1.0)
血中クレアチンホスホキナーゼ増加	17 (5.0)	35 (10.1)	52 (7.5)
血中クレアチニン増加	3 (0.9)	0	3 (0.4)
血中ブドウ糖増加	0	2 (0.6)	2 (0.3)
血中免疫グロブリン E 増加	6 (1.8)	2 (0.6)	8 (1.2)
血中乳酸脱水素酵素増加	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
臨床検査 (Cont.)			
血中カリウム増加	1 (0.3)	0	1 (0.1)
血圧上昇	1 (0.3)	0	1 (0.1)
血中トリグリセリド増加	3 (0.9)	0	3 (0.4)
血中尿酸増加	0	3 (0.9)	3 (0.4)
尿中血陽性	3 (0.9)	1 (0.3)	4 (0.6)
CD4 リンパ球減少	1 (0.3)	0	1 (0.1)
CD8 リンパ球百分率減少	1 (0.3)	0	1 (0.1)
CD8 リンパ球減少	0	1 (0.3)	1 (0.1)
心雑音	0	1 (0.3)	1 (0.1)
ケモカイン増加	1 (0.3)	0	1 (0.1)
胸部コンピュータ断層撮影異常	0	1 (0.3)	1 (0.1)
尿中結晶陽性	1 (0.3)	1 (0.3)	2 (0.3)
心電図 QT 間隔異常	1 (0.3)	0	1 (0.1)
好酸球百分率増加	1 (0.3)	0	1 (0.1)
尿中ブドウ糖陽性	0	1 (0.3)	1 (0.1)
ヘモグロビン減少	0	4 (1.1)	4 (0.6)
肝酵素上昇	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
臨床検査 (Cont.)			
高比重リポ蛋白増加	0	1 (0.3)	1 (0.1)
免疫グロブリン増加	1 (0.3)	0	1 (0.1)
肝機能検査値上昇	1 (0.3)	0	1 (0.1)
低比重リポ蛋白増加	0	2 (0.6)	2 (0.3)
リンパ節触知	1 (0.3)	0	1 (0.1)
リンパ球数減少	0	3 (0.9)	3 (0.4)
ナチュラルキラー細胞数減少	1 (0.3)	1 (0.3)	2 (0.3)
好中球数減少	2 (0.6)	3 (0.9)	5 (0.7)
血小板数増加	1 (0.3)	1 (0.3)	2 (0.3)
尿妊娠反応陽性	1 (0.3)	0	1 (0.1)
尿蛋白	1 (0.3)	0	1 (0.1)
尿中蛋白陽性	2 (0.6)	2 (0.6)	4 (0.6)
赤血球数減少	0	1 (0.3)	1 (0.1)
T リンパ球数減少	1 (0.3)	0	1 (0.1)
トランスアミナーゼ上昇	1 (0.3)	5 (1.4)	6 (0.9)
腫瘍マーカー上昇	0	1 (0.3)	1 (0.1)
尿円柱	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
臨床検査 (Cont.)			
尿中ケトン体陽性	1 (0.3)	0	1 (0.1)
尿中白血球エステラーゼ陽性	0	1 (0.3)	1 (0.1)
体重減少	0	3 (0.9)	3 (0.4)
体重増加	8 (2.3)	12 (3.4)	20 (2.9)
白血球数減少	1 (0.3)	4 (1.1)	5 (0.7)
代謝および栄養障害	21 (6.2)	26 (7.5)	47 (6.8)
食欲減退	1 (0.3)	3 (0.9)	4 (0.6)
糖尿病	1 (0.3)	0	1 (0.1)
脂質異常症	1 (0.3)	2 (0.6)	3 (0.4)
耐糖能障害	0	1 (0.3)	1 (0.1)
痛風	1 (0.3)	1 (0.3)	2 (0.3)
高コレステロール血症	2 (0.6)	5 (1.4)	7 (1.0)
高脂血症	4 (1.2)	1 (0.3)	5 (0.7)
高トリグリセリド血症	3 (0.9)	4 (1.1)	7 (1.0)
高尿酸血症	5 (1.5)	3 (0.9)	8 (1.2)
低血糖	0	1 (0.3)	1 (0.1)
低カリウム血症	0	3 (0.9)	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
代謝および栄養障害 (Cont.)			
低リン酸血症	1 (0.3)	0	1 (0.1)
食欲亢進	1 (0.3)	2 (0.6)	3 (0.4)
2 型糖尿病	0	1 (0.3)	1 (0.1)
ビタミン B12 欠乏	0	1 (0.3)	1 (0.1)
ビタミン D 欠乏	2 (0.6)	2 (0.6)	4 (0.6)
筋骨格系および結合組織障害	36 (10.6)	42 (12.1)	78 (11.3)
関節痛	6 (1.8)	9 (2.6)	15 (2.2)
関節炎	2 (0.6)	0	2 (0.3)
腋窩腫瘤	0	1 (0.3)	1 (0.1)
背部痛	8 (2.3)	16 (4.6)	24 (3.5)
骨嚢腫	1 (0.3)	0	1 (0.1)
滑液包炎	2 (0.6)	0	2 (0.3)
側腹部痛	1 (0.3)	0	1 (0.1)
足変形	1 (0.3)	0	1 (0.1)
椎間板変性症	0	1 (0.3)	1 (0.1)
椎間板突出	1 (0.3)	1 (0.3)	2 (0.3)
筋力低下	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
筋骨格系および結合組織障害 (Cont.)			
筋骨格系胸痛	0	2 (0.6)	2 (0.3)
筋骨格痛	4 (1.2)	2 (0.6)	6 (0.9)
筋肉痛	5 (1.5)	8 (2.3)	13 (1.9)
筋膜疼痛症候群	1 (0.3)	0	1 (0.1)
頚部痛	2 (0.6)	0	2 (0.3)
変形性関節症	1 (0.3)	2 (0.6)	3 (0.4)
四肢痛	1 (0.3)	6 (1.7)	7 (1.0)
顎痛	0	1 (0.3)	1 (0.1)
骨膜炎	0	1 (0.3)	1 (0.1)
肩回旋筋腱板症候群	0	2 (0.6)	2 (0.3)
変形性脊椎症	1 (0.3)	0	1 (0.1)
脊椎炎	0	1 (0.3)	1 (0.1)
腱炎	3 (0.9)	3 (0.9)	6 (0.9)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	12 (3.5)	17 (4.9)	29 (4.2)
肛門性器疣贅	2 (0.6)	0	2 (0.3)
基底細胞癌	0	1 (0.3)	1 (0.1)
骨新生物	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） (Cont.)			
ボーエン病	1 (0.3)	0	1 (0.1)
乳癌	1 (0.3)	0	1 (0.1)
真珠腫	0	1 (0.3)	1 (0.1)
結腸癌	1 (0.3)	0	1 (0.1)
胃癌	0	1 (0.3)	1 (0.1)
血管腫	1 (0.3)	0	1 (0.1)
浸潤性乳管癌	0	1 (0.3)	1 (0.1)
脂肪腫	1 (0.3)	1 (0.3)	2 (0.3)
メラノサイト性母斑	0	1 (0.3)	1 (0.1)
非分泌型下垂体腺腫	0	1 (0.3)	1 (0.1)
脂漏性角化症	0	1 (0.3)	1 (0.1)
皮膚乳頭腫	5 (1.5)	8 (2.3)	13 (1.9)
皮膚有棘細胞癌	0	2 (0.6)	2 (0.3)
神経系障害	37 (10.9)	33 (9.5)	70 (10.2)
健忘	0	1 (0.3)	1 (0.1)
手根管症候群	2 (0.6)	0	2 (0.3)
注意力障害	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
神経系障害 (Cont.)			
浮動性めまい	5 (1.5)	7 (2.0)	12 (1.7)
夢幻状態	1 (0.3)	0	1 (0.1)
味覚不全	0	1 (0.3)	1 (0.1)
頭痛	18 (5.3)	20 (5.7)	38 (5.5)
過眠症	1 (0.3)	0	1 (0.1)
虚血性脳卒中	1 (0.3)	0	1 (0.1)
片頭痛	2 (0.6)	2 (0.6)	4 (0.6)
前兆を伴う片頭痛	0	1 (0.3)	1 (0.1)
神経痛	0	2 (0.6)	2 (0.3)
錯感覚	2 (0.6)	0	2 (0.3)
失神寸前の状態	1 (0.3)	0	1 (0.1)
神経根障害	0	1 (0.3)	1 (0.1)
坐骨神経痛	2 (0.6)	2 (0.6)	4 (0.6)
感覚消失	1 (0.3)	0	1 (0.1)
傾眠	2 (0.6)	0	2 (0.3)
失神	0	1 (0.3)	1 (0.1)
緊張性頭痛	2 (0.6)	2 (0.6)	4 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
製品の問題	1 (0.3)	0	1 (0.1)
医療機器破損	1 (0.3)	0	1 (0.1)
精神障害	14 (4.1)	16 (4.6)	30 (4.4)
不安	4 (1.2)	8 (2.3)	12 (1.7)
無感情	1 (0.3)	0	1 (0.1)
注意欠陥多動性障害	1 (0.3)	1 (0.3)	2 (0.3)
抑うつ気分	0	1 (0.3)	1 (0.1)
うつ病	1 (0.3)	3 (0.9)	4 (0.6)
自傷性皮膚症	1 (0.3)	0	1 (0.1)
失見当識	0	1 (0.3)	1 (0.1)
不眠症	2 (0.6)	4 (1.1)	6 (0.9)
リビドー減退	1 (0.3)	0	1 (0.1)
大うつ病	0	1 (0.3)	1 (0.1)
躁病	1 (0.3)	0	1 (0.1)
混合性不安抑うつ障害	1 (0.3)	0	1 (0.1)
睡眠障害	2 (0.6)	0	2 (0.3)
ストレス	1 (0.3)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
腎および尿路障害	8 (2.3)	14 (4.0)	22 (3.2)
急性腎障害	0	1 (0.3)	1 (0.1)
アルブミン尿	1 (0.3)	2 (0.6)	3 (0.4)
排尿困難	1 (0.3)	3 (0.9)	4 (0.6)
血尿	2 (0.6)	1 (0.3)	3 (0.4)
高シュウ酸尿症	1 (0.3)	0	1 (0.1)
緊張性膀胱	0	1 (0.3)	1 (0.1)
尿意切迫	1 (0.3)	0	1 (0.1)
腎結石症	1 (0.3)	2 (0.6)	3 (0.4)
頻尿	0	1 (0.3)	1 (0.1)
蛋白尿	1 (0.3)	2 (0.6)	3 (0.4)
腎不全	0	1 (0.3)	1 (0.1)
尿路障害	1 (0.3)	0	1 (0.1)
生殖系および乳房障害	9 (2.6)	9 (2.6)	18 (2.6)
無月経	1 (0.3)	2 (0.6)	3 (0.4)
亀頭包皮炎	1 (0.3)	0	1 (0.1)
良性前立腺肥大症	1 (0.3)	1 (0.3)	2 (0.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
生殖系および乳房障害 (Cont.)			
乳房腫大	0	1 (0.3)	1 (0.1)
乳房圧痛	0	1 (0.3)	1 (0.1)
月経困難症	2 (0.6)	0	2 (0.3)
乳管拡張症	1 (0.3)	0	1 (0.1)
閉経期症状	0	1 (0.3)	1 (0.1)
月経過多	1 (0.3)	1 (0.3)	2 (0.3)
不規則月経	1 (0.3)	0	1 (0.1)
会陰瘙	0	1 (0.3)	1 (0.1)
多嚢胞性卵巣	1 (0.3)	1 (0.3)	2 (0.3)
精巣痛	0	1 (0.3)	1 (0.1)
腟分泌物	1 (0.3)	0	1 (0.1)
外陰腟乾燥	0	1 (0.3)	1 (0.1)
呼吸器、胸郭および縦隔障害	32 (9.4)	37 (10.6)	69 (10.0)
喘息	8 (2.3)	6 (1.7)	14 (2.0)
気管支反応性亢進	1 (0.3)	0	1 (0.1)
慢性閉塞性肺疾患	0	1 (0.3)	1 (0.1)
咳嗽	12 (3.5)	10 (2.9)	22 (3.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
呼吸器、胸郭および縦隔障害 (Cont.)			
嚢胞性肺疾患	1 (0.3)	0	1 (0.1)
発声障害	1 (0.3)	0	1 (0.1)
呼吸困難	2 (0.6)	2 (0.6)	4 (0.6)
労作性呼吸困難	0	1 (0.3)	1 (0.1)
鼻出血	2 (0.6)	4 (1.1)	6 (0.9)
鼻閉	1 (0.3)	3 (0.9)	4 (0.6)
鼻乾燥	0	1 (0.3)	1 (0.1)
口腔咽頭痛	7 (2.1)	10 (2.9)	17 (2.5)
気胸	0	1 (0.3)	1 (0.1)
湿性咳嗽	1 (0.3)	1 (0.3)	2 (0.3)
肺腫瘤	0	1 (0.3)	1 (0.1)
アレルギー性鼻炎	2 (0.6)	2 (0.6)	4 (0.6)
鼻漏	1 (0.3)	1 (0.3)	2 (0.3)
副鼻腔うっ血	0	1 (0.3)	1 (0.1)
咽喉刺激感	1 (0.3)	1 (0.3)	2 (0.3)
上気道の炎症	0	1 (0.3)	1 (0.1)
声帯肥厚	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
皮膚および皮下組織障害	104 (30.5)	138 (39.7)	242 (35.1)
ざ瘡	35 (10.3)	78 (22.4)	113 (16.4)
光線角化症	3 (0.9)	1 (0.3)	4 (0.6)
脱毛症	1 (0.3)	2 (0.6)	3 (0.4)
血管浮腫	1 (0.3)	1 (0.3)	2 (0.3)
水疱	1 (0.3)	0	1 (0.1)
冷汗	1 (0.3)	0	1 (0.1)
頭部粃糠疹	0	1 (0.3)	1 (0.1)
皮膚嚢腫	0	2 (0.6)	2 (0.3)
皮膚炎	3 (0.9)	3 (0.9)	6 (0.9)
ざ瘡様皮膚炎	3 (0.9)	14 (4.0)	17 (2.5)
アレルギー性皮膚炎	0	1 (0.3)	1 (0.1)
アトピー性皮膚炎	35 (10.3)	23 (6.6)	58 (8.4)
接触皮膚炎	3 (0.9)	10 (2.9)	13 (1.9)
びまん性脱毛症	0	1 (0.3)	1 (0.1)
薬疹	1 (0.3)	0	1 (0.1)
異汗性湿疹	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
皮膚および皮下組織障害 (Cont.)			
斑状出血	1 (0.3)	0	1 (0.1)
湿疹	4 (1.2)	4 (1.1)	8 (1.2)
紅斑	2 (0.6)	1 (0.3)	3 (0.4)
温熱性紅斑	1 (0.3)	0	1 (0.1)
毛包性ムチン沈着症	0	1 (0.3)	1 (0.1)
毛髪成長異常	0	1 (0.3)	1 (0.1)
逆むけ	0	1 (0.3)	1 (0.1)
汗腺炎	1 (0.3)	0	1 (0.1)
多汗症	0	2 (0.6)	2 (0.3)
嵌入爪	1 (0.3)	0	1 (0.1)
内方発育毛	1 (0.3)	0	1 (0.1)
間擦疹	0	1 (0.3)	1 (0.1)
機械性蕁麻疹	0	1 (0.3)	1 (0.1)
汗疹	1 (0.3)	0	1 (0.1)
神経皮膚炎	1 (0.3)	0	1 (0.1)
寝汗	1 (0.3)	1 (0.3)	2 (0.3)
爪破損	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
皮膚および皮下組織障害 (Cont.)			
皮膚疼痛	1 (0.3)	0	1 (0.1)
類乾癬	0	1 (0.3)	1 (0.1)
口囲皮膚炎	2 (0.6)	1 (0.3)	3 (0.4)
光線過敏性反応	1 (0.3)	2 (0.6)	3 (0.4)
そう痒症	5 (1.5)	0	5 (0.7)
紫斑	0	1 (0.3)	1 (0.1)
発疹	2 (0.6)	1 (0.3)	3 (0.4)
斑状丘疹状皮疹	1 (0.3)	0	1 (0.1)
丘疹性皮疹	1 (0.3)	0	1 (0.1)
酒さ	1 (0.3)	4 (1.1)	5 (0.7)
脂漏	1 (0.3)	0	1 (0.1)
脂漏性皮膚炎	2 (0.6)	2 (0.6)	4 (0.6)
皮膚障害	0	1 (0.3)	1 (0.1)
皮膚亀裂	1 (0.3)	0	1 (0.1)
皮膚病変	1 (0.3)	0	1 (0.1)
皮膚腫脹	2 (0.6)	0	2 (0.3)
日光黒子	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) n (%)	UPA 30 mg QD (N=348) n (%)	Total (N=689) n (%)
皮膚および皮下組織障害 (Cont.)			
毛細血管拡張症	1 (0.3)	0	1 (0.1)
中毒性表皮壊死融解症	1 (0.3)	0	1 (0.1)
蕁麻疹	7 (2.1)	8 (2.3)	15 (2.2)
コリン性蕁麻疹	1 (0.3)	0	1 (0.1)
黄色板腫	1 (0.3)	0	1 (0.1)
外科および内科処置	1 (0.3)	1 (0.3)	2 (0.3)
人工流産	1 (0.3)	1 (0.3)	2 (0.3)
血管障害	13 (3.8)	9 (2.6)	22 (3.2)
血性分泌物	1 (0.3)	0	1 (0.1)
深部静脈血栓症	1 (0.3)	0	1 (0.1)
潮紅	1 (0.3)	0	1 (0.1)
血腫	3 (0.9)	0	3 (0.4)
ほてり	0	1 (0.3)	1 (0.1)
高血圧	8 (2.3)	6 (1.7)	14 (2.0)
低血圧	0	1 (0.3)	1 (0.1)
血栓性静脈炎	0	1 (0.3)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W52 Table 14.3__1.5.1.3

表 4. ウパダシチニブ投与期間中の有害事象の 100 人年あたりの発現率：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
Any adverse event	1288 (262.4)	1658 (330.9)	2946 (297.0)
血液およびリンパ系障害	19 (3.9)	47 (9.4)	66 (6.7)
貧血	0	13 (2.6)	13 (1.3)
欠乏性貧血	1 (0.2)	1 (0.2)	2 (0.2)
鉄欠乏性貧血	0	1 (0.2)	1 (0.1)
白血球増加症	1 (0.2)	1 (0.2)	2 (0.2)
白血球減少症	0	2 (0.4)	2 (0.2)
リンパ節症	4 (0.8)	4 (0.8)	8 (0.8)
リンパ球減少症	2 (0.4)	2 (0.4)	4 (0.4)
好中球減少症	9 (1.8)	20 (4.0)	29 (2.9)
好中球増加症	2 (0.4)	0	2 (0.2)
汎血球減少症	0	1 (0.2)	1 (0.1)
脾腫	0	1 (0.2)	1 (0.1)
血小板減少症	0	1 (0.2)	1 (0.1)
心臓障害	1 (0.2)	5 (1.0)	6 (0.6)
心房細動	0	1 (0.2)	1 (0.1)
徐脈	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
心臓障害 (Cont.)			
心血管障害	1 (0.2)	0	1 (0.1)
冠動脈疾患	0	1 (0.2)	1 (0.1)
心筋梗塞	0	1 (0.2)	1 (0.1)
動悸	0	1 (0.2)	1 (0.1)
先天性、家族性および遺伝性障害	2 (0.4)	1 (0.2)	3 (0.3)
第 II 因子変異	1 (0.2)	0	1 (0.1)
ネザートン症候群	1 (0.2)	0	1 (0.1)
包茎	0	1 (0.2)	1 (0.1)
耳および迷路障害	6 (1.2)	9 (1.8)	15 (1.5)
耳垢栓塞	0	3 (0.6)	3 (0.3)
耳痛	0	1 (0.2)	1 (0.1)
突発性難聴	0	1 (0.2)	1 (0.1)
鼓膜障害	0	1 (0.2)	1 (0.1)
回転性めまい	6 (1.2)	3 (0.6)	9 (0.9)
内分泌障害	2 (0.4)	2 (0.4)	4 (0.4)
バセドウ病	0	1 (0.2)	1 (0.1)
甲状腺機能低下症	2 (0.4)	0	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
内分泌障害 (Cont.)			
甲状腺腫瘤	0	1 (0.2)	1 (0.1)
眼障害	15 (3.1)	24 (4.8)	39 (3.9)
眼瞼炎	0	2 (0.4)	2 (0.2)
白内障	1 (0.2)	0	1 (0.1)
霰粒腫	1 (0.2)	0	1 (0.1)
結膜出血	0	1 (0.2)	1 (0.1)
アレルギー性結膜炎	1 (0.2)	5 (1.0)	6 (0.6)
ドライアイ	1 (0.2)	3 (0.6)	4 (0.4)
眼瞼湿疹	0	1 (0.2)	1 (0.1)
眼瞼紅斑	0	1 (0.2)	1 (0.1)
眼そう痒症	0	1 (0.2)	1 (0.1)
眼部腫脹	1 (0.2)	1 (0.2)	2 (0.2)
眼瞼浮腫	0	1 (0.2)	1 (0.1)
緑内障	1 (0.2)	0	1 (0.1)
流涙増加	2 (0.4)	1 (0.2)	3 (0.3)
黄斑変性	1 (0.2)	0	1 (0.1)
黄斑円孔	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
眼障害 (Cont.)			
眼窩周囲腫脹	1 (0.2)	2 (0.4)	3 (0.3)
翼状片	1 (0.2)	0	1 (0.1)
網膜剥離	1 (0.2)	0	1 (0.1)
眼瞼腫脹	0	1 (0.2)	1 (0.1)
潰瘍性角膜炎	1 (0.2)	0	1 (0.1)
霧視	1 (0.2)	3 (0.6)	4 (0.4)
視力障害	1 (0.2)	0	1 (0.1)
胃腸障害	86 (17.5)	110 (22.0)	196 (19.8)
腹部不快感	1 (0.2)	1 (0.2)	2 (0.2)
腹部膨満	1 (0.2)	1 (0.2)	2 (0.2)
腹痛	1 (0.2)	8 (1.6)	9 (0.9)
上腹部痛	5 (1.0)	5 (1.0)	10 (1.0)
口角口唇炎	0	1 (0.2)	1 (0.1)
呼気臭	0	1 (0.2)	1 (0.1)
慢性胃炎	1 (0.2)	0	1 (0.1)
大腸炎	0	1 (0.2)	1 (0.1)
便秘	4 (0.8)	3 (0.6)	7 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
胃腸障害 (Cont.)			
齲歯	6 (1.2)	4 (0.8)	10 (1.0)
下痢	13 (2.6)	18 (3.6)	31 (3.1)
腸憩室	1 (0.2)	0	1 (0.1)
口内乾燥	0	4 (0.8)	4 (0.4)
細菌叢異常	0	1 (0.2)	1 (0.1)
消化不良	3 (0.6)	2 (0.4)	5 (0.5)
軟便	0	2 (0.4)	2 (0.2)
鼓腸	3 (0.6)	2 (0.4)	5 (0.5)
食中毒	1 (0.2)	3 (0.6)	4 (0.4)
胃潰瘍	1 (0.2)	1 (0.2)	2 (0.2)
胃炎	5 (1.0)	0	5 (0.5)
びらん性胃炎	0	1 (0.2)	1 (0.1)
胃腸障害	1 (0.2)	0	1 (0.1)
消化器痛	1 (0.2)	0	1 (0.1)
胃食道逆流性疾患	2 (0.4)	7 (1.4)	9 (0.9)
歯肉痛	1 (0.2)	1 (0.2)	2 (0.2)
痔核	2 (0.4)	4 (0.8)	6 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
胃腸障害 (Cont.)			
裂孔ヘルニア	2 (0.4)	0	2 (0.2)
歯の知覚過敏	0	1 (0.2)	1 (0.1)
腸管穿孔	1 (0.2)	0	1 (0.1)
過敏性腸症候群	0	1 (0.2)	1 (0.1)
口唇腫脹	0	1 (0.2)	1 (0.1)
口腔内潰瘍形成	0	2 (0.4)	2 (0.2)
悪心	15 (3.1)	16 (3.2)	31 (3.1)
食道狭窄	1 (0.2)	0	1 (0.1)
食道炎	1 (0.2)	0	1 (0.1)
大網梗塞	0	1 (0.2)	1 (0.1)
口腔障害	0	1 (0.2)	1 (0.1)
膵炎	0	1 (0.2)	1 (0.1)
ひだ舌	0	1 (0.2)	1 (0.1)
埋伏歯	3 (0.6)	0	3 (0.3)
歯痛	2 (0.4)	2 (0.4)	4 (0.4)
臍ヘルニア	0	1 (0.2)	1 (0.1)
嘔吐	8 (1.6)	11 (2.2)	19 (1.9)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
一般・全身障害および投与部位の状態	47 (9.6)	48 (9.6)	95 (9.6)
無力症	2 (0.4)	1 (0.2)	3 (0.3)
胸部不快感	2 (0.4)	2 (0.4)	4 (0.4)
胸痛	3 (0.6)	0	3 (0.3)
悪寒	0	2 (0.4)	2 (0.2)
嚢胞	1 (0.2)	0	1 (0.1)
不快感	0	1 (0.2)	1 (0.1)
薬効欠如	1 (0.2)	0	1 (0.1)
薬物不耐性	0	1 (0.2)	1 (0.1)
顔面浮腫	1 (0.2)	1 (0.2)	2 (0.2)
疲労	4 (0.8)	4 (0.8)	8 (0.8)
びくびく感	0	1 (0.2)	1 (0.1)
重力性浮腫	0	1 (0.2)	1 (0.1)
インフルエンザ様疾患	7 (1.4)	13 (2.6)	20 (2.0)
倦怠感	0	1 (0.2)	1 (0.1)
腫瘤	1 (0.2)	0	1 (0.1)
小結節	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
一般・全身障害および投与部位の状態 (Cont.)			
非心臓性胸痛	0	3 (0.6)	3 (0.3)
末梢性浮腫	2 (0.4)	1 (0.2)	3 (0.3)
疼痛	1 (0.2)	3 (0.6)	4 (0.4)
発熱	20 (4.1)	10 (2.0)	30 (3.0)
腫脹	1 (0.2)	0	1 (0.1)
顔面腫脹	1 (0.2)	0	1 (0.1)
血管穿刺部位内出血	0	1 (0.2)	1 (0.1)
乾燥症	0	1 (0.2)	1 (0.1)
肝胆道系障害	8 (1.6)	18 (3.6)	26 (2.6)
胆道仙痛	0	1 (0.2)	1 (0.1)
胆嚢炎	0	1 (0.2)	1 (0.1)
胆石症	2 (0.4)	1 (0.2)	3 (0.3)
胆嚢ポリープ	0	1 (0.2)	1 (0.1)
肝機能異常	1 (0.2)	4 (0.8)	5 (0.5)
脂肪肝	4 (0.8)	7 (1.4)	11 (1.1)
肝炎	0	1 (0.2)	1 (0.1)
肝腫大	0	2 (0.4)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
肝胆道系障害 (Cont.)			
高ビリルビン血症	1 (0.2)	0	1 (0.1)
免疫系障害	10 (2.0)	13 (2.6)	23 (2.3)
節足動物咬傷アレルギー	1 (0.2)	0	1 (0.1)
節足動物刺傷アレルギー	1 (0.2)	0	1 (0.1)
化学物質アレルギー	1 (0.2)	0	1 (0.1)
ワクチンアレルギー	1 (0.2)	0	1 (0.1)
アナフィラキシー反応	0	2 (0.4)	2 (0.2)
薬物過敏症	0	1 (0.2)	1 (0.1)
食物アレルギー	2 (0.4)	4 (0.8)	6 (0.6)
過敏症	2 (0.4)	1 (0.2)	3 (0.3)
乳アレルギー	0	1 (0.2)	1 (0.1)
複合アレルギー	1 (0.2)	0	1 (0.1)
季節性アレルギー	1 (0.2)	2 (0.4)	3 (0.3)
1 型過敏症	0	2 (0.4)	2 (0.2)
感染症および寄生虫症	464 (94.5)	604 (120.6)	1068 (107.7)
四肢膿瘍	0	2 (0.4)	2 (0.2)
ダニ皮膚炎	1 (0.2)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
膿疱性ざ瘡	1 (0.2)	0	1 (0.1)
急性副鼻腔炎	1 (0.2)	0	1 (0.1)
虫垂炎	2 (0.4)	0	2 (0.2)
異型肺炎	0	1 (0.2)	1 (0.1)
細菌感染	1 (0.2)	0	1 (0.1)
細菌性前立腺炎	1 (0.2)	0	1 (0.1)
細菌性膣症	0	2 (0.4)	2 (0.2)
細菌尿	0	1 (0.2)	1 (0.1)
体部白癬	4 (0.8)	2 (0.4)	6 (0.6)
乳房膿瘍	2 (0.4)	0	2 (0.2)
気管支炎	10 (2.0)	11 (2.2)	21 (2.1)
ウイルス性気管支炎	1 (0.2)	0	1 (0.1)
カンジダ感染	1 (0.2)	1 (0.2)	2 (0.2)
ネコ引っかき病	0	1 (0.2)	1 (0.1)
蜂巣炎	5 (1.0)	2 (0.4)	7 (0.7)
結膜炎	5 (1.0)	9 (1.8)	14 (1.4)
細菌性結膜炎	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
コロナウイルス感染	14 (2.9)	13 (2.6)	27 (2.7)
感染性クループ	1 (0.2)	0	1 (0.1)
膀胱炎	3 (0.6)	5 (1.0)	8 (0.8)
感染性皮膚炎	1 (0.2)	1 (0.2)	2 (0.2)
皮膚糸状菌症	1 (0.2)	5 (1.0)	6 (0.6)
爪の皮膚糸状菌症	1 (0.2)	0	1 (0.1)
憩室炎	0	2 (0.4)	2 (0.2)
耳感染	3 (0.6)	8 (1.6)	11 (1.1)
膿瘡	2 (0.4)	0	2 (0.2)
ヘルペス性状湿疹	3 (0.6)	7 (1.4)	10 (1.0)
感染性湿疹	1 (0.2)	3 (0.6)	4 (0.4)
蟯虫症	0	1 (0.2)	1 (0.1)
エプスタイン・バーウイルス感染	0	1 (0.2)	1 (0.1)
丹毒	0	1 (0.2)	1 (0.1)
大腸菌性尿路感染	1 (0.2)	1 (0.2)	2 (0.2)
外耳蜂巣炎	1 (0.2)	0	1 (0.1)
眼感染	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
毛包炎	12 (2.4)	19 (3.8)	31 (3.1)
真菌感染	1 (0.2)	0	1 (0.1)
皮膚真菌感染	1 (0.2)	0	1 (0.1)
せつ	11 (2.2)	4 (0.8)	15 (1.5)
胃腸炎	5 (1.0)	14 (2.8)	19 (1.9)
ウイルス性胃腸炎	2 (0.4)	3 (0.6)	5 (0.5)
ウイルス性消化管感染	0	1 (0.2)	1 (0.1)
陰部ヘルペス	1 (0.2)	1 (0.2)	2 (0.2)
陰部単純ヘルペス	0	3 (0.6)	3 (0.3)
真菌性性器感染	1 (0.2)	1 (0.2)	2 (0.2)
歯肉炎	2 (0.4)	0	2 (0.2)
手足口病	1 (0.2)	0	1 (0.1)
蠕虫感染	0	1 (0.2)	1 (0.1)
B 型肝炎	0	1 (0.2)	1 (0.1)
ヘルパンギーナ	0	1 (0.2)	1 (0.1)
ヘルペス性皮膚炎	0	2 (0.4)	2 (0.2)
ヘルペス眼感染	0	8 (1.6)	8 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
単純ヘルペス	15 (3.1)	24 (4.8)	39 (3.9)
ヘルペスウイルス感染	2 (0.4)	1 (0.2)	3 (0.3)
帯状疱疹	16 (3.3)	24 (4.8)	40 (4.0)
皮膚播種性帯状疱疹	0	2 (0.4)	2 (0.2)
麦粒腫	4 (0.8)	18 (3.6)	22 (2.2)
膿痂疹	18 (3.7)	7 (1.4)	25 (2.5)
感染性皮膚嚢腫	0	1 (0.2)	1 (0.1)
インフルエンザ	4 (0.8)	11 (2.2)	15 (1.5)
椎間板炎	1 (0.2)	0	1 (0.1)
カポジ水痘様発疹	2 (0.4)	7 (1.4)	9 (0.9)
喉頭炎	2 (0.4)	3 (0.6)	5 (0.5)
ウイルス性喉頭炎	1 (0.2)	0	1 (0.1)
潜伏結核	4 (0.8)	5 (1.0)	9 (0.9)
限局性感染	2 (0.4)	0	2 (0.2)
下気道感染	1 (0.2)	0	1 (0.1)
細菌性リンパ節炎	0	1 (0.2)	1 (0.1)
伝染性軟属腫	6 (1.2)	5 (1.0)	11 (1.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
マイコプラズマ感染	0	1 (0.2)	1 (0.1)
上咽頭炎	61 (12.4)	68 (13.6)	129 (13.0)
乳頭感染	1 (0.2)	0	1 (0.1)
食道カンジダ症	0	1 (0.2)	1 (0.1)
爪真菌症	2 (0.4)	3 (0.6)	5 (0.5)
眼部単純ヘルペス	2 (0.4)	6 (1.2)	8 (0.8)
眼帯状疱疹	1 (0.2)	2 (0.4)	3 (0.3)
口腔カンジダ症	2 (0.4)	5 (1.0)	7 (0.7)
口腔ヘルペス	15 (3.1)	38 (7.6)	53 (5.3)
骨髄炎	0	1 (0.2)	1 (0.1)
外耳炎	3 (0.6)	3 (0.6)	6 (0.6)
中耳炎	3 (0.6)	7 (1.4)	10 (1.0)
急性中耳炎	1 (0.2)	1 (0.2)	2 (0.2)
爪囲炎	2 (0.4)	7 (1.4)	9 (0.9)
ヘリコバクター性消化性潰瘍	0	1 (0.2)	1 (0.1)
インプラント周囲炎	0	1 (0.2)	1 (0.1)
歯周炎	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
咽頭膿瘍	0	1 (0.2)	1 (0.1)
咽頭炎	7 (1.4)	6 (1.2)	13 (1.3)
レンサ球菌性咽頭炎	1 (0.2)	0	1 (0.1)
咽頭扁桃炎	2 (0.4)	1 (0.2)	3 (0.3)
肺炎	4 (0.8)	3 (0.6)	7 (0.7)
細菌性肺炎	0	1 (0.2)	1 (0.1)
ブドウ球菌性肺炎	0	1 (0.2)	1 (0.1)
術後創感染	1 (0.2)	1 (0.2)	2 (0.2)
肺結核	1 (0.2)	0	1 (0.1)
膿疱	0	1 (0.2)	1 (0.1)
腎盂腎炎	0	2 (0.4)	2 (0.2)
膿皮症	1 (0.2)	0	1 (0.1)
膿疱性皮疹	1 (0.2)	1 (0.2)	2 (0.2)
RS ウイルス感染	0	1 (0.2)	1 (0.1)
気道感染	4 (0.8)	2 (0.4)	6 (0.6)
ウイルス性気道感染	1 (0.2)	2 (0.4)	3 (0.3)
鼻炎	5 (1.0)	6 (1.2)	11 (1.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
ライノウイルス感染	0	1 (0.2)	1 (0.1)
根管感染	0	1 (0.2)	1 (0.1)
敗血症	0	2 (0.4)	2 (0.2)
副鼻腔炎	10 (2.0)	8 (1.6)	18 (1.8)
皮膚細菌感染	2 (0.4)	3 (0.6)	5 (0.5)
皮膚カンジダ	1 (0.2)	1 (0.2)	2 (0.2)
植皮感染	0	1 (0.2)	1 (0.1)
皮膚感染	5 (1.0)	7 (1.4)	12 (1.2)
ブドウ球菌性膿痂疹	0	1 (0.2)	1 (0.1)
ブドウ球菌感染	1 (0.2)	5 (1.0)	6 (0.6)
ブドウ球菌性敗血症	1 (0.2)	1 (0.2)	2 (0.2)
ブドウ球菌皮膚感染	1 (0.2)	1 (0.2)	2 (0.2)
皮下組織膿瘍	0	1 (0.2)	1 (0.1)
股部白癬	0	5 (1.0)	5 (0.5)
足部白癬	4 (0.8)	6 (1.2)	10 (1.0)
癜風	4 (0.8)	1 (0.2)	5 (0.5)
扁桃炎	3 (0.6)	7 (1.4)	10 (1.0)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
細菌性扁桃炎	0	1 (0.2)	1 (0.1)
歯膿瘍	6 (1.2)	2 (0.4)	8 (0.8)
歯感染	3 (0.6)	3 (0.6)	6 (0.6)
気管炎	0	2 (0.4)	2 (0.2)
上気道感染	71 (14.5)	72 (14.4)	143 (14.4)
細菌性上気道感染	0	1 (0.2)	1 (0.1)
クラミジア性尿道炎	1 (0.2)	0	1 (0.1)
尿路感染	20 (4.1)	24 (4.8)	44 (4.4)
細菌性尿路感染	1 (0.2)	0	1 (0.1)
水痘	0	1 (0.2)	1 (0.1)
ウイルス性下痢	0	1 (0.2)	1 (0.1)
ウイルス感染	3 (0.6)	1 (0.2)	4 (0.4)
ウイルス性咽頭炎	2 (0.4)	0	2 (0.2)
ウイルス性発疹	1 (0.2)	0	1 (0.1)
ウイルス性上気道感染	11 (2.2)	17 (3.4)	28 (2.8)
外陰部腟カンジダ症	4 (0.8)	2 (0.4)	6 (0.6)
外陰腟真菌感染	2 (0.4)	0	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
外陰膣炎	1 (0.2)	0	1 (0.1)
創傷感染	0	1 (0.2)	1 (0.1)
ブドウ球菌性創感染	0	1 (0.2)	1 (0.1)
傷害、中毒および処置合併症	52 (10.6)	66 (13.2)	118 (11.9)
腹壁損傷	1 (0.2)	0	1 (0.1)
偶発的過量投与	0	1 (0.2)	1 (0.1)
アルコール中毒	0	1 (0.2)	1 (0.1)
動物咬傷	1 (0.2)	0	1 (0.1)
節足動物咬傷	4 (0.8)	3 (0.6)	7 (0.7)
節足動物刺傷	0	1 (0.2)	1 (0.1)
背部損傷	1 (0.2)	0	1 (0.1)
第 1 度熱傷	1 (0.2)	1 (0.2)	2 (0.2)
第 2 度熱傷	1 (0.2)	0	1 (0.1)
第 3 度熱傷	0	1 (0.2)	1 (0.1)
軟骨損傷	1 (0.2)	0	1 (0.1)
脳振盪	2 (0.4)	1 (0.2)	3 (0.3)
挫傷	3 (0.6)	1 (0.2)	4 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
転倒	4 (0.8)	6 (1.2)	10 (1.0)
大腿骨骨折	0	1 (0.2)	1 (0.1)
腓骨骨折	0	1 (0.2)	1 (0.1)
足骨折	2 (0.4)	3 (0.6)	5 (0.5)
前腕骨折	0	1 (0.2)	1 (0.1)
体内異物	0	1 (0.2)	1 (0.1)
手骨折	0	1 (0.2)	1 (0.1)
頭部損傷	1 (0.2)	1 (0.2)	2 (0.2)
熱疲労	1 (0.2)	0	1 (0.1)
損傷	1 (0.2)	0	1 (0.1)
関節脱臼	2 (0.4)	1 (0.2)	3 (0.3)
関節損傷	3 (0.6)	1 (0.2)	4 (0.4)
靱帯断裂	1 (0.2)	1 (0.2)	2 (0.2)
靱帯捻挫	3 (0.6)	4 (0.8)	7 (0.7)
四肢損傷	3 (0.6)	5 (1.0)	8 (0.8)
口唇損傷	0	1 (0.2)	1 (0.1)
半月板損傷	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
筋断裂	0	1 (0.2)	1 (0.1)
肉離れ	3 (0.6)	4 (0.8)	7 (0.7)
筋骨格系損傷	0	1 (0.2)	1 (0.1)
膝蓋骨骨折	1 (0.2)	0	1 (0.1)
処置による疼痛	0	2 (0.4)	2 (0.2)
橈骨骨折	0	1 (0.2)	1 (0.1)
肋骨骨折	0	1 (0.2)	1 (0.1)
交通事故	2 (0.4)	1 (0.2)	3 (0.3)
瘢痕	1 (0.2)	0	1 (0.1)
皮膚擦過傷	2 (0.4)	2 (0.4)	4 (0.4)
皮膚裂傷	1 (0.2)	3 (0.6)	4 (0.4)
スポーツ損傷	0	1 (0.2)	1 (0.1)
ストレス骨折	0	2 (0.4)	2 (0.2)
サンバーン	1 (0.2)	1 (0.2)	2 (0.2)
腱損傷	0	1 (0.2)	1 (0.1)
腱断裂	2 (0.4)	2 (0.4)	4 (0.4)
熱傷	1 (0.2)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
脛骨骨折	0	1 (0.2)	1 (0.1)
歯牙破折	0	1 (0.2)	1 (0.1)
尺骨骨折	1 (0.2)	0	1 (0.1)
上肢骨折	1 (0.2)	0	1 (0.1)
ワクチン接種合併症	0	1 (0.2)	1 (0.1)
臨床検査	118 (24.0)	168 (33.5)	286 (28.8)
アラニンアミノトランスフェラーゼ増加	11 (2.2)	15 (3.0)	26 (2.6)
アスパラギン酸アミノトランスフェラーゼ増加	6 (1.2)	14 (2.8)	20 (2.0)
B リンパ球数増加	1 (0.2)	1 (0.2)	2 (0.2)
血中アルカリホスファターゼ増加	1 (0.2)	0	1 (0.1)
血中ビリルビン増加	1 (0.2)	2 (0.4)	3 (0.3)
血中コレステロール増加	3 (0.6)	8 (1.6)	11 (1.1)
血中クレアチンホスホキナーゼ増加	36 (7.3)	58 (11.6)	94 (9.5)
血中クレアチニン増加	4 (0.8)	0	4 (0.4)
血中ブドウ糖増加	1 (0.2)	2 (0.4)	3 (0.3)
血中免疫グロブリン E 増加	6 (1.2)	2 (0.4)	8 (0.8)
血中乳酸脱水素酵素増加	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
臨床検査 (Cont.)			
血中カリウム増加	1 (0.2)	0	1 (0.1)
血圧上昇	1 (0.2)	0	1 (0.1)
血中トリグリセリド増加	3 (0.6)	0	3 (0.3)
血中尿酸増加	0	3 (0.6)	3 (0.3)
尿中血陽性	3 (0.6)	1 (0.2)	4 (0.4)
CD4 リンパ球減少	1 (0.2)	0	1 (0.1)
CD8 リンパ球百分率減少	1 (0.2)	0	1 (0.1)
CD8 リンパ球減少	0	1 (0.2)	1 (0.1)
心雑音	0	2 (0.4)	2 (0.2)
ケモカイン増加	1 (0.2)	0	1 (0.1)
胸部コンピュータ断層撮影異常	0	1 (0.2)	1 (0.1)
尿中結晶陽性	2 (0.4)	1 (0.2)	3 (0.3)
心電図 QT 間隔異常	1 (0.2)	0	1 (0.1)
好酸球百分率増加	1 (0.2)	0	1 (0.1)
尿中ブドウ糖陽性	0	1 (0.2)	1 (0.1)
ヘモグロビン減少	2 (0.4)	4 (0.8)	6 (0.6)
心拍数増加	0	2 (0.4)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
臨床検査 (Cont.)			
肝酵素上昇	1 (0.2)	1 (0.2)	2 (0.2)
高比重リポ蛋白増加	0	1 (0.2)	1 (0.1)
免疫グロブリン増加	1 (0.2)	0	1 (0.1)
肝機能検査値上昇	1 (0.2)	0	1 (0.1)
低比重リポ蛋白増加	0	2 (0.4)	2 (0.2)
リンパ節触知	1 (0.2)	0	1 (0.1)
リンパ球数減少	0	4 (0.8)	4 (0.4)
ナチュラルキラー細胞数減少	1 (0.2)	1 (0.2)	2 (0.2)
好中球数減少	2 (0.4)	3 (0.6)	5 (0.5)
血小板数増加	1 (0.2)	1 (0.2)	2 (0.2)
尿妊娠反応陽性	1 (0.2)	0	1 (0.1)
尿蛋白	1 (0.2)	0	1 (0.1)
尿中蛋白陽性	3 (0.6)	2 (0.4)	5 (0.5)
赤血球数減少	0	1 (0.2)	1 (0.1)
T リンパ球数減少	1 (0.2)	0	1 (0.1)
トランスアミナーゼ上昇	3 (0.6)	6 (1.2)	9 (0.9)
腫瘍マーカー上昇	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
臨床検査 (Cont.)			
尿円柱	1 (0.2)	0	1 (0.1)
尿中ケトン体陽性	1 (0.2)	0	1 (0.1)
尿中白血球エステラーゼ陽性	0	1 (0.2)	1 (0.1)
尿中シュウ酸塩	1 (0.2)	0	1 (0.1)
体重減少	0	3 (0.6)	3 (0.3)
体重増加	10 (2.0)	17 (3.4)	27 (2.7)
白血球数減少	1 (0.2)	5 (1.0)	6 (0.6)
代謝および栄養障害	26 (5.3)	32 (6.4)	58 (5.8)
食欲減退	1 (0.2)	3 (0.6)	4 (0.4)
糖尿病	1 (0.2)	0	1 (0.1)
脂質異常症	1 (0.2)	2 (0.4)	3 (0.3)
耐糖能障害	0	1 (0.2)	1 (0.1)
痛風	1 (0.2)	1 (0.2)	2 (0.2)
高コレステロール血症	2 (0.4)	6 (1.2)	8 (0.8)
高脂血症	5 (1.0)	1 (0.2)	6 (0.6)
高トリグリセリド血症	3 (0.6)	4 (0.8)	7 (0.7)
高尿酸血症	6 (1.2)	3 (0.6)	9 (0.9)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
代謝および栄養障害 (Cont.)			
低血糖	0	1 (0.2)	1 (0.1)
低カリウム血症	0	3 (0.6)	3 (0.3)
低リン酸血症	1 (0.2)	1 (0.2)	2 (0.2)
食欲亢進	2 (0.4)	2 (0.4)	4 (0.4)
2 型糖尿病	0	1 (0.2)	1 (0.1)
ビタミン B12 欠乏	0	1 (0.2)	1 (0.1)
ビタミン D 欠乏	3 (0.6)	2 (0.4)	5 (0.5)
筋骨格系および結合組織障害	51 (10.4)	67 (13.4)	118 (11.9)
関節痛	9 (1.8)	13 (2.6)	22 (2.2)
関節炎	2 (0.4)	0	2 (0.2)
腋窩腫瘤	0	1 (0.2)	1 (0.1)
背部痛	9 (1.8)	19 (3.8)	28 (2.8)
骨嚢腫	1 (0.2)	0	1 (0.1)
滑液包炎	2 (0.4)	0	2 (0.2)
側腹部痛	1 (0.2)	0	1 (0.1)
足変形	1 (0.2)	0	1 (0.1)
椎間板変性症	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
筋骨格系および結合組織障害 (Cont.)			
椎間板突出	1 (0.2)	1 (0.2)	2 (0.2)
筋力低下	1 (0.2)	0	1 (0.1)
筋骨格系胸痛	0	2 (0.4)	2 (0.2)
筋骨格痛	4 (0.8)	2 (0.4)	6 (0.6)
筋肉痛	8 (1.6)	8 (1.6)	16 (1.6)
筋膜疼痛症候群	1 (0.2)	0	1 (0.1)
頚部痛	2 (0.4)	0	2 (0.2)
変形性関節症	1 (0.2)	2 (0.4)	3 (0.3)
骨端症	0	1 (0.2)	1 (0.1)
四肢痛	1 (0.2)	9 (1.8)	10 (1.0)
顎痛	1 (0.2)	1 (0.2)	2 (0.2)
骨膜炎	0	1 (0.2)	1 (0.1)
肩回旋筋腱板症候群	0	2 (0.4)	2 (0.2)
側弯症	1 (0.2)	0	1 (0.1)
変形性脊椎症	1 (0.2)	0	1 (0.1)
脊椎炎	0	1 (0.2)	1 (0.1)
滑液嚢腫	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
筋骨格系および結合組織障害 (Cont.)			
腱炎	3 (0.6)	3 (0.6)	6 (0.6)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	14 (2.9)	21 (4.2)	35 (3.5)
肛門性器疣贅	2 (0.4)	0	2 (0.2)
基底細胞癌	0	1 (0.2)	1 (0.1)
骨新生物	1 (0.2)	0	1 (0.1)
ボーエン病	1 (0.2)	0	1 (0.1)
乳癌	1 (0.2)	0	1 (0.1)
真珠腫	0	2 (0.4)	2 (0.2)
結腸癌	1 (0.2)	0	1 (0.1)
胃癌	0	1 (0.2)	1 (0.1)
血管腫	1 (0.2)	0	1 (0.1)
浸潤性乳管癌	0	1 (0.2)	1 (0.1)
脂肪腫	1 (0.2)	1 (0.2)	2 (0.2)
メラノサイト性母斑	0	1 (0.2)	1 (0.1)
非分泌型下垂体腺腫	0	1 (0.2)	1 (0.1)
脂漏性角化症	0	1 (0.2)	1 (0.1)
皮膚乳頭腫	6 (1.2)	10 (2.0)	16 (1.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） (Cont.)			
皮膚有棘細胞癌	0	2 (0.4)	2 (0.2)
神経系障害	53 (10.8)	48 (9.6)	101 (10.2)
健忘	0	1 (0.2)	1 (0.1)
手根管症候群	2 (0.4)	0	2 (0.2)
注意力障害	1 (0.2)	0	1 (0.1)
浮動性めまい	5 (1.0)	7 (1.4)	12 (1.2)
夢幻状態	1 (0.2)	0	1 (0.1)
味覚不全	0	1 (0.2)	1 (0.1)
錐体外路障害	1 (0.2)	0	1 (0.1)
頭痛	27 (5.5)	27 (5.4)	54 (5.4)
過眠症	1 (0.2)	0	1 (0.1)
虚血性脳卒中	1 (0.2)	0	1 (0.1)
片頭痛	2 (0.4)	2 (0.4)	4 (0.4)
前兆を伴う片頭痛	0	1 (0.2)	1 (0.1)
神経痛	0	2 (0.4)	2 (0.2)
錯感覚	2 (0.4)	0	2 (0.2)
失神寸前の状態	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
神経系障害 (Cont.)			
神経根障害	0	1 (0.2)	1 (0.1)
坐骨神経痛	2 (0.4)	2 (0.4)	4 (0.4)
感覚消失	1 (0.2)	0	1 (0.1)
傾眠	3 (0.6)	0	3 (0.3)
失神	0	2 (0.4)	2 (0.2)
緊張性頭痛	3 (0.6)	2 (0.4)	5 (0.5)
製品の問題	1 (0.2)	0	1 (0.1)
医療機器破損	1 (0.2)	0	1 (0.1)
精神障害	25 (5.1)	23 (4.6)	48 (4.8)
適応障害	0	1 (0.2)	1 (0.1)
不安	6 (1.2)	8 (1.6)	14 (1.4)
不安障害	0	1 (0.2)	1 (0.1)
無感情	1 (0.2)	0	1 (0.1)
注意欠陥多動性障害	1 (0.2)	1 (0.2)	2 (0.2)
抑うつ気分	0	1 (0.2)	1 (0.1)
うつ病	3 (0.6)	3 (0.6)	6 (0.6)
自傷性皮膚症	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
精神障害 (Cont.)			
失見当識	0	1 (0.2)	1 (0.1)
不眠症	2 (0.4)	5 (1.0)	7 (0.7)
故意の自傷行為	1 (0.2)	0	1 (0.1)
リビドー減退	1 (0.2)	0	1 (0.1)
大うつ病	1 (0.2)	1 (0.2)	2 (0.2)
躁病	2 (0.4)	0	2 (0.2)
混合性不安抑うつ障害	1 (0.2)	0	1 (0.1)
パニック発作	0	1 (0.2)	1 (0.1)
睡眠障害	3 (0.6)	0	3 (0.3)
ストレス	1 (0.2)	0	1 (0.1)
自殺念慮	1 (0.2)	0	1 (0.1)
腎および尿路障害	13 (2.6)	19 (3.8)	32 (3.2)
急性腎障害	0	1 (0.2)	1 (0.1)
アルブミン尿	1 (0.2)	5 (1.0)	6 (0.6)
排尿困難	1 (0.2)	4 (0.8)	5 (0.5)
血尿	2 (0.4)	1 (0.2)	3 (0.3)
高シュウ酸尿症	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
腎および尿路障害 (Cont.)			
緊張性膀胱	0	1 (0.2)	1 (0.1)
ケトン尿	1 (0.2)	0	1 (0.1)
白血球尿	1 (0.2)	0	1 (0.1)
尿意切迫	1 (0.2)	0	1 (0.1)
腎結石症	1 (0.2)	2 (0.4)	3 (0.3)
頻尿	0	1 (0.2)	1 (0.1)
蛋白尿	3 (0.6)	3 (0.6)	6 (0.6)
腎不全	0	1 (0.2)	1 (0.1)
尿路障害	1 (0.2)	0	1 (0.1)
生殖系および乳房障害	12 (2.4)	13 (2.6)	25 (2.5)
無月経	1 (0.2)	4 (0.8)	5 (0.5)
亀頭包皮炎	1 (0.2)	0	1 (0.1)
良性前立腺肥大症	1 (0.2)	1 (0.2)	2 (0.2)
乳房腫大	0	1 (0.2)	1 (0.1)
乳房圧痛	0	1 (0.2)	1 (0.1)
月経困難症	3 (0.6)	0	3 (0.3)
乳管拡張症	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
生殖系および乳房障害 (Cont.)			
閉経期症状	0	1 (0.2)	1 (0.1)
月経過多	2 (0.4)	1 (0.2)	3 (0.3)
不規則月経	1 (0.2)	0	1 (0.1)
会陰瘙	0	1 (0.2)	1 (0.1)
多嚢胞性卵巣	1 (0.2)	1 (0.2)	2 (0.2)
精巣痛	0	1 (0.2)	1 (0.1)
腟分泌物	1 (0.2)	0	1 (0.1)
外陰腟乾燥	0	1 (0.2)	1 (0.1)
呼吸器、胸郭および縦隔障害	70 (14.3)	63 (12.6)	133 (13.4)
喘息	11 (2.2)	7 (1.4)	18 (1.8)
気管支反応性亢進	1 (0.2)	0	1 (0.1)
慢性閉塞性肺疾患	0	1 (0.2)	1 (0.1)
咳嗽	23 (4.7)	11 (2.2)	34 (3.4)
嚢胞性肺疾患	1 (0.2)	0	1 (0.1)
発声障害	1 (0.2)	0	1 (0.1)
呼吸困難	5 (1.0)	5 (1.0)	10 (1.0)
労作性呼吸困難	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
呼吸器、胸郭および縦隔障害 (Cont.)			
鼻出血	3 (0.6)	6 (1.2)	9 (0.9)
鼻閉	1 (0.2)	3 (0.6)	4 (0.4)
鼻乾燥	0	3 (0.6)	3 (0.3)
口腔咽頭痛	15 (3.1)	13 (2.6)	28 (2.8)
気胸	0	1 (0.2)	1 (0.1)
湿性咳嗽	2 (0.4)	1 (0.2)	3 (0.3)
肺腫瘤	0	2 (0.4)	2 (0.2)
アレルギー性鼻炎	2 (0.4)	2 (0.4)	4 (0.4)
鼻漏	3 (0.6)	1 (0.2)	4 (0.4)
副鼻腔うっ血	1 (0.2)	2 (0.4)	3 (0.3)
咽喉刺激感	1 (0.2)	1 (0.2)	2 (0.2)
扁桃結石	0	1 (0.2)	1 (0.1)
上気道の炎症	0	1 (0.2)	1 (0.1)
声帯肥厚	0	1 (0.2)	1 (0.1)
皮膚および皮下組織障害	176 (35.9)	246 (49.1)	422 (42.5)
ざ瘡	49 (10.0)	117 (23.4)	166 (16.7)
光線角化症	4 (0.8)	1 (0.2)	5 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
脱毛症	1 (0.2)	2 (0.4)	3 (0.3)
円形脱毛症	0	1 (0.2)	1 (0.1)
血管浮腫	1 (0.2)	2 (0.4)	3 (0.3)
水疱	1 (0.2)	0	1 (0.1)
冷汗	1 (0.2)	0	1 (0.1)
頭部粃糠疹	0	1 (0.2)	1 (0.1)
皮膚嚢腫	0	2 (0.4)	2 (0.2)
皮膚炎	3 (0.6)	4 (0.8)	7 (0.7)
ざ瘡様皮膚炎	3 (0.6)	16 (3.2)	19 (1.9)
アレルギー性皮膚炎	0	2 (0.4)	2 (0.2)
アトピー性皮膚炎	47 (9.6)	29 (5.8)	76 (7.7)
接触皮膚炎	3 (0.6)	14 (2.8)	17 (1.7)
びまん性脱毛症	0	1 (0.2)	1 (0.1)
薬疹	1 (0.2)	0	1 (0.1)
異汗性湿疹	0	1 (0.2)	1 (0.1)
斑状出血	1 (0.2)	0	1 (0.1)
湿疹	7 (1.4)	4 (0.8)	11 (1.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
紅斑	2 (0.4)	2 (0.4)	4 (0.4)
温熱性紅斑	1 (0.2)	0	1 (0.1)
毛包性ムチン沈着症	0	1 (0.2)	1 (0.1)
毛髪成長異常	0	1 (0.2)	1 (0.1)
逆むけ	0	1 (0.2)	1 (0.1)
汗腺炎	1 (0.2)	1 (0.2)	2 (0.2)
多汗症	0	5 (1.0)	5 (0.5)
嵌入爪	2 (0.4)	0	2 (0.2)
内方発育毛	1 (0.2)	0	1 (0.1)
間擦疹	0	1 (0.2)	1 (0.1)
機械性蕁麻疹	0	1 (0.2)	1 (0.1)
汗疹	1 (0.2)	1 (0.2)	2 (0.2)
神経皮膚炎	1 (0.2)	0	1 (0.1)
寝汗	1 (0.2)	1 (0.2)	2 (0.2)
爪破損	0	1 (0.2)	1 (0.1)
皮膚疼痛	1 (0.2)	0	1 (0.1)
類乾癬	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
口囲皮膚炎	3 (0.6)	1 (0.2)	4 (0.4)
光線過敏性反応	1 (0.2)	2 (0.4)	3 (0.3)
炎症後色素沈着変化	1 (0.2)	0	1 (0.1)
そう痒症	5 (1.0)	1 (0.2)	6 (0.6)
紫斑	0	1 (0.2)	1 (0.1)
発疹	2 (0.4)	3 (0.6)	5 (0.5)
斑状丘疹状皮疹	1 (0.2)	1 (0.2)	2 (0.2)
丘疹性皮疹	1 (0.2)	0	1 (0.1)
酒さ	1 (0.2)	5 (1.0)	6 (0.6)
脂漏	1 (0.2)	0	1 (0.1)
脂漏性皮膚炎	2 (0.4)	3 (0.6)	5 (0.5)
皮膚障害	0	1 (0.2)	1 (0.1)
皮膚剥脱	1 (0.2)	0	1 (0.1)
皮膚亀裂	1 (0.2)	0	1 (0.1)
皮膚病変	1 (0.2)	0	1 (0.1)
皮膚腫脹	2 (0.4)	0	2 (0.2)
日光黒子	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
毛細血管拡張症	1 (0.2)	0	1 (0.1)
中毒性表皮壊死融解症	1 (0.2)	0	1 (0.1)
蕁麻疹	15 (3.1)	12 (2.4)	27 (2.7)
コリン性蕁麻疹	1 (0.2)	0	1 (0.1)
尋常性白斑	0	1 (0.2)	1 (0.1)
黄色板腫	1 (0.2)	0	1 (0.1)
乾皮症	1 (0.2)	0	1 (0.1)
外科および内科処置	2 (0.4)	1 (0.2)	3 (0.3)
人工流産	1 (0.2)	1 (0.2)	2 (0.2)
収れん薬療法	1 (0.2)	0	1 (0.1)
血管障害	15 (3.1)	10 (2.0)	25 (2.5)
血性分泌物	1 (0.2)	0	1 (0.1)
深部静脈血栓症	1 (0.2)	0	1 (0.1)
潮紅	1 (0.2)	0	1 (0.1)
血腫	3 (0.6)	1 (0.2)	4 (0.4)
ほてり	0	1 (0.2)	1 (0.1)
高血圧	9 (1.8)	6 (1.2)	15 (1.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
血管障害 (Cont.)			
低血圧	0	1 (0.2)	1 (0.1)
血栓性静脈炎	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W52 Table 14.3__1.5.2.1

表 5. ウパダシチニブ投与期間中の有害事象の 100 人年あたりの発現率：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団，青少年）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
Any adverse event	181 (246.8)	219 (282.8)	400 (265.3)
血液およびリンパ系障害	3 (4.1)	6 (7.7)	9 (6.0)
白血球減少症	0	1 (1.3)	1 (0.7)
リンパ節症	1 (1.4)	0	1 (0.7)
好中球減少症	1 (1.4)	4 (5.2)	5 (3.3)
好中球増加症	1 (1.4)	0	1 (0.7)
血小板減少症	0	1 (1.3)	1 (0.7)
眼障害	0	3 (3.9)	3 (2.0)
眼瞼浮腫	0	1 (1.3)	1 (0.7)
流涙増加	0	1 (1.3)	1 (0.7)
霧視	0	1 (1.3)	1 (0.7)
胃腸障害	6 (8.2)	16 (20.7)	22 (14.6)
腹痛	0	1 (1.3)	1 (0.7)
上腹部痛	1 (1.4)	2 (2.6)	3 (2.0)
齲歯	1 (1.4)	1 (1.3)	2 (1.3)
下痢	1 (1.4)	5 (6.5)	6 (4.0)
食中毒	0	1 (1.3)	1 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
胃腸障害 (Cont.)			
胃腸障害	1 (1.4)	0	1 (0.7)
胃食道逆流性疾患	0	1 (1.3)	1 (0.7)
口唇腫脹	0	1 (1.3)	1 (0.7)
悪心	1 (1.4)	1 (1.3)	2 (1.3)
嘔吐	1 (1.4)	3 (3.9)	4 (2.7)
一般・全身障害および投与部位の状態	8 (10.9)	6 (7.7)	14 (9.3)
無力症	1 (1.4)	0	1 (0.7)
インフルエンザ様疾患	1 (1.4)	4 (5.2)	5 (3.3)
疼痛	1 (1.4)	0	1 (0.7)
発熱	5 (6.8)	2 (2.6)	7 (4.6)
免疫系障害	1 (1.4)	3 (3.9)	4 (2.7)
アナフィラキシー反応	0	1 (1.3)	1 (0.7)
薬物過敏症	0	1 (1.3)	1 (0.7)
食物アレルギー	0	1 (1.3)	1 (0.7)
過敏症	1 (1.4)	0	1 (0.7)
感染症および寄生虫症	56 (76.4)	84 (108.5)	140 (92.8)
四肢膿瘍	0	1 (1.3)	1 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
体部白癬	0	1 (1.3)	1 (0.7)
気管支炎	1 (1.4)	1 (1.3)	2 (1.3)
ネコ引っかき病	0	1 (1.3)	1 (0.7)
結膜炎	0	3 (3.9)	3 (2.0)
細菌性結膜炎	1 (1.4)	0	1 (0.7)
コロナウイルス感染	0	1 (1.3)	1 (0.7)
感染性クループ	1 (1.4)	0	1 (0.7)
膀胱炎	0	2 (2.6)	2 (1.3)
皮膚糸状菌症	0	1 (1.3)	1 (0.7)
耳感染	0	3 (3.9)	3 (2.0)
エプスタイン・バーウイルス感染	0	1 (1.3)	1 (0.7)
毛包炎	0	2 (2.6)	2 (1.3)
せつ	4 (5.5)	0	4 (2.7)
胃腸炎	1 (1.4)	2 (2.6)	3 (2.0)
ウイルス性胃腸炎	0	1 (1.3)	1 (0.7)
手足口病	1 (1.4)	0	1 (0.7)
単純ヘルペス	2 (2.7)	3 (3.9)	5 (3.3)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
帯状疱疹	1 (1.4)	2 (2.6)	3 (2.0)
麦粒腫	0	2 (2.6)	2 (1.3)
膿痂疹	6 (8.2)	3 (3.9)	9 (6.0)
インフルエンザ	0	3 (3.9)	3 (2.0)
潜伏結核	0	1 (1.3)	1 (0.7)
伝染性軟属腫	1 (1.4)	0	1 (0.7)
上咽頭炎	7 (9.5)	6 (7.7)	13 (8.6)
乳頭感染	1 (1.4)	0	1 (0.7)
眼部単純ヘルペス	0	1 (1.3)	1 (0.7)
眼帯状疱疹	0	2 (2.6)	2 (1.3)
口腔ヘルペス	0	4 (5.2)	4 (2.7)
骨髄炎	0	1 (1.3)	1 (0.7)
爪囲炎	0	1 (1.3)	1 (0.7)
咽頭炎	0	2 (2.6)	2 (1.3)
咽頭扁桃炎	2 (2.7)	0	2 (1.3)
肺炎	0	1 (1.3)	1 (0.7)
腎盂腎炎	0	1 (1.3)	1 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
気道感染	3 (4.1)	1 (1.3)	4 (2.7)
鼻炎	1 (1.4)	2 (2.6)	3 (2.0)
敗血症	0	1 (1.3)	1 (0.7)
副鼻腔炎	1 (1.4)	1 (1.3)	2 (1.3)
皮膚細菌感染	1 (1.4)	1 (1.3)	2 (1.3)
皮膚感染	1 (1.4)	1 (1.3)	2 (1.3)
ブドウ球菌感染	1 (1.4)	0	1 (0.7)
ブドウ球菌性敗血症	0	1 (1.3)	1 (0.7)
皮下組織膿瘍	0	1 (1.3)	1 (0.7)
足部白癬	0	1 (1.3)	1 (0.7)
上気道感染	17 (23.2)	15 (19.4)	32 (21.2)
尿路感染	1 (1.4)	3 (3.9)	4 (2.7)
ウイルス性下痢	0	1 (1.3)	1 (0.7)
ウイルス性上気道感染	1 (1.4)	2 (2.6)	3 (2.0)
傷害、中毒および処置合併症	4 (5.5)	7 (9.0)	11 (7.3)
脳振盪	1 (1.4)	0	1 (0.7)
転倒	0	1 (1.3)	1 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
頭部損傷	1 (1.4)	0	1 (0.7)
熱疲労	1 (1.4)	0	1 (0.7)
関節損傷	0	1 (1.3)	1 (0.7)
靱帯断裂	0	1 (1.3)	1 (0.7)
四肢損傷	0	1 (1.3)	1 (0.7)
半月板損傷	0	1 (1.3)	1 (0.7)
肉離れ	0	1 (1.3)	1 (0.7)
交通事故	0	1 (1.3)	1 (0.7)
皮膚擦過傷	1 (1.4)	0	1 (0.7)
臨床検査	24 (32.7)	19 (24.5)	43 (28.5)
アラニンアミノトランスフェラーゼ増加	1 (1.4)	0	1 (0.7)
アスパラギン酸アミノトランスフェラーゼ増加	1 (1.4)	0	1 (0.7)
血中アルカリホスファターゼ増加	1 (1.4)	0	1 (0.7)
血中ビリルビン増加	1 (1.4)	0	1 (0.7)
血中コレステロール増加	0	2 (2.6)	2 (1.3)
血中クレアチンホスホキナーゼ増加	13 (17.7)	10 (12.9)	23 (15.3)
血中ブドウ糖増加	1 (1.4)	0	1 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
臨床検査 (Cont.)			
心雑音	0	1 (1.3)	1 (0.7)
ヘモグロビン減少	2 (2.7)	0	2 (1.3)
心拍数増加	0	2 (2.6)	2 (1.3)
肝酵素上昇	1 (1.4)	0	1 (0.7)
トランスアミナーゼ上昇	1 (1.4)	0	1 (0.7)
尿中シュウ酸塩	1 (1.4)	0	1 (0.7)
体重増加	1 (1.4)	4 (5.2)	5 (3.3)
代謝および栄養障害	2 (2.7)	1 (1.3)	3 (2.0)
低リン酸血症	0	1 (1.3)	1 (0.7)
食欲亢進	1 (1.4)	0	1 (0.7)
ビタミン D 欠乏	1 (1.4)	0	1 (0.7)
筋骨格系および結合組織障害	6 (8.2)	3 (3.9)	9 (6.0)
関節痛	2 (2.7)	1 (1.3)	3 (2.0)
筋肉痛	1 (1.4)	0	1 (0.7)
骨端症	0	1 (1.3)	1 (0.7)
四肢痛	0	1 (1.3)	1 (0.7)
顎痛	1 (1.4)	0	1 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
筋骨格系および結合組織障害 (Cont.)			
側弯症	1 (1.4)	0	1 (0.7)
滑液嚢腫	1 (1.4)	0	1 (0.7)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (1.4)	1 (1.3)	2 (1.3)
皮膚乳頭腫	1 (1.4)	1 (1.3)	2 (1.3)
神経系障害	8 (10.9)	6 (7.7)	14 (9.3)
錐体外路障害	1 (1.4)	0	1 (0.7)
頭痛	6 (8.2)	5 (6.5)	11 (7.3)
失神	0	1 (1.3)	1 (0.7)
緊張性頭痛	1 (1.4)	0	1 (0.7)
精神障害	8 (10.9)	3 (3.9)	11 (7.3)
適応障害	0	1 (1.3)	1 (0.7)
不安	2 (2.7)	0	2 (1.3)
不安障害	0	1 (1.3)	1 (0.7)
うつ病	2 (2.7)	0	2 (1.3)
故意の自傷行為	1 (1.4)	0	1 (0.7)
大うつ病	1 (1.4)	0	1 (0.7)
パニック発作	0	1 (1.3)	1 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
精神障害 (Cont.)			
睡眠障害	1 (1.4)	0	1 (0.7)
自殺念慮	1 (1.4)	0	1 (0.7)
腎および尿路障害	4 (5.5)	2 (2.6)	6 (4.0)
排尿困難	0	1 (1.3)	1 (0.7)
ケトン尿	1 (1.4)	0	1 (0.7)
白血球尿	1 (1.4)	0	1 (0.7)
蛋白尿	2 (2.7)	1 (1.3)	3 (2.0)
生殖系および乳房障害	2 (2.7)	1 (1.3)	3 (2.0)
無月経	0	1 (1.3)	1 (0.7)
月経困難症	1 (1.4)	0	1 (0.7)
月経過多	1 (1.4)	0	1 (0.7)
呼吸器、胸郭および縦隔障害	20 (27.3)	10 (12.9)	30 (19.9)
咳嗽	8 (10.9)	1 (1.3)	9 (6.0)
呼吸困難	0	3 (3.9)	3 (2.0)
鼻出血	1 (1.4)	2 (2.6)	3 (2.0)
口腔咽頭痛	7 (9.5)	2 (2.6)	9 (6.0)
湿性咳嗽	1 (1.4)	0	1 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
呼吸器、胸郭および縦隔障害 (Cont.)			
鼻漏	2 (2.7)	0	2 (1.3)
副鼻腔うっ血	1 (1.4)	1 (1.3)	2 (1.3)
扁桃結石	0	1 (1.3)	1 (0.7)
皮膚および皮下組織障害	27 (36.8)	47 (60.7)	74 (49.1)
ざ瘡	6 (8.2)	22 (28.4)	28 (18.6)
円形脱毛症	0	1 (1.3)	1 (0.7)
血管浮腫	0	1 (1.3)	1 (0.7)
皮膚炎	0	1 (1.3)	1 (0.7)
ざ瘡様皮膚炎	0	1 (1.3)	1 (0.7)
アレルギー性皮膚炎	0	1 (1.3)	1 (0.7)
アトピー性皮膚炎	8 (10.9)	2 (2.6)	10 (6.6)
接触皮膚炎	0	3 (3.9)	3 (2.0)
湿疹	3 (4.1)	0	3 (2.0)
紅斑	0	1 (1.3)	1 (0.7)
汗腺炎	0	1 (1.3)	1 (0.7)
多汗症	0	3 (3.9)	3 (2.0)
汗疹	0	1 (1.3)	1 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=60) (PYS=73.3) Events (E/100PY)	UPA 30 mg QD (N=60) (PYS=77.4) Events (E/100PY)	Total (N=120) (PYS=150.8) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
口囲皮膚炎	1 (1.4)	0	1 (0.7)
炎症後色素沈着変化	1 (1.4)	0	1 (0.7)
そう痒症	0	1 (1.3)	1 (0.7)
発疹	0	2 (2.6)	2 (1.3)
斑状丘疹状皮疹	0	1 (1.3)	1 (0.7)
脂漏性皮膚炎	0	1 (1.3)	1 (0.7)
皮膚剥脱	1 (1.4)	0	1 (0.7)
蕁麻疹	6 (8.2)	3 (3.9)	9 (6.0)
尋常性白斑	0	1 (1.3)	1 (0.7)
乾皮症	1 (1.4)	0	1 (0.7)
外科および内科処置	1 (1.4)	0	1 (0.7)
収れん薬療法	1 (1.4)	0	1 (0.7)
血管障害	0	1 (1.3)	1 (0.7)
血腫	0	1 (1.3)	1 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

相互参照：M16-045 試験 CSR W52 Table 14.3__1.5.2.2

表 6. ウパダシチニブ投与期間中の有害事象の 100 人年あたりの発現率：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団, 成人）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
Any adverse event	1107 (265.1)	1439 (339.7)	2546 (302.7)
血液およびリンパ系障害	16 (3.8)	41 (9.7)	57 (6.8)
貧血	0	13 (3.1)	13 (1.5)
欠乏性貧血	1 (0.2)	1 (0.2)	2 (0.2)
鉄欠乏性貧血	0	1 (0.2)	1 (0.1)
白血球増加症	1 (0.2)	1 (0.2)	2 (0.2)
白血球減少症	0	1 (0.2)	1 (0.1)
リンパ節症	3 (0.7)	4 (0.9)	7 (0.8)
リンパ球減少症	2 (0.5)	2 (0.5)	4 (0.5)
好中球減少症	8 (1.9)	16 (3.8)	24 (2.9)
好中球増加症	1 (0.2)	0	1 (0.1)
汎血球減少症	0	1 (0.2)	1 (0.1)
脾腫	0	1 (0.2)	1 (0.1)
心臓障害	1 (0.2)	5 (1.2)	6 (0.7)
心房細動	0	1 (0.2)	1 (0.1)
徐脈	0	1 (0.2)	1 (0.1)
心血管障害	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
心臓障害 (Cont.)			
冠動脈疾患	0	1 (0.2)	1 (0.1)
心筋梗塞	0	1 (0.2)	1 (0.1)
動悸	0	1 (0.2)	1 (0.1)
先天性、家族性および遺伝性障害	2 (0.5)	1 (0.2)	3 (0.4)
第 II 因子変異	1 (0.2)	0	1 (0.1)
ネザートン症候群	1 (0.2)	0	1 (0.1)
包茎	0	1 (0.2)	1 (0.1)
耳および迷路障害	6 (1.4)	9 (2.1)	15 (1.8)
耳垢栓塞	0	3 (0.7)	3 (0.4)
耳痛	0	1 (0.2)	1 (0.1)
突発性難聴	0	1 (0.2)	1 (0.1)
鼓膜障害	0	1 (0.2)	1 (0.1)
回転性めまい	6 (1.4)	3 (0.7)	9 (1.1)
内分泌障害	2 (0.5)	2 (0.5)	4 (0.5)
バセドウ病	0	1 (0.2)	1 (0.1)
甲状腺機能低下症	2 (0.5)	0	2 (0.2)
甲状腺腫瘤	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
眼障害	15 (3.6)	21 (5.0)	36 (4.3)
眼瞼炎	0	2 (0.5)	2 (0.2)
白内障	1 (0.2)	0	1 (0.1)
霰粒腫	1 (0.2)	0	1 (0.1)
結膜出血	0	1 (0.2)	1 (0.1)
アレルギー性結膜炎	1 (0.2)	5 (1.2)	6 (0.7)
ドライアイ	1 (0.2)	3 (0.7)	4 (0.5)
眼瞼湿疹	0	1 (0.2)	1 (0.1)
眼瞼紅斑	0	1 (0.2)	1 (0.1)
眼そう痒症	0	1 (0.2)	1 (0.1)
眼部腫脹	1 (0.2)	1 (0.2)	2 (0.2)
緑内障	1 (0.2)	0	1 (0.1)
流涙増加	2 (0.5)	0	2 (0.2)
黄斑変性	1 (0.2)	0	1 (0.1)
黄斑円孔	0	1 (0.2)	1 (0.1)
眼窩周囲腫脹	1 (0.2)	2 (0.5)	3 (0.4)
翼状片	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
眼障害 (Cont.)			
網膜剥離	1 (0.2)	0	1 (0.1)
眼瞼腫脹	0	1 (0.2)	1 (0.1)
潰瘍性角膜炎	1 (0.2)	0	1 (0.1)
霧視	1 (0.2)	2 (0.5)	3 (0.4)
視力障害	1 (0.2)	0	1 (0.1)
胃腸障害	80 (19.2)	94 (22.2)	174 (20.7)
腹部不快感	1 (0.2)	1 (0.2)	2 (0.2)
腹部膨満	1 (0.2)	1 (0.2)	2 (0.2)
腹痛	1 (0.2)	7 (1.7)	8 (1.0)
上腹部痛	4 (1.0)	3 (0.7)	7 (0.8)
口角口唇炎	0	1 (0.2)	1 (0.1)
呼気臭	0	1 (0.2)	1 (0.1)
慢性胃炎	1 (0.2)	0	1 (0.1)
大腸炎	0	1 (0.2)	1 (0.1)
便秘	4 (1.0)	3 (0.7)	7 (0.8)
齲歯	5 (1.2)	3 (0.7)	8 (1.0)
下痢	12 (2.9)	13 (3.1)	25 (3.0)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
胃腸障害 (Cont.)			
腸憩室	1 (0.2)	0	1 (0.1)
口内乾燥	0	4 (0.9)	4 (0.5)
細菌叢異常	0	1 (0.2)	1 (0.1)
消化不良	3 (0.7)	2 (0.5)	5 (0.6)
軟便	0	2 (0.5)	2 (0.2)
鼓腸	3 (0.7)	2 (0.5)	5 (0.6)
食中毒	1 (0.2)	2 (0.5)	3 (0.4)
胃潰瘍	1 (0.2)	1 (0.2)	2 (0.2)
胃炎	5 (1.2)	0	5 (0.6)
びらん性胃炎	0	1 (0.2)	1 (0.1)
消化器痛	1 (0.2)	0	1 (0.1)
胃食道逆流性疾患	2 (0.5)	6 (1.4)	8 (1.0)
歯肉痛	1 (0.2)	1 (0.2)	2 (0.2)
痔核	2 (0.5)	4 (0.9)	6 (0.7)
裂孔ヘルニア	2 (0.5)	0	2 (0.2)
歯の知覚過敏	0	1 (0.2)	1 (0.1)
腸管穿孔	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
胃腸障害 (Cont.)			
過敏性腸症候群	0	1 (0.2)	1 (0.1)
口腔内潰瘍形成	0	2 (0.5)	2 (0.2)
悪心	14 (3.4)	15 (3.5)	29 (3.4)
食道狭窄	1 (0.2)	0	1 (0.1)
食道炎	1 (0.2)	0	1 (0.1)
大網梗塞	0	1 (0.2)	1 (0.1)
口腔障害	0	1 (0.2)	1 (0.1)
膵炎	0	1 (0.2)	1 (0.1)
ひだ舌	0	1 (0.2)	1 (0.1)
埋伏歯	3 (0.7)	0	3 (0.4)
歯痛	2 (0.5)	2 (0.5)	4 (0.5)
臍ヘルニア	0	1 (0.2)	1 (0.1)
嘔吐	7 (1.7)	8 (1.9)	15 (1.8)
一般・全身障害および投与部位の状態	39 (9.3)	42 (9.9)	81 (9.6)
無力症	1 (0.2)	1 (0.2)	2 (0.2)
胸部不快感	2 (0.5)	2 (0.5)	4 (0.5)
胸痛	3 (0.7)	0	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
一般・全身障害および投与部位の状態 (Cont.)			
悪寒	0	2 (0.5)	2 (0.2)
嚢胞	1 (0.2)	0	1 (0.1)
不快感	0	1 (0.2)	1 (0.1)
薬効欠如	1 (0.2)	0	1 (0.1)
薬物不耐性	0	1 (0.2)	1 (0.1)
顔面浮腫	1 (0.2)	1 (0.2)	2 (0.2)
疲労	4 (1.0)	4 (0.9)	8 (1.0)
びくびく感	0	1 (0.2)	1 (0.1)
重力性浮腫	0	1 (0.2)	1 (0.1)
インフルエンザ様疾患	6 (1.4)	9 (2.1)	15 (1.8)
倦怠感	0	1 (0.2)	1 (0.1)
腫瘤	1 (0.2)	0	1 (0.1)
小結節	0	1 (0.2)	1 (0.1)
非心臓性胸痛	0	3 (0.7)	3 (0.4)
末梢性浮腫	2 (0.5)	1 (0.2)	3 (0.4)
疼痛	0	3 (0.7)	3 (0.4)
発熱	15 (3.6)	8 (1.9)	23 (2.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
一般・全身障害および投与部位の状態 (Cont.)			
腫脹	1 (0.2)	0	1 (0.1)
顔面腫脹	1 (0.2)	0	1 (0.1)
血管穿刺部位内出血	0	1 (0.2)	1 (0.1)
乾燥症	0	1 (0.2)	1 (0.1)
肝胆道系障害	8 (1.9)	18 (4.2)	26 (3.1)
胆道仙痛	0	1 (0.2)	1 (0.1)
胆嚢炎	0	1 (0.2)	1 (0.1)
胆石症	2 (0.5)	1 (0.2)	3 (0.4)
胆嚢ポリープ	0	1 (0.2)	1 (0.1)
肝機能異常	1 (0.2)	4 (0.9)	5 (0.6)
脂肪肝	4 (1.0)	7 (1.7)	11 (1.3)
肝炎	0	1 (0.2)	1 (0.1)
肝腫大	0	2 (0.5)	2 (0.2)
高ビリルビン血症	1 (0.2)	0	1 (0.1)
免疫系障害	9 (2.2)	10 (2.4)	19 (2.3)
節足動物咬傷アレルギー	1 (0.2)	0	1 (0.1)
節足動物刺傷アレルギー	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
免疫系障害 (Cont.)			
化学物質アレルギー	1 (0.2)	0	1 (0.1)
ワクチンアレルギー	1 (0.2)	0	1 (0.1)
アナフィラキシー反応	0	1 (0.2)	1 (0.1)
食物アレルギー	2 (0.5)	3 (0.7)	5 (0.6)
過敏症	1 (0.2)	1 (0.2)	2 (0.2)
乳アレルギー	0	1 (0.2)	1 (0.1)
複合アレルギー	1 (0.2)	0	1 (0.1)
季節性アレルギー	1 (0.2)	2 (0.5)	3 (0.4)
1 型過敏症	0	2 (0.5)	2 (0.2)
感染症および寄生虫症	408 (97.7)	520 (122.8)	928 (110.3)
四肢膿瘍	0	1 (0.2)	1 (0.1)
ダニ皮膚炎	1 (0.2)	1 (0.2)	2 (0.2)
膿疱性ざ瘡	1 (0.2)	0	1 (0.1)
急性副鼻腔炎	1 (0.2)	0	1 (0.1)
虫垂炎	2 (0.5)	0	2 (0.2)
異型肺炎	0	1 (0.2)	1 (0.1)
細菌感染	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
細菌性前立腺炎	1 (0.2)	0	1 (0.1)
細菌性膣症	0	2 (0.5)	2 (0.2)
細菌尿	0	1 (0.2)	1 (0.1)
体部白癬	4 (1.0)	1 (0.2)	5 (0.6)
乳房膿瘍	2 (0.5)	0	2 (0.2)
気管支炎	9 (2.2)	10 (2.4)	19 (2.3)
ウイルス性気管支炎	1 (0.2)	0	1 (0.1)
カンジダ感染	1 (0.2)	1 (0.2)	2 (0.2)
蜂巣炎	5 (1.2)	2 (0.5)	7 (0.8)
結膜炎	5 (1.2)	6 (1.4)	11 (1.3)
コロナウイルス感染	14 (3.4)	12 (2.8)	26 (3.1)
膀胱炎	3 (0.7)	3 (0.7)	6 (0.7)
感染性皮膚炎	1 (0.2)	1 (0.2)	2 (0.2)
皮膚糸状菌症	1 (0.2)	4 (0.9)	5 (0.6)
爪の皮膚糸状菌症	1 (0.2)	0	1 (0.1)
憩室炎	0	2 (0.5)	2 (0.2)
耳感染	3 (0.7)	5 (1.2)	8 (1.0)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
膿瘡	2 (0.5)	0	2 (0.2)
ヘルペス性状湿疹	3 (0.7)	7 (1.7)	10 (1.2)
感染性湿疹	1 (0.2)	3 (0.7)	4 (0.5)
蟯虫症	0	1 (0.2)	1 (0.1)
丹毒	0	1 (0.2)	1 (0.1)
大腸菌性尿路感染	1 (0.2)	1 (0.2)	2 (0.2)
外耳蜂巣炎	1 (0.2)	0	1 (0.1)
眼感染	1 (0.2)	0	1 (0.1)
毛包炎	12 (2.9)	17 (4.0)	29 (3.4)
真菌感染	1 (0.2)	0	1 (0.1)
皮膚真菌感染	1 (0.2)	0	1 (0.1)
せつ	7 (1.7)	4 (0.9)	11 (1.3)
胃腸炎	4 (1.0)	12 (2.8)	16 (1.9)
ウイルス性胃腸炎	2 (0.5)	2 (0.5)	4 (0.5)
ウイルス性消化管感染	0	1 (0.2)	1 (0.1)
陰部ヘルペス	1 (0.2)	1 (0.2)	2 (0.2)
陰部単純ヘルペス	0	3 (0.7)	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
真菌性性器感染	1 (0.2)	1 (0.2)	2 (0.2)
歯肉炎	2 (0.5)	0	2 (0.2)
蠕虫感染	0	1 (0.2)	1 (0.1)
B 型肝炎	0	1 (0.2)	1 (0.1)
ヘルパンギーナ	0	1 (0.2)	1 (0.1)
ヘルペス性皮膚炎	0	2 (0.5)	2 (0.2)
ヘルペス眼感染	0	8 (1.9)	8 (1.0)
単純ヘルペス	13 (3.1)	21 (5.0)	34 (4.0)
ヘルペスウイルス感染	2 (0.5)	1 (0.2)	3 (0.4)
帯状疱疹	15 (3.6)	22 (5.2)	37 (4.4)
皮膚播種性帯状疱疹	0	2 (0.5)	2 (0.2)
麦粒腫	4 (1.0)	16 (3.8)	20 (2.4)
膿痂疹	12 (2.9)	4 (0.9)	16 (1.9)
感染性皮膚嚢腫	0	1 (0.2)	1 (0.1)
インフルエンザ	4 (1.0)	8 (1.9)	12 (1.4)
椎間板炎	1 (0.2)	0	1 (0.1)
カポジ水痘様発疹	2 (0.5)	7 (1.7)	9 (1.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
喉頭炎	2 (0.5)	3 (0.7)	5 (0.6)
ウイルス性喉頭炎	1 (0.2)	0	1 (0.1)
潜伏結核	4 (1.0)	4 (0.9)	8 (1.0)
限局性感染	2 (0.5)	0	2 (0.2)
下気道感染	1 (0.2)	0	1 (0.1)
細菌性リンパ節炎	0	1 (0.2)	1 (0.1)
伝染性軟属腫	5 (1.2)	5 (1.2)	10 (1.2)
マイコプラズマ感染	0	1 (0.2)	1 (0.1)
上咽頭炎	54 (12.9)	62 (14.6)	116 (13.8)
食道カンジダ症	0	1 (0.2)	1 (0.1)
爪真菌症	2 (0.5)	3 (0.7)	5 (0.6)
眼部単純ヘルペス	2 (0.5)	5 (1.2)	7 (0.8)
眼帯状疱疹	1 (0.2)	0	1 (0.1)
口腔カンジダ症	2 (0.5)	5 (1.2)	7 (0.8)
口腔ヘルペス	15 (3.6)	34 (8.0)	49 (5.8)
外耳炎	3 (0.7)	3 (0.7)	6 (0.7)
中耳炎	3 (0.7)	7 (1.7)	10 (1.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
急性中耳炎	1 (0.2)	1 (0.2)	2 (0.2)
爪囲炎	2 (0.5)	6 (1.4)	8 (1.0)
ヘリコバクター性消化性潰瘍	0	1 (0.2)	1 (0.1)
インプラント周囲炎	0	1 (0.2)	1 (0.1)
歯周炎	1 (0.2)	0	1 (0.1)
咽頭膿瘍	0	1 (0.2)	1 (0.1)
咽頭炎	7 (1.7)	4 (0.9)	11 (1.3)
レンサ球菌性咽頭炎	1 (0.2)	0	1 (0.1)
咽頭扁桃炎	0	1 (0.2)	1 (0.1)
肺炎	4 (1.0)	2 (0.5)	6 (0.7)
細菌性肺炎	0	1 (0.2)	1 (0.1)
ブドウ球菌性肺炎	0	1 (0.2)	1 (0.1)
術後創感染	1 (0.2)	1 (0.2)	2 (0.2)
肺結核	1 (0.2)	0	1 (0.1)
膿疱	0	1 (0.2)	1 (0.1)
腎盂腎炎	0	1 (0.2)	1 (0.1)
膿皮症	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
膿疱性皮疹	1 (0.2)	1 (0.2)	2 (0.2)
RS ウイルス感染	0	1 (0.2)	1 (0.1)
気道感染	1 (0.2)	1 (0.2)	2 (0.2)
ウイルス性気道感染	1 (0.2)	2 (0.5)	3 (0.4)
鼻炎	4 (1.0)	4 (0.9)	8 (1.0)
ライノウイルス感染	0	1 (0.2)	1 (0.1)
根管感染	0	1 (0.2)	1 (0.1)
敗血症	0	1 (0.2)	1 (0.1)
副鼻腔炎	9 (2.2)	7 (1.7)	16 (1.9)
皮膚細菌感染	1 (0.2)	2 (0.5)	3 (0.4)
皮膚カンジダ	1 (0.2)	1 (0.2)	2 (0.2)
植皮感染	0	1 (0.2)	1 (0.1)
皮膚感染	4 (1.0)	6 (1.4)	10 (1.2)
ブドウ球菌性膿痂疹	0	1 (0.2)	1 (0.1)
ブドウ球菌感染	0	5 (1.2)	5 (0.6)
ブドウ球菌性敗血症	1 (0.2)	0	1 (0.1)
ブドウ球菌皮膚感染	1 (0.2)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
股部白癬	0	5 (1.2)	5 (0.6)
足部白癬	4 (1.0)	5 (1.2)	9 (1.1)
癜風	4 (1.0)	1 (0.2)	5 (0.6)
扁桃炎	3 (0.7)	7 (1.7)	10 (1.2)
細菌性扁桃炎	0	1 (0.2)	1 (0.1)
歯膿瘍	6 (1.4)	2 (0.5)	8 (1.0)
歯感染	3 (0.7)	3 (0.7)	6 (0.7)
気管炎	0	2 (0.5)	2 (0.2)
上気道感染	54 (12.9)	57 (13.5)	111 (13.2)
細菌性上気道感染	0	1 (0.2)	1 (0.1)
クラミジア性尿道炎	1 (0.2)	0	1 (0.1)
尿路感染	19 (4.6)	21 (5.0)	40 (4.8)
細菌性尿路感染	1 (0.2)	0	1 (0.1)
水痘	0	1 (0.2)	1 (0.1)
ウイルス感染	3 (0.7)	1 (0.2)	4 (0.5)
ウイルス性咽頭炎	2 (0.5)	0	2 (0.2)
ウイルス性発疹	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
ウイルス性上気道感染	10 (2.4)	15 (3.5)	25 (3.0)
外陰部腟カンジダ症	4 (1.0)	2 (0.5)	6 (0.7)
外陰腟真菌感染	2 (0.5)	0	2 (0.2)
外陰腟炎	1 (0.2)	0	1 (0.1)
創傷感染	0	1 (0.2)	1 (0.1)
ブドウ球菌性創感染	0	1 (0.2)	1 (0.1)
傷害、中毒および処置合併症	48 (11.5)	59 (13.9)	107 (12.7)
腹壁損傷	1 (0.2)	0	1 (0.1)
偶発的過量投与	0	1 (0.2)	1 (0.1)
アルコール中毒	0	1 (0.2)	1 (0.1)
動物咬傷	1 (0.2)	0	1 (0.1)
節足動物咬傷	4 (1.0)	3 (0.7)	7 (0.8)
節足動物刺傷	0	1 (0.2)	1 (0.1)
背部損傷	1 (0.2)	0	1 (0.1)
第 1 度熱傷	1 (0.2)	1 (0.2)	2 (0.2)
第 2 度熱傷	1 (0.2)	0	1 (0.1)
第 3 度熱傷	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
軟骨損傷	1 (0.2)	0	1 (0.1)
脳振盪	1 (0.2)	1 (0.2)	2 (0.2)
挫傷	3 (0.7)	1 (0.2)	4 (0.5)
転倒	4 (1.0)	5 (1.2)	9 (1.1)
大腿骨骨折	0	1 (0.2)	1 (0.1)
腓骨骨折	0	1 (0.2)	1 (0.1)
足骨折	2 (0.5)	3 (0.7)	5 (0.6)
前腕骨折	0	1 (0.2)	1 (0.1)
体内異物	0	1 (0.2)	1 (0.1)
手骨折	0	1 (0.2)	1 (0.1)
頭部損傷	0	1 (0.2)	1 (0.1)
損傷	1 (0.2)	0	1 (0.1)
関節脱臼	2 (0.5)	1 (0.2)	3 (0.4)
関節損傷	3 (0.7)	0	3 (0.4)
靱帯断裂	1 (0.2)	0	1 (0.1)
靱帯捻挫	3 (0.7)	4 (0.9)	7 (0.8)
四肢損傷	3 (0.7)	4 (0.9)	7 (0.8)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
口唇損傷	0	1 (0.2)	1 (0.1)
筋断裂	0	1 (0.2)	1 (0.1)
肉離れ	3 (0.7)	3 (0.7)	6 (0.7)
筋骨格系損傷	0	1 (0.2)	1 (0.1)
膝蓋骨骨折	1 (0.2)	0	1 (0.1)
処置による疼痛	0	2 (0.5)	2 (0.2)
橈骨骨折	0	1 (0.2)	1 (0.1)
肋骨骨折	0	1 (0.2)	1 (0.1)
交通事故	2 (0.5)	0	2 (0.2)
瘢痕	1 (0.2)	0	1 (0.1)
皮膚擦過傷	1 (0.2)	2 (0.5)	3 (0.4)
皮膚裂傷	1 (0.2)	3 (0.7)	4 (0.5)
スポーツ損傷	0	1 (0.2)	1 (0.1)
ストレス骨折	0	2 (0.5)	2 (0.2)
サンバーン	1 (0.2)	1 (0.2)	2 (0.2)
腱損傷	0	1 (0.2)	1 (0.1)
腱断裂	2 (0.5)	2 (0.5)	4 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
傷害、中毒および処置合併症 (Cont.)			
熱傷	1 (0.2)	1 (0.2)	2 (0.2)
脛骨骨折	0	1 (0.2)	1 (0.1)
歯牙破折	0	1 (0.2)	1 (0.1)
尺骨骨折	1 (0.2)	0	1 (0.1)
上肢骨折	1 (0.2)	0	1 (0.1)
ワクチン接種合併症	0	1 (0.2)	1 (0.1)
臨床検査	94 (22.5)	149 (35.2)	243 (28.9)
アラニンアミノトランスフェラーゼ増加	10 (2.4)	15 (3.5)	25 (3.0)
アスパラギン酸アミノトランスフェラーゼ増加	5 (1.2)	14 (3.3)	19 (2.3)
B リンパ球数増加	1 (0.2)	1 (0.2)	2 (0.2)
血中ビリルビン増加	0	2 (0.5)	2 (0.2)
血中コレステロール増加	3 (0.7)	6 (1.4)	9 (1.1)
血中クレアチンホスホキナーゼ増加	23 (5.5)	48 (11.3)	71 (8.4)
血中クレアチニン増加	4 (1.0)	0	4 (0.5)
血中ブドウ糖増加	0	2 (0.5)	2 (0.2)
血中免疫グロブリン E 増加	6 (1.4)	2 (0.5)	8 (1.0)
血中乳酸脱水素酵素増加	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
臨床検査 (Cont.)			
血中カリウム増加	1 (0.2)	0	1 (0.1)
血圧上昇	1 (0.2)	0	1 (0.1)
血中トリグリセリド増加	3 (0.7)	0	3 (0.4)
血中尿酸増加	0	3 (0.7)	3 (0.4)
尿中血陽性	3 (0.7)	1 (0.2)	4 (0.5)
CD4 リンパ球減少	1 (0.2)	0	1 (0.1)
CD8 リンパ球百分率減少	1 (0.2)	0	1 (0.1)
CD8 リンパ球減少	0	1 (0.2)	1 (0.1)
心雑音	0	1 (0.2)	1 (0.1)
ケモカイン増加	1 (0.2)	0	1 (0.1)
胸部コンピュータ断層撮影異常	0	1 (0.2)	1 (0.1)
尿中結晶陽性	2 (0.5)	1 (0.2)	3 (0.4)
心電図 QT 間隔異常	1 (0.2)	0	1 (0.1)
好酸球百分率増加	1 (0.2)	0	1 (0.1)
尿中ブドウ糖陽性	0	1 (0.2)	1 (0.1)
ヘモグロビン減少	0	4 (0.9)	4 (0.5)
肝酵素上昇	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
臨床検査 (Cont.)			
高比重リポ蛋白増加	0	1 (0.2)	1 (0.1)
免疫グロブリン増加	1 (0.2)	0	1 (0.1)
肝機能検査値上昇	1 (0.2)	0	1 (0.1)
低比重リポ蛋白増加	0	2 (0.5)	2 (0.2)
リンパ節触知	1 (0.2)	0	1 (0.1)
リンパ球数減少	0	4 (0.9)	4 (0.5)
ナチュラルキラー細胞数減少	1 (0.2)	1 (0.2)	2 (0.2)
好中球数減少	2 (0.5)	3 (0.7)	5 (0.6)
血小板数増加	1 (0.2)	1 (0.2)	2 (0.2)
尿妊娠反応陽性	1 (0.2)	0	1 (0.1)
尿蛋白	1 (0.2)	0	1 (0.1)
尿中蛋白陽性	3 (0.7)	2 (0.5)	5 (0.6)
赤血球数減少	0	1 (0.2)	1 (0.1)
T リンパ球数減少	1 (0.2)	0	1 (0.1)
トランスアミナーゼ上昇	2 (0.5)	6 (1.4)	8 (1.0)
腫瘍マーカー上昇	0	1 (0.2)	1 (0.1)
尿円柱	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
臨床検査 (Cont.)			
尿中ケトン体陽性	1 (0.2)	0	1 (0.1)
尿中白血球エステラーゼ陽性	0	1 (0.2)	1 (0.1)
体重減少	0	3 (0.7)	3 (0.4)
体重増加	9 (2.2)	13 (3.1)	22 (2.6)
白血球数減少	1 (0.2)	5 (1.2)	6 (0.7)
代謝および栄養障害	24 (5.7)	31 (7.3)	55 (6.5)
食欲減退	1 (0.2)	3 (0.7)	4 (0.5)
糖尿病	1 (0.2)	0	1 (0.1)
脂質異常症	1 (0.2)	2 (0.5)	3 (0.4)
耐糖能障害	0	1 (0.2)	1 (0.1)
痛風	1 (0.2)	1 (0.2)	2 (0.2)
高コレステロール血症	2 (0.5)	6 (1.4)	8 (1.0)
高脂血症	5 (1.2)	1 (0.2)	6 (0.7)
高トリグリセリド血症	3 (0.7)	4 (0.9)	7 (0.8)
高尿酸血症	6 (1.4)	3 (0.7)	9 (1.1)
低血糖	0	1 (0.2)	1 (0.1)
低カリウム血症	0	3 (0.7)	3 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
代謝および栄養障害 (Cont.)			
低リン酸血症	1 (0.2)	0	1 (0.1)
食欲亢進	1 (0.2)	2 (0.5)	3 (0.4)
2 型糖尿病	0	1 (0.2)	1 (0.1)
ビタミン B12 欠乏	0	1 (0.2)	1 (0.1)
ビタミン D 欠乏	2 (0.5)	2 (0.5)	4 (0.5)
筋骨格系および結合組織障害	45 (10.8)	64 (15.1)	109 (13.0)
関節痛	7 (1.7)	12 (2.8)	19 (2.3)
関節炎	2 (0.5)	0	2 (0.2)
腋窩腫瘤	0	1 (0.2)	1 (0.1)
背部痛	9 (2.2)	19 (4.5)	28 (3.3)
骨嚢腫	1 (0.2)	0	1 (0.1)
滑液包炎	2 (0.5)	0	2 (0.2)
側腹部痛	1 (0.2)	0	1 (0.1)
足変形	1 (0.2)	0	1 (0.1)
椎間板変性症	0	1 (0.2)	1 (0.1)
椎間板突出	1 (0.2)	1 (0.2)	2 (0.2)
筋力低下	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
筋骨格系および結合組織障害 (Cont.)			
筋骨格系胸痛	0	2 (0.5)	2 (0.2)
筋骨格痛	4 (1.0)	2 (0.5)	6 (0.7)
筋肉痛	7 (1.7)	8 (1.9)	15 (1.8)
筋膜疼痛症候群	1 (0.2)	0	1 (0.1)
頚部痛	2 (0.5)	0	2 (0.2)
変形性関節症	1 (0.2)	2 (0.5)	3 (0.4)
四肢痛	1 (0.2)	8 (1.9)	9 (1.1)
顎痛	0	1 (0.2)	1 (0.1)
骨膜炎	0	1 (0.2)	1 (0.1)
肩回旋筋腱板症候群	0	2 (0.5)	2 (0.2)
変形性脊椎症	1 (0.2)	0	1 (0.1)
脊椎炎	0	1 (0.2)	1 (0.1)
腱炎	3 (0.7)	3 (0.7)	6 (0.7)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	13 (3.1)	20 (4.7)	33 (3.9)
肛門性器疣贅	2 (0.5)	0	2 (0.2)
基底細胞癌	0	1 (0.2)	1 (0.1)
骨新生物	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） (Cont.)			
ボーエン病	1 (0.2)	0	1 (0.1)
乳癌	1 (0.2)	0	1 (0.1)
真珠腫	0	2 (0.5)	2 (0.2)
結腸癌	1 (0.2)	0	1 (0.1)
胃癌	0	1 (0.2)	1 (0.1)
血管腫	1 (0.2)	0	1 (0.1)
浸潤性乳管癌	0	1 (0.2)	1 (0.1)
脂肪腫	1 (0.2)	1 (0.2)	2 (0.2)
メラノサイト性母斑	0	1 (0.2)	1 (0.1)
非分泌型下垂体腺腫	0	1 (0.2)	1 (0.1)
脂漏性角化症	0	1 (0.2)	1 (0.1)
皮膚乳頭腫	5 (1.2)	9 (2.1)	14 (1.7)
皮膚有棘細胞癌	0	2 (0.5)	2 (0.2)
神経系障害	45 (10.8)	42 (9.9)	87 (10.3)
健忘	0	1 (0.2)	1 (0.1)
手根管症候群	2 (0.5)	0	2 (0.2)
注意力障害	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
神経系障害 (Cont.)			
浮動性めまい	5 (1.2)	7 (1.7)	12 (1.4)
夢幻状態	1 (0.2)	0	1 (0.1)
味覚不全	0	1 (0.2)	1 (0.1)
頭痛	21 (5.0)	22 (5.2)	43 (5.1)
過眠症	1 (0.2)	0	1 (0.1)
虚血性脳卒中	1 (0.2)	0	1 (0.1)
片頭痛	2 (0.5)	2 (0.5)	4 (0.5)
前兆を伴う片頭痛	0	1 (0.2)	1 (0.1)
神経痛	0	2 (0.5)	2 (0.2)
錯感覚	2 (0.5)	0	2 (0.2)
失神寸前の状態	1 (0.2)	0	1 (0.1)
神経根障害	0	1 (0.2)	1 (0.1)
坐骨神経痛	2 (0.5)	2 (0.5)	4 (0.5)
感覚消失	1 (0.2)	0	1 (0.1)
傾眠	3 (0.7)	0	3 (0.4)
失神	0	1 (0.2)	1 (0.1)
緊張性頭痛	2 (0.5)	2 (0.5)	4 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
製品の問題	1 (0.2)	0	1 (0.1)
医療機器破損	1 (0.2)	0	1 (0.1)
精神障害	17 (4.1)	20 (4.7)	37 (4.4)
不安	4 (1.0)	8 (1.9)	12 (1.4)
無感情	1 (0.2)	0	1 (0.1)
注意欠陥多動性障害	1 (0.2)	1 (0.2)	2 (0.2)
抑うつ気分	0	1 (0.2)	1 (0.1)
うつ病	1 (0.2)	3 (0.7)	4 (0.5)
自傷性皮膚症	1 (0.2)	0	1 (0.1)
失見当識	0	1 (0.2)	1 (0.1)
不眠症	2 (0.5)	5 (1.2)	7 (0.8)
リビドー減退	1 (0.2)	0	1 (0.1)
大うつ病	0	1 (0.2)	1 (0.1)
躁病	2 (0.5)	0	2 (0.2)
混合性不安抑うつ障害	1 (0.2)	0	1 (0.1)
睡眠障害	2 (0.5)	0	2 (0.2)
ストレス	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
腎および尿路障害	9 (2.2)	17 (4.0)	26 (3.1)
急性腎障害	0	1 (0.2)	1 (0.1)
アルブミン尿	1 (0.2)	5 (1.2)	6 (0.7)
排尿困難	1 (0.2)	3 (0.7)	4 (0.5)
血尿	2 (0.5)	1 (0.2)	3 (0.4)
高シュウ酸尿症	1 (0.2)	0	1 (0.1)
緊張性膀胱	0	1 (0.2)	1 (0.1)
尿意切迫	1 (0.2)	0	1 (0.1)
腎結石症	1 (0.2)	2 (0.5)	3 (0.4)
頻尿	0	1 (0.2)	1 (0.1)
蛋白尿	1 (0.2)	2 (0.5)	3 (0.4)
腎不全	0	1 (0.2)	1 (0.1)
尿路障害	1 (0.2)	0	1 (0.1)
生殖系および乳房障害	10 (2.4)	12 (2.8)	22 (2.6)
無月経	1 (0.2)	3 (0.7)	4 (0.5)
亀頭包皮炎	1 (0.2)	0	1 (0.1)
良性前立腺肥大症	1 (0.2)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
生殖系および乳房障害 (Cont.)			
乳房腫大	0	1 (0.2)	1 (0.1)
乳房圧痛	0	1 (0.2)	1 (0.1)
月経困難症	2 (0.5)	0	2 (0.2)
乳管拡張症	1 (0.2)	0	1 (0.1)
閉経期症状	0	1 (0.2)	1 (0.1)
月経過多	1 (0.2)	1 (0.2)	2 (0.2)
不規則月経	1 (0.2)	0	1 (0.1)
会陰瘙	0	1 (0.2)	1 (0.1)
多嚢胞性卵巣	1 (0.2)	1 (0.2)	2 (0.2)
精巣痛	0	1 (0.2)	1 (0.1)
腟分泌物	1 (0.2)	0	1 (0.1)
外陰腟乾燥	0	1 (0.2)	1 (0.1)
呼吸器、胸郭および縦隔障害	50 (12.0)	53 (12.5)	103 (12.2)
喘息	11 (2.6)	7 (1.7)	18 (2.1)
気管支反応性亢進	1 (0.2)	0	1 (0.1)
慢性閉塞性肺疾患	0	1 (0.2)	1 (0.1)
咳嗽	15 (3.6)	10 (2.4)	25 (3.0)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
呼吸器、胸郭および縦隔障害 (Cont.)			
嚢胞性肺疾患	1 (0.2)	0	1 (0.1)
発声障害	1 (0.2)	0	1 (0.1)
呼吸困難	5 (1.2)	2 (0.5)	7 (0.8)
労作性呼吸困難	0	1 (0.2)	1 (0.1)
鼻出血	2 (0.5)	4 (0.9)	6 (0.7)
鼻閉	1 (0.2)	3 (0.7)	4 (0.5)
鼻乾燥	0	3 (0.7)	3 (0.4)
口腔咽頭痛	8 (1.9)	11 (2.6)	19 (2.3)
気胸	0	1 (0.2)	1 (0.1)
湿性咳嗽	1 (0.2)	1 (0.2)	2 (0.2)
肺腫瘤	0	2 (0.5)	2 (0.2)
アレルギー性鼻炎	2 (0.5)	2 (0.5)	4 (0.5)
鼻漏	1 (0.2)	1 (0.2)	2 (0.2)
副鼻腔うっ血	0	1 (0.2)	1 (0.1)
咽喉刺激感	1 (0.2)	1 (0.2)	2 (0.2)
上気道の炎症	0	1 (0.2)	1 (0.1)
声帯肥厚	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
皮膚および皮下組織障害	149 (35.7)	199 (47.0)	348 (41.4)
ざ瘡	43 (10.3)	95 (22.4)	138 (16.4)
光線角化症	4 (1.0)	1 (0.2)	5 (0.6)
脱毛症	1 (0.2)	2 (0.5)	3 (0.4)
血管浮腫	1 (0.2)	1 (0.2)	2 (0.2)
水疱	1 (0.2)	0	1 (0.1)
冷汗	1 (0.2)	0	1 (0.1)
頭部粃糠疹	0	1 (0.2)	1 (0.1)
皮膚嚢腫	0	2 (0.5)	2 (0.2)
皮膚炎	3 (0.7)	3 (0.7)	6 (0.7)
ざ瘡様皮膚炎	3 (0.7)	15 (3.5)	18 (2.1)
アレルギー性皮膚炎	0	1 (0.2)	1 (0.1)
アトピー性皮膚炎	39 (9.3)	27 (6.4)	66 (7.8)
接触皮膚炎	3 (0.7)	11 (2.6)	14 (1.7)
びまん性脱毛症	0	1 (0.2)	1 (0.1)
薬疹	1 (0.2)	0	1 (0.1)
異汗性湿疹	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
斑状出血	1 (0.2)	0	1 (0.1)
湿疹	4 (1.0)	4 (0.9)	8 (1.0)
紅斑	2 (0.5)	1 (0.2)	3 (0.4)
温熱性紅斑	1 (0.2)	0	1 (0.1)
毛包性ムチン沈着症	0	1 (0.2)	1 (0.1)
毛髪成長異常	0	1 (0.2)	1 (0.1)
逆むけ	0	1 (0.2)	1 (0.1)
汗腺炎	1 (0.2)	0	1 (0.1)
多汗症	0	2 (0.5)	2 (0.2)
嵌入爪	2 (0.5)	0	2 (0.2)
内方発育毛	1 (0.2)	0	1 (0.1)
間擦疹	0	1 (0.2)	1 (0.1)
機械性蕁麻疹	0	1 (0.2)	1 (0.1)
汗疹	1 (0.2)	0	1 (0.1)
神経皮膚炎	1 (0.2)	0	1 (0.1)
寝汗	1 (0.2)	1 (0.2)	2 (0.2)
爪破損	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
皮膚疼痛	1 (0.2)	0	1 (0.1)
類乾癬	0	1 (0.2)	1 (0.1)
口囲皮膚炎	2 (0.5)	1 (0.2)	3 (0.4)
光線過敏性反応	1 (0.2)	2 (0.5)	3 (0.4)
そう痒症	5 (1.2)	0	5 (0.6)
紫斑	0	1 (0.2)	1 (0.1)
発疹	2 (0.5)	1 (0.2)	3 (0.4)
斑状丘疹状皮疹	1 (0.2)	0	1 (0.1)
丘疹性皮疹	1 (0.2)	0	1 (0.1)
酒さ	1 (0.2)	5 (1.2)	6 (0.7)
脂漏	1 (0.2)	0	1 (0.1)
脂漏性皮膚炎	2 (0.5)	2 (0.5)	4 (0.5)
皮膚障害	0	1 (0.2)	1 (0.1)
皮膚亀裂	1 (0.2)	0	1 (0.1)
皮膚病変	1 (0.2)	0	1 (0.1)
皮膚腫脹	2 (0.5)	0	2 (0.2)
日光黒子	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=341) (PYS=417.5) Events (E/100PY)	UPA 30 mg QD (N=348) (PYS=423.6) Events (E/100PY)	Total (N=689) (PYS=841.1) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
毛細血管拡張症	1 (0.2)	0	1 (0.1)
中毒性表皮壊死融解症	1 (0.2)	0	1 (0.1)
蕁麻疹	9 (2.2)	9 (2.1)	18 (2.1)
コリン性蕁麻疹	1 (0.2)	0	1 (0.1)
黄色板腫	1 (0.2)	0	1 (0.1)
外科および内科処置	1 (0.2)	1 (0.2)	2 (0.2)
人工流産	1 (0.2)	1 (0.2)	2 (0.2)
血管障害	15 (3.6)	9 (2.1)	24 (2.9)
血性分泌物	1 (0.2)	0	1 (0.1)
深部静脈血栓症	1 (0.2)	0	1 (0.1)
潮紅	1 (0.2)	0	1 (0.1)
血腫	3 (0.7)	0	3 (0.4)
ほてり	0	1 (0.2)	1 (0.1)
高血圧	9 (2.2)	6 (1.4)	15 (1.8)
低血圧	0	1 (0.2)	1 (0.1)
血栓性静脈炎	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]
相互参照：M16-045 試験

表 7. ウパダシチニブ投与期間中に治験薬と関連ありの有害事象を発現した被験者数及び発現割合：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
Any adverse event	157 (39.2)	227 (55.6)	384 (47.5)
血液およびリンパ系障害	8 (2.0)	21 (5.1)	29 (3.6)
貧血	0	8 (2.0)	8 (1.0)
白血球増加症	1 (0.2)	0	1 (0.1)
白血球減少症	0	2 (0.5)	2 (0.2)
リンパ節症	0	2 (0.5)	2 (0.2)
リンパ球減少症	1 (0.2)	1 (0.2)	2 (0.2)
好中球減少症	7 (1.7)	13 (3.2)	20 (2.5)
好中球増加症	1 (0.2)	0	1 (0.1)
汎血球減少症	0	1 (0.2)	1 (0.1)
耳および迷路障害	1 (0.2)	1 (0.2)	2 (0.2)
突発性難聴	0	1 (0.2)	1 (0.1)
回転性めまい	1 (0.2)	0	1 (0.1)
眼障害	2 (0.5)	5 (1.2)	7 (0.9)
眼瞼炎	0	1 (0.2)	1 (0.1)
ドライアイ	1 (0.2)	1 (0.2)	2 (0.2)
眼瞼湿疹	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
眼障害 (Cont.)			
眼瞼浮腫	0	1 (0.2)	1 (0.1)
霧視	1 (0.2)	1 (0.2)	2 (0.2)
視力障害	1 (0.2)	0	1 (0.1)
胃腸障害	17 (4.2)	21 (5.1)	38 (4.7)
腹部膨満	1 (0.2)	0	1 (0.1)
腹痛	0	2 (0.5)	2 (0.2)
上腹部痛	3 (0.7)	1 (0.2)	4 (0.5)
便秘	0	1 (0.2)	1 (0.1)
齲歯	1 (0.2)	0	1 (0.1)
下痢	2 (0.5)	5 (1.2)	7 (0.9)
腸憩室	1 (0.2)	0	1 (0.1)
口内乾燥	0	1 (0.2)	1 (0.1)
消化不良	1 (0.2)	1 (0.2)	2 (0.2)
軟便	0	2 (0.5)	2 (0.2)
鼓腸	1 (0.2)	1 (0.2)	2 (0.2)
胃炎	1 (0.2)	0	1 (0.1)
胃腸障害	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
胃腸障害 (Cont.)			
消化器痛	1 (0.2)	0	1 (0.1)
胃食道逆流性疾患	0	1 (0.2)	1 (0.1)
口唇腫脹	0	1 (0.2)	1 (0.1)
口腔内潰瘍形成	0	1 (0.2)	1 (0.1)
悪心	8 (2.0)	8 (2.0)	16 (2.0)
大網梗塞	0	1 (0.2)	1 (0.1)
嘔吐	1 (0.2)	3 (0.7)	4 (0.5)
一般・全身障害および投与部位の状態	12 (3.0)	16 (3.9)	28 (3.5)
無力症	1 (0.2)	0	1 (0.1)
胸部不快感	0	1 (0.2)	1 (0.1)
胸痛	1 (0.2)	0	1 (0.1)
悪寒	0	1 (0.2)	1 (0.1)
薬効欠如	1 (0.2)	0	1 (0.1)
顔面浮腫	0	1 (0.2)	1 (0.1)
疲労	1 (0.2)	1 (0.2)	2 (0.2)
びくびく感	0	1 (0.2)	1 (0.1)
インフルエンザ様疾患	3 (0.7)	6 (1.5)	9 (1.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
一般・全身障害および投与部位の状態 (Cont.)			
末梢性浮腫	1 (0.2)	1 (0.2)	2 (0.2)
疼痛	0	1 (0.2)	1 (0.1)
発熱	4 (1.0)	4 (1.0)	8 (1.0)
乾燥症	0	1 (0.2)	1 (0.1)
肝胆道系障害	0	4 (1.0)	4 (0.5)
肝機能異常	0	3 (0.7)	3 (0.4)
肝炎	0	1 (0.2)	1 (0.1)
免疫系障害	2 (0.5)	2 (0.5)	4 (0.5)
アナフィラキシー反応	0	1 (0.2)	1 (0.1)
食物アレルギー	0	1 (0.2)	1 (0.1)
過敏症	1 (0.2)	0	1 (0.1)
複合アレルギー	1 (0.2)	0	1 (0.1)
感染症および寄生虫症	98 (24.4)	131 (32.1)	229 (28.3)
虫垂炎	1 (0.2)	0	1 (0.1)
細菌感染	1 (0.2)	0	1 (0.1)
細菌性膣症	0	1 (0.2)	1 (0.1)
体部白癬	1 (0.2)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
気管支炎	4 (1.0)	3 (0.7)	7 (0.9)
蜂巣炎	1 (0.2)	0	1 (0.1)
結膜炎	0	5 (1.2)	5 (0.6)
コロナウイルス感染	2 (0.5)	1 (0.2)	3 (0.4)
膀胱炎	0	1 (0.2)	1 (0.1)
感染性皮膚炎	1 (0.2)	1 (0.2)	2 (0.2)
皮膚糸状菌症	1 (0.2)	1 (0.2)	2 (0.2)
爪の皮膚糸状菌症	1 (0.2)	0	1 (0.1)
耳感染	1 (0.2)	3 (0.7)	4 (0.5)
膿瘡	1 (0.2)	0	1 (0.1)
ヘルペス性状湿疹	2 (0.5)	5 (1.2)	7 (0.9)
丹毒	0	1 (0.2)	1 (0.1)
大腸菌性尿路感染	0	1 (0.2)	1 (0.1)
眼感染	1 (0.2)	0	1 (0.1)
毛包炎	5 (1.2)	9 (2.2)	14 (1.7)
せつ	4 (1.0)	2 (0.5)	6 (0.7)
胃腸炎	0	2 (0.5)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
ウイルス性胃腸炎	1 (0.2)	1 (0.2)	2 (0.2)
陰部ヘルペス	1 (0.2)	0	1 (0.1)
陰部単純ヘルペス	0	1 (0.2)	1 (0.1)
手足口病	1 (0.2)	0	1 (0.1)
ヘルパンギーナ	0	1 (0.2)	1 (0.1)
ヘルペス性皮膚炎	0	2 (0.5)	2 (0.2)
ヘルペス眼感染	0	3 (0.7)	3 (0.4)
単純ヘルペス	7 (1.7)	12 (2.9)	19 (2.3)
ヘルペスウイルス感染	1 (0.2)	1 (0.2)	2 (0.2)
帯状疱疹	11 (2.7)	23 (5.6)	34 (4.2)
皮膚播種性帯状疱疹	0	2 (0.5)	2 (0.2)
麦粒腫	2 (0.5)	3 (0.7)	5 (0.6)
膿痂疹	4 (1.0)	3 (0.7)	7 (0.9)
インフルエンザ	0	2 (0.5)	2 (0.2)
椎間板炎	1 (0.2)	0	1 (0.1)
カポジ水痘様発疹	2 (0.5)	5 (1.2)	7 (0.9)
潜伏結核	2 (0.5)	4 (1.0)	6 (0.7)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
限局性感染	1 (0.2)	0	1 (0.1)
下気道感染	1 (0.2)	0	1 (0.1)
細菌性リンパ節炎	0	1 (0.2)	1 (0.1)
伝染性軟属腫	2 (0.5)	5 (1.2)	7 (0.9)
上咽頭炎	9 (2.2)	7 (1.7)	16 (2.0)
食道カンジダ症	0	1 (0.2)	1 (0.1)
爪真菌症	1 (0.2)	0	1 (0.1)
眼部単純ヘルペス	1 (0.2)	2 (0.5)	3 (0.4)
眼帯状疱疹	1 (0.2)	1 (0.2)	2 (0.2)
口腔カンジダ症	1 (0.2)	4 (1.0)	5 (0.6)
口腔ヘルペス	10 (2.5)	16 (3.9)	26 (3.2)
外耳炎	2 (0.5)	0	2 (0.2)
中耳炎	0	2 (0.5)	2 (0.2)
急性中耳炎	0	1 (0.2)	1 (0.1)
爪囲炎	0	2 (0.5)	2 (0.2)
咽頭膿瘍	0	1 (0.2)	1 (0.1)
咽頭炎	1 (0.2)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
レンサ球菌性咽頭炎	1 (0.2)	0	1 (0.1)
咽頭扁桃炎	1 (0.2)	0	1 (0.1)
肺炎	4 (1.0)	2 (0.5)	6 (0.7)
肺結核	1 (0.2)	0	1 (0.1)
腎盂腎炎	0	2 (0.5)	2 (0.2)
膿疱性皮疹	0	1 (0.2)	1 (0.1)
RS ウイルス感染	0	1 (0.2)	1 (0.1)
気道感染	1 (0.2)	0	1 (0.1)
鼻炎	1 (0.2)	3 (0.7)	4 (0.5)
敗血症	0	1 (0.2)	1 (0.1)
副鼻腔炎	2 (0.5)	1 (0.2)	3 (0.4)
皮膚細菌感染	0	1 (0.2)	1 (0.1)
皮膚カンジダ	0	1 (0.2)	1 (0.1)
皮膚感染	2 (0.5)	1 (0.2)	3 (0.4)
ブドウ球菌性膿痂疹	0	1 (0.2)	1 (0.1)
ブドウ球菌感染	0	2 (0.5)	2 (0.2)
ブドウ球菌性敗血症	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
感染症および寄生虫症 (Cont.)			
股部白癬	0	3 (0.7)	3 (0.4)
足部白癬	1 (0.2)	1 (0.2)	2 (0.2)
癜風	1 (0.2)	1 (0.2)	2 (0.2)
扁桃炎	0	1 (0.2)	1 (0.1)
歯膿瘍	1 (0.2)	2 (0.5)	3 (0.4)
気管炎	0	2 (0.5)	2 (0.2)
上気道感染	22 (5.5)	16 (3.9)	38 (4.7)
尿路感染	4 (1.0)	7 (1.7)	11 (1.4)
水痘	0	1 (0.2)	1 (0.1)
ウイルス感染	1 (0.2)	1 (0.2)	2 (0.2)
ウイルス性咽頭炎	1 (0.2)	0	1 (0.1)
ウイルス性上気道感染	1 (0.2)	6 (1.5)	7 (0.9)
外陰部腟カンジダ症	2 (0.5)	1 (0.2)	3 (0.4)
ブドウ球菌性創感染	0	1 (0.2)	1 (0.1)
傷害、中毒および処置合併症	0	2 (0.5)	2 (0.2)
節足動物咬傷	0	1 (0.2)	1 (0.1)
ワクチン接種合併症	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
臨床検査	41 (10.2)	58 (14.2)	99 (12.2)
アラニンアミノトランスフェラーゼ増加	4 (1.0)	9 (2.2)	13 (1.6)
アスパラギン酸アミノトランスフェラーゼ増加	2 (0.5)	7 (1.7)	9 (1.1)
B リンパ球数増加	1 (0.2)	1 (0.2)	2 (0.2)
血中コレステロール増加	2 (0.5)	4 (1.0)	6 (0.7)
血中クレアチンホスホキナーゼ増加	18 (4.5)	28 (6.9)	46 (5.7)
血中クレアチニン増加	2 (0.5)	0	2 (0.2)
血中免疫グロブリン E 増加	3 (0.7)	1 (0.2)	4 (0.5)
血中トリグリセリド増加	3 (0.7)	0	3 (0.4)
血中尿酸増加	0	1 (0.2)	1 (0.1)
尿中血陽性	1 (0.2)	0	1 (0.1)
CD4 リンパ球減少	1 (0.2)	0	1 (0.1)
CD8 リンパ球百分率減少	1 (0.2)	0	1 (0.1)
CD8 リンパ球減少	0	1 (0.2)	1 (0.1)
心雑音	0	1 (0.2)	1 (0.1)
心電図 QT 間隔異常	1 (0.2)	0	1 (0.1)
好酸球百分率増加	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
臨床検査 (Cont.)			
尿中ブドウ糖陽性	0	1 (0.2)	1 (0.1)
ヘモグロビン減少	1 (0.2)	3 (0.7)	4 (0.5)
心拍数増加	0	1 (0.2)	1 (0.1)
肝酵素上昇	1 (0.2)	0	1 (0.1)
肝機能検査値上昇	1 (0.2)	0	1 (0.1)
低比重リポ蛋白増加	0	1 (0.2)	1 (0.1)
リンパ球数減少	0	3 (0.7)	3 (0.4)
ナチュラルキラー細胞数減少	1 (0.2)	1 (0.2)	2 (0.2)
好中球数減少	2 (0.5)	3 (0.7)	5 (0.6)
血小板数増加	1 (0.2)	1 (0.2)	2 (0.2)
尿蛋白	1 (0.2)	0	1 (0.1)
T リンパ球数減少	1 (0.2)	0	1 (0.1)
トランスアミナーゼ上昇	2 (0.5)	4 (1.0)	6 (0.7)
腫瘍マーカー上昇	0	1 (0.2)	1 (0.1)
体重増加	7 (1.7)	11 (2.7)	18 (2.2)
白血球数減少	1 (0.2)	3 (0.7)	4 (0.5)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
代謝および栄養障害	7 (1.7)	10 (2.5)	17 (2.1)
食欲減退	1 (0.2)	2 (0.5)	3 (0.4)
脂質異常症	0	2 (0.5)	2 (0.2)
痛風	0	1 (0.2)	1 (0.1)
高コレステロール血症	2 (0.5)	4 (1.0)	6 (0.7)
高トリグリセリド血症	2 (0.5)	1 (0.2)	3 (0.4)
高尿酸血症	3 (0.7)	1 (0.2)	4 (0.5)
筋骨格系および結合組織障害	5 (1.2)	5 (1.2)	10 (1.2)
関節痛	1 (0.2)	0	1 (0.1)
関節炎	1 (0.2)	0	1 (0.1)
腋窩腫瘤	0	1 (0.2)	1 (0.1)
背部痛	0	1 (0.2)	1 (0.1)
滑液包炎	1 (0.2)	0	1 (0.1)
筋骨格痛	1 (0.2)	0	1 (0.1)
筋肉痛	2 (0.5)	4 (1.0)	6 (0.7)
四肢痛	0	1 (0.2)	1 (0.1)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	3 (0.7)	5 (1.2)	8 (1.0)
肛門性器疣贅	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） (Cont.)			
乳癌	1 (0.2)	0	1 (0.1)
結腸癌	1 (0.2)	0	1 (0.1)
皮膚乳頭腫	1 (0.2)	4 (1.0)	5 (0.6)
皮膚有棘細胞癌	0	1 (0.2)	1 (0.1)
神経系障害	9 (2.2)	16 (3.9)	25 (3.1)
健忘	0	1 (0.2)	1 (0.1)
手根管症候群	1 (0.2)	0	1 (0.1)
注意力障害	1 (0.2)	0	1 (0.1)
浮動性めまい	2 (0.5)	2 (0.5)	4 (0.5)
味覚不全	0	1 (0.2)	1 (0.1)
頭痛	5 (1.2)	10 (2.5)	15 (1.9)
虚血性脳卒中	1 (0.2)	0	1 (0.1)
片頭痛	0	1 (0.2)	1 (0.1)
前兆を伴う片頭痛	0	1 (0.2)	1 (0.1)
傾眠	1 (0.2)	0	1 (0.1)
失神	0	1 (0.2)	1 (0.1)
緊張性頭痛	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
精神障害	5 (1.2)	0	5 (0.6)
不安	1 (0.2)	0	1 (0.1)
無感情	1 (0.2)	0	1 (0.1)
うつ病	1 (0.2)	0	1 (0.1)
リビドー減退	1 (0.2)	0	1 (0.1)
睡眠障害	1 (0.2)	0	1 (0.1)
自殺念慮	1 (0.2)	0	1 (0.1)
腎および尿路障害	4 (1.0)	3 (0.7)	7 (0.9)
アルブミン尿	1 (0.2)	1 (0.2)	2 (0.2)
排尿困難	0	2 (0.5)	2 (0.2)
高シュウ酸尿症	1 (0.2)	0	1 (0.1)
尿意切迫	1 (0.2)	0	1 (0.1)
蛋白尿	1 (0.2)	0	1 (0.1)
生殖系および乳房障害	2 (0.5)	4 (1.0)	6 (0.7)
無月経	1 (0.2)	1 (0.2)	2 (0.2)
乳房腫大	0	1 (0.2)	1 (0.1)
乳房圧痛	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
生殖系および乳房障害 (Cont.)			
閉経期症状	0	1 (0.2)	1 (0.1)
月経過多	1 (0.2)	0	1 (0.1)
呼吸器、胸郭および縦隔障害	9 (2.2)	13 (3.2)	22 (2.7)
喘息	0	1 (0.2)	1 (0.1)
咳嗽	7 (1.7)	1 (0.2)	8 (1.0)
呼吸困難	2 (0.5)	1 (0.2)	3 (0.4)
鼻出血	0	1 (0.2)	1 (0.1)
鼻閉	0	1 (0.2)	1 (0.1)
口腔咽頭痛	3 (0.7)	6 (1.5)	9 (1.1)
湿性咳嗽	1 (0.2)	0	1 (0.1)
副鼻腔うっ血	1 (0.2)	2 (0.5)	3 (0.4)
皮膚および皮下組織障害	58 (14.5)	107 (26.2)	165 (20.4)
ざ瘡	34 (8.5)	81 (19.9)	115 (14.2)
脱毛症	0	1 (0.2)	1 (0.1)
円形脱毛症	0	1 (0.2)	1 (0.1)
皮膚嚢腫	0	1 (0.2)	1 (0.1)
皮膚炎	0	2 (0.5)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
皮膚および皮下組織障害 (Cont.)			
ざ瘡様皮膚炎	2 (0.5)	6 (1.5)	8 (1.0)
アトピー性皮膚炎	16 (4.0)	9 (2.2)	25 (3.1)
接触皮膚炎	0	1 (0.2)	1 (0.1)
湿疹	4 (1.0)	1 (0.2)	5 (0.6)
紅斑	1 (0.2)	1 (0.2)	2 (0.2)
毛髪成長異常	0	1 (0.2)	1 (0.1)
多汗症	0	1 (0.2)	1 (0.1)
間擦疹	0	1 (0.2)	1 (0.1)
機械性蕁麻疹	0	1 (0.2)	1 (0.1)
神経皮膚炎	1 (0.2)	0	1 (0.1)
爪破損	0	1 (0.2)	1 (0.1)
口囲皮膚炎	1 (0.2)	0	1 (0.1)
炎症後色素沈着変化	1 (0.2)	0	1 (0.1)
そう痒症	1 (0.2)	0	1 (0.1)
紫斑	0	1 (0.2)	1 (0.1)
酒さ	0	2 (0.5)	2 (0.2)
脂漏	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) n (%)	UPA 30 mg QD (N=408) n (%)	Total (N=809) n (%)
皮膚および皮下組織障害 (Cont.)			
脂漏性皮膚炎	0	1 (0.2)	1 (0.1)
皮膚障害	0	1 (0.2)	1 (0.1)
皮膚病変	1 (0.2)	0	1 (0.1)
日光黒子	0	1 (0.2)	1 (0.1)
蕁麻疹	1 (0.2)	2 (0.5)	3 (0.4)
尋常性白斑	0	1 (0.2)	1 (0.1)
血管障害	2 (0.5)	0	2 (0.2)
深部静脈血栓症	1 (0.2)	0	1 (0.1)
潮紅	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
Subjects are counted once in each row, regardless of the number of events they may have had.

Program Source Code: [redacted]
相互参照：M16-045 試験

表 8. ウパダシチニブ投与期間中の治験薬と関連ありの有害事象の 100 人年あたりの発現率：MedDRA 器官別大分類及び基本語別（全ウパダシチニブ投与集団）

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
Any adverse event	418 (85.2)	632 (126.1)	1050 (105.9)
血液およびリンパ系障害	12 (2.4)	33 (6.6)	45 (4.5)
貧血	0	9 (1.8)	9 (0.9)
白血球増加症	1 (0.2)	0	1 (0.1)
白血球減少症	0	2 (0.4)	2 (0.2)
リンパ節症	0	2 (0.4)	2 (0.2)
リンパ球減少症	2 (0.4)	1 (0.2)	3 (0.3)
好中球減少症	8 (1.6)	18 (3.6)	26 (2.6)
好中球増加症	1 (0.2)	0	1 (0.1)
汎血球減少症	0	1 (0.2)	1 (0.1)
耳および迷路障害	1 (0.2)	1 (0.2)	2 (0.2)
突発性難聴	0	1 (0.2)	1 (0.1)
回転性めまい	1 (0.2)	0	1 (0.1)
眼障害	3 (0.6)	5 (1.0)	8 (0.8)
眼瞼炎	0	1 (0.2)	1 (0.1)
ドライアイ	1 (0.2)	1 (0.2)	2 (0.2)
眼瞼湿疹	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
眼障害 (Cont.)			
眼瞼浮腫	0	1 (0.2)	1 (0.1)
霧視	1 (0.2)	1 (0.2)	2 (0.2)
視力障害	1 (0.2)	0	1 (0.1)
胃腸障害	26 (5.3)	29 (5.8)	55 (5.5)
腹部膨満	1 (0.2)	0	1 (0.1)
腹痛	0	2 (0.4)	2 (0.2)
上腹部痛	4 (0.8)	1 (0.2)	5 (0.5)
便秘	0	1 (0.2)	1 (0.1)
齲歯	1 (0.2)	0	1 (0.1)
下痢	2 (0.4)	5 (1.0)	7 (0.7)
腸憩室	1 (0.2)	0	1 (0.1)
口内乾燥	0	1 (0.2)	1 (0.1)
消化不良	1 (0.2)	1 (0.2)	2 (0.2)
軟便	0	2 (0.4)	2 (0.2)
鼓腸	1 (0.2)	1 (0.2)	2 (0.2)
胃炎	1 (0.2)	0	1 (0.1)
胃腸障害	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
胃腸障害 (Cont.)			
消化器痛	1 (0.2)	0	1 (0.1)
胃食道逆流性疾患	0	1 (0.2)	1 (0.1)
口唇腫脹	0	1 (0.2)	1 (0.1)
口腔内潰瘍形成	0	1 (0.2)	1 (0.1)
悪心	10 (2.0)	8 (1.6)	18 (1.8)
大網梗塞	0	1 (0.2)	1 (0.1)
嘔吐	2 (0.4)	3 (0.6)	5 (0.5)
一般・全身障害および投与部位の状態	12 (2.4)	19 (3.8)	31 (3.1)
無力症	1 (0.2)	0	1 (0.1)
胸部不快感	0	1 (0.2)	1 (0.1)
胸痛	1 (0.2)	0	1 (0.1)
悪寒	0	1 (0.2)	1 (0.1)
薬効欠如	1 (0.2)	0	1 (0.1)
顔面浮腫	0	1 (0.2)	1 (0.1)
疲労	1 (0.2)	1 (0.2)	2 (0.2)
びくびく感	0	1 (0.2)	1 (0.1)
インフルエンザ様疾患	3 (0.6)	6 (1.2)	9 (0.9)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
一般・全身障害および投与部位の状態 (Cont.)			
末梢性浮腫	1 (0.2)	1 (0.2)	2 (0.2)
疼痛	0	1 (0.2)	1 (0.1)
発熱	4 (0.8)	5 (1.0)	9 (0.9)
乾燥症	0	1 (0.2)	1 (0.1)
肝胆道系障害	0	5 (1.0)	5 (0.5)
肝機能異常	0	4 (0.8)	4 (0.4)
肝炎	0	1 (0.2)	1 (0.1)
免疫系障害	2 (0.4)	2 (0.4)	4 (0.4)
アナフィラキシー反応	0	1 (0.2)	1 (0.1)
食物アレルギー	0	1 (0.2)	1 (0.1)
過敏症	1 (0.2)	0	1 (0.1)
複合アレルギー	1 (0.2)	0	1 (0.1)
感染症および寄生虫症	149 (30.4)	234 (46.7)	383 (38.6)
虫垂炎	1 (0.2)	0	1 (0.1)
細菌感染	1 (0.2)	0	1 (0.1)
細菌性膣症	0	1 (0.2)	1 (0.1)
体部白癬	1 (0.2)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
気管支炎	4 (0.8)	3 (0.6)	7 (0.7)
蜂巣炎	1 (0.2)	0	1 (0.1)
結膜炎	0	7 (1.4)	7 (0.7)
コロナウイルス感染	2 (0.4)	1 (0.2)	3 (0.3)
膀胱炎	0	1 (0.2)	1 (0.1)
感染性皮膚炎	1 (0.2)	1 (0.2)	2 (0.2)
皮膚糸状菌症	1 (0.2)	2 (0.4)	3 (0.3)
爪の皮膚糸状菌症	1 (0.2)	0	1 (0.1)
耳感染	1 (0.2)	3 (0.6)	4 (0.4)
膿瘡	1 (0.2)	0	1 (0.1)
ヘルペス性状湿疹	2 (0.4)	7 (1.4)	9 (0.9)
丹毒	0	1 (0.2)	1 (0.1)
大腸菌性尿路感染	0	1 (0.2)	1 (0.1)
眼感染	1 (0.2)	0	1 (0.1)
毛包炎	5 (1.0)	9 (1.8)	14 (1.4)
せつ	5 (1.0)	2 (0.4)	7 (0.7)
胃腸炎	0	2 (0.4)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
ウイルス性胃腸炎	1 (0.2)	1 (0.2)	2 (0.2)
陰部ヘルペス	1 (0.2)	0	1 (0.1)
陰部単純ヘルペス	0	1 (0.2)	1 (0.1)
手足口病	1 (0.2)	0	1 (0.1)
ヘルパンギーナ	0	1 (0.2)	1 (0.1)
ヘルペス性皮膚炎	0	2 (0.4)	2 (0.2)
ヘルペス眼感染	0	3 (0.6)	3 (0.3)
単純ヘルペス	7 (1.4)	14 (2.8)	21 (2.1)
ヘルペスウイルス感染	1 (0.2)	1 (0.2)	2 (0.2)
帯状疱疹	11 (2.2)	23 (4.6)	34 (3.4)
皮膚播種性帯状疱疹	0	2 (0.4)	2 (0.2)
麦粒腫	2 (0.4)	4 (0.8)	6 (0.6)
膿痂疹	6 (1.2)	3 (0.6)	9 (0.9)
インフルエンザ	0	2 (0.4)	2 (0.2)
椎間板炎	1 (0.2)	0	1 (0.1)
カポジ水痘様発疹	2 (0.4)	7 (1.4)	9 (0.9)
潜伏結核	2 (0.4)	4 (0.8)	6 (0.6)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
限局性感染	1 (0.2)	0	1 (0.1)
下気道感染	1 (0.2)	0	1 (0.1)
細菌性リンパ節炎	0	1 (0.2)	1 (0.1)
伝染性軟属腫	2 (0.4)	5 (1.0)	7 (0.7)
上咽頭炎	9 (1.8)	11 (2.2)	20 (2.0)
食道カンジダ症	0	1 (0.2)	1 (0.1)
爪真菌症	1 (0.2)	0	1 (0.1)
眼部単純ヘルペス	1 (0.2)	3 (0.6)	4 (0.4)
眼帯状疱疹	1 (0.2)	2 (0.4)	3 (0.3)
口腔カンジダ症	1 (0.2)	4 (0.8)	5 (0.5)
口腔ヘルペス	12 (2.4)	22 (4.4)	34 (3.4)
外耳炎	2 (0.4)	0	2 (0.2)
中耳炎	0	2 (0.4)	2 (0.2)
急性中耳炎	0	1 (0.2)	1 (0.1)
爪囲炎	0	2 (0.4)	2 (0.2)
咽頭膿瘍	0	1 (0.2)	1 (0.1)
咽頭炎	1 (0.2)	1 (0.2)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
レンサ球菌性咽頭炎	1 (0.2)	0	1 (0.1)
咽頭扁桃炎	1 (0.2)	0	1 (0.1)
肺炎	4 (0.8)	2 (0.4)	6 (0.6)
肺結核	1 (0.2)	0	1 (0.1)
腎盂腎炎	0	2 (0.4)	2 (0.2)
膿疱性皮疹	0	1 (0.2)	1 (0.1)
RS ウイルス感染	0	1 (0.2)	1 (0.1)
気道感染	1 (0.2)	0	1 (0.1)
鼻炎	1 (0.2)	3 (0.6)	4 (0.4)
敗血症	0	1 (0.2)	1 (0.1)
副鼻腔炎	2 (0.4)	1 (0.2)	3 (0.3)
皮膚細菌感染	0	1 (0.2)	1 (0.1)
皮膚カンジダ	0	1 (0.2)	1 (0.1)
皮膚感染	2 (0.4)	1 (0.2)	3 (0.3)
ブドウ球菌性膿痂疹	0	1 (0.2)	1 (0.1)
ブドウ球菌感染	0	2 (0.4)	2 (0.2)
ブドウ球菌性敗血症	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
感染症および寄生虫症 (Cont.)			
股部白癬	0	4 (0.8)	4 (0.4)
足部白癬	1 (0.2)	1 (0.2)	2 (0.2)
癜風	2 (0.4)	1 (0.2)	3 (0.3)
扁桃炎	0	1 (0.2)	1 (0.1)
歯膿瘍	1 (0.2)	2 (0.4)	3 (0.3)
気管炎	0	2 (0.4)	2 (0.2)
上気道感染	26 (5.3)	22 (4.4)	48 (4.8)
尿路感染	4 (0.8)	7 (1.4)	11 (1.1)
水痘	0	1 (0.2)	1 (0.1)
ウイルス感染	1 (0.2)	1 (0.2)	2 (0.2)
ウイルス性咽頭炎	2 (0.4)	0	2 (0.2)
ウイルス性上気道感染	1 (0.2)	6 (1.2)	7 (0.7)
外陰部腟カンジダ症	3 (0.6)	1 (0.2)	4 (0.4)
ブドウ球菌性創感染	0	1 (0.2)	1 (0.1)
傷害、中毒および処置合併症	0	2 (0.4)	2 (0.2)
節足動物咬傷	0	1 (0.2)	1 (0.1)
ワクチン接種合併症	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
臨床検査	76 (15.5)	96 (19.2)	172 (17.3)
アラニンアミノトランスフェラーゼ増加	4 (0.8)	10 (2.0)	14 (1.4)
アスパラギン酸アミノトランスフェラーゼ増加	2 (0.4)	9 (1.8)	11 (1.1)
B リンパ球数増加	1 (0.2)	1 (0.2)	2 (0.2)
血中コレステロール増加	3 (0.6)	5 (1.0)	8 (0.8)
血中クレアチンホスホキナーゼ増加	30 (6.1)	32 (6.4)	62 (6.3)
血中クレアチニン増加	3 (0.6)	0	3 (0.3)
血中免疫グロブリン E 増加	3 (0.6)	1 (0.2)	4 (0.4)
血中トリグリセリド増加	3 (0.6)	0	3 (0.3)
血中尿酸増加	0	1 (0.2)	1 (0.1)
尿中血陽性	1 (0.2)	0	1 (0.1)
CD4 リンパ球減少	1 (0.2)	0	1 (0.1)
CD8 リンパ球百分率減少	1 (0.2)	0	1 (0.1)
CD8 リンパ球減少	0	1 (0.2)	1 (0.1)
心雑音	0	1 (0.2)	1 (0.1)
心電図 QT 間隔異常	1 (0.2)	0	1 (0.1)
好酸球百分率増加	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
臨床検査 (Cont.)			
尿中ブドウ糖陽性	0	1 (0.2)	1 (0.1)
ヘモグロビン減少	2 (0.4)	3 (0.6)	5 (0.5)
心拍数増加	0	1 (0.2)	1 (0.1)
肝酵素上昇	1 (0.2)	0	1 (0.1)
肝機能検査値上昇	1 (0.2)	0	1 (0.1)
低比重リポ蛋白増加	0	1 (0.2)	1 (0.1)
リンパ球数減少	0	3 (0.6)	3 (0.3)
ナチュラルキラー細胞数減少	1 (0.2)	1 (0.2)	2 (0.2)
好中球数減少	2 (0.4)	3 (0.6)	5 (0.5)
血小板数増加	1 (0.2)	1 (0.2)	2 (0.2)
尿蛋白	1 (0.2)	0	1 (0.1)
T リンパ球数減少	1 (0.2)	0	1 (0.1)
トランスアミナーゼ上昇	3 (0.6)	5 (1.0)	8 (0.8)
腫瘍マーカー上昇	0	1 (0.2)	1 (0.1)
体重増加	8 (1.6)	12 (2.4)	20 (2.0)
白血球数減少	1 (0.2)	3 (0.6)	4 (0.4)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
代謝および栄養障害	9 (1.8)	12 (2.4)	21 (2.1)
食欲減退	1 (0.2)	2 (0.4)	3 (0.3)
脂質異常症	0	2 (0.4)	2 (0.2)
痛風	0	1 (0.2)	1 (0.1)
高コレステロール血症	2 (0.4)	5 (1.0)	7 (0.7)
高トリグリセリド血症	2 (0.4)	1 (0.2)	3 (0.3)
高尿酸血症	4 (0.8)	1 (0.2)	5 (0.5)
筋骨格系および結合組織障害	6 (1.2)	8 (1.6)	14 (1.4)
関節痛	1 (0.2)	0	1 (0.1)
関節炎	1 (0.2)	0	1 (0.1)
腋窩腫瘤	0	1 (0.2)	1 (0.1)
背部痛	0	2 (0.4)	2 (0.2)
滑液包炎	1 (0.2)	0	1 (0.1)
筋骨格痛	1 (0.2)	0	1 (0.1)
筋肉痛	2 (0.4)	4 (0.8)	6 (0.6)
四肢痛	0	1 (0.2)	1 (0.1)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	4 (0.8)	5 (1.0)	9 (0.9)
肛門性器疣贅	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む） (Cont.)			
乳癌	1 (0.2)	0	1 (0.1)
結腸癌	1 (0.2)	0	1 (0.1)
皮膚乳頭腫	1 (0.2)	4 (0.8)	5 (0.5)
皮膚有棘細胞癌	0	1 (0.2)	1 (0.1)
神経系障害	13 (2.6)	19 (3.8)	32 (3.2)
健忘	0	1 (0.2)	1 (0.1)
手根管症候群	1 (0.2)	0	1 (0.1)
注意力障害	1 (0.2)	0	1 (0.1)
浮動性めまい	2 (0.4)	2 (0.4)	4 (0.4)
味覚不全	0	1 (0.2)	1 (0.1)
頭痛	6 (1.2)	11 (2.2)	17 (1.7)
虚血性脳卒中	1 (0.2)	0	1 (0.1)
片頭痛	0	1 (0.2)	1 (0.1)
前兆を伴う片頭痛	0	1 (0.2)	1 (0.1)
傾眠	2 (0.4)	0	2 (0.2)
失神	0	1 (0.2)	1 (0.1)
緊張性頭痛	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
精神障害	6 (1.2)	0	6 (0.6)
不安	1 (0.2)	0	1 (0.1)
無感情	1 (0.2)	0	1 (0.1)
うつ病	1 (0.2)	0	1 (0.1)
リビドー減退	1 (0.2)	0	1 (0.1)
睡眠障害	1 (0.2)	0	1 (0.1)
自殺念慮	1 (0.2)	0	1 (0.1)
腎および尿路障害	4 (0.8)	5 (1.0)	9 (0.9)
アルブミン尿	1 (0.2)	3 (0.6)	4 (0.4)
排尿困難	0	2 (0.4)	2 (0.2)
高シュウ酸尿症	1 (0.2)	0	1 (0.1)
尿意切迫	1 (0.2)	0	1 (0.1)
蛋白尿	1 (0.2)	0	1 (0.1)
生殖系および乳房障害	2 (0.4)	4 (0.8)	6 (0.6)
無月経	1 (0.2)	1 (0.2)	2 (0.2)
乳房腫大	0	1 (0.2)	1 (0.1)
乳房圧痛	0	1 (0.2)	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
生殖系および乳房障害 (Cont.)			
閉経期症状	0	1 (0.2)	1 (0.1)
月経過多	1 (0.2)	0	1 (0.1)
呼吸器、胸郭および縦隔障害	15 (3.1)	16 (3.2)	31 (3.1)
喘息	0	1 (0.2)	1 (0.1)
咳嗽	8 (1.6)	1 (0.2)	9 (0.9)
呼吸困難	2 (0.4)	3 (0.6)	5 (0.5)
鼻出血	0	1 (0.2)	1 (0.1)
鼻閉	0	1 (0.2)	1 (0.1)
口腔咽頭痛	3 (0.6)	7 (1.4)	10 (1.0)
湿性咳嗽	1 (0.2)	0	1 (0.1)
副鼻腔うっ血	1 (0.2)	2 (0.4)	3 (0.3)
皮膚および皮下組織障害	76 (15.5)	137 (27.3)	213 (21.5)
ざ瘡	42 (8.6)	95 (19.0)	137 (13.8)
脱毛症	0	1 (0.2)	1 (0.1)
円形脱毛症	0	1 (0.2)	1 (0.1)
皮膚嚢腫	0	1 (0.2)	1 (0.1)
皮膚炎	0	2 (0.4)	2 (0.2)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
ざ瘡様皮膚炎	2 (0.4)	7 (1.4)	9 (0.9)
アトピー性皮膚炎	20 (4.1)	9 (1.8)	29 (2.9)
接触皮膚炎	0	1 (0.2)	1 (0.1)
湿疹	4 (0.8)	1 (0.2)	5 (0.5)
紅斑	1 (0.2)	1 (0.2)	2 (0.2)
毛髪成長異常	0	1 (0.2)	1 (0.1)
多汗症	0	3 (0.6)	3 (0.3)
間擦疹	0	1 (0.2)	1 (0.1)
機械性蕁麻疹	0	1 (0.2)	1 (0.1)
神経皮膚炎	1 (0.2)	0	1 (0.1)
爪破損	0	1 (0.2)	1 (0.1)
口囲皮膚炎	1 (0.2)	0	1 (0.1)
炎症後色素沈着変化	1 (0.2)	0	1 (0.1)
そう痒症	1 (0.2)	0	1 (0.1)
紫斑	0	1 (0.2)	1 (0.1)
酒さ	0	2 (0.4)	2 (0.2)
脂漏	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]

MedDRA 22.1 System Organ Class Preferred Term	UPA 15 mg QD (N=401) (PYS=490.9) Events (E/100PY)	UPA 30 mg QD (N=408) (PYS=501.0) Events (E/100PY)	Total (N=809) (PYS=991.9) Events (E/100PY)
皮膚および皮下組織障害 (Cont.)			
脂漏性皮膚炎	0	1 (0.2)	1 (0.1)
皮膚障害	0	1 (0.2)	1 (0.1)
皮膚病変	1 (0.2)	0	1 (0.1)
日光黒子	0	1 (0.2)	1 (0.1)
蕁麻疹	1 (0.2)	4 (0.8)	5 (0.5)
尋常性白斑	0	1 (0.2)	1 (0.1)
血管障害	2 (0.4)	0	2 (0.2)
深部静脈血栓症	1 (0.2)	0	1 (0.1)
潮紅	1 (0.2)	0	1 (0.1)

Note: Treatment-emergent adverse events are defined as any adverse events with an onset or worsening date on or after the first dose of upadacitinib and no more than 30 days after the last dose of upadacitinib in the study.
E/100PY = Events per 100 patient-years.

Program Source Code: [redacted]
相互参照：M16-045 試験

死亡に至った有害事象の叙述

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
コロナウイルス感染	X			X
心筋梗塞	X	X	X	
気胸	X			
腎不全	X			X

Treatment Group	Age at Study Start	Sex	Race
UPA 30 MG QD/UPA 30 MG QD	6[redacted]	MALE	WHITE

Medical History	Onset Year
ROSACEA AT FACE	19[redacted]
TYPE 2 DIABETES	20[redacted]
VIRAL WARTS ON HAND	20[redacted]
HIGH CHOLESTEROL	20[redacted]
HYPERTENSION	20[redacted]
ACID REFLUX	20[redacted]
ARTHRITIS	20[redacted]
ATOPIC DERMATITIS	20[redacted]
ATOPIC DERMATITIS	20[redacted]

Prior Procedures	Procedure Year
PRIOR PROCEDURES: KNEE REPLACEMENT	20[redacted]
PRIOR PROCEDURES: SHOULDER SURGERY	20[redacted]
PRIOR PROCEDURES: SHOULDER SURGERY	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	30 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 113	113

UPA	30 MG	ORAL	QD	[redacted]20[redacted] / [redacted]20[redacted] / 371 114	258	

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y: 19[redacted]
LISINOPRIL	20 mg	QD	Y: 20[redacted]
HYDROCODONE	5 mg	QD	Y: 20[redacted]
PANTOPRAZOLE	20 mg	QD	Y: 20[redacted]
SIMVASTATIN	10 mg	QD	Y: 20[redacted]
METFORMIN	500 mg	QD	Y: 20[redacted]
HYDROCORTISONE	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]-[redacted] / -319
EUCERIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]-[redacted] / -7

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
LISINOPRIL	20 mg	QD	Y: 20[redacted]	ONGOING
HYDROCODONE	5 mg	QD	Y: 20[redacted]	ONGOING
PANTOPRAZOLE	20 mg	QD	Y: 20[redacted]	ONGOING
SIMVASTATIN	10 mg	QD	Y: 20[redacted]	ONGOING
METFORMIN	500 mg	QD	Y: 20[redacted]	ONGOING
EUCERIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]-[redacted] / -7	ONGOING
DEXAMETHASONE	10 mg	QD	Y-M: 20[redacted]-[redacted] / 375	Y-M: 20[redacted]-[redacted] / 399
ENOXAPARIN	150 mg	BID	Y-M: 20[redacted]-[redacted] / 375	Y-M: 20[redacted]-[redacted] / 399
VASOPRESSIN	0.01 OTHER: U/MIN	OTHER: EVERY OTHER DAY	Y-M: 20[redacted]-[redacted] / 391	Y-M: 20[redacted]-[redacted] / 399

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	COVID-19 INFECTION
Preferred term	コロナウイルス感染
AE Onset Date / Rx Day	[redacted]20[redacted] / 370
Age at AE Onset	6[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 375): Creatine Kinase: 322 [30 - 200] U/L; NPTST054-D DIMER QUANTITATIVE: 0.55 [0 - 0.54] UNIT NOT REPORTED; NPTST150-TROPONIN: <0.10 [0 - 0.4] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 376): NPTST046-CRP: 13.5 [0 - 10] MG/L; NPTST137-SARS-COV-2 NAAT: COVID-19 POSITIVE [0 - 1] UNIT NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 375): CHEST X-RAY: THERE HAS BEEN INTERVAL DEVELOPMENT OF A BILATERAL PULMONARY OPACITIES SUSPICIOUS FOR CARDIOGENIC EDEMA IN LIGHT OF THE CENTRAL SYMMETRIC APPEARANCE AND ENLARGED CARDIAC SILHOUETTE. ALSO SMALL RIGHTEFFUSION. REMAINDER OF THE MEDIASTINUM IS UNREMARKABLE. NO DEVELOPING CHEST WALL ABNORMALLY. CXR CONCERNING FOR BILATERAL PNEUMONIA. D-DIMER MINIMALLY ELEVATED, SUSPECT THIS IS DUE TO COVID RATHERTHAN VTE.; EKG: SINUS RHYTHM WITH SINUS ARRHYTHMIA, RATE

	85, NORMAL AXIS, MILDLY PROLONGED QTC AT 453, NONSPECIFIC ST CHANGES, NONSPECIFIC T WAVE CHANGES, INCOMPLETE RBBB, NO STEMI; VITALS COLLECTION: BP:140/64 PULSE: 86 RESP: 38 TEMP: 98.2 F TEMP SCR: ORAL SPO2: 88% PAIN LEVEL: 10; [redacted]20[redacted] (RX DAY 383): ENDOTRACHEAL TUBE: ET TUBE POORLY SEEN BUT THROUGH TO BE JUST ABOVE THE CARINA. NG TUBE TIP THOUGH TO BE IN THE FUNDUS OF THE STOMACH. RIGHT SIDED PICC LINE TIP IN THE SVC. DIFFUSE STRANDY BASILAR INFILTRATES HAVE INCREASED. OVERALL HAZY INFILTRATES THROUGHOUT. ET TUBE PLACEMENT WAS DUE TO MECHANICAL SUPPORT OF VENTILATION; [redacted]20[redacted] (RX DAY 391): HEMODIALYSIS TREATMENT: POST 4 HOUR DIALYSIS TREATMENT WITH 500 DFR AND @00 BFR WITH 1.5KG FLUID REMOVAL. LEVOPHED HAD TO BE TITRATED AND VASOPRESSIN STARTED DURING RUN. RECEIVED 10,00 UNITS EPOGEN. RIGHT IJ TEMPORARY DIALYSIS CATHETER BLEEDING AT INSERTION SITE. DRESSING CHANGED AND USED STAT SEAL. AIRBORNE PLUS PRECAUTIONS AND PPE WORN THROUGHOUT; [redacted]20[redacted] (RX DAY 399): CHEST XRAY: PATIENT HAS A LARGE LEFT SIDED TENSION PNEUMOTHORAX; LEFT SIDE CHEST TUBE INSERTION: THE CARDIOMEDIASTINAL SILHOUETTE IS WITHIN NORMAL LIMITS
AE Stopped Rx Day	399 (28 DAYS AFTER LAST TREATMENT)
Duration of AE	30 DAYS
Toxicity Grade	4
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	COVID 19 VIRUS
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Event #2: Serious Adverse Event, Event of Interest - Renal Dysfunction

Event Description	RENAL FAILURE
Preferred term	腎不全
AE Onset Date / Rx Day	[redacted]20[redacted] / 384 (13 DAYS AFTER LAST TREATMENT)
Age at AE Onset	6[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 375): Creatine Kinase: 322 [30 - 200] U/L; NPTST054-D DIMER QUANTITATIVE: 0.55 [0 - 0.54] UNIT NOT REPORTED; NPTST150-TROPONIN: <0.10 [0 - 0.4] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 376): NPTST046-CRP: 13.5 [0 - 10] MG/L; NPTST137-SARS-COV-2 NAAT: COVID-19 POSITIVE [0 - 1] UNIT NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 375): CHEST X-RAY: THERE HAS BEEN INTERVAL DEVELOPMENT OF A BILATERAL PULMONARY OPACITIES SUSPICIOUS FOR CARDIOGENIC EDEMA IN LIGHT OF THE CENTRAL SYMMETRIC APPEARANCE AND ENLARGED CARDIAC SILHOUETTE. ALSO SMALL RIGHTEFFUSION. REMAINDER OF THE MEDIASTINUM IS UNREMARKABLE. NO DEVELOPING CHEST WALL ABNORMALLY. CXR CONCERNING FOR BILATERAL PNEUMONIA. D-DIMER MINIMALLY ELEVATED, SUSPECT THIS IS DUE TO COVID RATHERTHAN VTE.; EKG: SINUS RHYTHM WITH SINUS ARRHYTHMIA, RATE 85, NORMAL AXIS, MILDLY PROLONGED QTC AT 453, NONSPECIFIC ST CHANGES, NONSPECIFIC T WAVE CHANGES, INCOMPLETE RBBB, NO STEMI; VITALS COLLECTION: BP:140/64 PULSE: 86 RESP: 38 TEMP: 98.2 F TEMP SCR: ORAL SPO2: 88% PAIN LEVEL: 10; [redacted]20[redacted] (RX DAY 383): ENDOTRACHEAL TUBE: ET TUBE POORLY SEEN BUT THROUGH TO BE JUST ABOVE THE CARINA. NG TUBE TIP THOUGH TO BE IN THE

	FUNDUS OF THE STOMACH. RIGHT SIDED PICC LINE TIP IN THE SVC. DIFFUSE STRANDY BASILAR INFILTRATES HAVE INCREASED. OVERALL HAZY INFILTRATES THROUGHOUT. ET TUBE PLACEMENT WAS DUE TO MECHANICAL SUPPORT OF VENTILATION; [redacted]20[redacted] (RX DAY 391): HEMODIALYSIS TREATMENT: POST 4 HOUR DIALYSIS TREATMENT WITH 500 DFR AND @00 BFR WITH 1.5KG FLUID REMOVAL. LEVOPHED HAD TO BE TITRATED AND VASOPRESSIN STARTED DURING RUN. RECEIVED 10,00 UNITS EPOGEN. RIGHT IJ TEMPORARY DIALYSIS CATHETER BLEEDING AT INSERTION SITE. DRESSING CHANGED AND USED STAT SEAL. AIRBORNE PLUS PRECAUTIONS AND PPE WORN THROUGHOUT; [redacted]20[redacted] (RX DAY 399): CHEST XRAY: PATIENT HAS A LARGE LEFT SIDED TENSION PNEUMOTHORAX; LEFT SIDE CHEST TUBE INSERTION: THE CARDIOMEDIASTINAL SILHOUETTE IS WITHIN NORMAL LIMITS
AE Stopped Rx Day	399 (28 DAYS AFTER LAST TREATMENT)
Duration of AE	16 DAYS
Toxicity Grade	4
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	SUSPECTED ITS A SECONDARY TO COVID RELATED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Event #3: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Death

Event Description	HEART ATTACK
Preferred term	心筋梗塞
AE Onset Date / Rx Day	[redacted]20[redacted] / 399 (28 DAYS AFTER LAST TREATMENT)
Age at AE Onset	6[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 375): Creatine Kinase: 322 [30 - 200] U/L; NPTST054-D DIMER QUANTITATIVE: 0.55 [0 - 0.54] UNIT NOT REPORTED; NPTST150-TROPONIN: <0.10 [0 - 0.4] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 376): NPTST046-CRP: 13.5 [0 - 10] MG/L; NPTST137-SARS-COV-2 NAAT: COVID-19 POSITIVE [0 - 1] UNIT NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 375): CHEST X-RAY: THERE HAS BEEN INTERVAL DEVELOPMENT OF A BILATERAL PULMONARY OPACITIES SUSPICIOUS FOR CARDIOGENIC EDEMA IN LIGHT OF THE CENTRAL SYMMETRIC APPEARANCE AND ENLARGED CARDIAC SILHOUETTE. ALSO SMALL RIGHTEFFUSION. REMAINDER OF THE MEDIASTINUM IS UNREMARKABLE. NO DEVELOPING CHEST WALL ABNORMALLY. CXR CONCERNING FOR BILATERAL PNEUMONIA. D-DIMER MINIMALLY ELEVATED, SUSPECT THIS IS DUE TO COVID RATHERTHAN VTE.; EKG: SINUS RHYTHM WITH SINUS ARRHYTHMIA, RATE 85, NORMAL AXIS, MILDLY PROLONGED QTC AT 453, NONSPECIFIC ST CHANGES, NONSPECIFIC T WAVE CHANGES, INCOMPLETE RBBB, NO STEMI; VITALS COLLECTION: BP:140/64 PULSE: 86 RESP: 38 TEMP: 98.2 F TEMP SCR: ORAL SPO2: 88% PAIN LEVEL: 10; [redacted]20[redacted] (RX DAY 383): ENDOTRACHEAL TUBE: ET TUBE POORLY SEEN BUT THROUGH TO BE JUST ABOVE THE CARINA. NG TUBE TIP THOUGH TO BE IN THE FUNDUS OF THE STOMACH. RIGHT SIDED PICC LINE TIP IN THE SVC. DIFFUSE STRANDY BASILAR INFILTRATES HAVE INCREASED. OVERALL HAZY INFILTRATES THROUGHOUT. ET TUBE PLACEMENT WAS DUE TO MECHANICAL SUPPORT OF VENTILATION; [redacted]20[redacted] (RX DAY 391): HEMODIALYSIS TREATMENT: POST 4 HOUR DIALYSIS TREATMENT WITH 500 DFR AND @00 BFR WITH 1.5KG FLUID REMOVAL.

	LEVOPHED HAD TO BE TITRATED AND VASOPRESSIN STARTED DURING RUN. RECEIVED 10,00 UNITS EPOGEN. RIGHT IJ TEMPORARY DIALYSIS CATHETER BLEEDING AT INSERTION SITE. DRESSING CHANGED AND USED STAT SEAL. AIRBORNE PLUS PRECAUTIONS AND PPE WORN THROUGHOUT; [redacted]20[redacted] (RX DAY 399): CHEST XRAY: PATIENT HAS A LARGE LEFT SIDED TENSION PNEUMOTHORAX; LEFT SIDE CHEST TUBE INSERTION: THE CARDIOMEDIASTINAL SILHOUETTE IS WITHIN NORMAL LIMITS
AE Stopped Rx Day	399 (28 DAYS AFTER LAST TREATMENT)
Duration of AE	1 DAY
Toxicity Grade	5
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	PNEUMONIA DUE TO COVID-19 VIRUS
Discontinued Study Drug Due to the Event	YES
SAE Criteria	RESULTS IN DEATH, REQUIRES OR PROLONGS HOSPITALIZATION, IS LIFE THREATENING

Event #4: Serious Adverse Event

Event Description	LEFT SIDED TENSION PNEUMOTHORAX
Preferred term	気胸
AE Onset Date / Rx Day	[redacted]20[redacted] / 399 (28 DAYS AFTER LAST TREATMENT)
Age at AE Onset	6[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 375): Creatine Kinase: 322 [30 - 200] U/L; NPTST054-D DIMER QUANTITATIVE: 0.55 [0 - 0.54] UNIT NOT REPORTED; NPTST150-TROPONIN: <0.10 [0 - 0.4] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 376): NPTST046-CRP: 13.5 [0 - 10] MG/L; NPTST137-SARS-COV-2 NAAT: COVID-19 POSITIVE [0 - 1] UNIT NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 375): CHEST X-RAY: THERE HAS BEEN INTERVAL DEVELOPMENT OF A BILATERAL PULMONARY OPACITIES SUSPICIOUS FOR CARDIOGENIC EDEMA IN LIGHT OF THE CENTRAL SYMMETRIC APPEARANCE AND ENLARGED CARDIAC SILHOUETTE. ALSO SMALL RIGHTEFFUSION. REMAINDER OF THE MEDIASTINUM IS UNREMARKABLE. NO DEVELOPING CHEST WALL ABNORMALLY. CXR CONCERNING FOR BILATERAL PNEUMONIA. D-DIMER MINIMALLY ELEVATED, SUSPECT THIS IS DUE TO COVID RATHERTHAN VTE.; EKG: SINUS RHYTHM WITH SINUS ARRHYTHMIA, RATE 85, NORMAL AXIS, MILDLY PROLONGED QTC AT 453, NONSPECIFIC ST CHANGES, NONSPECIFIC T WAVE CHANGES, INCOMPLETE RBBB, NO STEMI; VITALS COLLECTION: BP:140/64 PULSE: 86 RESP: 38 TEMP: 98.2 F TEMP SCR: ORAL SPO2: 88% PAIN LEVEL: 10; [redacted]20[redacted] (RX DAY 383): ENDOTRACHEAL TUBE: ET TUBE POORLY SEEN BUT THROUGH TO BE JUST ABOVE THE CARINA. NG TUBE TIP THOUGH TO BE IN THE FUNDUS OF THE STOMACH. RIGHT SIDED PICC LINE TIP IN THE SVC. DIFFUSE STRANDY BASILAR INFILTRATES HAVE INCREASED. OVERALL HAZY INFILTRATES THROUGHOUT. ET TUBE PLACEMENT WAS DUE TO MECHANICAL SUPPORT OF VENTILATION; [redacted]20[redacted] (RX DAY 391): HEMODIALYSIS TREATMENT: POST 4 HOUR DIALYSIS TREATMENT WITH 500 DFR AND @00 BFR WITH 1.5KG FLUID REMOVAL. LEVOPHED HAD TO BE TITRATED AND VASOPRESSIN STARTED DURING RUN. RECEIVED 10,00 UNITS EPOGEN. RIGHT IJ TEMPORARY DIALYSIS CATHETER BLEEDING AT INSERTION SITE. DRESSING CHANGED AND USED STAT SEAL. AIRBORNE PLUS PRECAUTIONS AND PPE WORN THROUGHOUT; [redacted]20[redacted] (RX DAY 399): CHEST XRAY: PATIENT HAS A LARGE LEFT SIDED TENSION PNEUMOTHORAX; LEFT SIDE CHEST TUBE INSERTION: THE CARDIOMEDIASTINAL SILHOUETTE IS WITHIN NORMAL LIMITS
AE Stopped Rx Day	399 (28 DAYS AFTER LAST TREATMENT)
Duration of AE	1 DAY
Toxicity Grade	4
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	RESPIRATORY FAILURE DUE TO COVID 19
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 6[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，左側緊張性気胸，新型コロナウイルス感染症（以下，「COVID-19」）および腎不全を発現し，心臓発作により死亡した。被験者は非飲酒者かつ非喫煙者であり，関連する病歴は 2 型糖尿病，コレステロール高値，高血圧，関節炎，アトピー性皮膚炎であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は COVID-19 を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は腎不全を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は心臓発作及び左側緊張性気胸を発現した。同日，被験者は死亡した。死因は心臓発作であると報告された。剖検は行われなかった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は救急治療室を受診し，喀痰を伴わない乾性咳嗽及び息切れが 1 週間持続していると訴えた。被験者によれば，自宅にて悪寒の自覚はなかった。咽喉痛および疲労もなかったが，普段よりも歩行時の息切れが強く，椅子に座ると息切れの自覚は軽減された。病人との接触や旅行歴はなかった。COVID-19 の流行期中，被験者は外出を控えて自宅で過ごしていた。被験者は胸痛，胸部うっ血および発熱を発現し，疼痛レベルは 10 であった。救急治療室にて，被験者が COVID-19 陽性であると判明した。その際の被験者のバイタルサインは，血圧 140/64 mmHg，脈拍数 86，呼吸数 38，酸素飽和度（室内気下）88%であった。ステロイドによる適切な治療，及び支援的ケアが開始された。酸素必要量が増加したため，被験者は集中治療室に入室して高流量カニュラ酸素療法を 4～5 日間受け続けたが，全般状態に明らかな改善や悪化は認められなかった。息切れは改善したが，依然として吸入酸素濃度 90～95%を必要とした。その後，呼吸窮迫が悪化したため，20[redacted] 年 [redacted] 月 [redacted] 日に気管内挿管が行われた。また，腎機能も悪化した。20[redacted] 年 [redacted] 月 [redacted] 日，腎透析（血液透析）が行われた。透析液流量 500 で 4 時間透析後，血流量 00 で体液 1.5kg を除去した。Levophed を漸減し，透析中にバソプレシンの投与を開始した。Epogen 10,00 単位が投与された。右内頚静脈の一次的透析カテーテル挿入部から出血があった。ドレッシング素材のシールを stat seal に変更した。被験者の全般状態の悪化は続き，人工呼吸器依存状態が持続した。血行動態保持のため，複数の昇圧薬にも依存していた。被験者は心停止により何度も緊急救命を要したが，心拍は再開した。胸部 X 線検査で左側緊張性気胸と確認され，左胸に胸腔ドレーンチューブを留置したところ，心縦隔の陰影は正常範囲内に回復した。同日（20[redacted] 年 [redacted] 月 [redacted] 日），被験者は心停止を来たし死亡した。

バソプレシン，LOVENOX（エノキサパリンナトリウム）およびデキサメタゾンが投与された。

The patient's past medications include:

HYDROCORTISONE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Heart attack (10019250) (Myocardial infarction (10028596)) [v.23.1] [10019250]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

2) Tension pneumothorax (10043274) (Pneumothorax (10035759)) [v.23.1] [10043274]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

3) COVID-19 (10084268) (COVID-19 (10084268)) [v.23.1] [10084268]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

4) Renal failure (10038435) (Renal failure (10038435)) [v.23.1] [10038435]

Causality as per reporter (Drug/Vaccine): No reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of HEART ATTACK

- Investigator: Pneumonia due to COVID-19 virus

- AbbVie: risk factors include pre-existing hypertension, diabetes, morbid obesity and advanced age.

Event of LEFT SIDED TENSION PNEUMOTHORAX

- Investigator: respiratory failure due to COVID 19

- AbbVie: Event more likely related to maximum support mechanical ventilation (per PI).

Event of COVID-19 INFECTION

- Investigator: Covid-19 virus

- AbbVie: Event is more likely related to the COVID-19 pandemic outbreak.

Event of RENAL FAILURE

- Investigator: suspected its a secondary to COVID related

- AbbVie: Event is more likely related to complication from COVID-19 infection.

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BLOOD PRESSURE:** 160/64 mmHg

[redacted] **20[redacted] BODY TEMPERATURE:** 98.2 F

[redacted] **20[redacted] BODY WEIGHT:** 343 Pounds

[redacted] **20[redacted] CARDIAC BIOMARKERS:** Not available

[redacted] **20[redacted] CHEST XRAY:** There has been interval development of a bilateral pulmonary opacities suspicious for cardiogenic edema in light of the central symmetric appearance and enlarged cardiac silhouette. Also small Right effusion. Remainder of the mediastinum is unremarkable. No developing chest wall abnormally. CXR concerning for bilateral pneumonia. D-dimer minimally elevated, suspect this is due to COVID rather than VTE.

[redacted] **20[redacted] CHEST XRAY:** Patient has a large left sided tension pneumothorax

[redacted] **20[redacted] CREATININE KINASE:** 322 IU/L (normal 30 to 200)

[redacted] **20[redacted] CRP:** 13.5 MG/L (normal 0 to 10)

[redacted] **20[redacted] D-DIMER:** 0.55 UG/ML (normal 0.00 to 0.54)

[redacted] **20[redacted] ECG:** SINUS RHYTHM WITH SINUS ARRHYTHMIA, RATE 85, NORMAL AXIS, MILDLY PROLONGED QTC AT 453, NONSPECIFIC ST CHANGES, NONSPECIFIC T WAVE CHANGES, INCOMPLETE RBBB, NO STEMI

[redacted] **20[redacted] ECG (SCREENING):** Abnormal, sinus L axis deviation, low voltages QRS, consider pulmonary disease.

[redacted] **20[redacted] OXYGEN SATURATION:** Remained at 90-95%

[redacted] **20[redacted] OXYGEN SATURATION:** saturating 88% room air.

[redacted] **20[redacted] PULSE:** 86 /min

[redacted] **20[redacted] SARS-COV-2 NAAT SWAB:** COVID-19 positive

[redacted] **20[redacted] TROPONIN:** <0.10 ng/ml (normal 0-0.4)

重篤な有害事象の叙述

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
虚血性脳卒中	X	X		X

Treatment Group	Age at Study Start	Sex	Race
PLACEBO/UPA 15 MG QD	6[redacted]	MALE	WHITE

Medical History	Onset Year
HYPERTENSION	19[redacted]
PSUEDOGOUT	20[redacted]
RHEUMATOID ARTHRITIS	20[redacted]
OBSTRUCTIVE SLEEP APNEA	20[redacted]
ATOPIC DERMATITIS	20[redacted]
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	20[redacted]
ATOPIC DERMATITIS	20[redacted]
HIDRADENITIS SUPPURATIVA	20[redacted]
SCARRING OF THE LEFT LUNG	20[redacted]
SMALL HIATAL HERNIA	20[redacted]

Prior Procedures	Procedure Year
PRIOR PROCEDURES: RIGHT INGUINAL HERNIA REPAIR	20[redacted]
PRIOR PROCEDURES: BILATERAL CATARACT SURGERY	20[redacted]
PRIOR PROCEDURES: TOTAL LEFT KNEE REPLACEMENT	20[redacted]
PRIOR PROCEDURES: VENOUS LASER ABLATION	20[redacted]
PRIOR PROCEDURES: CT CHEST	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	20 CIGARETTE	54	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 109	109

UPA	15 MG	ORAL	QD	[redacted]20[redacted] / [redacted]20[redacted] / 150 141		10

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
AMLODIPINE	10 mg	QD	Y-M: 20[redacted]
LOSARTAN	50 mg	QD	Y-M: 20[redacted]
IBUPROFEN	600 mg	QD	Y-M: 20[redacted]
HERPES ZOSTER IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted]
ERGOCALCIFEROL	400 IU	QD	Y-M: 20[redacted]
LEFLUNOMIDE	20 mg	QD	Y-M: 20[redacted]
CLINDAMYCIN	1 %	PRN	Y-M: 20[redacted]
TRIAMCINOLONE	01 %	BID	Y-M: 20[redacted]
BETAMETHASONE	0.05 %	BID	Y-M: 20[redacted]
MUPIROCIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
TRIAMCINOLONE	2.5 OTHER: MG/ML	OTHER: ONCE	Y-M: 20[redacted]
CETIRIZINE	10 mg	QD	Y-M: 20[redacted]
FEXOFENADINE	180 mg	QD	Y-M: 20[redacted]
FLUOCINONIDE	0.05 %	BID	Y-M: 20[redacted]
LORATADINE	10 mg	QD	Y-M: 20[redacted]
OTHER EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
PREDNISONE	40MG X 3 DAYS, 30MG X 3 DAYS, 20MG X 3 DAYS, 10MG X 3 DAYS mg	QD	Y-M: 20[redacted] / -306
HYDROXYZINE	25 mg	OTHER: HS	Y-M: 20[redacted] / -250
HONEY	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -222
TRIAMCINOLONE	2.5 OTHER: MG/ML	OTHER: ONCE	Y-M: 20[redacted] / -145
PREDNISONE	10 mg	QD	Y-M: 20[redacted] / -31

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
AMLODIPINE	10 mg	QD	Y-M: 20[redacted]	ONGOING
ERGOCALCIFEROL	400 IU	QD	Y-M: 20[redacted]	ONGOING
LEFLUNOMIDE	20 mg	QD	Y-M: 20[redacted]	ONGOING
CLINDAMYCIN	1 %	PRN	Y-M: 20[redacted]	ONGOING
MUPIROCIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]	ONGOING
OTHER EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]	ONGOING
LOSARTAN	100 mg	QD	Y-M: 20[redacted] / 56	ONGOING
PARACETAMOL	650MG mg	BID	Y-M: 20[redacted] / 83	ONGOING
UMECLIDINIUM	62.5MCG OTHER: MCG	QD	Y-M: 20[redacted] / 130	ONGOING
NEBIVOLOL	5MG mg	QD	Y-M: 20[redacted] / 130	Y-M: 20[redacted] / 144
NEBIVOLOL	10 mg	QD	Y-M: 20[redacted] / 144	ONGOING

POTASSIUM	10MG mg	QD	Y-M: 20[redacted]-[redacted] / 149	ONGOING
ACETYLSALICYLIC ACID	81MG mg	QD	Y-M: 20[redacted]-[redacted] / 150	ONGOING
CHLORTALIDONE	25MG mg	QD	Y-M: 20[redacted]-[redacted] / 150	ONGOING
NICOTINE	21 mg	QD	Y-M: 20[redacted]-[redacted] / 151	ONGOING
ATORVASTATIN	10MG mg	QD	Y-M: 20[redacted]-[redacted] / 159	ONGOING

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Event of Interest - MACE

Event Description	ISCHEMIC STROKE
Preferred term	虚血性脳卒中
AE Onset Date / Rx Day	[redacted]20[redacted] / 149
Age at AE Onset	6[redacted]
Laboratory Testing	NOT REPORTED
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 149): CHEST XRAY: NODULAR DENSITY PROJECTS LEFT LUNG BASE, INTERSTITIAL PROMINENCE BILATERALLY MAY REPRESENT SCARRING OR EDEMA/INFILTRATE. CT CHEST RECOMMENDED; CT CHEST WITHOUT CONTRAST: 1. AREAS OF ATELECTASIS IN LOWER LUNGS 2. ELONGATED THORACIC AORTA W FOCAL DILATION OF THE AORTIC ARCH. MAY REPRESENT A SACCULAR ANEURYSM VERSUS A DUCTUS DIVERTICULUM 3. COPD; CT HEAD WITHOUT CONTRAST: NO ACUTE INTRACRANIAL ABNORMALITIES; ECG: SINUS BRADYCARDIA, NONSPECIFIC ST & T WAVE CHANGES; [redacted]20[redacted] (RX DAY 150): MRI BRAIN WITHOUT AND WITH CONTRAST: ACUTE LUNAR INFARCTS IN THE LEFT PERIVENTRICULAR WHITE MATTER AND RIGHT BASAL GANGLIA. ADVANCE MICROVASCULAR DISEASE. NO ACUTE INTRACRANIAL HEMMORHAGE.; TRANS THORACIC ECHOCARDIOGRAM: LEFT VENTRICULAR EJECTION FRACTION, BY VISUAL ESTIMATION, IS 50 TO 55%. MILD DIASTOLIC DYSFUNCTION OF THE LEFT VENTRICLE. MODERATE SEPTAL LEFT VENTRICULAR HYPERTROPHY. NO FOCAL LEFT VENTRICULAR WALL MOTION ABNORMALITIES. MILDLY THICKENED MITRAL VALVE. MILD AORTIC REGURGITATION. MODERATE AORTIC VALVE SCLEROSIS/CALCIFICATION WITHOUT ANY EVIDENCE OF AORTIC STENOSIS. SALINE CONTRAST BUBBLE STUDY WAS NEGATIVE, WITH NO EVIDENCE OF ANY INTRACARDIAC SHUNT.; ULTRASOUND CAROTID DUPLEX: NO EVIDENCE OF HEMODYNAMICALLY SIGNIFICANT STENOSIS INVOLVING THE INTERNAL CAROTID ARTERIES BILATERALLY; [redacted]20[redacted] (RX DAY 151): CT ANGIOGRAPHY HEAD AND NECK: NO VASCULAR ABNORMALITY IDENTIFIED IN THE HEAD AND NECK
AE Stopped Rx Day	163 (13 DAYS AFTER LAST TREATMENT)
Duration of AE	15 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	SMALL VESSEL DISEASE RELATED TO UNCONTROLLED HYPERTENSION

Discontinued Study Drug Due to the Event YES
SAE Criteria REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 6[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，虚血性脳卒中を発現した。被験者は紙巻タバコ喫煙者（1 箱／日，54 年間）かつ飲酒者（2 杯未満／日）で，関連する病歴は高血圧，関節リウマチ，閉塞性睡眠時無呼吸（夜間に持続陽圧呼吸装置を使用），化膿性汗腺炎及びアトピー性皮膚炎であった。血管内レーザー焼灼術（下肢静脈逆流）による治療歴があり，家族歴に脳卒中（両親及び兄又は弟）があった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は虚血性脳卒中を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，虚血性脳卒中は消失した。

本事象発現前の数ヵ月間，被験者の血圧コントロールはやや難渋していた。無症状であったものの，被験者には本試験開始前から長期にわたる高血圧の病歴があった。かかりつけ医が降圧薬を調整しており，試験開始以降に大きな血圧上昇はなかった。家庭血圧は収縮期が 160 mmHg 台，拡張期が 100 mmHg 台を継続していた。本事象発現の 2 ヵ月前，losartan が増量され，Bystolic の投与が上乗せされた。これまで正常値であったクレアチニン値が上昇したため，慢性疼痛に対する非ステロイド系抗炎症薬の使用は中止された。被験者によれば，胸痛，息切れ，新規の咳嗽，発熱，悪寒，悪心，嘔吐，腹痛，排尿困難，下痢及び便秘はなかった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は初めて神経学的症状を自覚した。眼瞼から顔面下部にかけて，顔面右側が垂れ下がっているような感覚が生じた。被験者は幾分かの霧視及び軽度の会話障害を訴えたが，嚥下のトラブルや錯乱はなかった。被験者は断続的な軽度の頭痛を発現していた。翌日の 20[redacted] 年 [redacted] 月 [redacted] 日，症状は顔面非対称に持続していた。被験者は救急治療室を受診することにした。ほとんどの症状は救急治療室到着前に消失していた。

救急治療室にて神経科医が身体所見を診察したが，局所神経障害は認められなかった。症状は改善していった。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は入院した。臨床検査結果に特筆すべき所見はほとんどなく，頭部コンピュータ断層撮影の所見は正常であり，神経学的診察の所見も正常であった。入院時の血圧は 150/98 mmHg であった（血圧連続測定結果は収縮期が 140～150 mmHg 台，

拡張期が 80～100 mmHg 台）。核磁気共鳴画像の所見として，左脳室周囲の白質に急性ラクナ梗塞，右大脳基底核に進行した微小血管疾患が認められた。入院時の最初の診断は，構語障害を伴う顔面麻痺であった。アスピリンが投与された。被験者によれば，顔面のしびれ感，四肢の脱力，しびれ感又はピリピリ感，並びに歩行障害はなかった。（米）国立衛生研究所脳卒中スケールに関する記録はなかった。総合的に被験者の自覚として，会話は正常に復しつつあり，顔が垂れ下がる感覚は軽減し，正常に戻ったように見えた。入院中，被験者の血圧は 146～155/87～102 mmHg の範囲を推移した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者はアスピリン及び心イベントモニター装置の使用を継続しながら退院し，退院時モニター所見は心機能完全回復であった。被験者は本事象を理由に試験を中止した。

関連するリスク因子には家族歴の脳卒中（両親及び兄又は弟），及び本人の病歴の高血圧があり，後者については血圧上昇に対し降圧薬を追加投与したが反応しなかった。被験者は脳卒中や神経疾患の既往歴はないと申告した。

chlorthalidone，カリウム及びアスピリンが投与された。

The patient's past medications include:

IBUPROFEN for RHEUMATOID ARTHRITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

PREDNISONE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Ischemic stroke (10055221) (Ischaemic stroke (10061256)) [v.22.1] [10055221]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: No rechallenge was done, recurrence is not applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of ISCHEMIC STROKE

- Investigator: SMALL VESSEL DISEASE RELATED TO UNCONTROLLED HYPERTENSION

- AbbVie: Risk factors include pre-existing hypertension, current long term smoking status, family history of strokes, and advanced age.

RISK/BENEFIT STATEMENT:

There is no change to the risk/benefit profile for this study/product as a result of this individual report/event(s).

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] BLOOD PRESSURE:** on admission was 150/98 mmHg (continued readings of 140s-150s/80s-100s mmHg on day of admission)

[redacted] **20[redacted] CHEST X-RAY:** NODULAR DENSITY PROJECTS LEFT LUNG BASE, INTERSTITIAL PROMINENCE BILATERALLY MAY REPRESENT SCARRING OR EDEMA/INFILTRATE. CT CHEST RECOMMENDED

[redacted] **20[redacted] CHEST X-RAY (SCREENING):** ABNORMAL: SMALL HIATAL HERNIA AND AORTIC UNFOLDING, NO CARDIOMEGALY OR MEDIASTINAL LYMPHADENOPATHY. SCARRING THE LEFT LUNG MID ZONE AND LEFT BASE BUT NO ACUTE OR FOCAL DOMINANT CARDIOPULMONARY ABNORMALITY.

[redacted] **20[redacted] CT ANGIOGRAPHY HEAD AND NECK:** NO VASCULAR ABNORMALITY IDENTIFIED IN THE HEAD AND NECK

[redacted] **20[redacted] CT CHEST (PRIOR TO STUDY):** SMALL RIGHT LOWER LOBE PULMONARY NODULE APPEARS TO HAVE DEVELOPED CENTRAL BENIGN APPEARING CALCIFICATION

[redacted] **20[redacted] CT CHEST WITHOUT CONTRAST:** 1. AREAS OF ATELECTASIS IN LOWER LUNGS. 2. ELONGATED THORACIC AORTA WITH FOCAL DILATION OF THE AORTIC ARCH. MAY REPRESENT A SACCULAR ANEURYSM VERSUS A DUCTUS DIVERTICULUM. 3. COPD.

[redacted] **20[redacted] CT HEAD WITHOUT CONTRAST:** NO ACUTE INTRACRANIAL ABNORMALITIES

[redacted] **20[redacted] ECG:** SINUS BRADYCARDIA, NONSPECIFIC ST & T WAVE CHANGES

[redacted] **20[redacted] MRI BRAIN WITHOUT AND WITH CONTRAST:** ACUTE LUNAR INFARCTS IN THE LEFT PERIVENTRICULAR WHITE MATTER AND RIGHT BASAL GANGLIA. ADVANCE MICROVASCULAR DISEASE. NO ACUTE INTRACRANIAL HEMMORHAGE.

[redacted] **20[redacted] TRANSTHORACIC ECHOCARDIOGRAM:** LEFT VENTRICULAR EJECTION FRACTION, BY VISUAL ESTIMATION, IS 50 TO 55%. MILD DIASTOLIC DYSFUNCTION OF THE LEFT VENTRICLE. MODERATE SEPTAL LEFT VENTRICULAR HYPERTROPHY. NO FOCAL LEFT VENTRICULAR WALL MOTION ABNORMALITIES. MILDLY THICKENED MITRAL VALVE. MILD AORTIC REGURGITATION. MODERATE AORTIC VALVE SCLEROSIS/CALCIFICATION WITHOUT ANY EVIDENCE OF AORTIC STENOSIS. SALINE CONTRAST BUBBLE STUDY WAS NEGATIVE, WITH NO EVIDENCE OF ANY INTRACARDIAC SHUNT.

[redacted] **20[redacted] ULTRASOUND CAROTID DUPLEX:** NO EVIDENCE OF HEMODYNAMICALLY SIGNIFICANT STENOSIS INVOLVING THE INTERNAL CAROTID ARTERIES BILATERALLY

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
コロナウイルス感染	X			X
脂肪肝				X

Treatment Group	Age at Study Start	Sex	Race
UPA 15 MG QD/UPA 15 MG QD	4[redacted]	MALE	BLACK OR AFRICAN AMERICAN

Medical History	Onset Year
ALLERGY TO SHELLFISH	19[redacted]
ATOPIC DERMATITIS	19[redacted]
ATOPIC DERMATITIS	19[redacted]
SEASONAL ALLERGIES	19[redacted]
ALLERGIC RHINITIS	NOT REPORTED
FOOD ALLERGY	NOT REPORTED

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 118	118
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 119		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	NOT REPORTED
EUCERIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]
CLOBETASOL	0.05 %	QD	Y-M: 20[redacted] / -132

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
EUCERIN	1 OTHER: APPLICATION	BID	Y-M: 20[redacted]	NOT REPORTED
HYDROXYCHLOROQUINE	UNKNOWN OTHER: UNKNOWN	OTHER: UNKNOWN	Y: 20[redacted] / 295	NOT REPORTED
KALETRA	UNKOWN OTHER: UNKNOWN	OTHER: UNKNOWN	Y: 20[redacted] / 295	Y: 20[redacted] / 660
PARACETAMOL	325 mg	PRN	Y-M: 20[redacted] / 369	Y-M: 20[redacted] / 400
LIDOCAINE	1 %	OTHER: ONCE	Y-M: 20[redacted] / 387	Y-M: 20[redacted] / 387

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description COVID-19 INFECTION

Preferred term コロナウイルス感染

AE Onset Date / Rx Day [redacted]20[redacted] / 365

Age at AE Onset 4[redacted]

Laboratory Testing [redacted]20[redacted] (RX DAY 368): Creatinine: 106 [53 - 106] UMOL/L; Hemoglobin: 130 [127 - 181] G/L; Leukocytes: 5.1 [4.2 - 9.1] 10^9/L; Lymphocytes: 0.86 [1.32 - 3.57] 10^9/L; Neutrophils: 3.96 [1.78 - 5.38] 10^9/L; Platelets: 286 [163 - 337] 10^9/L; [redacted]20[redacted] (RX DAY 369): NPTST081-INFLUENZA A: NOT DETECTED [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST083-INFLUENZA B: NOT DETECTED [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; [redacted]20[redacted] (RX DAY 371): Glucose: 5.9 [3.9 - 5.5] MMOL/L; [redacted]20[redacted] (RX DAY 396): Creatinine: 62 [53 - 106] UMOL/L; Glucose: 4.7 [3.9 - 5.5] MMOL/L; [redacted]20[redacted] (RX DAY 399): Hemoglobin: 103 [127 - 181] G/L; Leukocytes: 7.4 [4.2 - 9.1] 10^9/L; Lymphocytes: 2.21 [1.32 - 3.57] 10^9/L; Neutrophils: 4.14 [1.78 - 5.38] 10^9/L; Platelets: 576 [163 - 337] 10^9/L

Microbiology [redacted]20[redacted] (RX DAY 368): OTHER UNKNOWN NPTST042-COVID-19: POSITIVE-UNKNOWN; [redacted]20[redacted] (RX DAY 372): SPUTUM NPTST063-GENERAL MICROBIOLOGY: NEGATIVE

SAE Supplemental Procedure [redacted]20[redacted] (RX DAY 368): CT OF ABDOMEN/PELVIS: 1. PATCHY GROUNDGLASS AIRSPACE INFILTRATES IN THE VISUALIZED LOWER LUNGS COMPATIBLE WITH NONSPECIFIC BRONCHPNEUMONIA. VIRAL PNEUMONIA WOULD BE A CONSIDERATION. 2.SMALL HIATAL HERNIA 3.FATTY CHANGES OFLIVER.; [redacted]20[redacted] (RX DAY 369): CT OF

	CHEST: 1.MODERATE PATCHY DIFFUSE LUNG CONSOLIDATION MOST LIKELY DUE TO PNEUMONIA OR VIRAL PNEUMONIA. 2.SMALL PLEURAL EFFUSIONS. 3.BORDERLINE MEDIASTINAL AND HYLAR LYMPH NODES NOTED. 4.SMALL HIATAL HERNIA. 5.MILD NONSPECIFIC LOWER ESOPHAGEAL WALL THICKENING MOST LIKELY DUE TO ACUTE ESOPHAGITIS AND BARRETT'S ESOPHAGITIS CANNOT BE EXCLUDED. 6.BORDERLINE PORTA HEPATIS LYMPH NODES NOTED. 7. MILD LIVER STEATOSIS.; [redacted]20[redacted] (RX DAY 370): CHEST RADIOGRAPH: BILATERAL PATCHY OPACITIES, SLIGHTLY MORE PRONOUNCED COMPLARED TO THE PRIOR STUDY FROM 3/15/20. FINDINGS MAY REFLECT WORSENING AIRSPACE DISEASE SUCH AS PNEUMONIA OR EDEMA. VIRAL PNEUMONIA SUCH AS COVID-19 COULD HAVE THIS APPEARANCE.; [redacted]20[redacted] (RX DAY 371): CHEST XRAY: PATCHY BILATERAL AIRSPACE OPACITIES. LEFT-SIDED PLEURAL EFFUSION IS NOT EXCLUDED. NO PNEUMOTHORAX.; [redacted]20[redacted] (RX DAY 372): ECG: T AXIS: 43 R AXIS: 10 P AXIS: 34 QTC:468 Q-T:394 QRS: 86 P-R:176 ATRIAL RATE: 85 VENT RATE: 85; [redacted]20[redacted] (RX DAY 375): CHEST XRAY: PERSISTENT BILATERAL PATCHY AREAS OF CONSOLIDATION CONSISTENT WITH PNEUMONIA.; [redacted]20[redacted] (RX DAY 379): CHEST XRAY: WORSENING BILATERAL PATCHY AIRSPACE OPACITIES. SMALL LEFT PLEURAL EFFUSION IS NOT EXCLUDED.; [redacted]20[redacted] (RX DAY 380): CHEST XRAY: INTERVAL PLACEMENT OF ENDOTRACHEAL TUBE WHICH HAS DISTAL TIP 6.4 CM ABOVE THE CARINA. NASOGASTRIC TUBE HEADS BELOW THE HEMIDIAPHRAGM. BILATERAL AIRSPACE DISEASE WITHOUT OVERALL SIGNIFICANT CHANGE.; [redacted]20[redacted] (RX DAY 381): UNLTRASOUND OF LOWER EXTREMITIES TO RULE OUT DVT.: NO BILATERAL LOWER EXTREMITY DVT.; [redacted]20[redacted] (RX DAY 382): CHEST XRAY: INTERVAL PROGRESSION OF BILATERAL AIR SPACE DISEASE.; [redacted]20[redacted] (RX DAY 386): CHEST XRAY: TUBES AGAIN SEEN. INFILTRATES PERSIST BILATERALLY BUT ARE LESS ADVANCED THAN IN RADIOGRAPH FROM SEVERAL DAYS EARLIER. MODERATE INTERIM IMPROVEMENT.; [redacted]20[redacted] (RX DAY 387): SP INSERTION MIDLINE CATHETER; LEFT UPPER EXTREMITY MIDLINE PLACEMENT: NA; ULTRASOUND GUIDED VASCULAR ACCESS TO ASSIST IN MIDLINE PLACEMENT: NA; [redacted]20[redacted] (RX DAY 389): CHEST XRAY: HEART WITHIN NORMAL LIMITS. ET TUBE TIP IS UNCHANGED. OROGASTRIC TUBE TIP APPEARS TO BE IN THE GASTRIC BODY. BILATERAL PARENCHYMAL LUNG INFILTRATES /AIRSPACE DISEASE MAY BE SLIGHTLY IMPROVED ADN DECREASED IN THE LEFT MIDLUNG.; [redacted]20[redacted] (RX DAY 391): CHEST XRAY: INTERIM WORSENING LEFT
AE Stopped Rx Day	400
Duration of AE	36 DAYS
Toxicity Grade	4
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	COVID-19
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Event #2: Event of Interest - Hepatic Disorder

Event Description	LIVER STEATOSIS
Preferred term	脂肪肝
AE Onset Date / Rx Day	[redacted]20[redacted] / 368
Age at AE Onset	4[redacted]
Laboratory Testing	NOT APPLICABLE

Microbiology	NOT APPLICABLE
SAE Supplemental Procedure	NOT APPLICABLE
AE Stopped Rx Day	NOT REPORTED
Duration of AE	NOT REPORTED
Toxicity Grade	1
Relation to Study Drug by Investigator	NO REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT APPLICABLE
Discontinued Study Drug Due to the Event	NO
SAE Criteria	NONE

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 4[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，新型コロナウイルス感染症（以下「COVID-19」）を発現した。被験者は非喫煙者かつ飲酒者（2 杯未満／日）であり，関連する病歴はアトピー性皮膚炎であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は COVID-19 を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，COVID-19 は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は息切れの症状で入院した。被験者の訴えでは下痢が 4 日間持続しており，症状が始まったのは食事摂取後であった。腹痛は間欠性であり，広範囲の腹部疝痛を伴った。この他に片頭痛も 2 週間持続していた。入院中，COVID-19 に関連した肺炎によって息切れが悪化し，気管挿管が行われた。

hydroxychloroquine が投与された。

The patient's past medications include:

CLOBETASOL for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) COVID-19 (10084268) (COVID-19 (10084268)) [v.23.1] [10084268]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of COVID-19 INFECTION

- Investigator: COVID-19.

- AbbVie: Event is more likely related to the COVID-19 pandemic outbreak.

COVID-19 RISK/BENEFIT STATEMENT:

The clinical trial data regarding the safety profile of UPADACITINIB in the setting of COVID-19 are limited and many trials remain blinded. Based on available data, the characterization of UPADACITINIB remains unchanged.

RISK/BENEFIT STATEMENT:

There is no change to the risk/benefit profile for this study/product as a result of this individual report/event(s).

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] CHEST RADIOGRAPH:** Bilateral patchy opacities, slightly more pronounced compared to the prior study from 3/15/20. Findings may reflect worsening airspace disease such as pneumonia or edema. Viral pneumonia such as COVID-19 could have this appearance

[redacted] **20[redacted] CHEST XRAY:** Patchy bilateral airspace opacities, left-sided pleural effusion is not excluded. No pneumothorax.

[redacted] **20[redacted] CHEST XRAY:** Persistent bilateral patchy areas of consolidation consistent with pneumonia.

[redacted] **20[redacted] CHEST XRAY:** Worsening bilateral patchy airspace opacities. Small left pleural effusion is not excluded.

[redacted] **20[redacted] CHEST XRAY:** Interval placement of endotracheal tube which has distal tip 6.4 cm above the carina. Nasogastric tube heads below the hemidiaphragm. Bilateral airspace disease without overall significant change.

[redacted] 20[redacted] **CHEST XRAY:** Interval progression of bilateral air space disease.

[redacted] 20[redacted] **CHEST XRAY:** Tubes again seen. Infiltrates persist bilaterally but are less advanced than in radiograph from several days earlier. Moderate interim improvement.

[redacted] 20[redacted] **CHEST XRAY:** Heart within normal limits. ET tube tip is unchanged. Orogastric tube tip appears to be in the gastric body. Bilateral parenchymal lung infiltrates /airspace disease may be slightly improved and decreased in the left midlung.

[redacted] 20[redacted] **CHEST XRAY:** Interim worsening left

[redacted] 20[redacted] **COVID-19 TEST:** Positive

[redacted] 20[redacted] **CT OF ABDOMEN/PELVIS:** 1. patchy ground glassairspace infiltrates in the visualized lower lungs compatible with nonspecific bronchpneumonia. Viral pneumonia would be a consideration. 2.small hiatal hernia 3.fatty changes of liver.

[redacted] 20[redacted] **CT OF CHEST:** 1.Moderate patchy diffuse lung consolidation most likely due to pneumonia or viral pneumonia. 2.small pleural effusions. 3.borderline mediastinal and hylar lymph nodes noted. 4.small hiatal hernia. 5.mild nonspecific lower esophageal wall thickening most likely due to acute esophagitis and Barretts esophagitis cannot be excluded. 6.Borderline porta hepatis lymph nodes noted. 7. Mild liver steatosis.

[redacted] 20[redacted] **INFLUENZA A TESTING:** Not detected

[redacted] 20[redacted] **INFLUENZA B TESTING:** Not detected

[redacted] 20[redacted] **SPUTUM GENERAL MICROBIOLOGY:** Negative

[redacted] 20[redacted] **ULTRASOUND OF LOWER EXTREMITIES:** No bilateral lower extremity DVT.

非重篤な有害事象

脂肪肝：無症状であり，COVID-19 のために入院した間に行われた腹部及び骨盤部のコンピュータ断層撮影検査で偶発的に発見された。

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
虫垂炎	X			X

Treatment Group	Age at Study Start	Sex	Race
PLACEBO/UPA 15 MG QD	3[redacted]	MALE	WHITE

Medical History	Onset Year
ACNE	19[redacted]
ANDROGENETEIC ALOPECIA	20[redacted]
ATOPIC DERMATITIS	20[redacted]

Prior Procedures	Procedure Year
Not reported.	

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	NEVER			
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	2 - 4

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 112	112
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 113		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y: 19[redacted]
EUCERIN	1 OTHER: APPLICATION	BID	Y: 20[redacted]
FINASTERIDE	1 mg	QD	Y: 20[redacted]
TRIAMCINOLONE	0.1 %	BID	Y-M: 20[redacted]-[redacted]
ALL OTHER NON-THERAPEUTIC PRODUCTS	1 OTHER: TREATMENT	OTHER: 3 X PER WEEK	Y-M: 20[redacted]-[redacted] / -128

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
EUCERIN	1 OTHER: APPLICATION	BID	Y: 20[redacted]	NOT REPORTED
FINASTERIDE	1 mg	QD	Y: 20[redacted]	NOT REPORTED
CEFALEXIN	500 mg	BID	Y-M: 20[redacted]-[redacted] / 175	Y-M: 20[redacted]-[redacted] / 185
METRONIDAZOLE	500 mg	TID	Y-M: 20[redacted]-[redacted] / 175	Y-M: 20[redacted]-[redacted] / 185
METRONIDAZOLE	500 mg	OTHER: Q8H	Y-M: 20[redacted]-[redacted] / 176	Y-M: 20[redacted]-[redacted] / 176
OXYCOCET	5/325 mg	PRN	Y-M: 20[redacted]-[redacted] / 208	Y-M: 20[redacted]-[redacted] / 210

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	APPENDICITIS
Preferred term	虫垂炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 173
Age at AE Onset	3[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 175): Leukocytes: 15.1 [3.1 - 8.4] 10^9/L; [redacted]20[redacted] (RX DAY 176): Leukocytes: 8.9 [3.1 - 8.4] 10^9/L
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 175): ABDOMINAL CT SCAN: FINDINGS CONSISTENT WITH ACUTE APPENDICITIS; [redacted]20[redacted] (RX DAY 208): APPENDECTOMY: NA
AE Stopped Rx Day	208
Duration of AE	36 DAYS
Toxicity Grade	3
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	REQUIRES OR PROLONGS HOSPITALIZATION, OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 3[redacted] 歳男性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，虫垂炎を発現した。被験者は非喫煙者かつ飲酒者（2～4 杯／日）であり，関連する病歴はアトピー性皮膚炎であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は虫垂炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，虫垂炎は消失した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は 2 日間持続する腹痛のため救急治療室を受診し，入院した。身体的診察の所見は，腹部が軟であり，腹部膨満はなく，圧痛，McBurney 点の圧痛，及びロブシング徴候が認められた。治療薬として，抗生物質の静脈内投与が 24 時間行われた。被験者の症状は消失し，経口薬による治療が開始された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は退院した。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は外来で虫垂切除を受けた。

PERCOCET，メトロニダゾール及び cephalexin が投与された。

The patient's past medications include:

TRIAMCINOLONE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Appendicitis (10003011) (Appendicitis (10003011)) [v.22.1] [10003011]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Yes

Rechallenge: rechallenge was done, reaction did not recur

Alternative Etiology for UPADACITINIB (Blinded)

Event of APPENDICITIS

- Investigator: Not applicable

- AbbVie: Event is common in the general population; lifetime incidence is 8.6 percent in males and 6.7 percent in females.

RISK/BENEFIT STATEMENT:

There is no change to the risk/benefit profile for this study/product as a result of this individual report/event(s).

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] ABDOMINAL CT SCAN:** Findings consistent with acute appendicitis

[redacted] **20[redacted] WHITE BLOOD CELLS:** 15.11 X10**3/MCL (normal 3.12 to 8.44)

[redacted] **20[redacted] WHITE BLOOD CELLS:** 8.87 X10**3/MCL (normal 3.12 to 8.44)

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
肺炎	X			X

Treatment Group	Age at Study Start	Sex	Race
UPA 15 MG QD/UPA 15 MG QD	4[redacted]	FEMALE	WHITE

Medical History	Onset Year
FOOD ALLERGY (LAMB)	19[redacted]
ATOPIC DERMATITIS	20[redacted]
TONSILLITIS	20[redacted]
APPENDICITIS	20[redacted]
HEARTBURN	20[redacted]
PNEUMONIA	20[redacted]
ATOPIC DERMATITIS	20[redacted]
ANTERIOR CRUCIATE LIGAMENT KNEE REPLACEMENT	20[redacted]
DIABETES	20[redacted]
HIGH CHOLESTEROL	20[redacted]
HYPERTENSION	20[redacted]
FOOD ALLERGY	NOT REPORTED

Prior Procedures	Procedure Year
PRIOR PROCEDURES: TONSILLECTOMY	20[redacted]
PRIOR PROCEDURES: APPENDECTOMY	20[redacted]
PRIOR PROCEDURES: ANTERIOR CRUCIATE LIGAMENT KNEE REPLACEMENT	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	FORMER	5 CIGARETTE	25	20[redacted]
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	CURRENT	Less than 2

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 1	[redacted]20[redacted] / 113	113
UPA	15 MG	ORAL	QD	[redacted]20[redacted] / 114		

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
PREDNISONE	30 mg	QD	Y-M: 20[redacted]
OMEPRAZOLE	20 mg	QD	Y: 20[redacted] / -281
CLOBETASOL	0.05 %	OTHER: BID PRN	Y-M: 20[redacted] / -234
ZESTORETIC	20/25 mg	QD	Y-M: 20[redacted] / -191
PREDNISONE	20 mg	QD	Y-M: 20[redacted] / -125
ATORVASTATIN	40 mg	QD	Y-M: 20[redacted] / -100
METFORMIN	500 mg	QD	Y-M: 20[redacted] / -100
EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -69
BETAMETHASONE	0.05 %	OTHER: BID PRN	Y-M: 20[redacted] / -64
PREDNISONE	20 mg	OTHER: EVERY OTHER DAY	Y-M: 20[redacted] / -64
HYDROCODONE	5/500 mg	PRN	Y-M: 20[redacted] / -28
NAPROXEN	375 mg	BID	Y-M: 20[redacted] / -28
TRAMADOL	50 mg	PRN	Y-M: 20[redacted] / -19
IBUPROFEN	800 mg	PRN	Y-M: 20[redacted] / -15
PARACETAMOL	500 mg	PRN	Y-M: 20[redacted] / -15
AQUAPHOR	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / -7

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
OMEPRAZOLE	20 mg	QD	Y: 20[redacted] / -281	NOT REPORTED
ZESTORETIC	20/25 mg	QD	Y-M: 20[redacted] / -191	Y-M: 20[redacted] / 159
ATORVASTATIN	40 mg	QD	Y-M: 20[redacted] / -100	Y-M: 20[redacted] / 159
METFORMIN	500 mg	QD	Y-M: 20[redacted] / -100	Y-M: 20[redacted] / 159

EMOLLIENTS AND PROTECTIVES	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / - NOT REPORTED 69
PARACETAMOL	500 mg	PRN	Y-M: 20[redacted] / - Y-M: 20[redacted] / 15 265
IBUPROFEN	800 mg	PRN	Y-M: 20[redacted] / - Y-M: 20[redacted] / 15 418
AQUAPHOR	1 OTHER: APPLICATION	BID	Y-M: 20[redacted] / - NOT REPORTED 7
SALBUTAMOL	90 OTHER: MCG	PRN	Y-M: 20[redacted] / NOT REPORTED 222
CLARITHROMYCIN	500 mg	OTHER: EVERY 12 HOURS	Y-M: 20[redacted] / Y-M: 20[redacted] / 222 231

Event #1: Serious Adverse Event, Event of Interest - Serious Infections

Event Description	PNEUMONIA
Preferred term	肺炎
AE Onset Date / Rx Day	[redacted]20[redacted] / 175
Age at AE Onset	4[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 222): Leukocytes: 10.6 [4 - 11] 10^9/L; Lymphocytes: 2.2 [0.9 - 3.9] 10^9/L; Neutrophils: 7.7 [1.5 - 7.8] 10^9/L
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 222): CHEST PA + LAT: NO RADIOGRAPHIC EVIDENCE OF ACUTE CARDIOPULMONARY ABNORMALITY. STABLE APPEARING EXAMINATION.; ELECTROCARDIOGRAM: NORMAL SINUS RHYTHM
AE Stopped Rx Day	231
Duration of AE	57 DAYS
Toxicity Grade	2
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	NO
SAE Criteria	OTHER MEDICALLY IMPORTANT SERIOUS EVENT

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 4[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，肺炎を発現した。被験者は元喫煙者（紙巻タバコ 5 本／日，25 年間）かつ飲酒者（2 杯未満／日）であり，関連する病歴は肺炎，アトピー性皮膚炎，高血圧，糖尿病及びコレステロール高値であった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月，被験者は肺炎を発現した。20[redacted] 年 [redacted] 月 [redacted] 日，肺炎は消失した。

被験者は 3 週間続く咳嗽のため救急治療室を受診した。被験者は肺炎と診断され，Biaxin 及び albuterol を処方されて救急治療室から帰宅した。

ALBUTEROL HFA 及び BIAXIN が投与された。

The patient's past medications include:

PREDNISONE for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted], [redacted] 20[redacted] - [redacted] 20[redacted])

CLOBETASOL CREAM for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

CLOBETASOL OINTMENT for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

BETAMETHASONE CREAM for ATOPIC DERMATITIS ([redacted] 20[redacted] - [redacted] 20[redacted])

Causality for UPADACITINIB (Blinded)

---

1) Pneumonia (10035664) (Pneumonia (10035664)) [v.22.1] [10035664]

Causality as per reporter (Drug/Vaccine): Reasonable possibility

Causality as per Mfr. (Drug/Vaccine): No reasonable possibility

Dechallenge: Not Applicable

Alternative Etiology for UPADACITINIB (Blinded)

Event of PNEUMONIA

- Investigator: Not applicable

- AbbVie: Risk factors include diabetes, prior history of pneumonia, long term prior tobacco use of 5 cigarettes per day for 25 years

RISK/BENEFIT STATEMENT:

There is no change to the risk/benefit profile for this study/product as a result of this individual report/event(s).

Relevant Laboratory & Other Diagnostic Tests

[redacted] **20[redacted] CHEST X-RAY:** No radiographic evidence of acute cardiopulmonary abnormality. Stable appearing examination.

[redacted] **20[redacted] ELECTROCARDIOGRAM:** normal sinus rhythm

[redacted] **20[redacted] SCREENING CHEST X-RAY:** normal

[redacted] **20[redacted] WBC:** 10.6 K/MM3 (normal 4.0 to 11.0)

Subject [redacted] ([redacted])

Reason for Narrative

Adverse Event Preferred Term(s)	Serious Adverse Event	Adverse Event Leading to Discontinuation of Study Drug	Death	Event of Interest
深部静脈血栓症	X	X		X

Treatment Group	Age at Study Start	Sex	Race
PLACEBO/UPA 15 MG QD	4[redacted]	FEMALE	WHITE

Medical History	Onset Year
ALLERGIC RHINITIS	19[redacted]
ASTHMA	19[redacted]
ATOPIC DERMATITIS	19[redacted]
FOOD ALLERGY (PINEAPPLE)	19[redacted]
OBESITY	20[redacted]
CHRONIC LEFT LOWER EXTREMITY PAIN	20[redacted]
CHRONIC LEFT LOWER EXTREMITY SWELLING	20[redacted]
DEEP VEIN THROMBOSIS	20[redacted]
PULMONARY EMBOLISM	20[redacted]
DIABETES	20[redacted]
HYPERMENORRHEA	20[redacted]
HYPERTENSION	20[redacted]
BOIL-LEFT CHEEK	20[redacted]
ALLERGIC RHINITIS	NOT REPORTED
ASTHMA	NOT REPORTED
FOOD ALLERGY	NOT REPORTED

Prior Procedures	Procedure Year
PRIOR PROCEDURES: GASTRIC SLEEVE	20[redacted]
PRIOR PROCEDURES: HYSTERECTOMY	20[redacted]

Tobacco Use	Status	Number/Day	Number of Years	Year Stopped
CHEWING TOBACCO	NEVER			
CIGARETTES	CURRENT	3 CIGARETTE	6	
CIGARS	NEVER			
E-CIGARETTES	NEVER			
PIPES	NEVER			

Alcohol Use	Status	Number/Day
ALCOHOL	NEVER	

Study Drug Administration

Study Drug	Dose/Units	Route	Frequency	First Dose Date/Day	Last Dose Date/Day	Duration (Days)
PLACEBO		ORAL	QD	[redacted] / 1	[redacted] / 115	115
UPA	15 MG	ORAL	QD	[redacted] / 116	[redacted] / 372	257

Previous Therapy - Prior to baseline/enrollment

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day
SALBUTAMOL	2 OTHER: PUFFS	PRN	Y: 19[redacted]
CETIRIZINE	10 mg	QD	Y: 20[redacted]
PARAFFIN	1 OTHER: APPLICATION	BID	Y: 20[redacted]
TRIAMCINOLONE	0.1 %	OTHER: BID PRN	Y: 20[redacted]
CEFALEXIN	500 mg	BID	Y-M: 20[redacted] / -46
HYDROXYZINE	50 mg	OTHER: QHS	Y-M: 20[redacted] / -46
PREDNISONE	20 mg	QD	Y-M: 20[redacted] / -46
ULOBETASOL	0.01 %	BID	Y-M: 20[redacted] / -46
PHENTERMINE	37.5 mg	QD	Y-M: 20[redacted] / -38
TOPIRAMATE	100 mg	QD	Y-M: 20[redacted] / -38
HEPATITIS B IMMUNIZATION	NOT REPORTED	NOT REPORTED	Y-M: 20[redacted] / -37

Other Medications - Medications taken within 30 days prior to each narrative event until AE stopped or end of study

Medication Name (WHO Drug)	Dose/Units	Frequency	Start Year-Month / RX Day	Stop Year-Month / RX Day
SALBUTAMOL	2 OTHER: PUFFS	PRN	Y: 19[redacted]	NOT REPORTED
CETIRIZINE	10 mg	QD	Y: 20[redacted]	NOT REPORTED
PARAFFIN	1 OTHER: APPLICATION	BID	Y: 20[redacted]	NOT REPORTED
HYDROXYZINE	50 mg	OTHER: QHS	Y-M: 20[redacted] / -46	NOT REPORTED
APIXABAN	10 mg	QD	Y-M: 20[redacted] / 373	NOT REPORTED
FLUOCINONIDE	0.05 %	OTHER: BID PRN	Y-M: 20[redacted] / 379	Y-M: 20[redacted] / 446
BETAMETHASONE	0.05 %	OTHER: BID PRN	Y-M: 20[redacted] / 458	NOT REPORTED
PREDNISONE	10 mg	OTHER: TAKE 4 PO QD X 3 DAYS, 3 PO QD X 3 DAYS, 2 PO QD X 3 DAYS, 1 PO QD X 3 DAYS, 1/2 PO QD X 4 DA	Y-M: 20[redacted] / 458	Y-M: 20[redacted] / 473

Event #1: Serious Adverse Event, AE Leading to Discontinuation of Study Drug, Event of Interest - Adjudicated Cardiovascular Event

Event Description	DEEP VEIN THROMBOSIS LEFT LOWER LEG
Preferred term	深部静脈血栓症
AE Onset Date / Rx Day	[redacted]20[redacted] / 365
Age at AE Onset	4[redacted]
Laboratory Testing	[redacted]20[redacted] (RX DAY 395): Leukocytes: 3.3 [4 - 11] 10^9/L; NPTST005-ACTIVATED PROTEIN C RESISTANCE: 2.91 [2.56 - NOT REPORTED] RATIO; NPTST012-ANC: 1.29 [1.6 - 9.3] UNIT NOT REPORTED; NPTST013-ANTI-THROMBIN III ACTIVITY: 111 [83 - 128] %; NPTST055-DILUTE RUSSELL VIPER VENOM TIME: 1.05 [NOT REPORTED - 1.2] RATIO; NPTST076-IGA: 408 [81 - 453] MG/DL; NPTST077-IGE: 2844 [NOT REPORTED - 100] IU/mL; NPTST078-IGG: 888 [694 - 1618] MG/DL; NPTST079-IGM: 85 [48 - 271] MG/DL; NPTST084-INR SPECIAL COAG: 1.1 [0.9 - 1.1] RATIO; NPTST093-LUPUS INTERPRETATION: NOT DETECTED [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST119-PARTIAL THROMBOPLASTIN TIME: 34.9 [24 - 36.5] SEC; NPTST126-PROTHROMBIN (FACTOR II) 20210G>: HETEROZYGOUS [NOT REPORTED - NOT REPORTED] UNIT NOT REPORTED; NPTST127-PROTIME: 12.4 [9.4 - 12.5] SEC; NPTST141-SILICA CLOTTING TIME (NORMALIZE: 0.98 [NOT REPORTED - 1.16] mm/h
Microbiology	NOT REPORTED
SAE Supplemental Procedure	[redacted]20[redacted] (RX DAY 373): ULTRASOUND: THERE IS NONOCCLUSIVE THROMBUS OF THE POPLITEAL VEIN. ECHOGENIC LINEAR COMPONENT IS CLEARLY CHRONIC. LESS SPECIFIC ROUNDED NONOCCLUSIVE THROMBUS IS AGE INDETERMINATE. POSSIBLY ACUTE ON CHRONIC DEEP VENOUS THROMBOSIS OF THE POPLITEAL VEIN.
AE Stopped Rx Day	NOT REPORTED

Duration of AE	NOT REPORTED
Toxicity Grade	4
Relation to Study Drug by Investigator	REASONABLE POSSIBILITY
Investigator Alternative Etiology	NOT REPORTED
Discontinued Study Drug Due to the Event	YES
SAE Criteria	OTHER MEDICALLY IMPORTANT SERIOUS EVENT, IS LIFE THREATENING

Generated: [redacted]
Program Source Code: [redacted]

Investigator No.: [redacted]

Subject Number: [redacted]

Protocol Number: M16-045

本被験者は米国の 4[redacted] 歳女性であり，ABT-494（ウパダシチニブ）の治験で盲検化された治験薬を投与され，左下肢の深部静脈血栓症を発現した。被験者は喫煙者（紙巻タバコ 3 本／日，6 年間）かつ非飲酒者で，関連する病歴は喘息，アトピー性皮膚炎，肥満，慢性左下肢痛，慢性左下肢腫脹，深部静脈血栓症，肺塞栓症，糖尿病，高血圧であり，家族歴に下肢血栓症（母親）があった。

被験者は本試験開始時の 16 週間の二重盲検投与期に参加した。20[redacted] 年 [redacted] 月 [redacted] 日に盲検下でウパダシチニブ投与が開始された。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左下肢の深部静脈血栓症を発現した。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者は左下肢の圧痛／疼痛，温感，腫脹及び発赤を自覚し始めた。20[redacted] 年 [redacted] 月 [redacted] 日，被験者はこれら症状のため医院を受診した。診察時に索状物が触知された。被験者は，精査のため救急治療室を受診するよう指示された。20[redacted] 年 [redacted] 月 [redacted] 日，被験者は救急治療室を受診し，超音波検査で左下肢の深部静脈血栓症と確認された。Eliquis の投与が開始された。被験者は入院しなかった。

20[redacted] 年 [redacted] 月 [redacted] 日，被験者がヘテロ接合性プロトロンビン遺伝子 G20210A 変異（非重篤）を保有することが判明した。

医療記録より:

被験者によれば，左下腿の大きさの変化（腫大）は本事象発現時の症状ではなく，過去に深部静脈血栓症（膝窩静脈の慢性深部静脈血栓症）を発症して以降，右下腿よりも左下腿の方が大きかった。左下肢に圧痛はなく，前面に表在静脈瘤が隆起しており，紅斑が認められた。身体的診察では，この他に特記すべき異常はなかった。被験者によれば，最近の旅行歴や損傷の病歴はなかった。